<SEC-DOCUMENT>0001062822-20-000027.txt : 20200427
<SEC-HEADER>0001062822-20-000027.hdr.sgml : 20200427
<ACCEPTANCE-DATETIME>20200427162033
ACCESSION NUMBER:		0001062822-20-000027
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		45
CONFORMED PERIOD OF REPORT:	20200331
FILED AS OF DATE:		20200427
DATE AS OF CHANGE:		20200427

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LEXICON PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001062822
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				760474169
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30111
		FILM NUMBER:		20820270

	BUSINESS ADDRESS:	
		STREET 1:		8800 TECHNOLOGY FOREST PLACE
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381
		BUSINESS PHONE:		2818633000

	MAIL ADDRESS:	
		STREET 1:		8800 TECHNOLOGY FOREST PLACE
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON PHARMACEUTICALS, INC./DE
		DATE OF NAME CHANGE:	20070426

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON GENETICS INC/TX
		DATE OF NAME CHANGE:	20000126
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>lxrx-20200331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:b6c3a7dc-b64d-45d6-bfee-77eb11f000ac,g:4bb55044-54d9-4307-a743-01e703a924d5,d:4e8a6d84e5e241588399a0cfd4660c18--><html xmlns:lxrx="http://www.lexpharma.com/20200331" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lxrx-20200331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80L2ZyYWc6NDZjNjc0YjdiODgxNDdkNGEyNzcyMGFhNjVhNDExZjAvdGFibGU6NjZlZjEzNzJhZGU4NGNlNTg3NjhhNWVhZGYzNzIzMjQvdGFibGVyYW5nZTo2NmVmMTM3MmFkZTg0Y2U1ODc2OGE1ZWFkZjM3MjMyNF81LTMtMS0xLTQwOQ_38e6f152-88d3-4167-8625-ed15634d6c43">Q1</ix:nonNumeric><ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80L2ZyYWc6NDZjNjc0YjdiODgxNDdkNGEyNzcyMGFhNjVhNDExZjAvdGFibGU6NjZlZjEzNzJhZGU4NGNlNTg3NjhhNWVhZGYzNzIzMjQvdGFibGVyYW5nZTo2NmVmMTM3MmFkZTg0Y2U1ODc2OGE1ZWFkZjM3MjMyNF85LTMtMS0xLTQ0MA_9bd7b305-d67b-4f25-9789-5e8f3bc28c10">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80L2ZyYWc6NDZjNjc0YjdiODgxNDdkNGEyNzcyMGFhNjVhNDExZjAvdGFibGU6NjZlZjEzNzJhZGU4NGNlNTg3NjhhNWVhZGYzNzIzMjQvdGFibGVyYW5nZTo2NmVmMTM3MmFkZTg0Y2U1ODc2OGE1ZWFkZjM3MjMyNF8xMC0zLTEtMS00NDA_9021772b-ace6-48e9-ac17-676341bd9018">2020</ix:nonNumeric><ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80L2ZyYWc6NDZjNjc0YjdiODgxNDdkNGEyNzcyMGFhNjVhNDExZjAvdGFibGU6NjZlZjEzNzJhZGU4NGNlNTg3NjhhNWVhZGYzNzIzMjQvdGFibGVyYW5nZTo2NmVmMTM3MmFkZTg0Y2U1ODc2OGE1ZWFkZjM3MjMyNF8xMS0zLTEtMS00Mzc_ba168edf-152e-4d53-9c4f-008f0623711a">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80L2ZyYWc6NDZjNjc0YjdiODgxNDdkNGEyNzcyMGFhNjVhNDExZjAvdGFibGU6NjZlZjEzNzJhZGU4NGNlNTg3NjhhNWVhZGYzNzIzMjQvdGFibGVyYW5nZTo2NmVmMTM3MmFkZTg0Y2U1ODc2OGE1ZWFkZjM3MjMyNF8xMy0zLTEtMS00NDA_f2058429-c706-4206-b258-33ad60c21b73">LEXICON PHARMACEUTICALS, INC./DE</ix:nonNumeric><ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80L2ZyYWc6NDZjNjc0YjdiODgxNDdkNGEyNzcyMGFhNjVhNDExZjAvdGFibGU6NjZlZjEzNzJhZGU4NGNlNTg3NjhhNWVhZGYzNzIzMjQvdGFibGVyYW5nZTo2NmVmMTM3MmFkZTg0Y2U1ODc2OGE1ZWFkZjM3MjMyNF8xNC0zLTEtMS00NDA_c1ee6fd0-a87a-45a8-9808-17fff4d48ef2">0001062822</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="lxrx-20200331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="id2404fdeff6740faada8a1fcc2da1bf3_I20200423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-04-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i363fbff4bcfa49938a12d82839eb6a03_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e1705cc437a4623985876b0a6850cd4_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7a2afb94e3d47888a4f5fb5cbad1728_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d1fdae96a904b22b9d37b0de77588fb_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bd9c5bf42c248cd9bf25b6dea04bd1a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bc51fbc5bfc475ea508dad359524362_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b7022476157494398816b99471e0697_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb01c97139de4c7da87be444c5833141_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcb21aab8fb742a4b472651ad313d600_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9b975fc81164d7cbff5a2763c95ef28_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa015c4922754b5d91743371bfe8a576_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib455b101c4484d4c8d9f69a783226edd_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a9b6cf9115b4d328637e78789aa34f1_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if43ffe172d1f4c68b5844235ee4289f7_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f6a44ebc0994be5a7cef652c7d2857e_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6910b93f33e4481fb289ea612c84f3ae_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i593c8c0affe34641adbf79593094ac0b_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie255744bc9f3477ba151d4eaa2718fe1_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2014f01922b408fa97848ffdeb88941_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba79016389514c5ebe72f001f7acf420_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1a8986ec8894a469fbd46f3df2dc202_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c9621fa321f4e9195d6603061f89e2f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i846c9d455edf4f1cb3d7646d362b3a11_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1112901d3eee474b98585e70b151f858_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d8f640e99d948e59de6f191b2509423_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f1459fd243c427791a12f208909ef19_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie225ba400e5842d2896152f546aedab5_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaac8e8918b3b48de8027ed5b977e799b_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f1cd0ed4c754265b45c85c1bc69396f_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4f4eb4f717648a1807ac159d3543e2c_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3daccec285f3488c8d44f5dc7865d44e_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92dc246d5c4e4b13a56fd11a7345454e_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cd8c8c5263c421b8fa978b95f7cd714_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i3f18a324e14b49309846f18ff6f8c0bc_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71615d600ea045f8b04f0104cca32e8c_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0feb9d4ec8584f3ba002dca3b78ba1a4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9befb60474ef4d338b2be4e84a752c34_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i006d636778dc433599008ebda0fae643_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i208e16ef59a04b3c8182732d53d1e2eb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb6eab599353423faf94057d3a06d361_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d895ee7aef1499d98cd6729af5ed070_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5874757311014de880a5b19a0ef172e9_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic70d1635899243dcae62140e9324e2e5_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fe1a3b2255e409c8e58bbc860ad020d_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ec309d5c8d74374add6eb8f7da20570_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic774c47684e0435aa7c3af7fdf7fe3fd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0f70c6928fb4964a9779e08a7863739_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7833aa4e5e984d3dba5516f674a6a6fd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5690a7970c9142c1b8c462b80f0e2ba2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a4c4a7f94924e29a9ae0e9f3ffd742f_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie20916e42c934ea59584c72016a49665_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b10f1125ee94d22854381cfc60caac9_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib827aa338f2c4aca8a2d4e234b9f0078_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc19c78530d54ec0a70b9d2bdd0a9db7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3d4c113ca4e4166a72c7baa6566b202_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd4832dfa32a43a6b0d3e7ac775c2680_D20141101-20141130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2014-11-01</xbrli:startDate><xbrli:endDate>2014-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a726c0e01c741f09f3d21d85cd63800_I20141120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2014-11-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id80805ff25ba4c6c9ddb0b2c60375c8a_I20180830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-08-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65c277c002ca41af9214fb16de22bcb8_I20171218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i723e1df096a74ef3a7ed1c4ee79e00cb_D20150301-20150331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2015-03-01</xbrli:startDate><xbrli:endDate>2015-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2f0442e8e3949d2acab519802cd9a7a_D20160701-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2016-07-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f3132da0556457c978c3721090d9425_D20170701-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-07-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i949545145223492aa3a8472aa5f75d6c_D20171001-20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb75b1b2778741648129edca9c77b0d1_D20171101-20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41e7bc56d8f44697acef137f70b02cef_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9940e83a99be4c0db47b16062f8cf74e_D20190201-20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="iace247b45bbe4d50be1b8046b7cf2019_D20141001-20141031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2014-10-01</xbrli:startDate><xbrli:endDate>2014-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2eee5e8c4bdb4710a81e6835c783b093_D20150101-20150630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1c464c977e64590a82ac8d115d0d92c_D20160101-20160630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-06-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i4e8a6d84e5e241588399a0cfd4660c18_1"></div><div style="height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">UNITED STATES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Washington, D.C. 20549</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;">FORM <ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xL2ZyYWc6MGJiNDQwZTdkYmY1NGQ1ZDg2M2M2Y2I2YzM0MjhiMTQvdGV4dHJlZ2lvbjowYmI0NDBlN2RiZjU0ZDVkODYzYzZjYjZjMzQyOGIxNF8zODQ4MjkwNjk5NDg5_5900730a-9864-4c83-b9dc-8783a3ff5a31">10-Q</ix:nonNumeric></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Mark One)</span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:95.175%;"><tr><td style="width:1.0%;"></td><td style="width:1.072%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:94.928%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Wingdings',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xL2ZyYWc6MGJiNDQwZTdkYmY1NGQ1ZDg2M2M2Y2I2YzM0MjhiMTQvdGFibGU6MGUyMWJmNDhlN2U4NDU0N2FmNTc1YWExNDhiZTAyYTYvdGFibGVyYW5nZTowZTIxYmY0OGU3ZTg0NTQ3YWY1NzVhYTE0OGJlMDJhNl8wLTAtMS0xLTQyMA_ec9bbd15-c0e7-45e0-833c-bcd943aaf937">&#9745;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-indent:27pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">                                       For the Quarterly Period Ended <ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xL2ZyYWc6MGJiNDQwZTdkYmY1NGQ1ZDg2M2M2Y2I2YzM0MjhiMTQvdGV4dHJlZ2lvbjowYmI0NDBlN2RiZjU0ZDVkODYzYzZjYjZjMzQyOGIxNF8zODQ4MjkwNjk5NDg2_48b2298e-4883-43c1-848b-955787a285e2">March 31, 2020</ix:nonNumeric> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">or</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:95.175%;"><tr><td style="width:1.0%;"></td><td style="width:1.072%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:94.928%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Wingdings',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xL2ZyYWc6MGJiNDQwZTdkYmY1NGQ1ZDg2M2M2Y2I2YzM0MjhiMTQvdGFibGU6MDViMWIzM2Q3NjQxNDc5OWExZGJlODhjYTkyMzcyMmMvdGFibGVyYW5nZTowNWIxYjMzZDc2NDE0Nzk5YTFkYmU4OGNhOTIzNzIyY18wLTAtMS0xLTQzMQ_a50e18b4-a582-46ae-95ce-5ebb5c4ed36d">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">For the Transition Period from _____________ to _____________</span></div><div style="text-align:center;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Commission File Number:&#160;&#160;<ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xL2ZyYWc6MGJiNDQwZTdkYmY1NGQ1ZDg2M2M2Y2I2YzM0MjhiMTQvdGV4dHJlZ2lvbjowYmI0NDBlN2RiZjU0ZDVkODYzYzZjYjZjMzQyOGIxNF8zODQ4MjkwNjk5NTMy_64963127-913a-4982-8290-4796f9ae9c9f">000-30111</ix:nonNumeric></span></div><div style="text-align:center;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:48.000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:48.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xL2ZyYWc6MGJiNDQwZTdkYmY1NGQ1ZDg2M2M2Y2I2YzM0MjhiMTQvdGFibGU6MDUxMWVhZGQwMzQwNGMyOWJkZGQ3M2JmNGQwMWJkYjAvdGFibGVyYW5nZTowNTExZWFkZDAzNDA0YzI5YmRkZDczYmY0ZDAxYmRiMF8wLTAtMS0xLTQ2Mw_ed445a3e-b02f-4a6c-b02f-582f0a51eda3">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xL2ZyYWc6MGJiNDQwZTdkYmY1NGQ1ZDg2M2M2Y2I2YzM0MjhiMTQvdGFibGU6MDUxMWVhZGQwMzQwNGMyOWJkZGQ3M2JmNGQwMWJkYjAvdGFibGVyYW5nZTowNTExZWFkZDAzNDA0YzI5YmRkZDczYmY0ZDAxYmRiMF8wLTEtMS0xLTQ3NA_bf0d9ffb-eac0-4401-857d-59eb625c2a55">76-0474169</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(State or Other Jurisdiction of<br/>Incorporation or Organization)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xL2ZyYWc6MGJiNDQwZTdkYmY1NGQ1ZDg2M2M2Y2I2YzM0MjhiMTQvdGV4dHJlZ2lvbjowYmI0NDBlN2RiZjU0ZDVkODYzYzZjYjZjMzQyOGIxNF8zODQ4MjkwNjk5NTY0_2070fd33-fcd0-4d93-b727-726f268abcf6">8800 Technology Forest Place</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xL2ZyYWc6MGJiNDQwZTdkYmY1NGQ1ZDg2M2M2Y2I2YzM0MjhiMTQvdGV4dHJlZ2lvbjowYmI0NDBlN2RiZjU0ZDVkODYzYzZjYjZjMzQyOGIxNF8zODQ4MjkwNjk5NTc5_9ccbca5f-f29e-48be-8319-d0392b35361b">The Woodlands</ix:nonNumeric>, <ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xL2ZyYWc6MGJiNDQwZTdkYmY1NGQ1ZDg2M2M2Y2I2YzM0MjhiMTQvdGV4dHJlZ2lvbjowYmI0NDBlN2RiZjU0ZDVkODYzYzZjYjZjMzQyOGIxNF8zODQ4MjkwNjk5NTg2_78710e08-3020-47c8-badc-69802b961eac">Texas</ix:nonNumeric> <ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xL2ZyYWc6MGJiNDQwZTdkYmY1NGQ1ZDg2M2M2Y2I2YzM0MjhiMTQvdGV4dHJlZ2lvbjowYmI0NDBlN2RiZjU0ZDVkODYzYzZjYjZjMzQyOGIxNF8zODQ4MjkwNjk5NTkz_b065f455-0630-426d-b79f-0fc0eba1d22d">77381</ix:nonNumeric></span></div><div style="text-align:center;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Address of Principal Executive Offices and Zip Code)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(<ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xL2ZyYWc6MGJiNDQwZTdkYmY1NGQ1ZDg2M2M2Y2I2YzM0MjhiMTQvdGV4dHJlZ2lvbjowYmI0NDBlN2RiZjU0ZDVkODYzYzZjYjZjMzQyOGIxNF8zODQ4MjkwNjk5NTk4_fa3886dc-8d9a-4f36-917e-f9e9ec665762">281</ix:nonNumeric>) <ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xL2ZyYWc6MGJiNDQwZTdkYmY1NGQ1ZDg2M2M2Y2I2YzM0MjhiMTQvdGV4dHJlZ2lvbjowYmI0NDBlN2RiZjU0ZDVkODYzYzZjYjZjMzQyOGIxNF8zODQ4MjkwNjk5NjA4_6ada45dc-6aec-429d-bc25-1726fbf38d60">863-3000</ix:nonNumeric></span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:31.235%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:19.522%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:43.243%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Title of each class</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Trading Symbol(s)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xL2ZyYWc6MGJiNDQwZTdkYmY1NGQ1ZDg2M2M2Y2I2YzM0MjhiMTQvdGFibGU6OTQ1YzJmMmVjMWM1NDBmZjlkZWExMGIyZDkyNTBlYmIvdGFibGVyYW5nZTo5NDVjMmYyZWMxYzU0MGZmOWRlYTEwYjJkOTI1MGViYl8xLTAtMS0xLTYwNw_2c00f7d5-eca3-42c7-b5df-46cfc02a9bf4">Common Stock, par value $0.001</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xL2ZyYWc6MGJiNDQwZTdkYmY1NGQ1ZDg2M2M2Y2I2YzM0MjhiMTQvdGFibGU6OTQ1YzJmMmVjMWM1NDBmZjlkZWExMGIyZDkyNTBlYmIvdGFibGVyYW5nZTo5NDVjMmYyZWMxYzU0MGZmOWRlYTEwYjJkOTI1MGViYl8xLTEtMS0xLTYxMg_05af65cb-5bf3-4c1e-a712-d18de0a30930">LXRX</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xL2ZyYWc6MGJiNDQwZTdkYmY1NGQ1ZDg2M2M2Y2I2YzM0MjhiMTQvdGFibGU6OTQ1YzJmMmVjMWM1NDBmZjlkZWExMGIyZDkyNTBlYmIvdGFibGVyYW5nZTo5NDVjMmYyZWMxYzU0MGZmOWRlYTEwYjJkOTI1MGViYl8xLTItMS0xLTYxNg_73d0278b-a6c6-4b52-bf58-a28000cb6449">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="text-indent:36pt;text-align:justify;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:30.263%;"><tr><td style="width:1.0%;"></td><td style="width:20.705%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.323%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.942%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.323%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:20.707%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xL2ZyYWc6MGJiNDQwZTdkYmY1NGQ1ZDg2M2M2Y2I2YzM0MjhiMTQvdGFibGU6NzcxZWE5MzlkMWFjNDc4NWJmOWQ3MzRkYzM0YWYwZWYvdGFibGVyYW5nZTo3NzFlYTkzOWQxYWM0Nzg1YmY5ZDczNGRjMzRhZjBlZl8wLTAtMS0xLTUwMA_04f25efa-555c-4780-abf1-63cbe8cf746b">Yes</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Wingdings',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9745;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">No</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;text-align:justify;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:30.263%;"><tr><td style="width:1.0%;"></td><td style="width:20.705%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.323%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.942%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.323%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:20.707%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xL2ZyYWc6MGJiNDQwZTdkYmY1NGQ1ZDg2M2M2Y2I2YzM0MjhiMTQvdGFibGU6ZTJjMmVkYWQ4NmE3NDQ1MmIyNTRjNTg2NmZlODM3ZDEvdGFibGVyYW5nZTplMmMyZWRhZDg2YTc0NDUyYjI1NGM1ODY2ZmU4MzdkMV8wLTAtMS0xLTA_b8eb8bd2-1627-464e-a739-e1d8a332c482">Yes</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Wingdings',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9745;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">No</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;text-align:justify;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.&#160;&#160;See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Large accelerated filer </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;     <ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xL2ZyYWc6MGJiNDQwZTdkYmY1NGQ1ZDg2M2M2Y2I2YzM0MjhiMTQvdGV4dHJlZ2lvbjowYmI0NDBlN2RiZjU0ZDVkODYzYzZjYjZjMzQyOGIxNF8zODQ4MjkwNjk5NjI5_3ca07447-611c-467e-970a-6c0cd0be1cf8">Accelerated filer</ix:nonNumeric> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;&#9745;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">          Non-accelerated filer </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Smaller reporting company </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;<ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xL2ZyYWc6MGJiNDQwZTdkYmY1NGQ1ZDg2M2M2Y2I2YzM0MjhiMTQvdGV4dHJlZ2lvbjowYmI0NDBlN2RiZjU0ZDVkODYzYzZjYjZjMzQyOGIxNF8xMDk5NTExNjMwMjgy_53fb5f83-0bac-4ca8-ba8a-7dc018302ede">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">     Emerging growth company </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;<ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xL2ZyYWc6MGJiNDQwZTdkYmY1NGQ1ZDg2M2M2Y2I2YzM0MjhiMTQvdGV4dHJlZ2lvbjowYmI0NDBlN2RiZjU0ZDVkODYzYzZjYjZjMzQyOGIxNF8xMDk5NTExNjMwMjc2_c9c9a2b7-91de-4bfb-aa9d-b7e555fd8b17">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If an emerging growth company, indicate by check mark if the registration has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  &#9744;</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:30.263%;"><tr><td style="width:1.0%;"></td><td style="width:20.705%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.323%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.942%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.323%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:20.707%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Yes</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xL2ZyYWc6MGJiNDQwZTdkYmY1NGQ1ZDg2M2M2Y2I2YzM0MjhiMTQvdGFibGU6Zjg0OWZkYTQ2MTNjNDZjZGJmNDBkMDNiMDJhZGE0MjQvdGFibGVyYW5nZTpmODQ5ZmRhNDYxM2M0NmNkYmY0MGQwM2IwMmFkYTQyNF8wLTEtMS0xLTI2Mzc_f34f3f9c-60f2-44d4-adae-9b20eeedb841">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">No</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9745;</span></td></tr></table></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of April&#160;23, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, <ix:nonFraction unitRef="shares" contextRef="id2404fdeff6740faada8a1fcc2da1bf3_I20200423" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xL2ZyYWc6MGJiNDQwZTdkYmY1NGQ1ZDg2M2M2Y2I2YzM0MjhiMTQvdGV4dHJlZ2lvbjowYmI0NDBlN2RiZjU0ZDVkODYzYzZjYjZjMzQyOGIxNF8yMTM3_892d7be4-240a-48e4-bb6b-0207bb6e7525">106,969,973</ix:nonFraction> shares of th</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">e registrant&#8217;s common stock, par value $0.001 per share, were outstanding.  &#9744;</span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div id="i4e8a6d84e5e241588399a0cfd4660c18_7"></div><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Table of Contents</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:7.809%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:81.308%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:4.883%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Page</span></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;" href="#i4e8a6d84e5e241588399a0cfd4660c18_10">Factors Affecting Forward-Looking Statements</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4e8a6d84e5e241588399a0cfd4660c18_10">2</a></span></div></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;" href="#i4e8a6d84e5e241588399a0cfd4660c18_13">Part I &#8211; Financial Information</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4e8a6d84e5e241588399a0cfd4660c18_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 1.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4e8a6d84e5e241588399a0cfd4660c18_16">Financial Statements</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4e8a6d84e5e241588399a0cfd4660c18_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Condensed Consolidated Balance Sheets - March 31, 2020 (unaudited) and December 31, 2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4e8a6d84e5e241588399a0cfd4660c18_19">3</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Condensed Consolidated Statements of Comprehensive Loss (unaudited) - Three Months Ended March 31, 2020 and 2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4e8a6d84e5e241588399a0cfd4660c18_25">4</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Condensed Consolidated Statements of Stockholders&#8217; Equity (Deficit) (unaudited) - Three Months Ended March 31, 2020 and 2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4e8a6d84e5e241588399a0cfd4660c18_31">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Condensed Consolidated Statements of Cash Flows (unaudited) - Three Months Ended March 31, 2020 and 2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4e8a6d84e5e241588399a0cfd4660c18_34">6</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Notes to Condensed Consolidated Financial Statements (unaudited)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4e8a6d84e5e241588399a0cfd4660c18_37">7</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 2.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4e8a6d84e5e241588399a0cfd4660c18_79">Management&#8217;s Discussion and Analysis of Financial Condition and Results&#160;of Operations</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4e8a6d84e5e241588399a0cfd4660c18_79">17</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 3.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4e8a6d84e5e241588399a0cfd4660c18_88">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4e8a6d84e5e241588399a0cfd4660c18_88">22</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 4.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4e8a6d84e5e241588399a0cfd4660c18_91">Controls and Procedures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4e8a6d84e5e241588399a0cfd4660c18_88">22</a></span></div></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;" href="#i4e8a6d84e5e241588399a0cfd4660c18_94">Part II &#8211; Other Information</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4e8a6d84e5e241588399a0cfd4660c18_94">23</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 1.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4e8a6d84e5e241588399a0cfd4660c18_97">Legal Proceedings</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4e8a6d84e5e241588399a0cfd4660c18_97">23</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 1A.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4e8a6d84e5e241588399a0cfd4660c18_100">Risk Factors</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4e8a6d84e5e241588399a0cfd4660c18_100">23</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 2</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4e8a6d84e5e241588399a0cfd4660c18_1062">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4e8a6d84e5e241588399a0cfd4660c18_1062">26</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 6.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4e8a6d84e5e241588399a0cfd4660c18_103">Exhibits</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4e8a6d84e5e241588399a0cfd4660c18_103">27</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4e8a6d84e5e241588399a0cfd4660c18_106">Signatures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4e8a6d84e5e241588399a0cfd4660c18_106">28</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Lexicon name and logo and XERMELO</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> are registered trademarks of Lexicon Pharmaceuticals, Inc.  Zynquista&#8482; is a trademark of Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div><span><br/></span></div><div id="i4e8a6d84e5e241588399a0cfd4660c18_10"></div><div style="text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Factors Affecting Forward Looking Statements</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This quarterly report on Form 10-Q contains forward-looking statements.  These statements relate to future events or our future financial performance. We have attempted to identify forward-looking statements by terminology including &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;should&#8221; or &#8220;will&#8221; or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks outlined under &#8220;Part&#160;II, Item 1A. - Risk Factors&#8221; and in our annual report on Form 10-K for the year ended December&#160;31, 2019, that may cause our or our industry&#8217;s actual results, levels of activity, performance or achievements to be materially different from any future results, levels or activity, performance or achievements expressed or implied by these forward-looking statements.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Although we believe that the expectations reflected in the forward-looking statements are reasonable, future results, levels of activity, performance or achievements may vary materially from our expectations. We are not undertaking any duty to update any of the forward-looking statements after the date of this quarterly report on Form 10-Q to conform these statements to actual results, unless required by law.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span><br/></span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2</span></div><div style="text-align:center;"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div id="i4e8a6d84e5e241588399a0cfd4660c18_13"></div><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Part I &#8211; Financial Information</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i4e8a6d84e5e241588399a0cfd4660c18_16"></div><div style="text-indent:-72pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 1.&#160;&#160;Financial Statements</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i4e8a6d84e5e241588399a0cfd4660c18_19"></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(In thousands, except par value)</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:59.932%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:16.594%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:16.010%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of March 31,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31,</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfNC0yLTEtMS0w_689e64e5-6b70-4a70-a03a-09c855cccf06">55,592</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfNC00LTEtMS0w_98d2b4e5-073c-495f-8ed3-1d5548c5f360">36,112</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfNS0yLTEtMS0w_934992ab-10b7-432d-9f12-7386666c6346">193,545</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfNS00LTEtMS0w_85f34df9-324b-4345-b789-ec4779f652b6">235,547</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfNi0yLTEtMS0w_ba43fddf-8fac-417c-a014-1ca7f5b45e10">30,135</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfNi00LTEtMS0w_27ceab8c-3b5f-493b-aad1-82e144e3be5b">56,532</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inventory</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfOC0yLTEtMS0w_d561675f-04f0-4c96-a4c9-0ef10b2e3b96">4,147</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfOC00LTEtMS0w_be235262-209c-4835-b70c-0556e35e44a7">4,243</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfOS0yLTEtMS0w_da5ac5e1-e0f5-4236-91aa-56039fb84976">8,195</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfOS00LTEtMS0w_aef4036a-9ec3-4532-842e-a58eb48c851d">5,320</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMTAtMi0xLTEtMA_8e1f0dc2-b7a3-4bc4-9ba0-de28fc3afb88">291,614</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMTAtNC0xLTEtMA_e080dbd1-42eb-4e2d-9f22-7118fddee500">337,754</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Property and equipment, net of accumulated depreciation and amortization of $<ix:nonFraction unitRef="usd" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMTEtMC0xLTEtMC90ZXh0cmVnaW9uOjFhMjAzNjkyMTJjZDQ1NTU4YWY1NmY0OTQ4NWNjYjk1XzEwOTk1MTE2Mjc4OTY_9e24c66e-476b-4e96-9acd-da9496bd3545">61,302</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i6e1705cc437a4623985876b0a6850cd4_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMTEtMC0xLTEtMC90ZXh0cmVnaW9uOjFhMjAzNjkyMTJjZDQ1NTU4YWY1NmY0OTQ4NWNjYjk1XzEwOTk1MTE2Mjc5MDY_94f013fa-fdd6-4ac9-90d4-1f2223052794">61,741</ix:nonFraction>, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMTEtMi0xLTEtMA_39acbc28-7170-4569-bdf2-ab07a250f7cb">13,582</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMTEtNC0xLTEtMA_c9e2ff82-e8e3-4bc2-9ce2-149194141e3f">14,047</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMTItMi0xLTEtMA_7e212510-6cf5-4644-a868-37bae3555c5d">44,543</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMTItNC0xLTEtMA_d5c50fce-53ab-49f7-bdc8-cdad760e6786">44,543</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Intangible assets, net of accumulated amortization of $<ix:nonFraction unitRef="usd" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMTMtMC0xLTEtMC90ZXh0cmVnaW9uOjViOTAxMzIyMWE3MTRhZjViMGVkOTdhYWYwNzU3NGE2XzEwOTk1MTE2Mjc4NzE_9de30d0b-f988-4672-a040-62b9e8ffcf15">5,444</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i6e1705cc437a4623985876b0a6850cd4_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMTMtMC0xLTEtMC90ZXh0cmVnaW9uOjViOTAxMzIyMWE3MTRhZjViMGVkOTdhYWYwNzU3NGE2XzEwOTk1MTE2Mjc4ODA_efdca08c-f570-4b46-b56f-06bbd02d8a75">5,003</ix:nonFraction>, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMTMtMi0xLTEtMA_863b4990-f46d-431a-b601-269886643baa">19,275</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMTMtNC0xLTEtMA_349355d9-9383-4b02-8073-305f98f8be30">19,716</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMTQtMi0xLTEtMA_53b49b20-7088-40ca-b00d-0146512ab7a0">1,553</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMTQtNC0xLTEtMA_91ccbd08-a183-4231-afa3-20613a48442d">1,655</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMTUtMi0xLTEtMA_d2bca3b7-9648-42f4-a4f1-b52a10c83a04">370,567</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMTUtNC0xLTEtMA_66be56d0-d117-4f86-8190-9fd8244cfd54">417,715</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities and Equity</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMTgtMi0xLTEtMA_bcf5e249-89f9-407b-b434-ad335ef4638e">18,236</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMTgtNC0xLTEtMA_2b8fe24e-9948-4051-b068-01233a5b1a37">12,178</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMTktMi0xLTEtMA_f6e3e991-339f-4c03-aa98-bf8b40c406b5">51,349</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMTktNC0xLTEtMA_5222011e-6f65-4329-959f-82ef09ab2924">42,151</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current portion of long-term debt, net of deferred issuance costs</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMjEtMi0xLTEtMA_9a249cf1-a7f9-4eb6-9e17-d837dc78dedd">10,734</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMjEtNC0xLTEtMA_d6543030-2f7a-4fa8-bfe3-04836dc8e2a9">11,012</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMjItMi0xLTEtMA_e197da08-5d6f-45ba-8de5-24a4b5bf7d30">80,319</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMjItNC0xLTEtMA_2f7eba51-75ba-4938-89ed-ffa27bd72012">65,341</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term debt, net of deferred issuance costs</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMjQtMi0xLTEtMA_3a0a1e76-78e2-4e2b-94d1-0ab33b9882b5">234,488</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMjQtNC0xLTEtMA_460739b5-9db7-4b7c-8bdc-a2240a1925ba">234,171</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMjYtMi0xLTEtMA_c782b84e-6245-4182-83fb-8f4e3acf3266">983</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMjYtNC0xLTEtMA_20cdedb0-07d8-49a0-a210-9cdd70493d30">1,102</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMjctMi0xLTEtMA_0aad4ad9-3284-407c-a165-d313f7ed7346">315,790</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMjctNC0xLTEtMA_c13d5730-fb4a-42a8-b276-eb4f9850dca2">300,614</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commitments and contingencies</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span><ix:nonFraction unitRef="usd" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMjgtMi0xLTEtMA_ed67e6fd-8191-4ea5-a532-8f7071642463"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span><ix:nonFraction unitRef="usd" contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMjgtNC0xLTEtMA_1a6b29e0-148b-41dd-88f4-0533fa8ce647"></ix:nonFraction></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stockholders&#8217; Equity:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i6e1705cc437a4623985876b0a6850cd4_I20190331" decimals="2" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzAtMC0xLTEtMjUxMi90ZXh0cmVnaW9uOmIxOGYxMWM5YWIxYTRiMjI5ZTVmMmY5N2M4OGUwNjUwXzEwOTk1MTE2Mjc4NzU_545d4705-f391-4920-b14b-ffc6de4ae80e"><ix:nonFraction unitRef="usdPerShare" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="2" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzAtMC0xLTEtMjUxMi90ZXh0cmVnaW9uOmIxOGYxMWM5YWIxYTRiMjI5ZTVmMmY5N2M4OGUwNjUwXzEwOTk1MTE2Mjc4NzU_63987c78-f6ba-45d4-95f8-a29d760a8ebd">0.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzAtMC0xLTEtMjUxMi90ZXh0cmVnaW9uOmIxOGYxMWM5YWIxYTRiMjI5ZTVmMmY5N2M4OGUwNjUwXzEwOTk1MTE2Mjc4ODQ_87fbd2b5-4429-4193-8794-b0942f61763f"><ix:nonFraction unitRef="shares" contextRef="i6e1705cc437a4623985876b0a6850cd4_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzAtMC0xLTEtMjUxMi90ZXh0cmVnaW9uOmIxOGYxMWM5YWIxYTRiMjI5ZTVmMmY5N2M4OGUwNjUwXzEwOTk1MTE2Mjc4ODQ_ed94fcba-d1bd-47c1-ad20-08643a85c97d">5,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzAtMC0xLTEtMjUxMi90ZXh0cmVnaW9uOmIxOGYxMWM5YWIxYTRiMjI5ZTVmMmY5N2M4OGUwNjUwXzEwOTk1MTE2Mjc4ODg_2f8ec445-ce3d-482e-9061-f990db6a485e"><ix:nonFraction unitRef="shares" contextRef="i6e1705cc437a4623985876b0a6850cd4_I20190331" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzAtMC0xLTEtMjUxMi90ZXh0cmVnaW9uOmIxOGYxMWM5YWIxYTRiMjI5ZTVmMmY5N2M4OGUwNjUwXzEwOTk1MTE2Mjc4ODg_639bcf51-efc3-4be7-a37d-3ca4b39f8419"><ix:nonFraction unitRef="shares" contextRef="i6e1705cc437a4623985876b0a6850cd4_I20190331" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzAtMC0xLTEtMjUxMi90ZXh0cmVnaW9uOmIxOGYxMWM5YWIxYTRiMjI5ZTVmMmY5N2M4OGUwNjUwXzEwOTk1MTE2Mjc4ODg_dad046b8-0e98-46f5-b400-fb6f04837791"><ix:nonFraction unitRef="shares" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzAtMC0xLTEtMjUxMi90ZXh0cmVnaW9uOmIxOGYxMWM5YWIxYTRiMjI5ZTVmMmY5N2M4OGUwNjUwXzEwOTk1MTE2Mjc4ODg_f32801b3-dbda-4074-a2d1-49a82d20a81a">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzAtMi0xLTEtMA_f1b9c80b-845a-4d1d-a3e9-ee2416e64a8b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzAtNC0xLTEtMA_76a63a28-7b39-4e4d-aefa-ed9cca664ab1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i6e1705cc437a4623985876b0a6850cd4_I20190331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmZhNDU1NmM2YTFkZTRlMWM5NWE2OWI2MjIxZGY4NDRhXzEwOTk1MTE2Mjc4OTA_70f4657f-5b3d-4ff6-ae20-83f7780e2e60"><ix:nonFraction unitRef="usdPerShare" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmZhNDU1NmM2YTFkZTRlMWM5NWE2OWI2MjIxZGY4NDRhXzEwOTk1MTE2Mjc4OTA_94e6d1f7-fec6-410c-9fe2-1d5045d69e3f">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i6e1705cc437a4623985876b0a6850cd4_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmZhNDU1NmM2YTFkZTRlMWM5NWE2OWI2MjIxZGY4NDRhXzEwOTk1MTE2Mjc5MDA_71d3a7a3-9087-43bb-aa6b-2b174b8c68e7"><ix:nonFraction unitRef="shares" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmZhNDU1NmM2YTFkZTRlMWM5NWE2OWI2MjIxZGY4NDRhXzEwOTk1MTE2Mjc5MDA_cc78fe79-e278-4017-9149-31052455dc59">225,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmZhNDU1NmM2YTFkZTRlMWM5NWE2OWI2MjIxZGY4NDRhXzEwOTk1MTE2Mjc5MDk_5055e18e-ffbc-4e4a-b904-4b0326142c0d">107,711</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i6e1705cc437a4623985876b0a6850cd4_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmZhNDU1NmM2YTFkZTRlMWM5NWE2OWI2MjIxZGY4NDRhXzEwOTk1MTE2Mjc5MTg_fe7c9c68-0e32-48c1-bf0f-c1b5fd604c7a">106,679</ix:nonFraction> shares issued, respectively</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzEtMi0xLTEtMA_dee62d2c-52c1-430f-a7df-44b493f28014">108</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzEtNC0xLTEtMA_bd2ea142-8598-4146-b1f6-a1e41caa94a5">106</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional paid-in capital</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzItMi0xLTEtMA_f301a9ec-ec60-4d13-8942-37e545133bb3">1,466,604</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzItNC0xLTEtMA_73ce01a5-2585-414b-8098-42da147cfda8">1,462,172</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated deficit</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzMtMi0xLTEtMA_d4dbf238-9f17-450f-83d0-30bf45f13497">1,408,055</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzMtNC0xLTEtMA_a9589ae4-474a-46b0-92aa-953a0186a85b">1,341,444</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzQtMi0xLTEtMA_ee649ae7-0998-48ff-97b7-5634c658a3a4">860</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzQtNC0xLTEtMA_c0bc4462-b968-4965-93bb-2299b69c5022">84</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Treasury stock, at cost, <ix:nonFraction unitRef="shares" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="-3" name="us-gaap:TreasuryStockShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjQ4OGMxMDNkN2NkODQyYTVhNjc3YjAzMjg3YTlmNmY0XzEwOTk1MTE2Mjc4NDA_f884ba01-ac08-452c-8968-410dc58a697d">741</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i6e1705cc437a4623985876b0a6850cd4_I20190331" decimals="-3" name="us-gaap:TreasuryStockShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjQ4OGMxMDNkN2NkODQyYTVhNjc3YjAzMjg3YTlmNmY0XzEwOTk1MTE2Mjc4NDU_94d166fb-95fd-4ee0-83e1-bd8e7b912548">407</ix:nonFraction> shares, respectively</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzUtMi0xLTEtMA_d9ac5401-5100-4a52-a57d-3f29101b7582">4,740</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzUtNC0xLTEtMA_6271097f-ea77-460c-8fe1-d8ce5792f19e">3,817</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzYtMi0xLTEtMA_6dbcd67b-1d96-40d4-be23-a417626f45f9">54,777</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzYtNC0xLTEtMA_6acdf108-34be-40e4-a808-3471881906b9">117,101</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities and equity</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzctMi0xLTEtMA_fb03cded-d57d-4a6f-bd7f-e069de3a7500">370,567</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzctNC0xLTEtMA_1693783b-e3af-4848-be27-10f2b3255eda">417,715</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3</span></div><div style="text-align:center;"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div id="i4e8a6d84e5e241588399a0cfd4660c18_25"></div><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Statements of Comprehensive Loss</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(In thousands, except per share amounts)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:79.385%;"><tr><td style="width:1.0%;"></td><td style="width:71.664%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.720%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.786%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.720%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.786%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.724%;"></td><td style="width:0.1%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net product revenue</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="lxrx:Netproductrevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfMy0yLTEtMS0w_f631b02d-bbfb-41a1-8706-6df4350b75cf">7,877</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="lxrx:Netproductrevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfMy00LTEtMS0w_77714aae-fa66-42a0-9719-cc4c6f692cdd">6,740</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Collaborative agreements</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfNC0yLTEtMS0w_460dbade-964f-4dfa-a72a-67367cdfe49d">8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfNC00LTEtMS0w_a3b1d1ea-c190-422c-9657-2c1dc1669d65">2,439</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Royalties and other revenue</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" decimals="-3" name="us-gaap:RoyaltyIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfNS0yLTEtMS0w_48c8d54f-7ae7-425f-88e0-12955cfac74e">114</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331" decimals="-3" name="us-gaap:RoyaltyIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfNS00LTEtMS0w_d4bce01d-4e76-4b8c-a009-469956003735">37</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfNi0yLTEtMS0w_6e1ee496-6ab9-40d6-bdcd-bb16c1b59153">7,999</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfNi00LTEtMS0w_e1111dbb-bd01-4747-97cf-9d32c9f9f606">9,216</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-18pt;padding-left:29.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Cost of sales (including finite-lived intangible asset amortization)</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfOC0yLTEtMS0w_df4be9f3-dc18-45e0-a658-73442523be62">568</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfOC00LTEtMS0w_12d0c3a3-58ae-466e-8f92-905929338577">553</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:29.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Research and development, including stock-based compensation of $<ix:nonFraction unitRef="usd" contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfOS0wLTEtMS0wL3RleHRyZWdpb246NjVlN2U2NjlhNDhiNGU2MWE3NTQyYTNlYjhmOGVmYWVfMTA5OTUxMTYyNzg4MQ_a56f6a6c-6091-41d5-a48f-9bb5dd770ca1">2,176</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfOS0wLTEtMS0wL3RleHRyZWdpb246NjVlN2U2NjlhNDhiNGU2MWE3NTQyYTNlYjhmOGVmYWVfMTA5OTUxMTYyNzg5MA_4baa3628-931a-40ae-8cd4-d7851c87400b">1,768</ix:nonFraction>, respectively</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfOS0yLTEtMS0w_c65413a8-0b86-4951-9fc4-130caa88ca6e">55,181</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfOS00LTEtMS0w_06004b37-390d-46e6-8c4b-0aa02b51142c">12,022</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:29.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Selling, general and administrative, including stock-based compensation of $<ix:nonFraction unitRef="usd" contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="lxrx:Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfMTEtMC0xLTEtMC90ZXh0cmVnaW9uOjE4MDQxNDA1ZDg3YjQ3OGY5NWFmNzliMjg1YTc5MmJiXzEwOTk1MTE2Mjc4OTI_c3c947d4-9a32-4e43-85d5-7a57d6bdaa2c">2,256</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="lxrx:Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfMTEtMC0xLTEtMC90ZXh0cmVnaW9uOjE4MDQxNDA1ZDg3YjQ3OGY5NWFmNzliMjg1YTc5MmJiXzEwOTk1MTE2Mjc5MDE_34d16177-059b-42f4-b640-4a211b1d01ac">1,643</ix:nonFraction>, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="lxrx:Sellinggeneralandadministrativeexpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfMTEtMi0xLTEtMA_30de8d93-5d0d-4e28-ac9a-c11442451668">14,688</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="lxrx:Sellinggeneralandadministrativeexpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfMTEtNC0xLTEtMA_5de6819b-e7b3-407d-876e-cafe06d6097c">14,110</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfMTMtMi0xLTEtMA_6c0229f0-5b5a-4280-9ee7-3a50063a79b3">70,437</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfMTMtNC0xLTEtMA_559bdcaa-0696-42a1-a8b9-4def9e2136d2">26,685</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfMTQtMi0xLTEtMA_af368696-08ac-414f-8e03-23636fa4649a">62,438</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfMTQtNC0xLTEtMA_f5486c51-995c-4730-b644-5ed14fed9773">17,469</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfMTYtMi0xLTEtMA_f5479ddd-433e-4c2f-be61-c6bbcb7f11de">5,131</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfMTYtNC0xLTEtMA_2c6cc2cd-3539-4a8a-a22b-6828112e70ec">5,117</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest and other income, net</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfMTctMi0xLTEtMA_92889f34-e875-4d48-8c0a-305cc7f4750c">958</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfMTctNC0xLTEtMA_8e0d828b-8289-48ea-b7ee-8f6fd4278e2e">789</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfMjAtMi0xLTEtMA_3cfa9bad-625f-4ba4-a7dd-22350909857a">66,611</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfMjAtNC0xLTEtMA_846c77e1-e40d-43e8-b864-89650a48e40c">21,797</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss per common share, basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfMjEtMi0xLTEtMA_65291304-4a93-48ad-aaea-0af9f1f6b4b8">0.63</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfMjEtNC0xLTEtMA_d311b46a-b756-488b-966a-ce910125bae7">0.21</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-18pt;padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Shares used in computing net loss per common share, basic and diluted</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfMjQtMi0xLTEtMA_266adef1-31eb-4825-a225-16a2e0c3ca81">106,536</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfMjQtNC0xLTEtMA_76015721-7d0b-4d79-93a6-461e28fc51c7">106,054</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-18pt;padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Other comprehensive loss:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-18pt;padding-left:29.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Unrealized gain on investments</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfMjgtMi0xLTEtMA_6422c48b-eff7-425e-a94d-e4eb08d676fe">776</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfMjgtNC0xLTEtMA_d78fbb2e-2469-43b4-b489-ef2c10e839b1">45</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-18pt;padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Comprehensive loss</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfMjktMi0xLTEtMA_a863fa24-3582-45cd-b833-37e12ea18bfc">65,835</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfMjktNC0xLTEtMA_359a4abd-2635-49e7-8bbd-5902e8e0b39e">21,752</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4</span></div><div style="text-align:center;"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div id="i4e8a6d84e5e241588399a0cfd4660c18_31"></div><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Statements of Stockholders&#8217; Equity (Deficit)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(In thousands)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.593%;"><tr><td style="width:1.0%;"></td><td style="width:41.468%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.348%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:4.256%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.348%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:3.378%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.348%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.013%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.348%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.659%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.348%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.769%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.348%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:4.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.348%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:4.926%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Other</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Par Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Paid-In Capital</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Deficit</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Comprehensive Gain (Loss)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Treasury Stock</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia7a2afb94e3d47888a4f5fb5cbad1728_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfMi0yLTEtMS0xODY4_190af5a5-3d91-4045-be66-d5c701b6dae1">106,162</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia7a2afb94e3d47888a4f5fb5cbad1728_I20181231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfMi00LTEtMS0xODY4_286bad70-403b-4388-a13e-a47fb5043827">106</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4d1fdae96a904b22b9d37b0de77588fb_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfMi02LTEtMS0xODY4_f0b6ebe5-3866-471c-aefd-f26dc79f6d47">1,447,954</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6bd9c5bf42c248cd9bf25b6dea04bd1a_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfMi04LTEtMS0xODY4_e754f991-b06d-4a65-a174-99d9e0a7b9b9">1,471,577</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7bc51fbc5bfc475ea508dad359524362_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfMi0xMC0xLTEtMTg2OA_665dd37b-a47d-48e2-80b1-06f15dab7da1">12</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5b7022476157494398816b99471e0697_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfMi0xMi0xLTEtMTg2OA_6960d531-ce41-4e73-aa16-ae8493ca3c7f">2,876</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifb01c97139de4c7da87be444c5833141_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfMi0xNC0xLTEtMTg2OA_d5d5b785-1779-4421-8b09-f844d5c522a6">26,405</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb21aab8fb742a4b472651ad313d600_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfNS00LTEtMS0xODY4_a14645aa-120a-41e6-9cf5-df1be37615be">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie9b975fc81164d7cbff5a2763c95ef28_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfNS02LTEtMS0xODY4_661f6963-a699-4cbe-bbc3-1c3ac2ca8819">3,411</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa015c4922754b5d91743371bfe8a576_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfNS04LTEtMS0xODY4_cb89294c-60f2-42d9-9493-59e4f724685f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib455b101c4484d4c8d9f69a783226edd_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfNS0xMC0xLTEtMTg2OA_9f9b7195-7bf2-4923-9df8-00154ccec4ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9a9b6cf9115b4d328637e78789aa34f1_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfNS0xMi0xLTEtMTg2OA_21f91f43-2a78-4517-ad33-dbfd92c6b8f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfNS0xNC0xLTEtMTg2OA_f4b13187-4367-42e3-9f34-b4d72c30103f">3,411</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock under Equity Incentive Plans</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ibcb21aab8fb742a4b472651ad313d600_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfNi0yLTEtMS0xODY4_084008e1-2407-475a-ac12-c9ec42135243">517</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb21aab8fb742a4b472651ad313d600_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfNi00LTEtMS0xODY4_00896b00-0079-4d8b-b513-cee2c0250278">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie9b975fc81164d7cbff5a2763c95ef28_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfNi02LTEtMS0xODY4_ec3b7bde-796d-4a1c-a79a-e5be2ba5c858">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa015c4922754b5d91743371bfe8a576_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfNi04LTEtMS0xODY4_4ec62a80-8a57-4b1f-b6da-b1a3d0ecc8ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib455b101c4484d4c8d9f69a783226edd_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfNi0xMC0xLTEtMTg2OA_eaae4370-b498-4174-867d-f6ed07391a65">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9a9b6cf9115b4d328637e78789aa34f1_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfNi0xMi0xLTEtMTg2OA_aa74fd8c-d253-4d33-a0a9-5f6163ff00bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfNi0xNC0xLTEtMTg2OA_395916b2-3df9-44f5-a454-20ba0da0c51a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Repurchase of common stock</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb21aab8fb742a4b472651ad313d600_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfOC00LTEtMS0xODY4_dcbe4b55-8bc4-46c7-9ac6-b6f8ad4de291">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie9b975fc81164d7cbff5a2763c95ef28_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfOC02LTEtMS0xODY4_7a8cf25b-8688-4ba9-ad98-37e08f9d1067">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa015c4922754b5d91743371bfe8a576_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfOC04LTEtMS0xODY4_58c77f0d-cf3e-4371-b775-9119fc574eb1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib455b101c4484d4c8d9f69a783226edd_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfOC0xMC0xLTEtMTg2OA_5257743a-1c30-471d-bfbd-850b5a450353">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9a9b6cf9115b4d328637e78789aa34f1_D20190101-20190331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfOC0xMi0xLTEtMTg2OA_1e52387a-070f-46b1-8515-3d5d59a5d85e">941</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfOC0xNC0xLTEtMTg2OA_447fbdfc-b2d3-4836-aee6-73a49f44fab0">941</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb21aab8fb742a4b472651ad313d600_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfOS00LTEtMS0xODY4_f11bf1eb-4860-4c43-9b5c-f9e81f7604d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie9b975fc81164d7cbff5a2763c95ef28_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfOS02LTEtMS0xODY4_f89cc261-25c6-4dda-b3f4-c9fefa7ac7e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifa015c4922754b5d91743371bfe8a576_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfOS04LTEtMS0xODY4_9710988d-3b8a-4da3-b7bd-f8a389cb8948">21,797</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib455b101c4484d4c8d9f69a783226edd_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfOS0xMC0xLTEtMTg2OA_6edb9789-1159-4c62-a8e4-44380203d894">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9a9b6cf9115b4d328637e78789aa34f1_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfOS0xMi0xLTEtMTg2OA_43f9de6b-4f18-4463-989e-66e41281c4b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifa015c4922754b5d91743371bfe8a576_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfOS0xNC0xLTEtMTg2OA_5b6dd330-2a3d-45a3-b1cd-df611c4a125a">21,797</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized gain on investments</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb21aab8fb742a4b472651ad313d600_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfMTAtNC0xLTEtMTg2OA_3500cea9-5f86-49f4-a96a-09b8d9ba0657">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie9b975fc81164d7cbff5a2763c95ef28_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfMTAtNi0xLTEtMTg2OA_134d36be-be2c-446c-a833-a4e0ac1a05bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa015c4922754b5d91743371bfe8a576_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfMTAtOC0xLTEtMTg2OA_928a5684-aa51-4f9c-bec6-204cfbf100ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib455b101c4484d4c8d9f69a783226edd_D20190101-20190331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfMTAtMTAtMS0xLTE4Njg_559d5605-bef0-4201-8ad9-a632cb2ab628">45</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9a9b6cf9115b4d328637e78789aa34f1_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfMTAtMTItMS0xLTE4Njg_f6513c8b-dcfe-461c-ad1a-9f71c59bdc13">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfMTAtMTQtMS0xLTE4Njg_0fbbbed0-1960-47ea-94aa-ff05d10fcdb4">45</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at March 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if43ffe172d1f4c68b5844235ee4289f7_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfMTItMi0xLTEtMTg2OA_b40137ea-6327-4947-b9cc-a35d5c4b2465">106,679</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if43ffe172d1f4c68b5844235ee4289f7_I20190331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfMTItNC0xLTEtMTg2OA_25d598b2-b919-474b-b33e-7b54ec98f96b">106</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f6a44ebc0994be5a7cef652c7d2857e_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfMTItNi0xLTEtMTg2OA_f0aa1725-092f-411b-abc3-b4fa09aef006">1,451,365</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6910b93f33e4481fb289ea612c84f3ae_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfMTItOC0xLTEtMTg2OA_d3a6202d-4f98-4e3e-84b5-058afceb35b2">1,493,374</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i593c8c0affe34641adbf79593094ac0b_I20190331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfMTItMTAtMS0xLTE4Njg_505984e7-3cee-4f35-8ee5-ab702f7b885e">33</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie255744bc9f3477ba151d4eaa2718fe1_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfMTItMTItMS0xLTE4Njg_3849ed20-ead9-4e26-9d3f-74b46d7579ef">3,817</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6e1705cc437a4623985876b0a6850cd4_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfMTItMTQtMS0xLTE4Njg_6b685ef7-0981-45d2-97bf-d78aeec3304f">45,687</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.917%;"><tr><td style="width:1.0%;"></td><td style="width:41.326%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.347%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:4.564%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.347%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:3.361%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.347%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.986%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.347%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.628%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.347%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.347%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:4.673%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.347%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:4.896%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if2014f01922b408fa97848ffdeb88941_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfMi0yLTEtMS0w_bf4f3ff0-875d-4073-aa4a-5d02b474b098">106,679</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if2014f01922b408fa97848ffdeb88941_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfMi00LTEtMS0w_1e516a6a-74a7-410e-8fe0-ba099aca1b5f">106</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iba79016389514c5ebe72f001f7acf420_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfMi02LTEtMS0w_ca83e4b9-d147-4446-af92-487668bc009a">1,462,172</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia1a8986ec8894a469fbd46f3df2dc202_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfMi04LTEtMS0w_06cf67f6-7822-458d-89a0-a9a1c46e7e5e">1,341,444</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2c9621fa321f4e9195d6603061f89e2f_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfMi0xMC0xLTEtMA_aad4fc2d-84c9-4680-96f9-4f9b27010402">84</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i846c9d455edf4f1cb3d7646d362b3a11_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfMi0xMi0xLTEtMA_71fe86e3-695c-4519-ae6e-cfc7d6a94072">3,817</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfMi0xNC0xLTEtMA_adcd153d-47ff-4da1-9a2a-5c06a65974d7">117,101</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1112901d3eee474b98585e70b151f858_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfNC00LTEtMS0w_3b690daa-d54f-4ccd-a0a7-26746570c5b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3d8f640e99d948e59de6f191b2509423_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfNC02LTEtMS0w_4b68d85b-7bc9-4db4-a244-9322de10daf5">4,432</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f1459fd243c427791a12f208909ef19_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfNC04LTEtMS0w_e823b55b-f446-4b10-bce4-0306109d6035">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie225ba400e5842d2896152f546aedab5_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfNC0xMC0xLTEtMA_0565faf0-e1eb-4f8e-8439-9ea991ec7c21">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaac8e8918b3b48de8027ed5b977e799b_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfNC0xMi0xLTEtMA_d8ad0fe8-5aa6-4c72-960b-720557e100e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfNC0xNC0xLTEtMA_0f09821c-4cf4-4499-8dba-57deaa0946dd">4,432</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock under Equity Incentive Plans</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1112901d3eee474b98585e70b151f858_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfNS0yLTEtMS0w_b756c506-17f1-47ca-8b6b-8071bb71be8b">1,032</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1112901d3eee474b98585e70b151f858_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfNS00LTEtMS0w_a2297fc8-c035-4bfe-a7f1-99af85d877af">2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3d8f640e99d948e59de6f191b2509423_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfNS02LTEtMS0w_d43f4228-1b54-47d5-b853-d14c9368e7f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f1459fd243c427791a12f208909ef19_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfNS04LTEtMS0w_27694e58-ddfa-45ca-a2ec-2df5886b5ec3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie225ba400e5842d2896152f546aedab5_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfNS0xMC0xLTEtMA_fa7e1749-0dd7-4de0-b047-54da3d1447b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaac8e8918b3b48de8027ed5b977e799b_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfNS0xMi0xLTEtMA_3e2607d5-00f9-4118-967f-a6f840167e28">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfNS0xNC0xLTEtMA_23e4831a-68e2-4570-8429-79e6384e813d">2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Repurchase of common stock</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1112901d3eee474b98585e70b151f858_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfNy00LTEtMS0w_47d4bc40-e118-4565-b5a3-4c6b587a9045">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3d8f640e99d948e59de6f191b2509423_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfNy02LTEtMS0w_7d2dd6fd-ace0-4ec7-8c00-375f64906304">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f1459fd243c427791a12f208909ef19_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfNy04LTEtMS0w_fd9ea4ea-f699-49e4-bf93-a467c3bfe306">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie225ba400e5842d2896152f546aedab5_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfNy0xMC0xLTEtMA_de7899f8-be26-4d52-88ac-0f9eedb9afeb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaac8e8918b3b48de8027ed5b977e799b_D20200101-20200331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfNy0xMi0xLTEtMA_2478d44c-8dd9-4308-a2fd-10621fc60665">923</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfNy0xNC0xLTEtMA_99b53118-46be-4661-a065-8157ce3b325c">923</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1112901d3eee474b98585e70b151f858_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfOC00LTEtMS0w_19534256-5605-4afd-9fe5-48f4e0c57e93">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3d8f640e99d948e59de6f191b2509423_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfOC02LTEtMS0w_e6f9dfc7-b76c-431e-90d0-996f961cb692">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8f1459fd243c427791a12f208909ef19_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfOC04LTEtMS0w_1d7ed101-b715-47b7-9a76-10161fc91cb5">66,611</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie225ba400e5842d2896152f546aedab5_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfOC0xMC0xLTEtMA_8b9e95c6-d5c9-4ff7-bb45-8d009b8faa3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaac8e8918b3b48de8027ed5b977e799b_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfOC0xMi0xLTEtMA_860a2528-86ca-46d2-b042-804af66e6d04">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8f1459fd243c427791a12f208909ef19_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfOC0xNC0xLTEtMA_5ccbb156-42e6-48a4-8ced-a13bfb3ee154">66,611</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized gain on investments</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1112901d3eee474b98585e70b151f858_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfOS00LTEtMS0w_b2c3304d-1ac2-4092-8926-55b6249e5aa8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3d8f640e99d948e59de6f191b2509423_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfOS02LTEtMS0w_26441351-f23a-4fa1-a1ef-f589ed296bf3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f1459fd243c427791a12f208909ef19_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfOS04LTEtMS0w_101e1089-93c9-4bd9-9ce8-ae5035d8df57">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie225ba400e5842d2896152f546aedab5_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfOS0xMC0xLTEtMA_00bfb920-4133-4cd6-a3a7-5ccfb7f7c474">776</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaac8e8918b3b48de8027ed5b977e799b_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfOS0xMi0xLTEtMA_8bcca751-91aa-49e9-8add-b9bd14bc1cad">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfOS0xNC0xLTEtMA_59b03450-d98e-4997-804b-5c034774c28c">776</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at March 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4f1cd0ed4c754265b45c85c1bc69396f_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfMTEtMi0xLTEtMA_407658d8-3d14-43f8-bf15-6d2f0f4d4cc5">107,711</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4f1cd0ed4c754265b45c85c1bc69396f_I20200331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfMTEtNC0xLTEtMA_d344a527-4320-4f88-bb9a-264f76a006f3">108</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if4f4eb4f717648a1807ac159d3543e2c_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfMTEtNi0xLTEtMA_5acd83ac-62c4-462f-b37a-a6b207275bf4">1,466,604</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3daccec285f3488c8d44f5dc7865d44e_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfMTEtOC0xLTEtMA_43b03278-b4f7-4f0d-8b5d-46c74ad82244">1,408,055</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92dc246d5c4e4b13a56fd11a7345454e_I20200331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfMTEtMTAtMS0xLTA_472f0ec0-1269-4b42-908a-cdd868aaa621">860</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9cd8c8c5263c421b8fa978b95f7cd714_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfMTEtMTItMS0xLTA_134d19de-fe2d-4086-83b4-86f8fb2f6984">4,740</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfMTEtMTQtMS0xLTA_fc2b59b2-6b39-44a2-9575-694cf950865a">54,777</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="text-align:center;"><span><br/></span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5</span></div><div style="text-align:center;"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div id="i4e8a6d84e5e241588399a0cfd4660c18_34"></div><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(In thousands)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:72.449%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.894%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.189%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from operating activities:&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMy0yLTEtMS0w_3252e041-f837-46a5-9669-bc200c25a663">66,611</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMy00LTEtMS0w_8982abbb-0d7c-4afa-9b5b-7718d3a80b7b">21,797</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments to reconcile net loss to net cash used in operating activities:&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfNS0yLTEtMS0w_64204879-17d3-4644-9dfd-20a9e89a2366">906</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfNS00LTEtMS0w_92891195-f077-4957-a9b0-857399797fd2">901</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfNy0yLTEtMS0w_2bc11876-53df-4491-8074-23be18bcbb9f">4,432</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfNy00LTEtMS0w_01c78543-80be-48d7-b835-500444363282">3,411</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of debt issuance costs&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfOC0yLTEtMS0w_55c92998-3cc8-4ad7-ada9-ba2ff1176237">362</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfOC00LTEtMS0w_a4cd6a63-a8da-4384-8465-02fe3342f8ed">346</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Changes in operating assets and liabilities:&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Decrease in accounts receivable&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMTItMi0xLTEtMA_24a6707a-7814-4338-b5a5-2f9a7eaad61f">26,397</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMTItNC0xLTEtMA_545a1cfe-fb8b-43f0-91c6-1f8e393a72e0">1,534</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Decrease in inventory&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMTMtMi0xLTEtMA_67262b3f-04b3-4a75-ad77-44ef68077513">96</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMTMtNC0xLTEtMA_cf5132b1-1122-4aea-81c6-4070b1c0cb27">74</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Increase in prepaid expenses and other current assets&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMTQtMi0xLTEtMA_e2b5ec9b-7870-4880-b226-651423c49d7c">2,875</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMTQtNC0xLTEtMA_05f00341-8bce-40b4-ba58-ea47875b03e4">2,018</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Decrease in other assets&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMTUtMi0xLTEtMA_cc77c298-0bd5-4fa4-af10-1156077a9b7a">102</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMTUtNC0xLTEtMA_4b896e64-43c9-49f6-834f-1bc479463932">91</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Increase (decrease) in accounts payable and other liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMTYtMi0xLTEtMA_154f4b54-bd9f-430f-b154-3cd5e0b88ea7">15,137</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMTYtNC0xLTEtMA_2ee8f2cc-ab5d-4896-9db3-b00caa5389b3">8,171</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Increase in deferred revenue&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMTctMi0xLTEtMA_0b1a1537-fa0e-4f55-be0c-4c1439ef3674">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMTctNC0xLTEtMA_79325fd0-649c-49a9-93e5-51c69ef5ffc3">9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:47.25pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in operating activities&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMTgtMi0xLTEtMA_1ec9bad0-68d5-46f9-9271-23d88d098818">22,054</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMTgtNC0xLTEtMA_55e6b6a2-fb23-41fc-8efa-b08186c8223c">25,620</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from investing activities:&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of property and equipment&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMjAtMi0xLTEtMA_711ce673-b449-4de5-bf3a-d7c6a1577dd8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMjAtNC0xLTEtMA_c7e37486-21b9-4a46-8860-d3374576a6f6">70</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of investments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMjItMi0xLTEtMA_4e47380e-9ac2-4340-8d87-8dd5f22622cb">33,222</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMjItNC0xLTEtMA_902b4aef-a7c9-4f90-bd6b-f48b41f0f112">87,256</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Maturities of investments</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMjMtMi0xLTEtMA_c955c724-c56c-4098-baa3-22fe821176e0">76,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMjMtNC0xLTEtMA_0bed98c4-fa5c-4f78-a5af-bc0941eeb9a9">79,600</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by (used in) investing activities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMjQtMi0xLTEtMA_b1001308-ba9c-473b-b67e-e80dea296a55">42,778</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMjQtNC0xLTEtMA_fe973dd0-4b1c-4706-956a-1a42c8ba1f5d">7,726</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from financing activities:&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Repurchase of common stock&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMjctMi0xLTEtMA_b96e5557-cf22-454e-bce3-72342c530cd7">923</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMjctNC0xLTEtMA_85caca17-9d30-4a43-9cd1-91b5bd7cec33">941</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Repayment of debt borrowings&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMjktMi0xLTEtMA_404ba0c2-4a42-4f15-a88b-c28f2ab5c45d">321</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMjktNC0xLTEtMA_c30485a8-7e41-418d-bb65-adb64941b691">321</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:47.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in financing activities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMzEtMi0xLTEtMA_d9a14b92-d398-433f-852f-447d6c64182b">1,244</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMzEtNC0xLTEtMA_f7eb2a0e-14bb-4a34-9e47-d14de30ee820">1,262</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net increase (decrease) in cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMzItMi0xLTEtMA_46be6666-13d2-47f3-8a41-6fafaf18fd0a">19,480</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMzItNC0xLTEtMA_c38d75e8-f137-4c45-9a5c-0ba6dbed34e2">34,608</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents at beginning of period&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMzMtMi0xLTEtMA_07bd24d0-453d-4396-80be-9153bd6fd3ef">36,112</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifb01c97139de4c7da87be444c5833141_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMzMtNC0xLTEtMA_b086110d-7a57-4008-9971-47a67e61bb4d">80,386</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents at end of period&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMzQtMi0xLTEtMA_2161500a-5835-43b7-aee7-8ada7bd9e110">55,592</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6e1705cc437a4623985876b0a6850cd4_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMzQtNC0xLTEtMA_f17af563-4fd3-4824-a9db-8e01b0e24bd4">45,778</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Supplemental disclosure of cash flow information:&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid for interest&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMzctMi0xLTEtMA_2fc63cc1-348a-437b-a152-7ed8a8fd1339">3,658</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMzctNC0xLTEtMA_37c0d2fc-53fd-421b-a6e0-6e78c26b7f3c">3,698</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">6</span></div><div style="text-align:center;"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div id="i4e8a6d84e5e241588399a0cfd4660c18_37"></div><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i4e8a6d84e5e241588399a0cfd4660c18_40"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RleHRyZWdpb246MDkyOWE5NjdiMTAwNDI5ZmIzOTljZGJkMWVhNTQxNTlfMTc4NzI_8c495c6d-ada6-4e21-9411-716913d0a105" continuedAt="i3c2d9dbb5c624ed882b379eb630a0e20" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i3c2d9dbb5c624ed882b379eb630a0e20" continuedAt="i7ec3b575cd944c41ba3b98e2f197c32f"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Basis of Presentation:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The accompanying unaudited condensed consolidated financial statements of Lexicon Pharmaceuticals, Inc. (&#8220;Lexicon&#8221; or the &#8220;Company&#8221;) have been prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three-month period ended March&#160;31, 2020 are not necessarily indicative of the results that may be expected for the year ended December&#160;31, 2020.</span></div><div style="text-indent:36pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RleHRyZWdpb246MDkyOWE5NjdiMTAwNDI5ZmIzOTljZGJkMWVhNTQxNTlfMTc5NDc_6d0a56d7-0ee1-4e4d-b4b1-ffb1835500c3" escape="true">The accompanying condensed consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries. Intercompany transactions and balances are eliminated in consolidation.</ix:nonNumeric></span></div><div style="text-indent:36pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For further information, refer to the financial statements and footnotes thereto included in Lexicon&#8217;s annual report on Form 10-K for the year ended December&#160;31, 2019, as filed with the SEC.&#160;</span></div><div style="text-indent:36pt;"><ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RleHRyZWdpb246MDkyOWE5NjdiMTAwNDI5ZmIzOTljZGJkMWVhNTQxNTlfMTc4OTY_f2f34036-63f9-46ae-b309-5004f4b03245" escape="true"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Use of Estimates:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The preparation of financial statements in conformity with U. S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</span></ix:nonNumeric></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RleHRyZWdpb246MDkyOWE5NjdiMTAwNDI5ZmIzOTljZGJkMWVhNTQxNTlfMTc5MzM_0be67a7d-56ce-4e91-9909-5293f0600d23" escape="true"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cash, Cash Equivalents and Short-Term Investments:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of March&#160;31, 2020 and December&#160;31, 2019, short-term investments consisted of U.S. treasury bills.  The Company&#8217;s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security.&#160;&#160;Unrealized gains and losses on such securities are reported as a separate component of stockholders&#8217; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.</span></ix:nonNumeric></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RleHRyZWdpb246MDkyOWE5NjdiMTAwNDI5ZmIzOTljZGJkMWVhNTQxNTlfMTc4ODM_f15338eb-3a05-438a-9e64-2df87765a5c0" escape="true"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Accounts Receivable:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;Lexicon records trade accounts receivable in the normal course of business related to the sale of products or services, net of an allowance for expected credit losses.</span></ix:nonNumeric></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RleHRyZWdpb246MDkyOWE5NjdiMTAwNDI5ZmIzOTljZGJkMWVhNTQxNTlfMTc4ODQ_ce351c3b-b2f4-4a5d-a29b-e6900342d046" continuedAt="iae65161633104e1a84d68ad60dfbb68c" escape="true"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Inventory: </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Inventory is comprised of the Company&#8217;s approved product it is commercializing in the United States, XERMELO</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174; </sup></ix:nonNumeric><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="iae65161633104e1a84d68ad60dfbb68c">(telotristat ethyl).  Inventories are determined at the lower of cost or market value with cost determined under the specific identification method and may consist of raw materials, work in process and finished goods.</ix:continuation> Inventory consisted of the following:</span></div><div style="text-align:center;margin-bottom:6pt;"><ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" name="us-gaap:InventoryMajorClassesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RleHRyZWdpb246MDkyOWE5NjdiMTAwNDI5ZmIzOTljZGJkMWVhNTQxNTlfMTc5Mjk_8f785e75-c0ab-4154-be93-fe1041a56635" escape="true"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:82.163%;"><tr><td style="width:1.0%;"></td><td style="width:51.380%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.689%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:19.886%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.757%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:19.888%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of March 31,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31,</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterials" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOmY2NjU0OWE0ZTNjMzQ2NDY5OWU1ZDcwMDQwNWU4YTQ0L3RhYmxlcmFuZ2U6ZjY2NTQ5YTRlM2MzNDY0Njk5ZTVkNzAwNDA1ZThhNDRfMy0yLTEtMS0w_ad719df1-43df-4e62-a2b9-2fe30fe6bfb4">2,218</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterials" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOmY2NjU0OWE0ZTNjMzQ2NDY5OWU1ZDcwMDQwNWU4YTQ0L3RhYmxlcmFuZ2U6ZjY2NTQ5YTRlM2MzNDY0Njk5ZTVkNzAwNDA1ZThhNDRfMy00LTEtMS0w_23794b2d-3521-40bb-bcde-794dd1639a3e">3,182</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Work-in-process</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOmY2NjU0OWE0ZTNjMzQ2NDY5OWU1ZDcwMDQwNWU4YTQ0L3RhYmxlcmFuZ2U6ZjY2NTQ5YTRlM2MzNDY0Njk5ZTVkNzAwNDA1ZThhNDRfNC0yLTEtMS0w_4aabdb6f-1d61-4e99-9161-6af108cd84b4">1,117</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231" decimals="0" name="us-gaap:InventoryWorkInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOmY2NjU0OWE0ZTNjMzQ2NDY5OWU1ZDcwMDQwNWU4YTQ0L3RhYmxlcmFuZ2U6ZjY2NTQ5YTRlM2MzNDY0Njk5ZTVkNzAwNDA1ZThhNDRfNC00LTEtMS0w_75da5ad9-abf2-44f3-a526-73de3af5fcd3">153</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOmY2NjU0OWE0ZTNjMzQ2NDY5OWU1ZDcwMDQwNWU4YTQ0L3RhYmxlcmFuZ2U6ZjY2NTQ5YTRlM2MzNDY0Njk5ZTVkNzAwNDA1ZThhNDRfNS0yLTEtMS0w_c1d6a042-2ef1-42c4-8c26-52465cf7bcfa">812</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231" decimals="-3" name="us-gaap:InventoryFinishedGoods" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOmY2NjU0OWE0ZTNjMzQ2NDY5OWU1ZDcwMDQwNWU4YTQ0L3RhYmxlcmFuZ2U6ZjY2NTQ5YTRlM2MzNDY0Njk5ZTVkNzAwNDA1ZThhNDRfNS00LTEtMS0w_1ac80397-bd65-4dcf-ac5c-429be1dc89a5">908</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventory</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOmY2NjU0OWE0ZTNjMzQ2NDY5OWU1ZDcwMDQwNWU4YTQ0L3RhYmxlcmFuZ2U6ZjY2NTQ5YTRlM2MzNDY0Njk5ZTVkNzAwNDA1ZThhNDRfNi0yLTEtMS0w_de53ccb2-9e9c-4c51-929b-ddbc8acffbab">4,147</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOmY2NjU0OWE0ZTNjMzQ2NDY5OWU1ZDcwMDQwNWU4YTQ0L3RhYmxlcmFuZ2U6ZjY2NTQ5YTRlM2MzNDY0Njk5ZTVkNzAwNDA1ZThhNDRfNi00LTEtMS0w_025aa42a-dd61-4975-9f59-0bcf1c0b89c4">4,243</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:nonNumeric></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">7</span></div><div style="text-align:center;"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;"><span><br/></span></div><ix:continuation id="i7ec3b575cd944c41ba3b98e2f197c32f" continuedAt="ifc9f2aae143c43c2a3ff748d07d626ea"><ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RleHRyZWdpb246MDkyOWE5NjdiMTAwNDI5ZmIzOTljZGJkMWVhNTQxNTlfMTc5MTA_123f812b-16b7-4807-9b40-d5ce58474a2a" continuedAt="i14742bd3c41a4680872547b9be586a7f" escape="true"><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue Recognition:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Product Revenues</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Product revenues consist of commercial sales of XERMELO in the United States and sales of bulk tablets of XERMELO to Ipsen Pharma SAS (&#8220;Ipsen&#8221;).  Product revenues are recognized when the customer obtains control of the Company&#8217;s product, which occurs upon delivery to the customer.  The Company recognizes product revenue net of applicable reserves for variable consideration, including allowances for customer credits, estimated rebates, chargebacks, discounts, returns, distribution service fees, and government rebates, such as Medicare Part D coverage gap reimbursements in the U.S.  These estimates are based on the most likely amount method for relevant factors such as current contractual and statutory requirements, industry data and forecasted customer buying and payment patterns.  The Company&#8217;s net product revenues reflect the Company&#8217;s best estimates of the amounts of consideration to which it is entitled based on the terms of the respective underlying contracts.  Product shipping and handling costs are considered a fulfillment activity when control transfers to the Company&#8217;s customers and such costs are included in cost of sales.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#160;&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Collaborative Agreements</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues under collaborative agreements include both license revenue and contract research revenue.  The Company performs the following five steps in determining the amount of revenue to recognize as it fulfills its performance obligations under each of its agreements:  (i) identify the contract(s) with a customer; (ii) identify the performance obligation in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation.  The Company applies this five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.  At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct.  The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.  The Company develops assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At contract inception, the Company evaluates whether development milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.  If it is probable that a significant revenue reversal will not occur, the associated development milestone value is included in the transaction price.  Development milestones that are not within the control of the Company or the licensee, including those requiring regulatory approval, are not considered probable of being achieved until those approvals are received.  The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue when (or as) the performance obligation is satisfied.  At the end of each reporting period, the Company re-evaluates the probability of achievement of the development milestones and any related constraint, and if necessary, adjusts its estimates of the overall transaction price.  Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In agreements in which a license to the Company&#8217;s intellectual property is determined distinct from other performance obligations identified in the agreement, the Company recognizes revenue when the license is transferred to the licensee and the licensee is able to use and benefit from the license.  </span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For agreements that include sales-based royalties, including milestones based on a level of sales, the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div></ix:nonNumeric><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i14742bd3c41a4680872547b9be586a7f">The Company may receive payments from its licensees based on billing schedules established in each contract.  Up-front payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these agreements.  Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional.</ix:continuation> </span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" name="us-gaap:CostOfSalesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RleHRyZWdpb246MDkyOWE5NjdiMTAwNDI5ZmIzOTljZGJkMWVhNTQxNTlfMTc5NTE_e8080f24-a565-4940-a79a-d71b1a5157de" continuedAt="iafe2634aacbd4d0ea62d60f1aaa77555" escape="true">Cost of Sales: </ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="iafe2634aacbd4d0ea62d60f1aaa77555"> Cost of sales consists of third-party manufacturing costs, freight and indirect overhead costs associated with sales of XERMELO. Product shipping and handling costs are included in cost of sales. Cost of sales also includes the amortization of the in-process research and development intangible asset for XERMELO using the straight-line method over the estimated useful life of 14 years.</ix:continuation> </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">8</span></div><div style="text-align:center;"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;"><span><br/></span></div><ix:continuation id="ifc9f2aae143c43c2a3ff748d07d626ea" continuedAt="i021940fcaa684feab037cfaaffb83589"><div style="text-indent:36pt;"><ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RleHRyZWdpb246MDkyOWE5NjdiMTAwNDI5ZmIzOTljZGJkMWVhNTQxNTlfMTc5MTg_4788584c-1703-4806-a735-98c58280231c" escape="true"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Research and Development Expenses:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#8217;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company&#8217;s estimates of the clinical study costs and costs to transition activities from Sanofi for development of sotagliflozin for type 2 diabetes, heart failure and chronic kidney disease, including the costs to close out those studies, were based on actual costs incurred for activities completed subsequent to the transition date and estimates of the services to be received and efforts to be expended pursuant to contracts with multiple vendors and the CRO that has conducted and managed and is now closing out the clinical studies on its behalf.  The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#8217;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.</span></ix:nonNumeric></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RleHRyZWdpb246MDkyOWE5NjdiMTAwNDI5ZmIzOTljZGJkMWVhNTQxNTlfMTc4ODA_aa95d882-3431-4414-8ed3-92478b579ee5" continuedAt="i43356237dd2c47ab8833eee7728cdf5e" escape="true"><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Stock-Based Compensation:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;The Company recognizes compensation expense in its condensed consolidated statements of comprehensive loss for share-based payments, including stock options and restricted stock units issued to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div></ix:nonNumeric><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i43356237dd2c47ab8833eee7728cdf5e">The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#8217;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in a change in the assumptions used for expected option lives.&#160;&#160;Historical data is used to estimate the expected option life for each group.  Expected volatility is based on the historical volatility in the Company&#8217;s stock price.</ix:continuation>&#160;&#160;The Company utilized the Black-Scholes valuation model for estimating the fair value of the stock option compensation granted, with the following weighted-average assumptions for options granted in the three months ended March&#160;31, 2020 and 2019:</span></div><div style="margin-bottom:6pt;"><ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RleHRyZWdpb246MDkyOWE5NjdiMTAwNDI5ZmIzOTljZGJkMWVhNTQxNTlfMTc5MzE_4dd15fca-0c68-4e34-aaf4-ac6c644070c2" escape="true"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:50.422%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.069%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.719%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.838%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.016%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected Volatility</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free Interest Rate</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected Term</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dividend<br/>Rate</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employees</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i3f18a324e14b49309846f18ff6f8c0bc_D20200101-20200331" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjhhZDY3MDc5NGJhYTRlYTY4MWQxMGJmMjc2NWFjZmM5L3RhYmxlcmFuZ2U6OGFkNjcwNzk0YmFhNGVhNjgxZDEwYmYyNzY1YWNmYzlfMi0yLTEtMS0w_401d2936-6e7d-4500-aa3f-c83aaa673bb1">89</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i3f18a324e14b49309846f18ff6f8c0bc_D20200101-20200331" decimals="3" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjhhZDY3MDc5NGJhYTRlYTY4MWQxMGJmMjc2NWFjZmM5L3RhYmxlcmFuZ2U6OGFkNjcwNzk0YmFhNGVhNjgxZDEwYmYyNzY1YWNmYzlfMi00LTEtMS0w_836853ba-a9c5-4eca-9750-4f3f874f2722">1.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i3f18a324e14b49309846f18ff6f8c0bc_D20200101-20200331" format="ixt-sec:duryear" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjhhZDY3MDc5NGJhYTRlYTY4MWQxMGJmMjc2NWFjZmM5L3RhYmxlcmFuZ2U6OGFkNjcwNzk0YmFhNGVhNjgxZDEwYmYyNzY1YWNmYzlfMi02LTEtMS0w_22177d64-cbf3-4e93-b7c2-81446f883b3c">4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i3f18a324e14b49309846f18ff6f8c0bc_D20200101-20200331" decimals="2" format="ixt:zerodash" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjhhZDY3MDc5NGJhYTRlYTY4MWQxMGJmMjc2NWFjZmM5L3RhYmxlcmFuZ2U6OGFkNjcwNzk0YmFhNGVhNjgxZDEwYmYyNzY1YWNmYzlfMi04LTEtMS0w_b26b58fa-83b0-4500-a795-31d915f95d19">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Officers and non-employee directors</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i3f18a324e14b49309846f18ff6f8c0bc_D20200101-20200331" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjhhZDY3MDc5NGJhYTRlYTY4MWQxMGJmMjc2NWFjZmM5L3RhYmxlcmFuZ2U6OGFkNjcwNzk0YmFhNGVhNjgxZDEwYmYyNzY1YWNmYzlfMy0yLTEtMS0w_9a4494ee-caa4-49ec-862c-6353904bd98c">77</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i3f18a324e14b49309846f18ff6f8c0bc_D20200101-20200331" decimals="3" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjhhZDY3MDc5NGJhYTRlYTY4MWQxMGJmMjc2NWFjZmM5L3RhYmxlcmFuZ2U6OGFkNjcwNzk0YmFhNGVhNjgxZDEwYmYyNzY1YWNmYzlfMy00LTEtMS0w_061e585c-5c3c-4efd-9a02-2bb38d67ae28">1.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i3f18a324e14b49309846f18ff6f8c0bc_D20200101-20200331" format="ixt-sec:duryear" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjhhZDY3MDc5NGJhYTRlYTY4MWQxMGJmMjc2NWFjZmM5L3RhYmxlcmFuZ2U6OGFkNjcwNzk0YmFhNGVhNjgxZDEwYmYyNzY1YWNmYzlfMy02LTEtMS0w_91c88d6b-5868-4457-a2c6-18a2adac708c">8</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i3f18a324e14b49309846f18ff6f8c0bc_D20200101-20200331" decimals="2" format="ixt:zerodash" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjhhZDY3MDc5NGJhYTRlYTY4MWQxMGJmMjc2NWFjZmM5L3RhYmxlcmFuZ2U6OGFkNjcwNzk0YmFhNGVhNjgxZDEwYmYyNzY1YWNmYzlfMy04LTEtMS0w_e8a5b58d-bf5d-484e-b6d9-f3b80372fd69">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2019:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employees</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i71615d600ea045f8b04f0104cca32e8c_D20190101-20190331" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjhhZDY3MDc5NGJhYTRlYTY4MWQxMGJmMjc2NWFjZmM5L3RhYmxlcmFuZ2U6OGFkNjcwNzk0YmFhNGVhNjgxZDEwYmYyNzY1YWNmYzlfNS0yLTEtMS0w_578075b1-195d-42e8-baad-7ab25781d003">63</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i71615d600ea045f8b04f0104cca32e8c_D20190101-20190331" decimals="3" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjhhZDY3MDc5NGJhYTRlYTY4MWQxMGJmMjc2NWFjZmM5L3RhYmxlcmFuZ2U6OGFkNjcwNzk0YmFhNGVhNjgxZDEwYmYyNzY1YWNmYzlfNS00LTEtMS0w_b0466e6e-54fb-4155-9c1c-e45edc898c35">2.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i71615d600ea045f8b04f0104cca32e8c_D20190101-20190331" format="ixt-sec:duryear" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjhhZDY3MDc5NGJhYTRlYTY4MWQxMGJmMjc2NWFjZmM5L3RhYmxlcmFuZ2U6OGFkNjcwNzk0YmFhNGVhNjgxZDEwYmYyNzY1YWNmYzlfNS02LTEtMS0w_84da0214-42c2-4cb5-9638-02f682eea092">4</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i71615d600ea045f8b04f0104cca32e8c_D20190101-20190331" decimals="2" format="ixt:zerodash" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjhhZDY3MDc5NGJhYTRlYTY4MWQxMGJmMjc2NWFjZmM5L3RhYmxlcmFuZ2U6OGFkNjcwNzk0YmFhNGVhNjgxZDEwYmYyNzY1YWNmYzlfNS04LTEtMS0w_fc9069b9-cce5-4a07-b491-d96b34534168">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Officers and non-employee directors</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i71615d600ea045f8b04f0104cca32e8c_D20190101-20190331" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjhhZDY3MDc5NGJhYTRlYTY4MWQxMGJmMjc2NWFjZmM5L3RhYmxlcmFuZ2U6OGFkNjcwNzk0YmFhNGVhNjgxZDEwYmYyNzY1YWNmYzlfNi0yLTEtMS0w_4498effc-7f44-4c19-baf0-2de2750e4877">63</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i71615d600ea045f8b04f0104cca32e8c_D20190101-20190331" decimals="3" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjhhZDY3MDc5NGJhYTRlYTY4MWQxMGJmMjc2NWFjZmM5L3RhYmxlcmFuZ2U6OGFkNjcwNzk0YmFhNGVhNjgxZDEwYmYyNzY1YWNmYzlfNi00LTEtMS0w_c3b7758e-69e6-45b7-a6fb-559cd3d1d6b5">2.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i71615d600ea045f8b04f0104cca32e8c_D20190101-20190331" format="ixt-sec:duryear" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjhhZDY3MDc5NGJhYTRlYTY4MWQxMGJmMjc2NWFjZmM5L3RhYmxlcmFuZ2U6OGFkNjcwNzk0YmFhNGVhNjgxZDEwYmYyNzY1YWNmYzlfNi02LTEtMS0w_6b115799-8e88-40f6-866d-fe6406f475aa">8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i71615d600ea045f8b04f0104cca32e8c_D20190101-20190331" decimals="2" format="ixt:zerodash" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjhhZDY3MDc5NGJhYTRlYTY4MWQxMGJmMjc2NWFjZmM5L3RhYmxlcmFuZ2U6OGFkNjcwNzk0YmFhNGVhNjgxZDEwYmYyNzY1YWNmYzlfNi04LTEtMS0w_413973ec-5256-499a-9bd0-bc66c91643e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></ix:nonNumeric></div></ix:continuation><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">9</span></div><div style="text-align:center;"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i021940fcaa684feab037cfaaffb83589" continuedAt="i0223e90a401740e2ac86c16030f6173c"><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following is a summary of stock option activity under Lexicon&#8217;s stock-based compensation plans for the three months ended March&#160;31, 2020:</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RleHRyZWdpb246MDkyOWE5NjdiMTAwNDI5ZmIzOTljZGJkMWVhNTQxNTlfMTc5MDU_386e6624-aea5-4fe3-90bf-b7358362774f" escape="true"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:66.035%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.929%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.570%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i0feb9d4ec8584f3ba002dca3b78ba1a4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOmY0MTEzMDZiODllMTRmZjY4ZjMxOTcwMTc2YjRjMWUxL3RhYmxlcmFuZ2U6ZjQxMTMwNmI4OWUxNGZmNjhmMzE5NzAxNzZiNGMxZTFfMi0yLTEtMS0w_fc9f8645-8fce-4728-88b7-98c15e63db19">7,695</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i0feb9d4ec8584f3ba002dca3b78ba1a4_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOmY0MTEzMDZiODllMTRmZjY4ZjMxOTcwMTc2YjRjMWUxL3RhYmxlcmFuZ2U6ZjQxMTMwNmI4OWUxNGZmNjhmMzE5NzAxNzZiNGMxZTFfMi00LTEtMS0w_792bf944-99a4-4620-9dbd-7ca8d83b5773">8.95</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i9befb60474ef4d338b2be4e84a752c34_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOmY0MTEzMDZiODllMTRmZjY4ZjMxOTcwMTc2YjRjMWUxL3RhYmxlcmFuZ2U6ZjQxMTMwNmI4OWUxNGZmNjhmMzE5NzAxNzZiNGMxZTFfMy0yLTEtMS0w_5c10c5ee-9943-45a7-934a-bd1be35c5353">3,301</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i9befb60474ef4d338b2be4e84a752c34_D20200101-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOmY0MTEzMDZiODllMTRmZjY4ZjMxOTcwMTc2YjRjMWUxL3RhYmxlcmFuZ2U6ZjQxMTMwNmI4OWUxNGZmNjhmMzE5NzAxNzZiNGMxZTFfMy00LTEtMS0w_e3a431e5-8e9c-495b-b3f9-6679e068b9a6">3.31</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expired</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i9befb60474ef4d338b2be4e84a752c34_D20200101-20200331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOmY0MTEzMDZiODllMTRmZjY4ZjMxOTcwMTc2YjRjMWUxL3RhYmxlcmFuZ2U6ZjQxMTMwNmI4OWUxNGZmNjhmMzE5NzAxNzZiNGMxZTFfNS0yLTEtMS0w_2498b368-4c12-4813-8aad-1d6569a25a88">202</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i9befb60474ef4d338b2be4e84a752c34_D20200101-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOmY0MTEzMDZiODllMTRmZjY4ZjMxOTcwMTc2YjRjMWUxL3RhYmxlcmFuZ2U6ZjQxMTMwNmI4OWUxNGZmNjhmMzE5NzAxNzZiNGMxZTFfNS00LTEtMS0w_ff93eec8-4bc9-4892-9ffa-00bad066cb55">13.30</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i9befb60474ef4d338b2be4e84a752c34_D20200101-20200331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOmY0MTEzMDZiODllMTRmZjY4ZjMxOTcwMTc2YjRjMWUxL3RhYmxlcmFuZ2U6ZjQxMTMwNmI4OWUxNGZmNjhmMzE5NzAxNzZiNGMxZTFfNi0yLTEtMS0w_8f625790-fb5f-449d-ba0c-2e7398b45bd9">73</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i9befb60474ef4d338b2be4e84a752c34_D20200101-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOmY0MTEzMDZiODllMTRmZjY4ZjMxOTcwMTc2YjRjMWUxL3RhYmxlcmFuZ2U6ZjQxMTMwNmI4OWUxNGZmNjhmMzE5NzAxNzZiNGMxZTFfNi00LTEtMS0w_8ceb3429-ce82-4ab1-94a7-d999475fcb4b">11.10</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at March 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i006d636778dc433599008ebda0fae643_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOmY0MTEzMDZiODllMTRmZjY4ZjMxOTcwMTc2YjRjMWUxL3RhYmxlcmFuZ2U6ZjQxMTMwNmI4OWUxNGZmNjhmMzE5NzAxNzZiNGMxZTFfNy0yLTEtMS0w_ce626104-e8d0-46b6-873e-5fe0d16a57e7">10,721</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i006d636778dc433599008ebda0fae643_I20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOmY0MTEzMDZiODllMTRmZjY4ZjMxOTcwMTc2YjRjMWUxL3RhYmxlcmFuZ2U6ZjQxMTMwNmI4OWUxNGZmNjhmMzE5NzAxNzZiNGMxZTFfNy00LTEtMS0w_214b2091-52d8-4dde-8da8-568945f82c2e">7.11</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable at March 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i006d636778dc433599008ebda0fae643_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOmY0MTEzMDZiODllMTRmZjY4ZjMxOTcwMTc2YjRjMWUxL3RhYmxlcmFuZ2U6ZjQxMTMwNmI4OWUxNGZmNjhmMzE5NzAxNzZiNGMxZTFfOC0yLTEtMS0w_63e0900c-9b09-4e1d-a47e-774325ef1d00">4,731</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i006d636778dc433599008ebda0fae643_I20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOmY0MTEzMDZiODllMTRmZjY4ZjMxOTcwMTc2YjRjMWUxL3RhYmxlcmFuZ2U6ZjQxMTMwNmI4OWUxNGZmNjhmMzE5NzAxNzZiNGMxZTFfOC00LTEtMS0w_e936fa32-9876-4a7f-98ac-015168971a7c">9.83</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:nonNumeric></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended March&#160;31, 2020, Lexicon granted its employees annual restricted stock units. Outstanding employee restricted stock units vest in three to four annual installments.  The following is a summary of restricted stock units activity under Lexicon&#8217;s stock-based compensation plans for the three months ended March&#160;31, 2020:</span></div><div style="margin-bottom:6pt;"><ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RleHRyZWdpb246MDkyOWE5NjdiMTAwNDI5ZmIzOTljZGJkMWVhNTQxNTlfMTc4ODE_8ae9e864-d22d-4520-92ad-fade43d98a11" escape="true"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:65.008%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.929%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.597%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i208e16ef59a04b3c8182732d53d1e2eb_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjk1MGMxNWZhNjMwNzQ3NTU4NDlkZWQ3YTY4ZWM5NWZmL3RhYmxlcmFuZ2U6OTUwYzE1ZmE2MzA3NDc1NTg0OWRlZDdhNjhlYzk1ZmZfMi0yLTEtMS0w_af81c9e5-12eb-40f1-97aa-3e93c83c0e2d">2,830</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i208e16ef59a04b3c8182732d53d1e2eb_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjk1MGMxNWZhNjMwNzQ3NTU4NDlkZWQ3YTY4ZWM5NWZmL3RhYmxlcmFuZ2U6OTUwYzE1ZmE2MzA3NDc1NTg0OWRlZDdhNjhlYzk1ZmZfMi00LTEtMS0w_5cfb66c8-dc4e-4bd8-a827-5dd02fa47ead">6.35</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="icb6eab599353423faf94057d3a06d361_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjk1MGMxNWZhNjMwNzQ3NTU4NDlkZWQ3YTY4ZWM5NWZmL3RhYmxlcmFuZ2U6OTUwYzE1ZmE2MzA3NDc1NTg0OWRlZDdhNjhlYzk1ZmZfMy0yLTEtMS0w_5dfb87bd-75b9-47c4-a303-d4273c4c4922">3,060</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="icb6eab599353423faf94057d3a06d361_D20200101-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjk1MGMxNWZhNjMwNzQ3NTU4NDlkZWQ3YTY4ZWM5NWZmL3RhYmxlcmFuZ2U6OTUwYzE1ZmE2MzA3NDc1NTg0OWRlZDdhNjhlYzk1ZmZfMy00LTEtMS0w_34c1cb1f-b6e0-40c7-bdae-1361b31ae321">3.31</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="icb6eab599353423faf94057d3a06d361_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjk1MGMxNWZhNjMwNzQ3NTU4NDlkZWQ3YTY4ZWM5NWZmL3RhYmxlcmFuZ2U6OTUwYzE1ZmE2MzA3NDc1NTg0OWRlZDdhNjhlYzk1ZmZfNC0yLTEtMS0w_6701bb4c-d140-44f7-94ea-4992a51309d7">1,032</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="icb6eab599353423faf94057d3a06d361_D20200101-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjk1MGMxNWZhNjMwNzQ3NTU4NDlkZWQ3YTY4ZWM5NWZmL3RhYmxlcmFuZ2U6OTUwYzE1ZmE2MzA3NDc1NTg0OWRlZDdhNjhlYzk1ZmZfNC00LTEtMS0w_f1553bb3-af1d-4c19-85a2-e396eb24b9c3">7.02</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="icb6eab599353423faf94057d3a06d361_D20200101-20200331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjk1MGMxNWZhNjMwNzQ3NTU4NDlkZWQ3YTY4ZWM5NWZmL3RhYmxlcmFuZ2U6OTUwYzE1ZmE2MzA3NDc1NTg0OWRlZDdhNjhlYzk1ZmZfNS0yLTEtMS0w_1c3a4d11-fa1a-4ba0-bef9-9130bc76c0ea">34</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="icb6eab599353423faf94057d3a06d361_D20200101-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjk1MGMxNWZhNjMwNzQ3NTU4NDlkZWQ3YTY4ZWM5NWZmL3RhYmxlcmFuZ2U6OTUwYzE1ZmE2MzA3NDc1NTg0OWRlZDdhNjhlYzk1ZmZfNS00LTEtMS0w_64c85938-6964-4c01-bfee-b72c964d84f6">5.28</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at March 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i6d895ee7aef1499d98cd6729af5ed070_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjk1MGMxNWZhNjMwNzQ3NTU4NDlkZWQ3YTY4ZWM5NWZmL3RhYmxlcmFuZ2U6OTUwYzE1ZmE2MzA3NDc1NTg0OWRlZDdhNjhlYzk1ZmZfNi0yLTEtMS0w_d7df2984-67c4-4456-bb5e-2114ddded7da">4,824</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i6d895ee7aef1499d98cd6729af5ed070_I20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjk1MGMxNWZhNjMwNzQ3NTU4NDlkZWQ3YTY4ZWM5NWZmL3RhYmxlcmFuZ2U6OTUwYzE1ZmE2MzA3NDc1NTg0OWRlZDdhNjhlYzk1ZmZfNi00LTEtMS0w_e81f69b6-fbb0-4d48-81da-6d41e93f8123">4.29</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:nonNumeric></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div></ix:continuation><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"><ix:continuation id="i0223e90a401740e2ac86c16030f6173c" continuedAt="iaeabea3d3fb349b696b1e2cd5b485d84"><ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RleHRyZWdpb246MDkyOWE5NjdiMTAwNDI5ZmIzOTljZGJkMWVhNTQxNTlfMTc5MjM_dfb27d8b-dbc6-4a1d-8d59-38ec9078ec9a" continuedAt="i7037398d44b84128a8681f081b50b1d9" escape="true">Net Loss per Common Share:</ix:nonNumeric></ix:continuation></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="iaeabea3d3fb349b696b1e2cd5b485d84"><ix:continuation id="i7037398d44b84128a8681f081b50b1d9"> Net loss per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with convertible debt, stock options and restricted stock units are not included because they are antidilutive.</ix:continuation></ix:continuation> </span></div><div style="text-indent:36pt;"><span><br/></span></div><div id="i4e8a6d84e5e241588399a0cfd4660c18_46"></div><div style="text-indent:-22.5pt;padding-left:22.5pt;"><span><br/></span></div><div style="text-indent:-36pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80Ni9mcmFnOmZjNjYwOWZmODdmMDRlNzI4YTYwMTEzMDUyZTU5ODcyL3RleHRyZWdpb246ZmM2NjA5ZmY4N2YwNGU3MjhhNjAxMTMwNTJlNTk4NzJfMTA5OTUxMTYzMjY1Nw_5f1b624b-37b9-4ff6-adbc-966fcea8041d" continuedAt="i1cd8bc657fa64192b15c45e072599ab1" escape="true">Recent Accounting Pronouncements</ix:nonNumeric></span></div><ix:continuation id="i1cd8bc657fa64192b15c45e072599ab1"><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2018, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606.  This targeted amendment to Topic 808 clarifies that certain transactions resulting from a collaborative agreement should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer for a good or service that is a distinct unit-of-account.  This amendment is effective for fiscal years, and interim periods within years presented, beginning after December 15, 2019, and should be applied retrospectively to the date of initial application of Topic 606.  The Company has applied the provisions of Topic 606 to account for its transactions for collaboration arrangements, including recognition, measurement, presentation and disclosure requirement, and adoption of this ASU did not have a material impact on the condensed consolidated financial statements.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and Other, which is intended to simplify the subsequent measurement of goodwill.  The pronouncement allows an entity, during its annual or interim goodwill impairment evaluation, to compare the fair value of a reporting unit with its carrying amount.  An impairment charge is immediately recognized by which the carrying amount exceeds the fair value.  This ASU is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019.  The adoption of this ASU did not have a material impact on the condensed consolidated financial statements.</span></div></ix:continuation><div style="text-indent:36pt;margin-bottom:9pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">10</span></div><div style="text-align:center;"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div id="i4e8a6d84e5e241588399a0cfd4660c18_49"></div><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:-36pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" name="us-gaap:CashAndCashEquivalentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RleHRyZWdpb246OGJkOWQ0MGY0MWJlNDYyM2IzZTk1Njk4Y2M1NDRjYmZfMzIw_115bdcf4-0cd1-4577-9c8e-7408cefbb948" continuedAt="i892fae9369d04a44bb42ecd0055af9c7" escape="true">Cash and Cash Equivalents and Investments</ix:nonNumeric></span></div><ix:continuation id="i892fae9369d04a44bb42ecd0055af9c7"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of cash and cash equivalents and investments held at March&#160;31, 2020 and December&#160;31, 2019 are as follows:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RleHRyZWdpb246OGJkOWQ0MGY0MWJlNDYyM2IzZTk1Njk4Y2M1NDRjYmZfMzI2_1297cde6-8149-4226-99d2-578a4478bddf" escape="true"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:51.147%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.980%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.980%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.980%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.985%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of March 31, 2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5874757311014de880a5b19a0ef172e9_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfMy0yLTEtMS0w_2249feaf-dd2d-43dd-a31e-4f6743cf800e">55,592</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5874757311014de880a5b19a0ef172e9_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfMy00LTEtMS0w_7da65675-e4f5-4900-8e07-4ca67a6e7809">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5874757311014de880a5b19a0ef172e9_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfMy02LTEtMS0w_d040a3d0-2f7c-4d7a-b491-693f62b0685e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5874757311014de880a5b19a0ef172e9_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfMy04LTEtMS0w_9d53ae3b-20bd-42c4-a992-8dd0e7bbca07">55,592</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic70d1635899243dcae62140e9324e2e5_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfNS0yLTEtMS0w_2ab5255f-f91b-4178-9cfd-696226e38841">192,685</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic70d1635899243dcae62140e9324e2e5_I20200331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfNS00LTEtMS0w_0aec86f7-f809-4ed0-b4cf-c0ea438f4428">860</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span><ix:nonFraction unitRef="usd" contextRef="ic70d1635899243dcae62140e9324e2e5_I20200331" sign="-" xsi:nil="true" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfNS02LTEtMS0w_edd0e519-321b-4f7a-bb3b-7643ca43a4a0"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic70d1635899243dcae62140e9324e2e5_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfNS04LTEtMS0w_7611e858-d8f5-4098-895b-61510a78fa77">193,545</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total short-term investments</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9fe1a3b2255e409c8e58bbc860ad020d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfNy0yLTEtMS0w_155e7c56-0020-4e8d-82cc-7769ea10c4f9">192,685</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9fe1a3b2255e409c8e58bbc860ad020d_I20200331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfNy00LTEtMS0w_e909d163-0b48-4cb6-8b97-c981d1a77cfe">860</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9fe1a3b2255e409c8e58bbc860ad020d_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfNy02LTEtMS0w_b7ddbf48-2bf7-4f56-88e5-e136f7a7f3ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9fe1a3b2255e409c8e58bbc860ad020d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfNy04LTEtMS0w_1e6d7e67-dcaf-42a7-ad15-f8d3bdb10b77">193,545</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2ec309d5c8d74374add6eb8f7da20570_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfOC0yLTEtMS0w_e40b1244-ae77-4c56-8e0b-0b4b2ae0df40">248,277</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2ec309d5c8d74374add6eb8f7da20570_I20200331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfOC00LTEtMS0w_9af8fac0-902c-4e3f-9813-54b3c9079db5">860</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2ec309d5c8d74374add6eb8f7da20570_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfOC02LTEtMS0w_86520240-343d-427a-b2cc-a098b6fc76f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2ec309d5c8d74374add6eb8f7da20570_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfOC04LTEtMS0w_cdf6b402-907f-4fa9-a2c5-6bcbd7896ae5">249,137</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic774c47684e0435aa7c3af7fdf7fe3fd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfMTMtMi0xLTEtMA_f90e3a41-1934-4952-807f-f3946b2728f7">36,112</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic774c47684e0435aa7c3af7fdf7fe3fd_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfMTMtNC0xLTEtMA_01bf5c9b-2be0-4c26-84fd-c502b0f11f9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic774c47684e0435aa7c3af7fdf7fe3fd_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfMTMtNi0xLTEtMA_437335bb-cfb5-42ec-8682-aaf4f9328355">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic774c47684e0435aa7c3af7fdf7fe3fd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfMTMtOC0xLTEtMA_3e7d69be-ad9e-4a4f-a214-8d283d4d8062">36,112</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie0f70c6928fb4964a9779e08a7863739_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfMTUtMi0xLTEtMA_87b8ec05-2f08-4ce8-a5df-d10bd3d0fb65">235,463</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie0f70c6928fb4964a9779e08a7863739_I20191231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfMTUtNC0xLTEtMA_726d972c-d130-4e39-96bf-37f4e8457209">94</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie0f70c6928fb4964a9779e08a7863739_I20191231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfMTUtNi0xLTEtMA_47bbbda3-0423-45eb-972a-a9aadfb00246">10</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie0f70c6928fb4964a9779e08a7863739_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfMTUtOC0xLTEtMA_66c02517-10ba-4c05-a924-2f51087f3842">235,547</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total short-term investments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7833aa4e5e984d3dba5516f674a6a6fd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfMTctMi0xLTEtMA_d8792a58-9a0a-432f-b733-7913bff8db49">235,463</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7833aa4e5e984d3dba5516f674a6a6fd_I20191231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfMTctNC0xLTEtMA_cb58e9f7-9357-4271-ba36-6e5e10ab7c30">94</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7833aa4e5e984d3dba5516f674a6a6fd_I20191231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfMTctNi0xLTEtMA_0bbd31dd-bacf-4765-8fdc-007010d295f8">10</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7833aa4e5e984d3dba5516f674a6a6fd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfMTctOC0xLTEtMA_8162d845-f463-4d09-9345-c8c025bf5efc">235,547</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-18pt;padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total cash and cash equivalents and investments</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5690a7970c9142c1b8c462b80f0e2ba2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfMTgtMi0xLTEtMA_2b77010e-c3c8-445a-927f-b5e81c4a4917">271,575</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5690a7970c9142c1b8c462b80f0e2ba2_I20191231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfMTgtNC0xLTEtMA_bd7b24b4-51c2-44d8-97da-a57f133e3f03">94</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5690a7970c9142c1b8c462b80f0e2ba2_I20191231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfMTgtNi0xLTEtMA_faac951e-cc54-4a01-8ef7-2abc9f832f8a">10</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5690a7970c9142c1b8c462b80f0e2ba2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfMTgtOC0xLTEtMA_56ca2f31-d194-4116-8104-3b66ade0b002">271,659</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:nonNumeric></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There were <ix:nonFraction unitRef="usd" contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:RealizedInvestmentGainsLosses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RleHRyZWdpb246OGJkOWQ0MGY0MWJlNDYyM2IzZTk1Njk4Y2M1NDRjYmZfMTYx_1eb59a67-51e3-4880-bc0c-d2952ce45ad3"><ix:nonFraction unitRef="usd" contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:RealizedInvestmentGainsLosses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RleHRyZWdpb246OGJkOWQ0MGY0MWJlNDYyM2IzZTk1Njk4Y2M1NDRjYmZfMTYx_928bfdd4-3a25-4cdd-ba30-b474813a7473">no</ix:nonFraction></ix:nonFraction> realized losses during either of the three months ended March&#160;31, 2020 and 2019, respectively.  The cost of securities sold is based on the specific identification method.</span></div></ix:continuation><div id="i4e8a6d84e5e241588399a0cfd4660c18_55"></div><div style="text-indent:-36pt;padding-left:36pt;"><span><br/></span></div><div style="text-indent:-36pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" name="us-gaap:FairValueMeasurementInputsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RleHRyZWdpb246MDlmYzc1YThiMTE2NGNlMTkyNDQ2ODM3ZWI4N2RlNzFfMTg0NA_b549da40-4666-4fa1-a08c-51e0ef0bd107" continuedAt="ieef072dfd5d84976aaab1c0db770310b" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="ieef072dfd5d84976aaab1c0db770310b" continuedAt="i5f9ec546eb314f26b3d8c292a97677ef"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis.  Assets and liabilities recorded at fair value in the condensed consolidated balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value.  The following levels are directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities:</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 1 - quoted prices in active markets for identical investments, which include U.S. treasury securities </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 2 - other significant observable inputs (including quoted prices for similar investments, market corroborated inputs, etc.), which includes corporate debt securities</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 3 - significant unobservable inputs </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">11</span></div><div style="text-align:center;"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i5f9ec546eb314f26b3d8c292a97677ef"><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The inputs or methodology used for valuing securities are not necessarily an indication of the credit risk associated with investing in those securities.  The following table provides the fair value measurements of applicable Company assets that are measured at fair value on a recurring basis according to the fair value levels defined above as of March&#160;31, 2020 and December&#160;31, 2019.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RleHRyZWdpb246MDlmYzc1YThiMTE2NGNlMTkyNDQ2ODM3ZWI4N2RlNzFfMTg1Nw_02c28e14-a22e-4221-8d4d-57611d8fb273" escape="true"><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:45.723%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.334%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.334%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.334%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.339%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets and Liabilities at Fair Value as of March 31, 2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6a4c4a7f94924e29a9ae0e9f3ffd742f_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RhYmxlOmYxNDczOTNiNmFkMzQ5MGRiN2U4M2ZjZmFhNmVmNDUwL3RhYmxlcmFuZ2U6ZjE0NzM5M2I2YWQzNDkwZGI3ZTgzZmNmYWE2ZWY0NTBfNC0yLTEtMS0w_d696a02f-6065-492e-9252-15ce38d5ea68">55,592</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie20916e42c934ea59584c72016a49665_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RhYmxlOmYxNDczOTNiNmFkMzQ5MGRiN2U4M2ZjZmFhNmVmNDUwL3RhYmxlcmFuZ2U6ZjE0NzM5M2I2YWQzNDkwZGI3ZTgzZmNmYWE2ZWY0NTBfNC00LTEtMS0w_4cb2c7d9-ddd8-4c18-8b7c-71a28f4a02e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b10f1125ee94d22854381cfc60caac9_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RhYmxlOmYxNDczOTNiNmFkMzQ5MGRiN2U4M2ZjZmFhNmVmNDUwL3RhYmxlcmFuZ2U6ZjE0NzM5M2I2YWQzNDkwZGI3ZTgzZmNmYWE2ZWY0NTBfNC02LTEtMS0w_3f0a9162-f067-46af-93b5-693bca442381">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RhYmxlOmYxNDczOTNiNmFkMzQ5MGRiN2U4M2ZjZmFhNmVmNDUwL3RhYmxlcmFuZ2U6ZjE0NzM5M2I2YWQzNDkwZGI3ZTgzZmNmYWE2ZWY0NTBfNC04LTEtMS0w_e594f603-d992-4cbb-9013-5bed77ac58ac">55,592</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6a4c4a7f94924e29a9ae0e9f3ffd742f_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RhYmxlOmYxNDczOTNiNmFkMzQ5MGRiN2U4M2ZjZmFhNmVmNDUwL3RhYmxlcmFuZ2U6ZjE0NzM5M2I2YWQzNDkwZGI3ZTgzZmNmYWE2ZWY0NTBfNS0yLTEtMS0w_b80dadb9-91ba-4834-a182-92477108bb8e">193,545</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie20916e42c934ea59584c72016a49665_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RhYmxlOmYxNDczOTNiNmFkMzQ5MGRiN2U4M2ZjZmFhNmVmNDUwL3RhYmxlcmFuZ2U6ZjE0NzM5M2I2YWQzNDkwZGI3ZTgzZmNmYWE2ZWY0NTBfNS00LTEtMS0w_ba2271f8-f5cc-444d-bfb6-af65dfe5e2ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b10f1125ee94d22854381cfc60caac9_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RhYmxlOmYxNDczOTNiNmFkMzQ5MGRiN2U4M2ZjZmFhNmVmNDUwL3RhYmxlcmFuZ2U6ZjE0NzM5M2I2YWQzNDkwZGI3ZTgzZmNmYWE2ZWY0NTBfNS02LTEtMS0w_76a2d618-f57d-49b4-97e2-717734721014">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RhYmxlOmYxNDczOTNiNmFkMzQ5MGRiN2U4M2ZjZmFhNmVmNDUwL3RhYmxlcmFuZ2U6ZjE0NzM5M2I2YWQzNDkwZGI3ZTgzZmNmYWE2ZWY0NTBfNS04LTEtMS0w_f7da36d0-523f-4023-9722-c59c891cbe22">193,545</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6a4c4a7f94924e29a9ae0e9f3ffd742f_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RhYmxlOmYxNDczOTNiNmFkMzQ5MGRiN2U4M2ZjZmFhNmVmNDUwL3RhYmxlcmFuZ2U6ZjE0NzM5M2I2YWQzNDkwZGI3ZTgzZmNmYWE2ZWY0NTBfNi0yLTEtMS0w_47b13d47-33d5-4760-a4f6-62a348430525">249,137</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie20916e42c934ea59584c72016a49665_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RhYmxlOmYxNDczOTNiNmFkMzQ5MGRiN2U4M2ZjZmFhNmVmNDUwL3RhYmxlcmFuZ2U6ZjE0NzM5M2I2YWQzNDkwZGI3ZTgzZmNmYWE2ZWY0NTBfNi00LTEtMS0w_9fa78619-0418-4a77-85cf-4d180604d148">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b10f1125ee94d22854381cfc60caac9_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RhYmxlOmYxNDczOTNiNmFkMzQ5MGRiN2U4M2ZjZmFhNmVmNDUwL3RhYmxlcmFuZ2U6ZjE0NzM5M2I2YWQzNDkwZGI3ZTgzZmNmYWE2ZWY0NTBfNi02LTEtMS0w_a58c5ed6-5646-4c5e-a108-8c1af7cb7b9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RhYmxlOmYxNDczOTNiNmFkMzQ5MGRiN2U4M2ZjZmFhNmVmNDUwL3RhYmxlcmFuZ2U6ZjE0NzM5M2I2YWQzNDkwZGI3ZTgzZmNmYWE2ZWY0NTBfNi04LTEtMS0w_80df6cb6-50a8-4712-a001-2d265d4688a1">249,137</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:45.723%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.334%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.334%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.334%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.339%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets and Liabilities at Fair Value as of December 31, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib827aa338f2c4aca8a2d4e234b9f0078_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RhYmxlOjNlMWZkZGY3NmZjOTQxYzVhNWRlYjRiODViMDY0YTU5L3RhYmxlcmFuZ2U6M2UxZmRkZjc2ZmM5NDFjNWE1ZGViNGI4NWIwNjRhNTlfNC0yLTEtMS0w_4bb80280-4f1b-48e0-9f71-272ac23d0803">36,112</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc19c78530d54ec0a70b9d2bdd0a9db7_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RhYmxlOjNlMWZkZGY3NmZjOTQxYzVhNWRlYjRiODViMDY0YTU5L3RhYmxlcmFuZ2U6M2UxZmRkZjc2ZmM5NDFjNWE1ZGViNGI4NWIwNjRhNTlfNC00LTEtMS0w_28670e5c-4e34-4732-a39b-e34d1519d1cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic3d4c113ca4e4166a72c7baa6566b202_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RhYmxlOjNlMWZkZGY3NmZjOTQxYzVhNWRlYjRiODViMDY0YTU5L3RhYmxlcmFuZ2U6M2UxZmRkZjc2ZmM5NDFjNWE1ZGViNGI4NWIwNjRhNTlfNC02LTEtMS0w_162e0ad8-4593-4b73-881f-90cad246f77b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RhYmxlOjNlMWZkZGY3NmZjOTQxYzVhNWRlYjRiODViMDY0YTU5L3RhYmxlcmFuZ2U6M2UxZmRkZjc2ZmM5NDFjNWE1ZGViNGI4NWIwNjRhNTlfNC04LTEtMS0w_58a72c5c-a4ba-47dc-a526-72461b57c0e8">36,112</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib827aa338f2c4aca8a2d4e234b9f0078_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RhYmxlOjNlMWZkZGY3NmZjOTQxYzVhNWRlYjRiODViMDY0YTU5L3RhYmxlcmFuZ2U6M2UxZmRkZjc2ZmM5NDFjNWE1ZGViNGI4NWIwNjRhNTlfNS0yLTEtMS0w_4f6dc6bf-1386-4ba5-ab63-2d80b0228d6a">235,547</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc19c78530d54ec0a70b9d2bdd0a9db7_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RhYmxlOjNlMWZkZGY3NmZjOTQxYzVhNWRlYjRiODViMDY0YTU5L3RhYmxlcmFuZ2U6M2UxZmRkZjc2ZmM5NDFjNWE1ZGViNGI4NWIwNjRhNTlfNS00LTEtMS0w_2e9fd97c-d8fd-45c4-b6a5-30735b9db475">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic3d4c113ca4e4166a72c7baa6566b202_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RhYmxlOjNlMWZkZGY3NmZjOTQxYzVhNWRlYjRiODViMDY0YTU5L3RhYmxlcmFuZ2U6M2UxZmRkZjc2ZmM5NDFjNWE1ZGViNGI4NWIwNjRhNTlfNS02LTEtMS0w_2b395af0-c6c2-4119-a12b-3a9fa9456388">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RhYmxlOjNlMWZkZGY3NmZjOTQxYzVhNWRlYjRiODViMDY0YTU5L3RhYmxlcmFuZ2U6M2UxZmRkZjc2ZmM5NDFjNWE1ZGViNGI4NWIwNjRhNTlfNS04LTEtMS0w_f30dcb6c-1d12-47c6-acf0-e6bd1962854f">235,547</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib827aa338f2c4aca8a2d4e234b9f0078_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RhYmxlOjNlMWZkZGY3NmZjOTQxYzVhNWRlYjRiODViMDY0YTU5L3RhYmxlcmFuZ2U6M2UxZmRkZjc2ZmM5NDFjNWE1ZGViNGI4NWIwNjRhNTlfNi0yLTEtMS0w_7292a0d3-926f-431d-942a-efebe2fe6c83">271,659</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc19c78530d54ec0a70b9d2bdd0a9db7_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RhYmxlOjNlMWZkZGY3NmZjOTQxYzVhNWRlYjRiODViMDY0YTU5L3RhYmxlcmFuZ2U6M2UxZmRkZjc2ZmM5NDFjNWE1ZGViNGI4NWIwNjRhNTlfNi00LTEtMS0w_69e3c747-e734-4db1-8275-75fb6640050a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic3d4c113ca4e4166a72c7baa6566b202_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RhYmxlOjNlMWZkZGY3NmZjOTQxYzVhNWRlYjRiODViMDY0YTU5L3RhYmxlcmFuZ2U6M2UxZmRkZjc2ZmM5NDFjNWE1ZGViNGI4NWIwNjRhNTlfNi02LTEtMS0w_e8951fc9-7f30-4537-831e-abb825c4947b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RhYmxlOjNlMWZkZGY3NmZjOTQxYzVhNWRlYjRiODViMDY0YTU5L3RhYmxlcmFuZ2U6M2UxZmRkZjc2ZmM5NDFjNWE1ZGViNGI4NWIwNjRhNTlfNi04LTEtMS0w_d771d759-fb2b-4faa-822e-5101f83574e2">271,659</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company did not have any Level 3 assets or liabilities as of March&#160;31, 2020 or December&#160;31, 2019. Transfers between levels are recognized at the actual date of circumstance that caused the transfer.  There were no transfers between Level 1 and Level 2 during the periods presented.</span></div><div style="text-indent:36pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company also has assets that under certain conditions are subject to measurement at fair value on a non-recurring basis.  These assets include goodwill associated with the acquisitions of Coelacanth Corporation in 2001 and Symphony Icon in 2010, and intangible assets associated with the acquisition of Symphony Icon in 2010. For these assets, measurement at fair value in periods subsequent to their initial recognition is applicable if one or more is determined to be impaired.</span></div><div style="text-indent:36pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Refer to Note 5, Debt Obligations, for fair value measurements of debt obligations.</span></div></ix:continuation><div style="text-indent:36pt;margin-top:9pt;"><span><br/></span></div><div id="i4e8a6d84e5e241588399a0cfd4660c18_58"></div><div style="text-indent:-31.5pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81OC9mcmFnOjAzNWRiOWFhYmMyYjQxZGE4MGVmZTAzZDdlZGJkODNlL3RleHRyZWdpb246MDM1ZGI5YWFiYzJiNDFkYTgwZWZlMDNkN2VkYmQ4M2VfNjk3Nw_17611cac-666c-48fa-ab24-755a2c0e0c9c" continuedAt="i09afd1417bf840729aba90a72f5d270c" escape="true">Debt Obligations</ix:nonNumeric></span></div><ix:continuation id="i09afd1417bf840729aba90a72f5d270c" continuedAt="i1f7453af5a5a42b698fe6c55909a91f9"><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Convertible Debt.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> In November 2014, Lexicon completed an offering of $<ix:nonFraction unitRef="usd" contextRef="ibd4832dfa32a43a6b0d3e7ac775c2680_D20141101-20141130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81OC9mcmFnOjAzNWRiOWFhYmMyYjQxZGE4MGVmZTAzZDdlZGJkODNlL3RleHRyZWdpb246MDM1ZGI5YWFiYzJiNDFkYTgwZWZlMDNkN2VkYmQ4M2VfOTQ_ca486937-201c-4c4c-8019-a96a56ec712d">87.5</ix:nonFraction> million in aggregate principal amount of its <ix:nonFraction unitRef="number" contextRef="i7a726c0e01c741f09f3d21d85cd63800_I20141120" decimals="4" name="lxrx:ConvDebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81OC9mcmFnOjAzNWRiOWFhYmMyYjQxZGE4MGVmZTAzZDdlZGJkODNlL3RleHRyZWdpb246MDM1ZGI5YWFiYzJiNDFkYTgwZWZlMDNkN2VkYmQ4M2VfMTM0_d3abe6d0-5787-42d6-aa5b-055174b78021">5.25</ix:nonFraction>% Convertible Senior Notes due 2021 (the &#8220;Convertible Notes&#8221;).  The conversion feature did not meet the criteria for bifurcation as required by generally accepted accounting principles and the entire principal amount was recorded as long-term debt on the Company&#8217;s condensed consolidated balance sheets.  </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Convertible Notes are governed by an indenture (the &#8220;Indenture&#8221;), dated as of November&#160;26, 2014, between the Company and Wells Fargo Bank, N.A., as trustee.  The Convertible Notes bear interest at a rate of <ix:nonFraction unitRef="number" contextRef="i7a726c0e01c741f09f3d21d85cd63800_I20141120" decimals="4" name="lxrx:ConvDebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81OC9mcmFnOjAzNWRiOWFhYmMyYjQxZGE4MGVmZTAzZDdlZGJkODNlL3RleHRyZWdpb246MDM1ZGI5YWFiYzJiNDFkYTgwZWZlMDNkN2VkYmQ4M2VfNjUy_d3abe6d0-5787-42d6-aa5b-055174b78021">5.25</ix:nonFraction>%&#160;per year, payable semiannually in arrears on June&#160;1 and December&#160;1 of each year, beginning on June&#160;1, 2015. The Convertible Notes mature on December&#160;1, 2021. The Company may not redeem the Convertible Notes prior to the maturity date, and no sinking fund is provided for the Convertible Notes.  </span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Holders of the Convertible Notes may convert their Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, the Company will deliver for each $1,000 principal amount of converted Convertible Notes a number of shares of its common stock equal to the conversion rate, as described in the Indenture. The conversion rate is initially <ix:nonFraction unitRef="number" contextRef="ibd4832dfa32a43a6b0d3e7ac775c2680_D20141101-20141130" decimals="4" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81OC9mcmFnOjAzNWRiOWFhYmMyYjQxZGE4MGVmZTAzZDdlZGJkODNlL3RleHRyZWdpb246MDM1ZGI5YWFiYzJiNDFkYTgwZWZlMDNkN2VkYmQ4M2VfMTM3OQ_a74980af-6b5b-4509-bfd4-b6ec39a5c45e">118.4553</ix:nonFraction> shares of common stock per $1,000 principal amount of Convertible Notes (equivalent to an initial conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i7a726c0e01c741f09f3d21d85cd63800_I20141120" decimals="3" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81OC9mcmFnOjAzNWRiOWFhYmMyYjQxZGE4MGVmZTAzZDdlZGJkODNlL3RleHRyZWdpb246MDM1ZGI5YWFiYzJiNDFkYTgwZWZlMDNkN2VkYmQ4M2VfMTUwMA_63aea6e2-6b5d-4a04-88cc-a614bfc36b90">8.442</ix:nonFraction> per share of common stock). The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date, the Company will increase the conversion rate for a holder who elects to convert its Convertible Notes in connection with such a corporate event in certain circumstances.</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">12</span></div><div style="text-align:center;"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i1f7453af5a5a42b698fe6c55909a91f9" continuedAt="ie772e05ffcc248ae9d415f9f232591ef"><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If the Company undergoes a fundamental change, holders may require the Company to repurchase for cash all or any portion of their Convertible Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.</span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the issuance of the Convertible Notes, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="ibd4832dfa32a43a6b0d3e7ac775c2680_D20141101-20141130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81OC9mcmFnOjAzNWRiOWFhYmMyYjQxZGE4MGVmZTAzZDdlZGJkODNlL3RleHRyZWdpb246MDM1ZGI5YWFiYzJiNDFkYTgwZWZlMDNkN2VkYmQ4M2VfMjM1Mw_5d06c895-5be9-465d-bcac-632c52de76e7">3.4</ix:nonFraction> million of debt issuance costs.  The debt issuance costs are amortized as interest expense over the expected life of the Convertible Notes using the effective interest method.  The Company determined the expected life of the debt was equal to the seven-year term of the Convertible Notes.  As of March&#160;31, 2020, the balance of unamortized debt issuance costs was $<ix:nonFraction unitRef="usd" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnamortizedDebtIssuanceExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81OC9mcmFnOjAzNWRiOWFhYmMyYjQxZGE4MGVmZTAzZDdlZGJkODNlL3RleHRyZWdpb246MDM1ZGI5YWFiYzJiNDFkYTgwZWZlMDNkN2VkYmQ4M2VfMjY5OQ_bf329ce5-576f-4d49-8fc8-51e4f7c6db70">0.8</ix:nonFraction>&#160;million, which offsets long-term debt on the condensed consolidated balance sheets.  As of March&#160;31, 2020, the carrying value of the Convertible Notes was $86.7 million.</span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of the Convertible Notes was $<ix:nonFraction unitRef="usd" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81OC9mcmFnOjAzNWRiOWFhYmMyYjQxZGE4MGVmZTAzZDdlZGJkODNlL3RleHRyZWdpb246MDM1ZGI5YWFiYzJiNDFkYTgwZWZlMDNkN2VkYmQ4M2VfMjgyMg_4a33e44c-f93d-471c-b4b2-3c0d72adeace">55.2</ix:nonFraction>&#160;million as of March&#160;31, 2020 and was determined using Level&#160;2 inputs based on the indicative pricing published by certain investment banks or trading levels of the Convertible Notes, which are not listed on any securities exchange or quoted on an inter-dealer automated quotation system.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Mortgage Loan.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;In August 2018, a wholly owned subsidiary of Lexicon entered into a term loan and security agreement, refinancing the previously existing mortgage on its facilities in The Woodlands, Texas (the &#8220;Property&#8221;).  The loan agreement provides for a $<ix:nonFraction unitRef="usd" contextRef="id80805ff25ba4c6c9ddb0b2c60375c8a_I20180830" decimals="-5" format="ixt:numdotdecimal" name="lxrx:MortgageDebtInstrument_Revere_LXRX" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81OC9mcmFnOjAzNWRiOWFhYmMyYjQxZGE4MGVmZTAzZDdlZGJkODNlL3RleHRyZWdpb246MDM1ZGI5YWFiYzJiNDFkYTgwZWZlMDNkN2VkYmQ4M2VfMzQ3MQ_97ffd612-d505-490a-bc7a-5505f23907a0">12.9</ix:nonFraction> million mortgage on the Property and has a two-year term with a 10-year amortization.  The mortgage loan bears interest at a rate per annum equal to the greater of (a) the 30-day LIBOR rate plus <ix:nonFraction unitRef="number" contextRef="id80805ff25ba4c6c9ddb0b2c60375c8a_I20180830" decimals="INF" name="lxrx:MortgageDebtInterestRate_Base_Revere_LXRX" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81OC9mcmFnOjAzNWRiOWFhYmMyYjQxZGE4MGVmZTAzZDdlZGJkODNlL3RleHRyZWdpb246MDM1ZGI5YWFiYzJiNDFkYTgwZWZlMDNkN2VkYmQ4M2VfMzY2MQ_1eae08b7-56c1-437d-b3cd-a09875a3df94">5.5</ix:nonFraction>% and (b) <ix:nonFraction unitRef="number" contextRef="id80805ff25ba4c6c9ddb0b2c60375c8a_I20180830" decimals="INF" name="lxrx:MortgageDebtInterestRateBasePlus_Revere_LXRX" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81OC9mcmFnOjAzNWRiOWFhYmMyYjQxZGE4MGVmZTAzZDdlZGJkODNlL3RleHRyZWdpb246MDM1ZGI5YWFiYzJiNDFkYTgwZWZlMDNkN2VkYmQ4M2VfMzY3Mg_bb17b621-c61d-4df1-88b8-7e393d9938d2">7.5</ix:nonFraction>% and provides for a balloon payment of $<ix:nonFraction unitRef="usd" contextRef="id80805ff25ba4c6c9ddb0b2c60375c8a_I20180830" decimals="-5" format="ixt:numdotdecimal" name="lxrx:MortgageDebtBalloonPayment_LXRX" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81OC9mcmFnOjAzNWRiOWFhYmMyYjQxZGE4MGVmZTAzZDdlZGJkODNlL3RleHRyZWdpb246MDM1ZGI5YWFiYzJiNDFkYTgwZWZlMDNkN2VkYmQ4M2VfMzcxMw_da39d526-f441-4e02-8859-33dd8a0e41d5">10.3</ix:nonFraction> million due in August 2020.  Lexicon incurred $<ix:nonFraction unitRef="usd" contextRef="id80805ff25ba4c6c9ddb0b2c60375c8a_I20180830" decimals="-5" format="ixt:numdotdecimal" name="lxrx:MortgageDebtIssueCosts_Revere_LXRX" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81OC9mcmFnOjAzNWRiOWFhYmMyYjQxZGE4MGVmZTAzZDdlZGJkODNlL3RleHRyZWdpb246MDM1ZGI5YWFiYzJiNDFkYTgwZWZlMDNkN2VkYmQ4M2VfMzc1NA_3bfa3612-272d-43c2-9b9e-aafc486cc9e5">0.4</ix:nonFraction> million of debt issuance costs in connection with the mortgage loan, which offsets the current portion of long-term debt on the condensed consolidated balance sheets and are amortized as interest expense over the two-year term of the loan agreement.  As of March&#160;31, 2020, the balance of unamortized debt issuance costs was $<ix:nonFraction unitRef="usd" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="-5" format="ixt:numdotdecimal" name="lxrx:MortgageDebtIssueCosts_Revere_LXRX" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81OC9mcmFnOjAzNWRiOWFhYmMyYjQxZGE4MGVmZTAzZDdlZGJkODNlL3RleHRyZWdpb246MDM1ZGI5YWFiYzJiNDFkYTgwZWZlMDNkN2VkYmQ4M2VfNDAyOA_0820e636-713f-44be-aba4-0ab9e3388a39">0.1</ix:nonFraction> million.  The condensed consolidated balance sheet includes mortgage debt, the carrying value of the debt, of $<ix:nonFraction unitRef="usd" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="-5" format="ixt:numdotdecimal" name="lxrx:MortgageDebtInstrument_Revere_LXRX" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81OC9mcmFnOjAzNWRiOWFhYmMyYjQxZGE4MGVmZTAzZDdlZGJkODNlL3RleHRyZWdpb246MDM1ZGI5YWFiYzJiNDFkYTgwZWZlMDNkN2VkYmQ4M2VfNDEwMA_9e6f5324-87ce-4606-a6f5-bd18e4202389">10.7</ix:nonFraction> million as of March&#160;31, 2020 and is included in current portion of long-term debt.  The buildings and land that serve as collateral for the mortgage loan are included in property and equipment at $<ix:nonFraction unitRef="usd" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="-5" format="ixt:numdotdecimal" name="lxrx:BuildingsCollateral" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81OC9mcmFnOjAzNWRiOWFhYmMyYjQxZGE4MGVmZTAzZDdlZGJkODNlL3RleHRyZWdpb246MDM1ZGI5YWFiYzJiNDFkYTgwZWZlMDNkN2VkYmQ4M2VfNDI3OQ_8aeb2013-cfb2-4f8f-8897-854496b53343">59.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="-5" format="ixt:numdotdecimal" name="lxrx:LandCollateral" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81OC9mcmFnOjAzNWRiOWFhYmMyYjQxZGE4MGVmZTAzZDdlZGJkODNlL3RleHRyZWdpb246MDM1ZGI5YWFiYzJiNDFkYTgwZWZlMDNkN2VkYmQ4M2VfNDI4Ng_5a484e7f-7006-4f19-ae7b-99b7d611f7c1">2.7</ix:nonFraction>&#160;million, respectively, before accumulated depreciation, as of March&#160;31, 2020.  The fair value of the loan agreement approximates its carrying value.&#160;&#160;The fair value of the loan agreement was determined using Level&#160;2 inputs using discounted cash flow analysis, based on the Company&#8217;s estimated current incremental borrowing rate.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2020, Lexicon's wholly owned subsidiary entered into a real estate purchase and sale agreement under which Lexicon agreed to sell its facilities in The Woodlands, Texas.  Such sale is subject to normal and customary closing conditions, including a study period, which extends until June 8, 2020, during which the purchaser may conduct inspections, analyses and other studies of the property and may terminate the agreement in its discretion.  Such sale is also subject to the negotiation and execution by the parties of a leaseback agreement for a period of up to six months with respect to a portion of the property concurrently with closing.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">BioPharma Term Loan.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;In December 2017, Lexicon entered into a loan agreement with BioPharma Credit PLC and BioPharma Credit Investments IV Sub LP under which $<ix:nonFraction unitRef="usd" contextRef="i65c277c002ca41af9214fb16de22bcb8_I20171218" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81OC9mcmFnOjAzNWRiOWFhYmMyYjQxZGE4MGVmZTAzZDdlZGJkODNlL3RleHRyZWdpb246MDM1ZGI5YWFiYzJiNDFkYTgwZWZlMDNkN2VkYmQ4M2VfNDc1OA_b08922a2-89da-47d6-8bbd-fadb96984bc2">150.0</ix:nonFraction> million was funded in December 2017 (the &#8220;BioPharma Term Loan&#8221;). The BioPharma Term Loan matures in December 2022, bears interest at <ix:nonFraction unitRef="number" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="2" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81OC9mcmFnOjAzNWRiOWFhYmMyYjQxZGE4MGVmZTAzZDdlZGJkODNlL3RleHRyZWdpb246MDM1ZGI5YWFiYzJiNDFkYTgwZWZlMDNkN2VkYmQ4M2VfNDg4Ng_642e5ee6-fd56-41c2-86ac-318121124c13">9</ix:nonFraction>% per year, subject to additional interest if an event of default occurs and is continuing, and is payable quarterly. </span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The BioPharma Term Loan is subject to mandatory prepayment provisions that require prepayment upon a change of control or receipt of proceeds from certain non-ordinary course transfers of assets.  The Company may prepay the BioPharma Term Loan in whole at its option at any time.  Any prepayment of the BioPharma Term Loan is subject to customary make-whole premiums and prepayment premiums.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s obligations under the BioPharma Term Loan are secured by a first lien security interest in substantially all of the assets of the Company and certain of its subsidiaries, other than its facilities in The Woodlands, Texas.  The loan agreement contains certain customary representations and warranties, affirmative and negative covenants and events of default applicable to the Company and certain of its subsidiaries, including among other things, covenants restricting dispositions, fundamental changes in the business, mergers or acquisitions, indebtedness, encumbrances, distributions, investments, transactions with affiliates and subordinated debt.  If an event of default occurs and is continuing, all amounts outstanding under the BioPharma Term Loan may be declared immediately due and payable.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the BioPharma Term Loan, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="i65c277c002ca41af9214fb16de22bcb8_I20171218" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81OC9mcmFnOjAzNWRiOWFhYmMyYjQxZGE4MGVmZTAzZDdlZGJkODNlL3RleHRyZWdpb246MDM1ZGI5YWFiYzJiNDFkYTgwZWZlMDNkN2VkYmQ4M2VfNjI4Mg_04739e8f-ab56-4eb5-b4fc-3e51bce9bb90">4.1</ix:nonFraction> million of debt issuance costs.  The debt issuance costs are amortized as interest expense over the expected life of the BioPharma Term Loan using the effective interest method.  The Company determined the expected life of the debt was equal to the five-year term of the BioPharma Term Loan. As of March&#160;31, 2020, the balance of unamortized debt issuance costs was $<ix:nonFraction unitRef="usd" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81OC9mcmFnOjAzNWRiOWFhYmMyYjQxZGE4MGVmZTAzZDdlZGJkODNlL3RleHRyZWdpb246MDM1ZGI5YWFiYzJiNDFkYTgwZWZlMDNkN2VkYmQ4M2VfNjYzMA_275a6efc-49da-403a-9ac0-0f5b6ef1baaf">2.2</ix:nonFraction> million, which offsets long-term debt on the </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">13</span></div><div style="text-align:center;"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ie772e05ffcc248ae9d415f9f232591ef" continuedAt="ia87783bf8fdc4d31aec86ca429492e5a">condensed consolidated balance sheets.  As of March&#160;31, 2020, the carrying value of the BioPharma Term Loan was $147.8 million.</ix:continuation></span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ia87783bf8fdc4d31aec86ca429492e5a">The fair value of the BioPharma Term Loan approximates its carrying value.  The fair value of the BioPharma Term Loan was determined using Level&#160;2 inputs using discounted cash flow analysis, based on the Company&#8217;s estimated current incremental borrowing rate.</ix:continuation> </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span><br/></span></div><div id="i4e8a6d84e5e241588399a0cfd4660c18_61"></div><div style="text-indent:-22.5pt;padding-left:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF82MS9mcmFnOjJjY2U0MmJjMWY4ZjQ1ZGI4MTkxYzgzMTJjY2M1MDQyL3RleHRyZWdpb246MmNjZTQyYmMxZjhmNDVkYjgxOTFjODMxMmNjYzUwNDJfMjc1NA_60d0079b-e864-43f9-99c4-1e5bbd50e86f" continuedAt="i34420f48b6f840c4a0f701bc2f51fc4b" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i34420f48b6f840c4a0f701bc2f51fc4b" continuedAt="ia9ebed83dbc2407daf9bef7799f4b4b7"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Legal Proceedings.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;On January 28, 2019, a purported securities class action complaint captioned Daniel Manopla v. Lexicon Pharmaceuticals, Inc., Lonnel Coats, Jeffrey L. Wade and Pablo Lapuerta, M.D. was filed against the Company and certain of its officers in the U.S. District Court for the Southern District of Texas, Houston Division.  A first amended complaint was filed on July 30, 2019 and Lexicon filed a motion to dismiss such first amended complaint on September 30, 2019.  The plaintiff filed an opposition to Lexicon's motion to dismiss on November 14, 2019 and Lexicon filed a reply in support of its motion to dismiss on December 13, 2019.  The lawsuit purports to be a class action brought on behalf of purchasers of the Company&#8217;s securities during the period from March&#160;11, 2016 through July 29, 2019.  The complaint alleges that the defendants violated federal securities laws by making materially false and misleading statements and/or omissions concerning data from its Phase 3 clinical trials of sotagliflozin in type 1 diabetes patients and the prospects of FDA approval of sotagliflozin for the treatment of type 1 diabetes.  The complaint purports to assert claims for violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.  The complaint seeks, on behalf of the purported class, an unspecified amount of monetary damages, interest, fees and expenses of attorneys and experts, and other relief.</span></div></ix:continuation><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ia9ebed83dbc2407daf9bef7799f4b4b7">In addition, Lexicon is from time to time party to claims and legal proceedings that arise in the normal course of its business and that it believes will not have, individually or in the aggregate, a material adverse effect on its results of operations, financial condition or liquidity.</ix:continuation>&#160;</span></div><div style="text-indent:36pt;"><span><br/></span></div><div id="i4e8a6d84e5e241588399a0cfd4660c18_64"></div><div style="text-indent:-36pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF82NC9mcmFnOjhlNjRhZTVhYWQ2MDQ3OTc5MDBlM2JhMDEzNmRlNzRhL3RleHRyZWdpb246OGU2NGFlNWFhZDYwNDc5NzkwMGUzYmEwMTM2ZGU3NGFfMTk2NDI_4f6dd749-b8ad-40fa-a144-f861f77baf7c" continuedAt="if93058ced1f3414981b31897686bb091" escape="true">Collaboration and License Agreements</ix:nonNumeric></span></div><ix:continuation id="if93058ced1f3414981b31897686bb091" continuedAt="if762a72550934597b1d8dc6f4ade97e1"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Lexicon has derived substantially all of its revenues from drug discovery and development alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, product sales, government grants and contracts, technology licenses, subscriptions to its databases and compound library sales. </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Ipsen.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  In October 2014, Lexicon entered into a License and Collaboration Agreement, which was subsequently amended in March 2015 (collectively, the &#8220;Ipsen Agreement&#8221;), with Ipsen for the development and commercialization of XERMELO outside of the United States and Japan (the &#8220;Licensed Territory&#8221;).  </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Ipsen Agreement, Lexicon granted Ipsen an exclusive, royalty-bearing right and license under its patent rights and know-how to commercialize XERMELO in the Licensed Territory.  Ipsen is responsible for using diligent efforts to commercialize XERMELO in the Licensed Territory pursuant to a mutually approved commercialization plan.  Subject to certain exceptions, Lexicon was responsible for conducting clinical trials required to obtain regulatory approval for XERMELO for carcinoid syndrome in the European Union, including those contemplated by a mutually approved initial development plan, and has the first right to conduct most other clinical trials of XERMELO.  Lexicon was responsible for the costs of all clinical trials contemplated by the initial development plan. The costs of additional clinical trials will be allocated between the parties based on the nature of such clinical trials.  Under the Ipsen Agreement, Ipsen has paid Lexicon an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331" decimals="-5" format="ixt:numdotdecimal" name="lxrx:IpsenTotalPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF82NC9mcmFnOjhlNjRhZTVhYWQ2MDQ3OTc5MDBlM2JhMDEzNmRlNzRhL3RleHRyZWdpb246OGU2NGFlNWFhZDYwNDc5NzkwMGUzYmEwMTM2ZGU3NGFfMTMwOTg_c308680c-fc8f-4149-97b4-c106fa0a6454">47.2</ix:nonFraction> million through March&#160;31, 2020, consisting of $<ix:nonFraction unitRef="usd" contextRef="i723e1df096a74ef3a7ed1c4ee79e00cb_D20150301-20150331" decimals="-5" format="ixt:numdotdecimal" name="lxrx:IpsenTotalUpfrontPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF82NC9mcmFnOjhlNjRhZTVhYWQ2MDQ3OTc5MDBlM2JhMDEzNmRlNzRhL3RleHRyZWdpb246OGU2NGFlNWFhZDYwNDc5NzkwMGUzYmEwMTM2ZGU3NGFfMTMxMjc_e4d9cde2-6244-4716-9383-d97f719ab439">24.5</ix:nonFraction> million in upfront payments and a $<ix:nonFraction unitRef="usd" contextRef="if2f0442e8e3949d2acab519802cd9a7a_D20160701-20160930" decimals="-5" format="ixt:numdotdecimal" name="lxrx:IpsenMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF82NC9mcmFnOjhlNjRhZTVhYWQ2MDQ3OTc5MDBlM2JhMDEzNmRlNzRhL3RleHRyZWdpb246OGU2NGFlNWFhZDYwNDc5NzkwMGUzYmEwMTM2ZGU3NGFfMTMxNTY_d98d939a-db39-4a6b-93ce-5434f92f1b2b">6.4</ix:nonFraction> million milestone payment upon the acceptance of the filing submitted by Ipsen to the European Medicines Agency for XERMELO as an adjunct to somatostatin analog therapy for the long-term treatment of carcinoid syndrome, a $<ix:nonFraction unitRef="usd" contextRef="i9f3132da0556457c978c3721090d9425_D20170701-20170930" decimals="-5" format="ixt:numdotdecimal" name="lxrx:IpsenMilestonePaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF82NC9mcmFnOjhlNjRhZTVhYWQ2MDQ3OTc5MDBlM2JhMDEzNmRlNzRhL3RleHRyZWdpb246OGU2NGFlNWFhZDYwNDc5NzkwMGUzYmEwMTM2ZGU3NGFfMTMzNzM_0ff4595a-e98c-4b62-aa37-fd23c6b857b3">5.1</ix:nonFraction> million milestone upon Ipsen&#8217;s receipt of approval from the European Commission for the marketing of XERMELO in all member states of the European Union, Norway and Iceland, a $<ix:nonFraction unitRef="usd" contextRef="i949545145223492aa3a8472aa5f75d6c_D20171001-20171031" decimals="-4" format="ixt:numdotdecimal" name="lxrx:IpsenMilestonePaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF82NC9mcmFnOjhlNjRhZTVhYWQ2MDQ3OTc5MDBlM2JhMDEzNmRlNzRhL3RleHRyZWdpb246OGU2NGFlNWFhZDYwNDc5NzkwMGUzYmEwMTM2ZGU3NGFfMTM1NDM_f94ab3b4-f2b2-40b1-a26c-933e1eb59f8b">3.8</ix:nonFraction> million milestone upon Ipsen&#8217;s first commercial sale in Germany, a $<ix:nonFraction unitRef="usd" contextRef="icb75b1b2778741648129edca9c77b0d1_D20171101-20171130" decimals="-4" format="ixt:numdotdecimal" name="lxrx:IpsenMilestonePaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF82NC9mcmFnOjhlNjRhZTVhYWQ2MDQ3OTc5MDBlM2JhMDEzNmRlNzRhL3RleHRyZWdpb246OGU2NGFlNWFhZDYwNDc5NzkwMGUzYmEwMTM2ZGU3NGFfMTM2MDU_9f118d8f-4ee4-4c26-b1d4-ec6d308f02c8">3.8</ix:nonFraction> million milestone upon Ipsen&#8217;s first commercial sale in the United Kingdom, a $<ix:nonFraction unitRef="usd" contextRef="i41e7bc56d8f44697acef137f70b02cef_D20190401-20190630" decimals="-4" format="ixt:numdotdecimal" name="lxrx:IpsenMilestonePaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF82NC9mcmFnOjhlNjRhZTVhYWQ2MDQ3OTc5MDBlM2JhMDEzNmRlNzRhL3RleHRyZWdpb246OGU2NGFlNWFhZDYwNDc5NzkwMGUzYmEwMTM2ZGU3NGFfMTM2Nzg_178fcb02-6b94-4d16-b0f7-818517ba1df0">1.3</ix:nonFraction> million milestone upon Ipsen&#8217;s receipt of approval from Health Canada and a $<ix:nonFraction unitRef="usd" contextRef="i9940e83a99be4c0db47b16062f8cf74e_D20190201-20190228" decimals="-4" format="ixt:numdotdecimal" name="lxrx:IpsenMilestonePaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF82NC9mcmFnOjhlNjRhZTVhYWQ2MDQ3OTc5MDBlM2JhMDEzNmRlNzRhL3RleHRyZWdpb246OGU2NGFlNWFhZDYwNDc5NzkwMGUzYmEwMTM2ZGU3NGFfMTM3NTc_4ad2fe41-f459-4649-90fb-9d4fc944d185">2.3</ix:nonFraction> million milestone upon Ipsen&#8217;s first commercial sale in Canada.  In addition, Lexicon is eligible to receive from Ipsen (a) up to an aggregate of approximately $<ix:nonFraction unitRef="usd" contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="lxrx:IpsenMaximumRegulatoryAndCommercialMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF82NC9mcmFnOjhlNjRhZTVhYWQ2MDQ3OTc5MDBlM2JhMDEzNmRlNzRhL3RleHRyZWdpb246OGU2NGFlNWFhZDYwNDc5NzkwMGUzYmEwMTM2ZGU3NGFfMTM5MTI_27e79ba8-14e1-4124-b830-d354daa20c33">9.6</ix:nonFraction>&#160;million upon the achievement of specified regulatory and commercial launch milestones and (b) up to an aggregate of &#8364;<ix:nonFraction unitRef="eur" contextRef="iace247b45bbe4d50be1b8046b7cf2019_D20141001-20141031" decimals="-6" format="ixt:numdotdecimal" name="lxrx:IpsenMaximumSalesMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF82NC9mcmFnOjhlNjRhZTVhYWQ2MDQ3OTc5MDBlM2JhMDEzNmRlNzRhL3RleHRyZWdpb246OGU2NGFlNWFhZDYwNDc5NzkwMGUzYmEwMTM2ZGU3NGFfMTQwMjM_1d15da33-5671-4763-8098-b220a829d58d">72</ix:nonFraction>&#160;million upon the achievement of specified sales milestones. Milestone payments that are contingent upon the achievement of a substantive milestone are deemed constrained.  Lexicon is also entitled to tiered, escalating royalties ranging from low twenties to mid-thirties percentages of net sales of XERMELO in the Licensed Territory, subject to a credit for amounts previously paid to Lexicon by Ipsen for the manufacture and supply of such units of XERMELO.  </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">14</span></div><div style="text-align:center;"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="if762a72550934597b1d8dc6f4ade97e1" continuedAt="i7d532a6d543748119c35c7d4544ce7b2"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Lexicon and Ipsen have entered into a commercial supply agreement pursuant to which Lexicon will supply Ipsen&#8217;s commercial requirements of XERMELO, and Ipsen pays an agreed upon transfer price for such commercial supply.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company considered the following as its performance obligations with respect to the revenue recognition of the $<ix:nonFraction unitRef="usd" contextRef="i723e1df096a74ef3a7ed1c4ee79e00cb_D20150301-20150331" decimals="-5" format="ixt:numdotdecimal" name="lxrx:IpsenTotalUpfrontPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF82NC9mcmFnOjhlNjRhZTVhYWQ2MDQ3OTc5MDBlM2JhMDEzNmRlNzRhL3RleHRyZWdpb246OGU2NGFlNWFhZDYwNDc5NzkwMGUzYmEwMTM2ZGU3NGFfMTQ4MTQ_e4d9cde2-6244-4716-9383-d97f719ab439">24.5</ix:nonFraction>&#160;million upfront payments: </span></div><div style="text-indent:-36pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">The exclusive license granted to Ipsen to develop and commercialize XERMELO in the Licensed Territory;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">The development services Lexicon is performing for XERMELO;</span></div><div style="text-indent:-36pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">The obligation to participate in committees which govern the development of XERMELO until commercialization; and</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">The obligation to supply commercial supply of XERMELO, under a commercial supply agreement.</span></div><div><span><br/></span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company determined that the license had stand-alone value because it is an exclusive license that gives Ipsen the right to develop and commercialize XERMELO or to sublicense its rights.  In addition, at the time of the agreement, it would have been possible for Ipsen or another third party to conduct clinical trials without assistance from Lexicon.  As a result, the Company considers the license and the development services under the Ipsen Agreement to be separate performance obligations.  The Company recognized the portion of the transaction price allocated to the license immediately because Lexicon delivered the license and earned the revenue at the inception of the arrangement.  The Company recognized as revenue the amount allocated to the development services and the obligation to participate in committees over the period of time Lexicon performed the services, which was completed in 2018.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company determined that the commercial supply agreement is a contingent deliverable at the onset of the Agreement.  There was inherent uncertainty in obtaining regulatory approval at the time of the agreement, thus, making the applicability of the commercial supply agreement outside the control of Lexicon and Ipsen.  As a result, the Company has determined the commercial supply agreement does not meet the definition of a performance obligation that needs to be accounted for at the inception of the arrangement.  The Company has also determined that there is no significant and incremental discount related to the commercial supply agreement that should be accounted for at the inception of the arrangement.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company determined that the initial transaction price was the $<ix:nonFraction unitRef="usd" contextRef="i723e1df096a74ef3a7ed1c4ee79e00cb_D20150301-20150331" decimals="-5" format="ixt:numdotdecimal" name="lxrx:IpsenTotalUpfrontPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF82NC9mcmFnOjhlNjRhZTVhYWQ2MDQ3OTc5MDBlM2JhMDEzNmRlNzRhL3RleHRyZWdpb246OGU2NGFlNWFhZDYwNDc5NzkwMGUzYmEwMTM2ZGU3NGFfMTY4OTQ_e4d9cde2-6244-4716-9383-d97f719ab439">24.5</ix:nonFraction>&#160;million upfront payments because they were the only payments that were fixed and determinable at the inception of the arrangement.  There was considerable uncertainty at the date of the agreement as to whether Lexicon would earn milestone payments, royalty payments or payments for finished drug product.  As such, the Company did not include those payments in the transaction price.  The Company allocated the transaction price based on the relative best estimate of selling price of each performance obligation.  The Company estimated the selling price of the license deliverable by applying a probability-based income approach utilizing an appropriate discount rate.  The significant inputs the Company used to determine the projected income of the license included: estimated future product sales, estimated cost of goods sold, estimated operating expenses, income taxes, and an appropriate discount rate.  The Company estimated the selling price of the development services by using internal estimates of the cost to hire third parties to perform the services over the expected period to perform the development.  The Company estimated the selling price of the obligation to participate in committees by using internal estimates of the number of internal hours and salary and benefits costs to perform these services. </span></div></ix:continuation><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i7d532a6d543748119c35c7d4544ce7b2">As a result of the allocation, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i2eee5e8c4bdb4710a81e6835c783b093_D20150101-20150630" decimals="-5" format="ixt:numdotdecimal" name="lxrx:IpsenRevenueAllocatedtoLicenseDeliverable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF82NC9mcmFnOjhlNjRhZTVhYWQ2MDQ3OTc5MDBlM2JhMDEzNmRlNzRhL3RleHRyZWdpb246OGU2NGFlNWFhZDYwNDc5NzkwMGUzYmEwMTM2ZGU3NGFfMTgyNjc_ae2c8ba6-601d-4ff9-b803-20958cc82046">21.2</ix:nonFraction>&#160;million of the $<ix:nonFraction unitRef="usd" contextRef="i723e1df096a74ef3a7ed1c4ee79e00cb_D20150301-20150331" decimals="-5" format="ixt:numdotdecimal" name="lxrx:IpsenTotalUpfrontPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF82NC9mcmFnOjhlNjRhZTVhYWQ2MDQ3OTc5MDBlM2JhMDEzNmRlNzRhL3RleHRyZWdpb246OGU2NGFlNWFhZDYwNDc5NzkwMGUzYmEwMTM2ZGU3NGFfMTgyNzc_e4d9cde2-6244-4716-9383-d97f719ab439">24.5</ix:nonFraction>&#160;million upfront payments for the license in 2014, and an additional $<ix:nonFraction unitRef="usd" contextRef="ic1c464c977e64590a82ac8d115d0d92c_D20160101-20160630" decimals="-5" format="ixt:numdotdecimal" name="lxrx:IpsenRevenueAllocatedtoLicenseDeliverable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF82NC9mcmFnOjhlNjRhZTVhYWQ2MDQ3OTc5MDBlM2JhMDEzNmRlNzRhL3RleHRyZWdpb246OGU2NGFlNWFhZDYwNDc5NzkwMGUzYmEwMTM2ZGU3NGFfMTgzNDA_f5e10aed-16c7-4398-8774-15f8d762074e">1.4</ix:nonFraction>&#160;million in 2015 upon entering into the amendment.  The Company recognized the $<ix:nonFraction unitRef="usd" contextRef="iace247b45bbe4d50be1b8046b7cf2019_D20141001-20141031" decimals="-5" format="ixt:numdotdecimal" name="lxrx:IpsenRevenueAllocatedtoDevelopmentDeliverable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF82NC9mcmFnOjhlNjRhZTVhYWQ2MDQ3OTc5MDBlM2JhMDEzNmRlNzRhL3RleHRyZWdpb246OGU2NGFlNWFhZDYwNDc5NzkwMGUzYmEwMTM2ZGU3NGFfMTg0MTM_f09cf3a2-4375-42dd-88ec-e6d9c6231358">1.7</ix:nonFraction>&#160;million allocated to the development services performance obligation over the period of performance as development occurred, and recognized the $<ix:nonFraction unitRef="usd" contextRef="iace247b45bbe4d50be1b8046b7cf2019_D20141001-20141031" decimals="-5" format="ixt:numdotdecimal" name="lxrx:IpsenRevenueAllocatedtoCommitteeDeliverable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF82NC9mcmFnOjhlNjRhZTVhYWQ2MDQ3OTc5MDBlM2JhMDEzNmRlNzRhL3RleHRyZWdpb246OGU2NGFlNWFhZDYwNDc5NzkwMGUzYmEwMTM2ZGU3NGFfMTg1NTI_b354899c-c69d-44af-8819-50fa6e5d9780">0.1</ix:nonFraction>&#160;million allocated to the committee participation performance obligation ratably over the period of performance.  Milestone payments that are contingent upon the achievement of a substantive milestone are deemed constrained.  If or when the constraint is determined to be resolved, the Company will re-evaluate the overall transaction price and recognize an adjustment on a cumulative catch-up basis in the period that the adjustment was evaluated.  Revenue recognized under the Agreement was $<ix:nonFraction unitRef="usd" contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="lxrx:IpsenRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF82NC9mcmFnOjhlNjRhZTVhYWQ2MDQ3OTc5MDBlM2JhMDEzNmRlNzRhL3RleHRyZWdpb246OGU2NGFlNWFhZDYwNDc5NzkwMGUzYmEwMTM2ZGU3NGFfMTkzNTA_8d7a2893-e77d-4703-9ea3-a43f52b3c343">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331" decimals="-5" format="ixt:numdotdecimal" name="lxrx:IpsenRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF82NC9mcmFnOjhlNjRhZTVhYWQ2MDQ3OTc5MDBlM2JhMDEzNmRlNzRhL3RleHRyZWdpb246OGU2NGFlNWFhZDYwNDc5NzkwMGUzYmEwMTM2ZGU3NGFfMTkzNTc_5406fef8-9e7c-4160-bd33-b25624113b07">2.4</ix:nonFraction> million for the three months ended March&#160;31, 2020 and 2019, respectively.</ix:continuation>   </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Sanofi.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2015, Lexicon entered into a Collaboration and License Agreement, which was subsequently amended in July 2017 (collectively, the &#8220;Sanofi Agreement&#8221;), with Sanofi for the worldwide development of Lexicon&#8217;s diabetes drug candidate sotagliflozin.  In December 2016, Sanofi terminated its rights under the Sanofi Agreement with respect to Japan.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Effective as of September 9, 2019 (the &#8220;Settlement Date&#8221;), Lexicon entered into a Termination and Settlement Agreement and Mutual Releases (the &#8220;Termination Agreement&#8221;) with Sanofi, pursuant to which the Sanofi Agreement was terminated and certain associated disputes between Lexicon and Sanofi were settled.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">15</span></div><div style="text-align:center;"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the terms of the Termination Agreement, Lexicon regained all rights to sotagliflozin and assumed full responsibility for the worldwide development and commercialization of sotagliflozin in all indications. Sanofi paid Lexicon $<ix:nonFraction unitRef="usd" contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="lxrx:Lxrx_Sanofiterminationcashpayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF82NC9mcmFnOjhlNjRhZTVhYWQ2MDQ3OTc5MDBlM2JhMDEzNmRlNzRhL3RleHRyZWdpb246OGU2NGFlNWFhZDYwNDc5NzkwMGUzYmEwMTM2ZGU3NGFfNjU5NzA2OTc4ODIxNQ_89149d9f-aa4f-485d-be70-f2a60dff369a">208</ix:nonFraction> million in September 2019, $<ix:nonFraction unitRef="usd" contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="lxrx:Lxrx_sanofiInitialCashPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF82NC9mcmFnOjhlNjRhZTVhYWQ2MDQ3OTc5MDBlM2JhMDEzNmRlNzRhL3RleHRyZWdpb246OGU2NGFlNWFhZDYwNDc5NzkwMGUzYmEwMTM2ZGU3NGFfNjU5NzA2OTc4ODIzNw_0d19cfc9-d660-48cf-8ea4-9a5d53e9e4e0">26</ix:nonFraction> million in March 2020 (less amounts withheld by Sanofi offsetting certain third party costs and internal costs incurred by Sanofi and asserted by Sanofi to be payable by Lexicon under the terms of the Termination Agreement) and is obligated to pay $<ix:nonFraction unitRef="usd" contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="lxrx:Lxrx_sanofifuturecashpayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF82NC9mcmFnOjhlNjRhZTVhYWQ2MDQ3OTc5MDBlM2JhMDEzNmRlNzRhL3RleHRyZWdpb246OGU2NGFlNWFhZDYwNDc5NzkwMGUzYmEwMTM2ZGU3NGFfNjU5NzA2OTc4ODQ4MA_5e40d93c-ae84-47fd-876c-60196887e578">26</ix:nonFraction> million within twelve months of the Settlement Date, and neither party will owe any additional payments pursuant to the Sanofi Agreement. The parties have cooperated in the transition of responsibility for ongoing clinical studies and other activities, and each party is responsible for its own expenses associated with such transition, subject to certain exceptions. In March 2020, Lexicon announced its plan to close out the clinical studies related to the Phase 3 development program for sotagliflozin in type 2 diabetes, heart failure and chronic kidney disease. Revenue relating to the Termination Agreement was recognized in the third quarter of 2019.  Revenue recognized under collaboration agreements with Sanofi was $<ix:nonFraction unitRef="usd" contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="lxrx:SanofiRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF82NC9mcmFnOjhlNjRhZTVhYWQ2MDQ3OTc5MDBlM2JhMDEzNmRlNzRhL3RleHRyZWdpb246OGU2NGFlNWFhZDYwNDc5NzkwMGUzYmEwMTM2ZGU3NGFfNjU5NzA2OTgwMDMzNQ_364c6289-e234-43e2-88f4-259aa2f6c62d">0.1</ix:nonFraction> million for the three months ended March&#160;31, 2019. </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">16</span></div><div style="text-align:center;"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div id="i4e8a6d84e5e241588399a0cfd4660c18_79"></div><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 2.&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Overview</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a biopharmaceutical company with a mission of pioneering medicines that transform patients&#8217; lives. We are devoting most of our resources to the commercialization or development of our three most advanced drugs and drug candidates:</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We are commercializing XERMELO</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (telotristat ethyl), an orally-delivered small molecule drug, in the United States for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog, or SSA, therapy in adults inadequately controlled by SSA therapy.  We have granted Ipsen Pharma SAS, or Ipsen, an exclusive, royalty-bearing right to commercialize XERMELO outside of the United States and Japan.  Ipsen is commercializing XERMELO in the United Kingdom, Germany and multiple additional countries.  We are also developing telotristat ethyl as a treatment for biliary tract cancer and are conducting a Phase 2a clinical trial of telotristat ethyl in biliary tract cancer patients.</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We are developing Zynquista&#8482; (sotagliflozin), an orally-delivered small molecule drug candidate, as a treatment for type&#160;1 diabetes.  The FDA has issued a complete response letter regarding our application for regulatory approval to market sotagliflozin for type 1 diabetes in the United States and has confirmed that position in denying two appeals of the complete response letter.  Zynquista has been approved in the European Union for use as an adjunct to insulin therapy to improve glycemic control in adults with type 1 diabetes and a body mass index &#8805; </span><span style="background-color:rgb(255,255,255, 0.0);color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">27 kg/m</span><sup style="background-color:rgb(255,255,255, 0.0);color:#333333;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">2</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, who could not achieve adequate glycemic control despite optimal insulin therapy.  </span></div><div style="padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We were previously conducting a comprehensive Phase 3 development program for sotagliflozin in type 2 diabetes, heart failure and chronic kidney disease and are currently closing out the clinical trials included in such development program.</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We are developing LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain.  We have reported top-line results from two Phase 1 clinical trials of LX9211 and are preparing to initiate a Phase 2 clinical trial of LX9211.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Compounds from our most advanced drug programs, as well as compounds from a number of additional drug discovery and development programs that we have advanced into various stages of clinical and preclinical development, originated from our own internal drug discovery efforts. These efforts were driven by a systematic, target biology-driven approach in which we used gene knockout technologies and an integrated platform of advanced medical technologies to systematically study the physiological and behavioral functions of almost 5,000 genes in mice and assessed the utility of the proteins encoded by the corresponding human genes as potential drug targets. We have identified and validated in living animals, or </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, more than 100 targets with promising profiles for drug discovery.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are working both independently and through strategic collaborations and alliances with third parties to capitalize on our drug target discoveries and drug discovery and development programs.  We seek to retain exclusive or co-exclusive rights to the benefits of certain drug discovery and development programs by developing and commercializing drug candidates from those programs internally, particularly in the United States for indications treated by specialist physicians.  We seek to collaborate with other pharmaceutical and biotechnology companies with respect to drug discovery or the development and commercialization of certain of our drug candidates, particularly with respect to commercialization in territories outside the United States or commercialization in the United States for indications treated by primary care physicians, or when the collaboration may otherwise provide us with access to expertise and resources that we do not possess internally or are complementary to our own.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We commercially launched XERMELO following regulatory approval in the United States in February 2017 for the treatment of carcinoid syndrome diarrhea in combination with SSA therapy in adults inadequately controlled by SSA therapy.  Prior to the launch of XERMELO, we derived substantially all of our revenues from strategic collaborations and other research and development collaborations and technology licenses.  To date, we have generated a substantial portion of our revenues from a limited number of sources.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our operating results and, in particular, our ability to generate additional revenues are dependent on many factors, including our ability to successfully commercialize XERMELO in the United States and the amount of revenues generated from such commercialization efforts; Ipsen's ability to successfully commercialize XERMELO outside of the United States and Japan and our receipt of any milestone payments and royalties; the success of our ongoing nonclinical and clinical development efforts and ability to obtain necessary regulatory approvals of the drug candidates which are the subject of such efforts; our ability to effectively close out the Phase 3 development program for sotagliflozin in type 2 diabetes, heart failure and chronic </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">17</span></div><div style="text-align:center;"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">kidney disease in a timely manner; our success in establishing new collaborations and licenses; and general and industry-specific economic conditions which may affect research and development expenditures.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Future revenues from our commercialization of XERMELO are uncertain because they depend on a number of factors, including market acceptance of XERMELO, the success of our sales, marketing, distribution and other commercialization activities and the cost and availability of reimbursement for XERMELO.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Future revenues from our collaboration with Ipsen are uncertain because they depend, to a large degree, on the achievement of milestones and payment of royalties we earn from Ipsen&#8217;s commercialization of XERMELO.  Our ability to secure future revenue-generating agreements will depend upon our ability to address the needs of our potential future collaborators and licensees, and to negotiate agreements that we believe are in our long-term best interests.&#160;&#160;We may determine, as we have with certain of our drug candidates, including XERMELO in the United States and Japan, that our interests are better served by retaining rights to our discoveries and advancing our therapeutic programs to a later stage, which could limit our near-term revenues and increase expenses.&#160;&#160;Because of these and other factors, our operating results have fluctuated in the past and are likely to do so in the future, and we do not believe that period-to-period comparisons of our operating results are a good indication of our future performance.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Since our inception, we have incurred significant losses and, as of March&#160;31, 2020, we had an accumulated deficit of $1.4&#160;billion. Our losses have resulted principally from costs incurred in research and development, selling, general and administrative costs associated with our operations, and non-cash stock-based compensation expenses associated with stock options and restricted stock granted to employees and consultants. Research and development expenses consist primarily of salaries and related personnel costs, external research costs related to our nonclinical and clinical efforts, material costs, facility costs, depreciation on property and equipment, and other expenses related to our drug discovery and development programs. Selling, general and administrative expenses consist primarily of salaries and related expenses for executive, sales and marketing, and administrative personnel, professional fees and other corporate expenses, including information technology, facilities costs and general legal activities. We expect to continue to incur significant research and development costs in connection with the continuing development of our drug candidates. As a result, we will need to generate significantly higher revenues to achieve profitability. </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Critical Accounting Policies</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of financial statements in conformity with generally accepted accounting principles requires us to make judgments, estimates and assumptions in the preparation of our condensed consolidated financial statements and accompanying notes.&#160;&#160;Actual results could differ from those estimates.&#160;&#160;We believe there have been no significant changes in our critical accounting policies as discussed in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2019.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Recent Accounting Pronouncements</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There are no recent accounting pronouncements that have a material impact to our condensed consolidated financial statements.   </span></div><div style="margin-bottom:9pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">18</span></div><div style="text-align:center;"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div id="i4e8a6d84e5e241588399a0cfd4660c18_82"></div><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Results of Operations</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenues</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total revenues and dollar and percentage changes as compared to the corresponding period in the prior year are as follows (dollar amounts are presented in millions):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:89.181%;"><tr><td style="width:1.0%;"></td><td style="width:64.721%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.619%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.901%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.275%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.262%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.622%;"></td><td style="width:0.1%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dollar decrease</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Percentage decrease</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(13)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Net product revenue</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#8211; Net product revenue for the three months ended March&#160;31, 2020 increased 17% to $7.9 million as compared to the corresponding period in 2019 from revenues recognized from the sale of XERMELO in the United States.  Product revenues are recorded net of estimated product returns, pricing discounts including rebates offered pursuant to mandatory federal and state government programs and chargebacks, prompt pay discounts and distribution fees and co-pay assistance.  Revenue recognition policies require estimates of the aforementioned sales allowances each period.</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Collaborative agreements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#8211; Revenue from collaborative agreements for the three months ended March&#160;31, 2019 was $2.4 million, primarily due to revenues recognized from a milestone for the first commercial sale in Canada under the collaboration and license agreement with Ipsen.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cost of Sales</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cost of sales for each of the three months ended March&#160;31, 2020 and 2019 was $0.6 million.  Cost of sales consists of third-party manufacturing costs, freight and indirect overhead costs associated with sales of XERMELO.  The pre-commercialization inventory is expected to be sold over approximately the next twelve months.  As a result, cost of sales for the next twelve months will reflect a lower average per unit cost of materials.  Cost of sales for each of the three months ended March&#160;31, 2020 and 2019 includes $0.4 million of amortization of intangible assets relating to XERMELO.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development Expenses</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development expenses and dollar and percentage changes as compared to the corresponding period in the prior year are as follows (dollar amounts are presented in millions):</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:89.181%;"><tr><td style="width:1.0%;"></td><td style="width:64.721%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.619%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.901%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.619%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.918%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.622%;"></td><td style="width:0.1%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total research and development expense</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dollar increase</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Percentage increase</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">359&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-indent:36pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development expenses consist primarily of third-party and other services principally related to nonclinical and clinical development activities, salaries and other personnel-related expenses, stock-based compensation expense, and facility and equipment costs.&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Third-party and other services &#8211;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Third-party and other services for the three months ended March&#160;31, 2020 increased  to $45.3 million from $2.4 million in the corresponding period in 2019 primarily due to increases in external clinical development costs relating to sotagliflozin subsequent to the Termination Agreement with Sanofi.  Third-party and other services relate principally to our clinical trial and related development activities, such as nonclinical and clinical studies and contract manufacturing.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Personnel &#8211;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Personnel costs for the three months ended March&#160;31, 2020 decreased 7% to $5.5 million as compared to the corresponding period in 2019, primarily due to lower headcount.  Salaries, bonuses, employee benefits, payroll taxes, recruiting and relocation costs are included in personnel costs.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">19</span></div><div style="text-align:center;"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Stock-based compensation</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#8211; Stock-based compensation expense for the three months ended March&#160;31, 2020 increased 23% to $2.2 million as compared to the corresponding period in 2019, primarily due to shorter vesting periods of the annual restricted stock unit awards granted in recent years.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Facilities and equipment &#8211; </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Facilities and equipment costs for each of the three months ended March&#160;31, 2020 and 2019 was $0.7 million.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Other &#8211;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Other costs for the three months ended March&#160;31, 2020 increased 16% to $1.5 million as compared to the corresponding period in 2019, primarily due to an increase in insurance premiums related to the sotagliflozin clinical studies.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Selling, General and Administrative Expenses</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Selling, general and administrative expenses and dollar and percentage changes as compared to the corresponding period in the prior year are as follows (dollar amounts are presented in millions):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:89.327%;"><tr><td style="width:1.0%;"></td><td style="width:64.775%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.618%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.875%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.618%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.893%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.621%;"></td><td style="width:0.1%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total selling, general and administrative expense</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dollar increase</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Percentage increase</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-indent:36pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Selling, general and administrative expenses consist primarily of personnel costs to sell XERMELO and to support our research and development activities, professional and consulting fees, stock-based compensation expense, and facility and equipment costs.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Personnel</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#8211; Personnel costs for the three months ended March&#160;31, 2020 decreased 4% to $7.5 million as compared to the corresponding period in 2019, primarily due to lower headcount.  Salaries, bonuses, employee benefits, payroll taxes, recruiting and relocation costs are included in personnel costs.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Professional and consulting fees</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#8211; Professional and consulting fees for the three months ended March&#160;31, 2020 increased 10% to $2.8 million as compared to the corresponding period in 2019, primarily due to higher legal fees.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Stock-based compensation</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#8211; Stock-based compensation expense for the three months ended March&#160;31, 2020 increased 37% to $2.3 million as compared to the corresponding period in 2019, primarily due to shorter vesting periods of the annual restricted stock unit awards granted in recent years.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Facilities and equipment</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#8211; Facilities and equipment costs for each of the three months ended March&#160;31, 2020 and 2019 were $0.5 million. </span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Other &#8211;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Other costs for each the three months ended March&#160;31, 2020 and 2019 were $1.6 million. </span></div><div style="padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Interest Expense and Interest and Other Income, Net</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Interest Expense</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.&#160;&#160;Interest expense for each of the three months ended March&#160;31, 2020 and 2019 was $5.1 million. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Interest and Other Income, Net.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  Interest and other income, net for the three months ended March&#160;31, 2020 and 2019 was $1.0 million and $0.8 million, respectively. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Net loss and Net loss per Common Share</span></div><div><span><br/></span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Net loss and Net loss per Common Share.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net loss increased to $66.6&#160;million in the three months ended March&#160;31, 2020 from $21.8 million in the corresponding period in 2019.  Net loss per common share increased to $0.63 in the three months ended March&#160;31, 2020 from $0.21 in the corresponding period in 2019.  </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our quarterly operating results have fluctuated in the past and are likely to do so in the future, and we believe that quarter-to-quarter comparisons of our operating results are not a good indication of our future performance.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">20</span></div><div style="text-align:center;"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;margin-bottom:9pt;"><span><br/></span></div><div id="i4e8a6d84e5e241588399a0cfd4660c18_85"></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Liquidity and Capital Resources</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have financed our operations from inception primarily through sales of common and preferred stock, contract and milestone payments we received under our strategic and other collaborations, target validation, database subscription and technology license agreements, product sales, government grants and contracts, and financing under debt and lease arrangements.  We have also financed certain of our research and development activities under our agreements with Symphony Icon, Inc. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March&#160;31, 2020, we had $249.1&#160;million in cash, cash equivalents and short-term investments.  As of December&#160;31, 2019, we had $271.7&#160;million in cash, cash equivalents and short-term investments.  We used cash of $22.1&#160;million from operations in the three months ended March&#160;31, 2020.  The net loss for the period of $66.6 million was partially offset by a net decrease in operating assets net of liabilities of $38.9 million, non-cash charges of $4.4&#160;million related to stock-based compensation expense and $1.3 million related to depreciation and amortization expense, including amortization of debt issuance costs. Investing activities provided cash of $42.8&#160;million in the three&#160;months ended March&#160;31, 2020, primarily due to net maturities of investments of $42.8&#160;million.  Financing activities used cash of $1.2 million, primarily to repurchase $0.9 million of common stock and to repay $0.3 million of debt borrowings. </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Other commitments.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2019, Zynquista was approved in the European Union for use as an adjunct to insulin therapy to improve glycemic control in adults with type 1 diabetes and a body mass index &#8805; </span><span style="background-color:rgb(255,255,255, 0.0);color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">27 kg/m</span><sup style="background-color:rgb(255,255,255, 0.0);color:#333333;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">2</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, who could not achieve adequate glycemic control despite optimal insulin therapy.  Upon the achievement of certain European regulatory pricing approvals, we will be required to make certain royalty payments, totaling $4.5 million, in three equal annual installments of $1.5 million. </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Facilities.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  In August 2018, our subsidiary Lex-Gen Woodlands, L.P. entered into a term loan and security agreement, refinancing the previously existing mortgage on our facilities in The Woodlands, Texas.  The loan agreement provides for a $12.9 million mortgage on the property and has a two-year term with a 10-year amortization.  The mortgage loan bears interest at a rate per annum equal to the greater of (a) the 30-day LIBOR rate plus 5.5% and (b) 7.5% and provides for a balloon payment of $10.3 million due in August 2020.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2020, Lex-Gen Woodlands, L.P. entered into a real estate purchase and sale agreement under which we agreed to sell our facilities in The Woodlands, Texas for a purchase price of $15.0 million.  Such sale is subject to normal and customary closing conditions, including a study period, which extends until June 8, 2020, during which the purchaser may conduct inspections, analyses and other studies of the property and may terminate the agreement in its discretion.  Such sale is also subject to the negotiation and execution by the parties of a leaseback agreement for a period of up to six months with respect to a portion of the property concurrently with closing.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2015, our subsidiary Lexicon Pharmaceuticals (New Jersey), Inc. leased a 25,000 square-foot office space in Basking Ridge, New Jersey.  The term of the lease extends from June&#160;1, 2015 through December&#160;31, 2022, and provides for escalating yearly base rent payments starting at $482,000 and increasing to $646,000 in the final year of the lease. </span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our future capital requirements will be substantial and will depend on many factors, including our ability to successfully commercialize XERMELO in the United States and the amount of revenues generated from such commercialization efforts; Ipsen&#8217;s ability to successfully commercialize XERMELO outside of the United States and Japan and our receipt of any milestone payments and royalties; our ability to effectively close out the Phase 3 development program for sotagliflozin in type 2 diabetes, heart failure and chronic kidney disease in a timely manner; the success of our ongoing nonclinical and clinical development efforts and ability to obtain necessary regulatory approvals of the drug candidates which are the subject of such efforts; our success in establishing new collaborations and licenses; the amount and timing of our research, development and commercialization expenditures; the resources we devote to developing and supporting our products and other factors.&#160;&#160;Our capital requirements will also be affected by any expenditures we make in connection with license agreements and acquisitions of and investments in complementary technologies and businesses.&#160;&#160;We expect to continue to devote substantial capital resources to continue commercializing XERMELO in the United States; to successfully complete our nonclinical and clinical development efforts with respect to telotristat ethyl, sotagliflozin, LX9211 and our other drug candidates; and for other general corporate activities.&#160;&#160;We believe that our current unrestricted cash and investment balances and cash and revenues we expect to derive from XERMELO product sales and other sources will be sufficient to fund our operations for at least the next 12 months.&#160;&#160;During or after this period, if cash generated by operations is insufficient to satisfy our liquidity requirements, we will need to sell additional equity or debt securities or obtain additional credit arrangements.&#160;&#160;Additional financing may not be available on terms acceptable to us or at all. The sale of additional equity or convertible debt securities may result in additional dilution to our stockholders.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">21</span></div><div style="text-align:center;"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From time to time, our board of directors may authorize us to repurchase shares of our common stock, repurchase, in cash or common stock, our outstanding convertible notes, or make a cash payment to holders of our convertible notes to induce conversion pursuant to the terms of the convertible notes, in each case, in privately negotiated transactions, publicly announced programs or otherwise.  If and when our board of directors should determine to authorize any such action, it would be on terms and under market conditions that our board of directors determines are in the best interest of us and our stockholders.  Any such actions could deplete significant amounts of our cash resources and/or result in additional dilution to our stockholders.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Disclosure about Market Risk</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are exposed to limited market and credit risk on our cash equivalents which have maturities of three months or less at the time of purchase. We maintain a short-term investment portfolio which consists of U.S. Treasury bills and corporate debt securities that mature three to 12 months from the time of purchase, which we believe are subject to limited market and credit risk. We currently do not hedge interest rate exposure or hold any derivative financial instruments in our investment portfolio.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We had approximately $249.1&#160;million in cash and cash equivalents and short-term investments as of March&#160;31, 2020.  We believe that the working capital available to us will be sufficient to meet our cash requirements for at least the next 12&#160;months. We are not subject to interest rate sensitivity on our outstanding Convertible Notes and our BioPharma Term Loan as each generally have a fixed rate of 5.25% and 9% per annum, respectively.  The Convertible Notes interest is payable in cash semi-annually in arrears and matures in December 2021, unless earlier converted or repurchased in accordance with their terms.  The BioPharma Term Loan bears interest payable quarterly in arrears, and provides for interest-only payments followed by payment of principal at maturity in December 2022.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have operated primarily in the United States and substantially all sales to date have been made in U.S. dollars. Accordingly, we have not had any material exposure to foreign currency rate fluctuations.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span><br/></span></div><div id="i4e8a6d84e5e241588399a0cfd4660c18_88"></div><div style="text-indent:-72pt;padding-left:72pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 3.&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See &#8220;Disclosure about Market Risk&#8221; under &#8220;Item 2. Management&#8217;s Discussion and Analysis</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">of Financial Condition and Results of Operations&#8221; for quantitative and qualitative disclosures about market risk.</span></div><div><span><br/></span></div><div id="i4e8a6d84e5e241588399a0cfd4660c18_91"></div><div style="text-indent:-72pt;padding-left:72pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 4.&#160;&#160;Controls and Procedures</span></div><div style="text-indent:36pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures (as defined in rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) are effective to ensure that the information required to be disclosed by us in the reports we file under the Securities Exchange Act is gathered, analyzed and disclosed with adequate timeliness, accuracy and completeness, based on an evaluation of such controls and procedures as of the end of the period covered by this report. There were no changes in our internal control over financial reporting during the three months ended March&#160;31, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">22</span></div><div style="text-align:center;"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div id="i4e8a6d84e5e241588399a0cfd4660c18_94"></div><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Part II -- Other Information&#160;</span></div><div style="text-align:center;"><span><br/></span></div><div id="i4e8a6d84e5e241588399a0cfd4660c18_97"></div><div style="text-indent:-72pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 1.&#160;&#160;Legal Proceedings</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Securities Class Action Litigation.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On January 28, 2019, a purported securities class action complaint captioned Daniel Manopla v. Lexicon Pharmaceuticals, Inc., Lonnel Coats, Jeffrey L. Wade and Pablo Lapuerta, M.D. was filed against us and certain of our officers in the U.S. District Court for the Southern District of Texas, Houston Division.  A first amended complaint was filed on July 30, 2019 and we filed a motion to dismiss such first amended complaint on September 30, 2019.  The plaintiff filed an opposition to our motion to dismiss on November 14, 2019 and we filed a reply in support of our motion to dismiss on December 13, 2019.  The lawsuit purports to be a class action brought on behalf of purchasers of our securities during the period from March 11, 2016 through July 29, 2019.  The complaint alleges that the defendants violated federal securities laws by making materially false and misleading statements and/or omissions concerning data from our Phase 3 clinical trials of sotagliflozin in type 1 diabetes patients and the prospects of FDA approval of sotagliflozin for the treatment of type 1 diabetes.  The complaint purports to assert claims for violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.  The complaint seeks, on behalf of the purported class, an unspecified amount of monetary damages, interest, fees and expenses of attorneys and experts, and other relief.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Normal Course Legal Proceedings.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, we are from time to time party to claims and legal proceedings that arise in the normal course of our business and that we believe will not have, individually or in the aggregate, a material adverse effect on our results of operations, financial condition or liquidity.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-align:justify;"><span><br/></span></div><div id="i4e8a6d84e5e241588399a0cfd4660c18_100"></div><div style="text-indent:-72pt;padding-left:72pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 1A.&#160;&#160;Risk Factors</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following risks and uncertainties are important factors that could cause actual results or events to differ materially from those indicated by forward-looking statements.  The factors described below are not the only ones we face and additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Risks Related to Our Business and Industry</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We face business disruption and related risks resulting from the outbreak of the novel coronavirus 2019 (COVID-19), including significant restrictions in the ability of our field commercial and medical teams to interact with third parties, delays in the enrollment of ongoing clinical trials and the initiation of planned clinical trials and other operational impacts, each of which could have a material adverse effect on our business.</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We depend heavily on the commercial success of XERMELO.  If we do not achieve commercial success with XERMELO, our business will suffer and our stock price will likely decline.</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We depend heavily on our ability to obtain regulatory approval in the United States for sotagliflozin in type 1 diabetes.  If we fail to obtain such regulatory approval or fail to successfully commercialize sotagliflozin for type 1 diabetes in the United States upon regulatory approval, our business will suffer and our stock price will likely decline.</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We depend heavily on our ability to effectively close out the clinical trials included in the Phase 3 clinical development program for sotagliflozin in type 2 diabetes, heart failure and chronic kidney disease in a timely manner.  If we fail to effectively close out such program on the anticipated timelines, our cash position will suffer and our stock price will likely decline.</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Clinical testing of our drug candidates in humans is an inherently risky and time-consuming process that may fail to demonstrate safety and efficacy, which could result in the delay, limitation or prevention of regulatory approval.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Our drug candidates are subject to a lengthy and uncertain regulatory process that may not result in the necessary regulatory approvals, which could adversely affect our and our collaborators&#8217; ability to commercialize products.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The commercial success of any products that we or our collaborators may develop will depend upon the degree of market acceptance among physicians, patients, health care payers and the medical community.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">23</span></div><div style="text-align:center;"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">If we are unable to maintain an effective and specialized sales force, marketing infrastructure and distribution capabilities, we will not be able to successfully commercialize any products that we or our collaborators may develop.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">If we are unable to obtain adequate coverage and reimbursement from third-party payers for any products that we or our collaborators may develop, our revenues and prospects for profitability will suffer.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We may not be able to manufacture products that we or our collaborators may develop in commercial quantities, which would impair our ability to commercialize such products.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We and our collaborators are subject to extensive and rigorous ongoing regulation relating to any products that we or our collaborators may develop.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We are subject to certain healthcare laws, regulation and enforcement; our failure to comply with those laws could have a material adverse effect on our results of operations and financial condition.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Current healthcare laws and regulations and future legislative or regulatory reforms to the healthcare system may negatively affect our revenues and prospects for profitability.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Pricing for pharmaceutical products has come under increasing scrutiny by governments, legislative bodies and enforcement agencies.  These activities may result in actions that have the effect of reducing our revenue or harming our business or reputation.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Our competitors may develop products that impair the value of any products that we or our collaborators may develop.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Risks Related to Our Capital Requirements and Financial Results </span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We will need additional capital in the future and, if it is unavailable, we will be forced to delay, reduce or eliminate our commercialization efforts or product development programs.  If additional capital is not available on reasonable terms, we will be forced to obtain funds, if at all, by entering into financing agreements on unattractive terms.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We have a history of net losses, and we expect to continue to incur net losses and may not achieve or maintain profitability.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Our operating results have been and likely will continue to fluctuate, and we believe that period-to-period comparisons of our operating results are not a good indication of our future performance.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We have substantial indebtedness that may limit cash flow available to invest in the ongoing needs of our business.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">If we do not effectively manage our affirmative and restrictive covenants under the BioPharma Term Loan, our financial condition and results of operations could be adversely affected.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Risks Related to Our Relationships with Third Parties</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We are significantly dependent upon our collaborations with Ipsen and other pharmaceutical and biotechnology companies.  If pharmaceutical products are not successfully and timely developed and commercialized under our collaborations, our opportunities to generate revenues from milestones and royalties will be greatly reduced.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Conflicts with our collaborators could jeopardize the success of our collaborative agreements and harm our product development efforts.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We depend on third-party manufacturers, including sole source suppliers, to manufacture commercial quantities of XERMELO.  We may not be able to maintain these relationships and could experience supply disruptions outside of our control.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We rely on a single third-party logistics provider and a limited distribution network of specialty pharmacies and specialty distributors for distribution of XERMELO in fulfillment of prescriptions in the United States, and their failure to distribute XERMELO effectively would adversely affect sales of XERMELO.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We rely on third parties to carry out drug development activities.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">24</span></div><div style="text-align:center;"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We lack the capability to manufacture materials for nonclinical studies, clinical trials or commercial sales and rely on third parties to manufacture our drug candidates, which may harm or delay our product development and commercialization efforts.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Risks Related to Our Intellectual Property </span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">If we are unable to adequately protect our intellectual property, third parties may be able to use our products and technologies, which could adversely affect our ability to compete in the market.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We may be involved in patent litigation and other disputes regarding intellectual property rights and may require licenses from third parties for our planned nonclinical and clinical development and commercialization activities.  We may not prevail in any such litigation or other dispute or be able to obtain required licenses.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Data breaches and cyber-attacks could compromise our intellectual property or other sensitive information and cause significant damage to our business and reputation.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We may be subject to damages resulting from claims that we, our employees or independent contractors have wrongfully used or disclosed alleged trade secrets of their former employers.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Risks Related to Employees and Facilities Operations </span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">If we are unable to manage our growth, our business, financial condition, results of operations and prospects may be adversely affected.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The loss of key personnel or the inability to attract and retain additional personnel could impair our ability to operate and expand our operations.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Facility security breaches may disrupt our operations, subject us to liability and harm our operating results.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Our facilities are located near coastal zones, and the occurrence of a hurricane or other disaster could damage our facilities and equipment, which could harm our operations.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Risks Related to Environmental and Product Liability </span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We have used hazardous chemicals and radioactive and biological materials in our business.  Any claims relating to improper handling, storage or disposal of these materials could be time consuming and costly.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Our business has a substantial risk of product liability and we face potential product liability exposure far in excess of our limited insurance coverage.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Risks Related to Our Common Stock</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Invus, L.P., Invus C.V. and their affiliates own a controlling interest in our outstanding common stock and may have interests which conflict with those of our other stockholders.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Invus has additional rights under our stockholders&#8217; agreement with Invus, L.P. relating to the membership of our board of directors, which provides Invus with substantial influence over significant corporate matters.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Our stock price may be extremely volatile.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We are subject to securities litigation, which is expensive and could divert management attention. </span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Future sales of our common stock, or the perception that such sales may occur, may depress our stock price.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Conversion of our 5.25% Convertible Senior Notes due 2021 may dilute the ownership interest of our existing stockholders, including holders who had previously converted their notes, or may otherwise depress the price of our common stock.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">25</span></div><div style="text-align:center;"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We may engage in future acquisitions, which may be expensive and time consuming and from which we may not realize anticipated benefits.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For additional discussion of the risks and uncertainties that affect our business, see &#8220;Item&#160;1A. Risk Factors&#8221; included in our annual report on Form 10-K for the year ended December&#160;31, 2019 as filed with the Securities and Exchange Commission. </span></div><div><span><br/></span></div><div id="i4e8a6d84e5e241588399a0cfd4660c18_1062"></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 2.&#160;Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides information about our purchases of shares of our common stock during the three months ended March&#160;31, 2020:</span></div><div><span><br/></span></div><div style="padding-left:36pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:93.128%;"><tr><td style="width:1.0%;"></td><td style="width:39.287%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.526%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.930%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.610%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.675%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.610%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.930%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.296%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.936%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Period</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Number of Shares Purchased</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Average Price Paid Per Share</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Maximum Number of Shares that May Yet be Purchased Under the Plans or Programs </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;vertical-align:top;">(3)</sup></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January 1-31, 2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">February 1-29, 2020</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">333,440</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.77&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 1-31, 2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:-36pt;padding-left:72pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">(1) &#160;Represents shares retained by us in satisfaction of the tax withholding obligations of recipients of restricted stock units granted in February 2016, February 2017, February 2018 and February 2019 under our 2017 Equity Incentive Plan with respect to the vesting of such restricted stock units.</span></div><div style="text-indent:-36pt;padding-left:72pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">(2)&#160;Represents the market price of our common stock on the date of vesting of such restricted stock units, calculated in accordance with the process for determination of fair market value under our 2017 Equity Incentive Plan.</span></div><div style="text-indent:-36pt;padding-left:72pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">(3) &#160;In the future, we may grant additional equity securities under our 2017 Equity Incentive Plan for which the recipient's tax withholding obligations with respect to the grant or vesting of such securities may be satisfied by our retention of a portion of such securities.  Further, for any such equity securities which are subject to vesting conditions, the number of equity securities which we may retain in satisfaction of the recipient's tax withholding obligations may be dependent on the continued employment of such recipient or other performance-based conditions.  Accordingly, we cannot predict with any certainty either the total amount of equity securities or the approximate dollar value of such securities that we may purchase in future years.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">26</span></div><div style="text-align:center;"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div id="i4e8a6d84e5e241588399a0cfd4660c18_103"></div><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:-72pt;padding-left:72pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 6.&#160;&#160;Exhibits</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:9.323%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:3.882%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:80.795%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exhibit No.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Description</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:4.5pt;text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">*10.1</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exh101realestateagrame.htm">First Amendment to Real Estate Purchase and Sale Agreement</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">, dated February 13, 2020, between Lex-Gen Woodlands, L.P. and FFC Equity Holdings, L.P.</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:4.5pt;text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">*10.2</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exh102realestateagrame.htm">Second Amendment to Real Estate Purchase and Sale Agreement</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">, dated March 19, 2020, between Lex-Gen Woodlands, L.P. and FFC Equity Holdings, L.P.</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.3</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282220000025/exh1012017equityincent.htm">2017 Equity Incentive Plan, as amended </a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">(filed as Exhibit 10.1 to the Company's Current Report on Form 8-K dated April 23, 2020 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:4.5pt;text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">*31.1</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exh311certificationofp.htm">Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:4.5pt;text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">*31.2</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exh312certificationofp.htm">Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:4.5pt;text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">*32.1</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exh321certificationofp.htm">Certification of Principal Executive and Principal Financial Officers Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:4.5pt;text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">101.INS</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Instance Document</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:4.5pt;text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">101.SCH</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:4.5pt;text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">101.CAL</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:4.5pt;text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">101.DEF</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension  Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:4.5pt;text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">101.LAB</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:4.5pt;text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">101.PRE</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr></table></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">_____________________</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:0.1%;"></td><td style="width:1.996%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:95.804%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Filed herewith.</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">27</span></div><div style="text-align:center;"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div id="i4e8a6d84e5e241588399a0cfd4660c18_106"></div><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Signatures</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:4.911%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:40.794%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:5.205%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:41.090%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lexicon Pharmaceuticals, Inc.</span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">April 27, 2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Lonnel Coats</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lonnel Coats</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">President and Chief Executive Officer</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:5.058%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:40.500%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:5.058%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:41.384%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">April 27, 2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Jeffrey L. Wade</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Jeffrey L. Wade</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer</span></td></tr></table></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">28</span></div><div style="text-align:center;"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Index to Exhibits</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:9.323%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:3.882%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:80.795%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exhibit No.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Description</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:4.5pt;text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">*10.1</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="exh101realestateagrame.htm">First Amendment to Real Estate Purchase and Sale Agreement</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">, dated February 13, 2020, between Lex-Gen Woodlands, L.P. and FFC Equity Holdings, L.P.</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:4.5pt;text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">*10.2</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="exh102realestateagrame.htm">Second Amendment to Real Estate Purchase and Sale Agreement</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">, dated March 19, 2020, between Lex-Gen Woodlands, L.P. and FFC Equity Holdings, L.P.</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.3</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="http://www.sec.gov/Archives/edgar/data/1062822/000106282220000025/exh1012017equityincent.htm">2017 Equity Incentive Plan, as amended</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> (filed as Exhibit 10.1 to the Company's Current Report on Form 8-K dated April 23, 2020 and incorporated by reference herein).</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:4.5pt;text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">*31.1</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="exh311certificationofp.htm">Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:4.5pt;text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">*31.2</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="exh312certificationofp.htm">Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:4.5pt;text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">*32.1</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="exh321certificationofp.htm">Certification of Principal Executive and Principal Financial Officers Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:4.5pt;text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">101.INS</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Instance Document</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:4.5pt;text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">101.SCH</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:4.5pt;text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">101.CAL</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:4.5pt;text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">101.DEF</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension  Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:4.5pt;text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">101.LAB</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:4.5pt;text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">101.PRE</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr></table></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">_____________________</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:0.1%;"></td><td style="width:1.996%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:95.804%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Filed herewith.</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">29</span></div><div style="text-align:center;"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exh101realestateagrame.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ida4f9a908ee74520a9a4e66a8d5871c7_34"></div><div style="height:72pt;width:100%;"><div><font><br></font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Exhibit 10.1</font></div></div><div style="text-align:center;margin-top:2.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:111%;">FIRST AMENDMENT TO</font></div><div style="text-align:center;margin-top:2.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:111%;">REAL ESTATE PURCHASE AND SALE AGREEMENT</font></div><div style="margin-top:0.15pt;"><font><br></font></div><div><font><br></font></div><div style="text-indent:36pt;padding-right:9pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;">This First Amendment to Real Estate Purchase and Sale Agreement (&#34;</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;text-decoration: underline;">First Amendment</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;">&#34;) is made and entered into by and between Lex-Gen Woodlands, L.P., a Delaware limited partnership (&#34;Seller&#34;) and FFC Equity Holdings, L.P., a Texas limited partnership (&#34;Purchaser''), to be effective February 13, 2020 (the &#34;</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;text-decoration: underline;">First Amendment Effective Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;">&#34;).</font></div><div style="padding-right:9pt;margin-top:0.2pt;"><font><br></font></div><div style="text-indent:34.55pt;padding-left:11pt;padding-right:9pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">For and in consideration of the mutual covenants and agreements set forth below and other good and valuable consideration, the receipt and sufficiency of which are acknowledged, Seller and Purchaser hereby recite and agree as follows&#58;</font></div><div style="padding-right:9pt;margin-top:0.85pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:81pt;padding-right:9pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:27.75pt;">Recitals.</font></div><div style="padding-right:9pt;margin-top:0.95pt;"><font><br></font></div><div style="text-indent:81pt;padding-right:9pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;text-decoration: underline;padding-left:14.8pt;">Purchase A</font><font style="background-color:rgb(255,255,255, 0.0);color:#606060;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;text-decoration: underline;">gr</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;text-decoration: underline;">eement</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;">. Seller and Purchaser entered into that certain Real Estate Purchase and Sale Agreement (the &#34;</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;text-decoration: underline;">A</font><font style="background-color:rgb(255,255,255, 0.0);color:#525252;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;text-decoration: underline;">g</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;text-decoration: underline;">reement</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;">&#34;), dated effective January 10, 2020, pursuant to which Seller agreed to sell and Purchaser agreed to purchase, pursuant to the tenns, provisions and conditions therein, certain real property in Montgomery County, Texas, and being more particularly described therein. All capitalized terms not otherwise defined herein shall have the meaning ascribed to them in the Agreement.</font></div><div style="text-indent:81pt;padding-right:9pt;margin-top:1pt;"><font><br></font></div><div style="text-indent:81pt;padding-right:9pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;text-decoration: underline;padding-left:14.18pt;">Amendment.</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;"> Seller and Purchaser desire to amend the Agreement pursuant to this First Amendment as hereinafter provided.</font></div><div style="padding-right:9pt;margin-top:0.2pt;"><font><br></font></div><div style="padding-left:45pt;padding-right:9pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;">The third sentence in </font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;text-decoration: underline;">Section 3.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;"> of the Agreement is hereby deleted in its entirety and replaced with the following&#58;</font></div><div style="padding-left:45pt;padding-right:9pt;margin-top:0.9pt;"><font><br></font></div><div style="text-indent:0.7pt;padding-left:45pt;padding-right:9pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#8220;In the event that this Agreement is not terminated pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> within seventy-five (75) days after the Effective  Date, One Hundred Thousand and No&#47;100 Dollars ($100,000.00) of the Deposit (the &#34;Non-Refundable Amount shall become non-refundable and shall be delivered by Escrow Agent to Seller upon the termination of this Agreement for any reason other than a default by Seller under this Agreement, failure of a condition precedent favoring Purchaser as outlined in Section 6.1 hereof, or a termination of this Agreement pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> (Risk of Loss) or </font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;">6.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> (Condemnation).''</font></div><div style="padding-left:45pt;padding-right:9pt;margin-top:0.35pt;"><font><br></font></div><div style="text-indent:45pt;padding-right:9pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:18.75pt;">Other Terms</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">. All other terms, conditions and provisions of the Agreement are hereby ratified and confirmed and shall remain in full force and effect as of the date thereof, except as expressly modified hereby.</font></div><div style="padding-left:45pt;padding-right:9pt;text-align:justify;"><font><br></font></div><div style="text-indent:45pt;padding-right:9pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:18.75pt;">Counte</font><font style="background-color:rgb(255,255,255, 0.0);color:#606060;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;">rp</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;">arts</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">. This First Amendment may be executed by facsimile or other electronic transmission in two or more counterparts, each of which shall be deemed to be an original, but all of which taken together shall constitute but one and the same instrument.</font></div><div style="padding-left:36pt;"><font><br></font></div><div style="text-indent:45pt;padding-right:9pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:18.75pt;">Bindin</font><font style="background-color:rgb(255,255,255, 0.0);color:#606060;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;">g </font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;">Effect</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">. This First Amendment shall be binding upon and inure to the benefit of the Seller and Purchaser and their respective successors and permitted assigns.</font></div><div style="padding-left:36pt;"><font><br></font></div><div style="padding-left:45pt;padding-right:9pt;text-align:justify;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div><div style="text-align:right;"><font><br></font></div></div><div style="padding-left:45pt;padding-right:9pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">EXECUTED to be effective as of the First Amendment Effective Date.</font></div><div style="padding-left:216pt;margin-bottom:12pt;"><font><br></font></div><div style="padding-left:216pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">SELLER</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#58;</font></div><div style="padding-left:216pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">LEX-GEN WOODLANDS, L.P.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, a Delaware limited partnership</font></div><div style="text-indent:-36pt;padding-left:252pt;margin-bottom:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By&#58;&#160;Lex-Gen Woodlands GP, LLC, a Delaware limited liability company, its sole general partner</font></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By&#58; ________________________</font></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Name&#58; ______________________</font></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Title&#58; _______________________</font></div><div style="padding-left:252pt;"><font><br></font></div><div style="padding-left:252pt;"><font><br></font></div><div style="padding-left:216pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">PURCHASER</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#58;</font></div><div style="padding-left:216pt;margin-bottom:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">FFC EQUITY HOLDINGS, L.P.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, a Texas limited partnership</font></div><div style="text-indent:-36pt;padding-left:252pt;margin-bottom:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By&#58;&#160;FFC Equity Investments, L.L.C., a Texas limited liability company, its sole general partner</font></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By&#58; ________________________</font></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Name&#58; ______________________</font></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Title&#58; _______________________</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>exh102realestateagrame.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ie6dbe74fdcae48c688690f92e9eecb90_34"></div><div style="height:72pt;width:100%;"><div><font><br></font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Exhibit 10.2</font></div></div><div style="text-align:center;margin-top:2.65pt;"><font><br></font></div><div style="text-align:center;margin-top:2.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:111%;">SECOND AMENDMENT TO</font></div><div style="text-align:center;margin-top:2.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:111%;">REAL ESTATE PURCHASE AND SALE AGREEMENT</font></div><div style="margin-top:0.15pt;"><font><br></font></div><div style="padding-right:9pt;margin-top:0.85pt;"><font><br></font></div><div style="text-indent:36pt;padding-right:9pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;">This Second Amendment to Real Estate Purchase and Sale Agreement (&#34;</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;text-decoration: underline;">Second Amendment</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;">&#34;) is made and entered into by and between Lex-Gen Woodlands, L.P., a Delaware limited partnership (&#34;</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;text-decoration: underline;">Seller</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;">&#34;) and FFC Equity Holdings, L.P, a Texas limited partnership (&#34;</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;text-decoration: underline;">Purchaser</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;">&#34;), to be effective March 19, 2020 (the &#34;</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;text-decoration: underline;">Second Amendment Effective Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;">&#34;).</font></div><div style="text-indent:36pt;padding-right:9pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;padding-right:9pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;">For and in consideration of the mutual covenants and agreements set forth below and other good and valuable consideration, the receipt and sufficiency of which are acknowledged, Seller and Purchaser hereby recite and agree as follows&#58;</font></div><div style="margin-top:0.3pt;"><font><br></font></div><div style="margin-top:0.3pt;"><font><br></font></div><div style="padding-right:9pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;">RECITALS</font></div><div style="padding-right:9pt;margin-top:0.95pt;"><font><br></font></div><div style="text-indent:36pt;padding-right:9pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;">(A)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;text-decoration: underline;">Purchase Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;">. Seller and Purchaser entered into that certain Real Estate Purchase and Sale Agreement (the &#34;</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;text-decoration: underline;">Initial Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;">&#34;), dated effective January I0, 2020, as amended by that certain First Amendment dated effective February 13, 2020 (the &#34;</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;text-decoration: underline;">First Amendment</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;">&#34; and, together with the Initial Agreement, the &#34;</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;text-decoration: underline;">Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;">&#34;), pursuant to which Seller agreed to sell and Purchaser agreed to purchase, pursuant to the terms, provisions and conditions therein, certain real property in Montgomery County, Texas, and being more particularly described therein. All capitalized terms not otherwise defined herein shall have the meaning ascribed to them in the Agreement.</font></div><div style="text-indent:36pt;padding-right:9pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;padding-right:9pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;">(B)&#160;Seller and Purchaser desire to amend the Agreement on the terms and conditions set forth herein.</font></div><div style="text-indent:36pt;padding-right:9pt;text-align:justify;"><font><br></font></div><div style="padding-right:9pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;">AGREEMENTS</font></div><div style="text-indent:36pt;padding-right:9pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;padding-right:9pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;">Now, therefore, in consideration of the mutual agreements set forth below, and for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned agree as follows&#58;</font></div><div style="text-indent:36pt;padding-right:9pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;padding-right:9pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;">1.&#160;The definition of &#34;Study Period&#34; in Article 1 of the Agreement is hereby deleted in its entirety and replaced with the following&#58;</font></div><div style="text-indent:36pt;padding-right:9pt;text-align:justify;"><font><br></font></div><div style="padding-left:18pt;padding-right:9pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;text-decoration: underline;">Study Period</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;">&#8221; shall mean the period commencing on the Effective Date and ending at 5&#58;00 p.m., Houston, Texas time, on the date that is one hundred fifty (150) days after the Effective Date.&#34;</font></div><div style="padding-right:9pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;padding-right:9pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;">2.&#160;The third sentence in Section 3.1 of the Agreement is hereby deleted in its entirety and replaced with the following&#58;</font></div><div style="text-indent:36pt;padding-right:9pt;text-align:justify;"><font><br></font></div><div style="padding-left:18pt;padding-right:9pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;">&#34;In the event that this Agreement is not terminated pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;text-decoration: underline;">Section 5.2</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;"> within one hundred thirty-five (135) days after the Effective Date, One Hundred Thousand and No&#47;100 Dollars ($100,000.00) of the Deposit (the &#34;Non-Refundable Amount&#34;) shall become non-refundable and </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div><div style="text-align:right;"><font><br></font></div></div><div style="padding-left:18pt;padding-right:9pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;">shall be delivered by Escrow Agent to Seller upon the termination of this Agreement for any reason other than a default by Seller under this Agreement, failure of a condition precedent favoring Purchaser as outlined in </font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;text-decoration: underline;">Section 6.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;"> hereof, or a termination of this Agreement pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;text-decoration: underline;">Section 6.3 </font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;">(Risk of Loss) or </font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;text-decoration: underline;">6.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;"> (Condemnation).&#34;</font></div><div style="padding-right:9pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;padding-right:9pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;">3.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;text-decoration: underline;">Other Terms</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;">. All other terms, conditions and provisions of the Agreement are hereby ratified and confirmed and shall remain in full force and effect as of the date thereof, except as expressly modified hereby.</font></div><div style="padding-left:18pt;padding-right:9pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;padding-right:9pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;">4.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;text-decoration: underline;">Counterparts</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;">. This Second Amendment may be executed by facsimile or other electronic transmission in two or more counterparts, each of which shall be deemed to be an original, but all of which taken together shall constitute but one and the same instrument.</font></div><div style="padding-left:36pt;"><font><br></font></div><div style="text-indent:36pt;padding-right:9pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;">5.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;text-decoration: underline;">Binding Effect</font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:121%;">. This Second Amendment shall be binding upon and inure to the benefit of the Seller and Purchaser and their respective successors and permitted assigns.</font></div><div style="padding-left:36pt;"><font><br></font></div><div style="padding-left:45pt;padding-right:9pt;text-align:justify;"><font><br></font></div><div style="margin-bottom:8pt;"><font><br></font></div><div style="padding-right:9pt;text-align:center;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div><div style="text-align:right;"><font><br></font></div></div><div style="padding-right:9pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">EXECUTED to be effective as of the Second Amendment Effective Date.</font></div><div style="padding-left:216pt;margin-bottom:12pt;"><font><br></font></div><div style="padding-left:216pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">SELLER</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#58;</font></div><div style="padding-left:216pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">LEX-GEN WOODLANDS, L.P.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, a Delaware limited partnership</font></div><div style="text-indent:-36pt;padding-left:252pt;margin-bottom:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By&#58;&#160;Lex-Gen Woodlands GP, LLC, a Delaware limited liability company, its sole general partner</font></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By&#58; ______________________</font></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Name&#58; ____________________</font></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Title&#58; _____________________</font></div><div style="padding-left:252pt;"><font><br></font></div><div style="padding-left:252pt;"><font><br></font></div><div style="padding-left:216pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">PURCHASER</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#58;</font></div><div style="padding-left:216pt;margin-bottom:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">FFC EQUITY HOLDINGS, L.P.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, a Texas limited partnership</font></div><div style="text-indent:-36pt;padding-left:252pt;margin-bottom:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By&#58;&#160;FFC Equity Investments, L.L.C., a Texas limited liability company, its sole general partner</font></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By&#58; ______________________</font></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Name&#58; ____________________</font></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Title&#58; _____________________</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>exh311certificationofp.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i514aa43970604bb1a64b75925867bc56_1"></div><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Exhibit 31.1</font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATIONS</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, Lonnel Coats, certify that&#58;</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">I have reviewed this Quarterly Report on Form 10-Q of Lexicon Pharmaceuticals, Inc.&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;  </font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt;">evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt;">disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Date&#58; April&#160;27, 2020 </font></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:95.321%;"><tr><td style="width:1.0%;"></td><td style="width:45.699%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:50.301%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Lonnel Coats</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lonnel Coats</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">President and Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>exh312certificationofp.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i048be5b38fd5447096d0dcb669466a34_1"></div><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 31.2</font></div><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATIONS</font></div><div style="text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, Jeffrey L. Wade, certify that&#58;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">I have reviewed this Quarterly Report on Form 10-Q of Lexicon Pharmaceuticals, Inc.&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;  </font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt;">evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt;">disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Date&#58; April&#160;27, 2020 </font></div><div style="text-align:right;"><font><br></font></div><div style="text-align:right;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:51.023%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Jeffrey L. Wade</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Jeffrey L. Wade</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer</font></td></tr></table></div><div style="text-align:right;"><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>exh321certificationofp.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i0560be98a7cf4515affe6ef308d26b1d_1"></div><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 32.1</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION</font></div><div style="text-indent:36pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350, as adopted), Lonnel Coats, Principal Executive Officer of Lexicon Pharmaceuticals, Inc. (&#8220;Lexicon&#8221;), and Jeffrey L. Wade, Principal Financial Officer of Lexicon, each hereby certify that&#58;</font></div><div style="text-indent:-36pt;padding-left:72pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt;">Lexicon's Quarterly Report on Form 10-Q for the period ended March&#160;31, 2020, and to which this Certification is attached as Exhibit 32.1 (the &#8220;Periodic Report&#8221;), fully complies with the requirements of section 13(a) or section 15(d) of the Securities Exchange Act of 1934, and </font></div><div style="text-indent:-36pt;padding-left:72pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt;">The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of Lexicon. </font></div><div style="text-indent:36pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">IN WITNESS WHEREOF, the undersigned have set their hands hereto as of the 27th day of April, 2020.</font></div><div><font><br></font></div><div style="text-align:right;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:56.432%;"><tr><td style="width:1.0%;"></td><td style="width:7.067%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:88.933%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Lonnel Coats</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lonnel Coats</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">President and Chief Executive Officer</font></td></tr></table></div><div style="text-align:right;"><font><br></font></div><div style="text-align:right;"><font><br></font></div><div style="text-align:right;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:56.286%;"><tr><td style="width:1.0%;"></td><td style="width:7.350%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:88.650%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Jeffrey L. Wade</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Jeffrey L. Wade</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">Executive Vice President, Corporate and Administrative</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">Affairs and Chief Financial Officer</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;"> </font></div></td></tr></table></div><div style="text-align:right;"><font><br></font></div><div style="text-align:right;"><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>lxrx-20200331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:b6c3a7dc-b64d-45d6-bfee-77eb11f000ac,g:4bb55044-54d9-4307-a743-01e703a924d5-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lxrx="http://www.lexpharma.com/20200331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.lexpharma.com/20200331">
  <xs:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20200331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20200331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20200331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20200331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformation" roleURI="http://www.lexpharma.com/role/DocumentandEntityInformation">
        <link:definition>0001001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsUnaudited" roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited">
        <link:definition>1001002 - Statement - Consolidated Balance Sheets-Unaudited</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParentheticals" roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals">
        <link:definition>1002003 - Statement - Consolidated Balance Sheets Parentheticals</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLossUnaudited" roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited">
        <link:definition>1003004 - Statement - Consolidated Statements of Comprehensive Loss-Unaudited</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLossParentheticals" roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals">
        <link:definition>1004005 - Statement - Consolidated Statements of Comprehensive Loss Parentheticals</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited">
        <link:definition>1005006 - Statement - Consolidated Statements of Stockholders' Equity/Deficit-Unaudited</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>1006007 - Statement - Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNotes" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes">
        <link:definition>2101101 - Disclosure - Summary of Significant Accounting Policies (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2303301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables">
        <link:definition>2304302 - Disclosure - Summary of Significant Accounting Policies Equity Incentive Awards (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesInventoryDetails" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails">
        <link:definition>2405401 - Disclosure - Summary of Significant Accounting Policies Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation Valuation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1">
        <link:definition>2407403 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation Summary (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2">
        <link:definition>2408404 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation Summary (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentAccountingPronouncementsLevel1Notes" roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes">
        <link:definition>2109102 - Disclosure - Recent Accounting Pronouncements Level 1 (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentAccountingPronouncementsDetails" roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails">
        <link:definition>0402405 - Document - Recent Accounting Pronouncements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandCashEquivalentsandInvestments" roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments">
        <link:definition>2110103 - Disclosure - Cash and Cash Equivalents and Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandCashEquivalentsandInvestmentsTables" roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables">
        <link:definition>2311303 - Disclosure - Cash and Cash Equivalents and Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandCashEquivalentsandInvestmentsDetails1" roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1">
        <link:definition>2412406 - Disclosure - Cash and Cash Equivalents and Investments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandCashEquivalentsandInvestmentsDetails2" roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2">
        <link:definition>2413407 - Disclosure - Cash and Cash Equivalents and Investments (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.lexpharma.com/role/FairValueMeasurements">
        <link:definition>2114104 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.lexpharma.com/role/FairValueMeasurementsTables">
        <link:definition>2315304 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails1" roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails1">
        <link:definition>2416408 - Disclosure - Fair Value Measurements (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtObligations" roleURI="http://www.lexpharma.com/role/DebtObligations">
        <link:definition>2117105 - Disclosure - Debt Obligations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtObligationsTables" roleURI="http://www.lexpharma.com/role/DebtObligationsTables">
        <link:definition>2318305 - Disclosure - Debt Obligations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtObligationsDetails" roleURI="http://www.lexpharma.com/role/DebtObligationsDetails">
        <link:definition>2419409 - Disclosure - Debt Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.lexpharma.com/role/CommitmentsandContingencies">
        <link:definition>2120106 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreements" roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreements">
        <link:definition>2121107 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsTables" roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsTables">
        <link:definition>2322306 - Disclosure - Collaboration and License Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsDetails" roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails">
        <link:definition>2423410 - Disclosure - Collaboration and License Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="lxrx_IpsenRevenueRecognized" abstract="false" name="IpsenRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_IpsenMaximumSalesMilestones" abstract="false" name="IpsenMaximumSalesMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lxrx_Lxrx_Sanofiterminationcashpayment" abstract="false" name="Lxrx_Sanofiterminationcashpayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SanofiRevenueRecognized" abstract="false" name="SanofiRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lxrx_Lxrx_sanofifuturecashpayment" abstract="false" name="Lxrx_sanofifuturecashpayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_Lxrx_sanofiInitialCashPayment" abstract="false" name="Lxrx_sanofiInitialCashPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_MortgageDebtInstrument_Revere_LXRX" abstract="false" name="MortgageDebtInstrument_Revere_LXRX" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_InventoryAbstract" abstract="true" name="InventoryAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_IpsenMilestonePayment" abstract="false" name="IpsenMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_MortgageDebtBalloonPayment_LXRX" abstract="false" name="MortgageDebtBalloonPayment_LXRX" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_IpsenRevenueAllocatedtoLicenseDeliverable" abstract="false" name="IpsenRevenueAllocatedtoLicenseDeliverable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" abstract="true" name="CashAndCashEquivalentsAndInvestmentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_MortgageDebtIssueCosts_Revere_LXRX" abstract="false" name="MortgageDebtIssueCosts_Revere_LXRX" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract" abstract="true" name="ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_ConsolidatedStatementsOfCashFlowsAbstract" abstract="true" name="ConsolidatedStatementsOfCashFlowsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lxrx_ConsolidatedBalanceSheetsAbstract" abstract="true" name="ConsolidatedBalanceSheetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_DebtObligationsAbstract" abstract="true" name="DebtObligationsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX" abstract="false" name="MortgageDebtInterestRateBasePlus_Revere_LXRX" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" abstract="false" name="IpsenRevenueAllocatedtoDevelopmentDeliverable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ConsolidatedStatementsOfOperationsAbstract" abstract="true" name="ConsolidatedStatementsOfOperationsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_IpsenTotalPayments" abstract="false" name="IpsenTotalPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_BuildingsCollateral" abstract="false" name="BuildingsCollateral" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_Sellinggeneralandadministrativeexpenses" abstract="false" name="Sellinggeneralandadministrativeexpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lxrx_SummaryOfSignificantAccountingPoliciesAbstract" abstract="true" name="SummaryOfSignificantAccountingPoliciesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_ConvDebtInstrumentInterestRateStatedPercentage" abstract="false" name="ConvDebtInstrumentInterestRateStatedPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" abstract="false" name="StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_RecentAccountingPronouncementsAbstract" abstract="true" name="RecentAccountingPronouncementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" abstract="false" name="Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable" abstract="false" name="IpsenRevenueAllocatedtoCommitteeDeliverable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_LandCollateral" abstract="false" name="LandCollateral" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_CollaborationAndLicenseAgreementsAbstract" abstract="true" name="CollaborationAndLicenseAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_IpsenMilestonePaymentReceived" abstract="false" name="IpsenMilestonePaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lxrx_MortgageDebtInterestRate_Base_Revere_LXRX" abstract="false" name="MortgageDebtInterestRate_Base_Revere_LXRX" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lxrx_Netproductrevenue" abstract="false" name="Netproductrevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" abstract="true" name="ConsolidatedStatementsOfStockholdersEquityAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_IpsenMaximumRegulatoryAndCommercialMilestones" abstract="false" name="IpsenMaximumRegulatoryAndCommercialMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_IpsenTotalUpfrontPayments" abstract="false" name="IpsenTotalUpfrontPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_FairValueMeasurementsAbstract" abstract="true" name="FairValueMeasurementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>lxrx-20200331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:b6c3a7dc-b64d-45d6-bfee-77eb11f000ac,g:4bb55044-54d9-4307-a743-01e703a924d5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lexpharma.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="lxrx-20200331.xsd#DocumentandEntityInformation"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/DocumentandEntityInformation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="lxrx-20200331.xsd#ConsolidatedBalanceSheetsUnaudited"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e468a23f-d35c-433d-b359-fdb64459c74b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_cc3f0755-e56b-41d0-9f48-2f25a98f27ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e468a23f-d35c-433d-b359-fdb64459c74b" xlink:to="loc_us-gaap_LiabilitiesCurrent_cc3f0755-e56b-41d0-9f48-2f25a98f27ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_c2ba10f8-ecb8-4b51-95de-a404e457b1db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e468a23f-d35c-433d-b359-fdb64459c74b" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_c2ba10f8-ecb8-4b51-95de-a404e457b1db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_29f1c845-2b1c-4ab8-b4b7-ff59a06ac286" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e468a23f-d35c-433d-b359-fdb64459c74b" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_29f1c845-2b1c-4ab8-b4b7-ff59a06ac286" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f34f4603-f5be-45d4-962c-c75d89158e7b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c1b71893-0857-4981-b521-55dbe08c0e3b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f34f4603-f5be-45d4-962c-c75d89158e7b" xlink:to="loc_us-gaap_AssetsCurrent_c1b71893-0857-4981-b521-55dbe08c0e3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8e1e091d-a5af-44b6-b7ad-894158499dea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f34f4603-f5be-45d4-962c-c75d89158e7b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8e1e091d-a5af-44b6-b7ad-894158499dea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_fb0d33e2-777b-4be7-9900-6903066fc2a6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f34f4603-f5be-45d4-962c-c75d89158e7b" xlink:to="loc_us-gaap_Goodwill_fb0d33e2-777b-4be7-9900-6903066fc2a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_ceaec3f4-2d65-4bd6-869d-1d9b98a1c41f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f34f4603-f5be-45d4-962c-c75d89158e7b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_ceaec3f4-2d65-4bd6-869d-1d9b98a1c41f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_4b3f4ab0-9f71-4ffc-8376-1e82a07415f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f34f4603-f5be-45d4-962c-c75d89158e7b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_4b3f4ab0-9f71-4ffc-8376-1e82a07415f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1e10ed8f-2450-4019-b645-2152873ef444" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_959335c0-f2cf-4dbf-ad82-67849f36c62f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1e10ed8f-2450-4019-b645-2152873ef444" xlink:to="loc_us-gaap_AccountsPayableCurrent_959335c0-f2cf-4dbf-ad82-67849f36c62f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_831e1d7d-a081-4bba-9d49-19abcec9b052" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1e10ed8f-2450-4019-b645-2152873ef444" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_831e1d7d-a081-4bba-9d49-19abcec9b052" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_1ecfbbd0-cac5-4698-9e74-2e03f92d9d61" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1e10ed8f-2450-4019-b645-2152873ef444" xlink:to="loc_us-gaap_LongTermDebtCurrent_1ecfbbd0-cac5-4698-9e74-2e03f92d9d61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9a2ab581-4c9c-4bdb-8aa0-83994e2893c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_474ef50d-402c-4bc7-9a68-0f0aa00dea2f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9a2ab581-4c9c-4bdb-8aa0-83994e2893c2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_474ef50d-402c-4bc7-9a68-0f0aa00dea2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_29f8ad8d-093a-43fe-ae05-0a1394d024ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9a2ab581-4c9c-4bdb-8aa0-83994e2893c2" xlink:to="loc_us-gaap_ShortTermInvestments_29f8ad8d-093a-43fe-ae05-0a1394d024ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_c4d7fc64-eb01-4a81-8b95-d1def7f265ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9a2ab581-4c9c-4bdb-8aa0-83994e2893c2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_c4d7fc64-eb01-4a81-8b95-d1def7f265ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_358972d7-a9ca-457d-aa2b-06b02dabc770" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9a2ab581-4c9c-4bdb-8aa0-83994e2893c2" xlink:to="loc_us-gaap_InventoryNet_358972d7-a9ca-457d-aa2b-06b02dabc770" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_e9ca3da1-7725-4057-b8ae-abf3f513e5a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9a2ab581-4c9c-4bdb-8aa0-83994e2893c2" xlink:to="loc_us-gaap_OtherAssetsCurrent_e9ca3da1-7725-4057-b8ae-abf3f513e5a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_59b3985e-25f1-4c03-9f90-3f5829606412" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_4126e918-24ee-439c-b59d-870bb91b13a7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_59b3985e-25f1-4c03-9f90-3f5829606412" xlink:to="loc_us-gaap_Liabilities_4126e918-24ee-439c-b59d-870bb91b13a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3d76534d-4c7b-4570-9b18-933888cf4651" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_59b3985e-25f1-4c03-9f90-3f5829606412" xlink:to="loc_us-gaap_StockholdersEquity_3d76534d-4c7b-4570-9b18-933888cf4651" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3e7a36c5-49bd-40fb-9fbf-373ded2e69d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_2ac3c59a-6526-4125-badf-e1a075c1f7e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3e7a36c5-49bd-40fb-9fbf-373ded2e69d8" xlink:to="loc_us-gaap_PreferredStockValue_2ac3c59a-6526-4125-badf-e1a075c1f7e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_ce1d0252-9dbc-4f95-ba34-d57e932b625b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3e7a36c5-49bd-40fb-9fbf-373ded2e69d8" xlink:to="loc_us-gaap_CommonStockValue_ce1d0252-9dbc-4f95-ba34-d57e932b625b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_4dc99677-2b56-4cf7-8a00-bbeb95aa863c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3e7a36c5-49bd-40fb-9fbf-373ded2e69d8" xlink:to="loc_us-gaap_AdditionalPaidInCapital_4dc99677-2b56-4cf7-8a00-bbeb95aa863c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b823e62d-ccc6-456b-9af8-9e942184058c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3e7a36c5-49bd-40fb-9fbf-373ded2e69d8" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b823e62d-ccc6-456b-9af8-9e942184058c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e7fecbc0-96ac-4c84-be08-1d7fb133521b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3e7a36c5-49bd-40fb-9fbf-373ded2e69d8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e7fecbc0-96ac-4c84-be08-1d7fb133521b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_f0b6a76d-4a04-404f-a758-633311c5d9e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3e7a36c5-49bd-40fb-9fbf-373ded2e69d8" xlink:to="loc_us-gaap_TreasuryStockValue_f0b6a76d-4a04-404f-a758-633311c5d9e1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals" xlink:type="simple" xlink:href="lxrx-20200331.xsd#ConsolidatedBalanceSheetsParentheticals"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="simple" xlink:href="lxrx-20200331.xsd#ConsolidatedStatementsofComprehensiveLossUnaudited"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6efcc3d3-5b6e-4422-89db-07d5cff92496" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_005702ae-11c9-4f7d-b6f6-526f87946f9c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Netproductrevenue_8941bdae-dd95-44e7-8ee3-4eb40f95b3d5" xlink:href="lxrx-20200331.xsd#lxrx_Netproductrevenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_005702ae-11c9-4f7d-b6f6-526f87946f9c" xlink:to="loc_lxrx_Netproductrevenue_8941bdae-dd95-44e7-8ee3-4eb40f95b3d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a2f59e12-0928-43b9-b1ef-00f59f26a440" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_005702ae-11c9-4f7d-b6f6-526f87946f9c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a2f59e12-0928-43b9-b1ef-00f59f26a440" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating_045b54f5-13fe-4ea2-ad30-a5c5297eedf7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_005702ae-11c9-4f7d-b6f6-526f87946f9c" xlink:to="loc_us-gaap_RoyaltyIncomeNonoperating_045b54f5-13fe-4ea2-ad30-a5c5297eedf7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_6e53e8e8-c0c4-4864-9ffd-fd3261e9eccb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cd1216ae-4e96-4ccf-8994-8b21985543d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_6e53e8e8-c0c4-4864-9ffd-fd3261e9eccb" xlink:to="loc_us-gaap_NetIncomeLoss_cd1216ae-4e96-4ccf-8994-8b21985543d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_196b2d6b-08ce-4871-831b-46e68aa86774" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_6e53e8e8-c0c4-4864-9ffd-fd3261e9eccb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_196b2d6b-08ce-4871-831b-46e68aa86774" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_cb29cbe7-99cd-456a-952c-a1a75acbaaf8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_a64f3d12-c0c2-472f-9ba4-4b283c0694e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_cb29cbe7-99cd-456a-952c-a1a75acbaaf8" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_a64f3d12-c0c2-472f-9ba4-4b283c0694e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3b630c91-17b1-4bfa-9d84-eb3348548551" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_cb29cbe7-99cd-456a-952c-a1a75acbaaf8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3b630c91-17b1-4bfa-9d84-eb3348548551" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Sellinggeneralandadministrativeexpenses_4ee74e05-b34d-48e0-bddc-bbfac8f86552" xlink:href="lxrx-20200331.xsd#lxrx_Sellinggeneralandadministrativeexpenses"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_cb29cbe7-99cd-456a-952c-a1a75acbaaf8" xlink:to="loc_lxrx_Sellinggeneralandadministrativeexpenses_4ee74e05-b34d-48e0-bddc-bbfac8f86552" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_71260d03-df39-4333-b533-88ab72018bf0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_0836898c-1222-4722-938e-207e6cfa110c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_71260d03-df39-4333-b533-88ab72018bf0" xlink:to="loc_us-gaap_Revenues_0836898c-1222-4722-938e-207e6cfa110c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_fa7b3d42-2129-436b-a423-8aefcdad3166" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_71260d03-df39-4333-b533-88ab72018bf0" xlink:to="loc_us-gaap_OperatingExpenses_fa7b3d42-2129-436b-a423-8aefcdad3166" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals" xlink:type="simple" xlink:href="lxrx-20200331.xsd#ConsolidatedStatementsofComprehensiveLossParentheticals"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" xlink:type="simple" xlink:href="lxrx-20200331.xsd#ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="lxrx-20200331.xsd#ConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2aab8f7a-9106-4fd7-a339-b352d2206a41" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d59df3e1-51f4-4d8e-93c9-1afc2338254a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2aab8f7a-9106-4fd7-a339-b352d2206a41" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d59df3e1-51f4-4d8e-93c9-1afc2338254a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_b035bbcb-8c3f-4e50-8fa8-85925bbf9ab0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2aab8f7a-9106-4fd7-a339-b352d2206a41" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_b035bbcb-8c3f-4e50-8fa8-85925bbf9ab0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_fd839e42-1e52-48ef-9ef3-a998c5ed39af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2aab8f7a-9106-4fd7-a339-b352d2206a41" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_fd839e42-1e52-48ef-9ef3-a998c5ed39af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_60fac0a6-8edd-4553-a566-138140a323a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_ab3ce1da-dc03-46ab-818e-911806a2c868" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_60fac0a6-8edd-4553-a566-138140a323a3" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_ab3ce1da-dc03-46ab-818e-911806a2c868" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_edc23480-eea1-4dff-8b86-9e2a5d71709e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_60fac0a6-8edd-4553-a566-138140a323a3" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_edc23480-eea1-4dff-8b86-9e2a5d71709e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_3c9e9174-9540-49d7-a4b9-7de6eb9297af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7626f171-1b26-49f5-bec5-bfc9001d3dd4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_3c9e9174-9540-49d7-a4b9-7de6eb9297af" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7626f171-1b26-49f5-bec5-bfc9001d3dd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d97b79ed-5576-4497-9773-aab8ce430672" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_3c9e9174-9540-49d7-a4b9-7de6eb9297af" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d97b79ed-5576-4497-9773-aab8ce430672" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fd3c27f0-0613-4f67-8dae-0d96cfdceaff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_3c9e9174-9540-49d7-a4b9-7de6eb9297af" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fd3c27f0-0613-4f67-8dae-0d96cfdceaff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b4b086f9-2d96-49fe-8081-198732c57a29" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7efdfb2e-1a31-4283-933c-344a2a6896b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b4b086f9-2d96-49fe-8081-198732c57a29" xlink:to="loc_us-gaap_NetIncomeLoss_7efdfb2e-1a31-4283-933c-344a2a6896b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_c83ac526-6fe6-49bf-abe1-37d7c796bd05" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b4b086f9-2d96-49fe-8081-198732c57a29" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_c83ac526-6fe6-49bf-abe1-37d7c796bd05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_909fc241-a9d0-4304-bad6-9ec0e1340975" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b4b086f9-2d96-49fe-8081-198732c57a29" xlink:to="loc_us-gaap_ShareBasedCompensation_909fc241-a9d0-4304-bad6-9ec0e1340975" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_75a62e37-5dd7-4044-b9b1-abd1509bd66c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b4b086f9-2d96-49fe-8081-198732c57a29" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_75a62e37-5dd7-4044-b9b1-abd1509bd66c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_208ef063-f13b-42dd-b758-f3860f10ff01" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b4b086f9-2d96-49fe-8081-198732c57a29" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_208ef063-f13b-42dd-b758-f3860f10ff01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_bebfe6ea-7d79-453b-8f12-4a35dd25b203" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b4b086f9-2d96-49fe-8081-198732c57a29" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_bebfe6ea-7d79-453b-8f12-4a35dd25b203" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c7fdeb6c-3eaa-454c-8da0-084a5345d495" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b4b086f9-2d96-49fe-8081-198732c57a29" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c7fdeb6c-3eaa-454c-8da0-084a5345d495" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_827c7a7e-a3ed-428a-a0fe-17fe1cc13cce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b4b086f9-2d96-49fe-8081-198732c57a29" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_827c7a7e-a3ed-428a-a0fe-17fe1cc13cce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_70b039ec-d657-4471-ba07-303bd89dd8e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b4b086f9-2d96-49fe-8081-198732c57a29" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_70b039ec-d657-4471-ba07-303bd89dd8e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_a554fddb-6adc-485d-840d-c7078fa6d4b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b4b086f9-2d96-49fe-8081-198732c57a29" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_a554fddb-6adc-485d-840d-c7078fa6d4b1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes" xlink:type="simple" xlink:href="lxrx-20200331.xsd#SummaryofSignificantAccountingPoliciesNotes"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="lxrx-20200331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="lxrx-20200331.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables" xlink:type="simple" xlink:href="lxrx-20200331.xsd#SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails" xlink:type="simple" xlink:href="lxrx-20200331.xsd#SummaryofSignificantAccountingPoliciesInventoryDetails"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" xlink:type="simple" xlink:href="lxrx-20200331.xsd#SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" xlink:type="simple" xlink:href="lxrx-20200331.xsd#SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2" xlink:type="simple" xlink:href="lxrx-20200331.xsd#SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes" xlink:type="simple" xlink:href="lxrx-20200331.xsd#RecentAccountingPronouncementsLevel1Notes"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails" xlink:type="simple" xlink:href="lxrx-20200331.xsd#RecentAccountingPronouncementsDetails"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments" xlink:type="simple" xlink:href="lxrx-20200331.xsd#CashandCashEquivalentsandInvestments"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables" xlink:type="simple" xlink:href="lxrx-20200331.xsd#CashandCashEquivalentsandInvestmentsTables"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1" xlink:type="simple" xlink:href="lxrx-20200331.xsd#CashandCashEquivalentsandInvestmentsDetails1"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2" xlink:type="simple" xlink:href="lxrx-20200331.xsd#CashandCashEquivalentsandInvestmentsDetails2"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="lxrx-20200331.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="lxrx-20200331.xsd#FairValueMeasurementsTables"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:type="simple" xlink:href="lxrx-20200331.xsd#FairValueMeasurementsDetails1"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligations" xlink:type="simple" xlink:href="lxrx-20200331.xsd#DebtObligations"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/DebtObligations" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsTables" xlink:type="simple" xlink:href="lxrx-20200331.xsd#DebtObligationsTables"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/DebtObligationsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsDetails" xlink:type="simple" xlink:href="lxrx-20200331.xsd#DebtObligationsDetails"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/DebtObligationsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="lxrx-20200331.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreements" xlink:type="simple" xlink:href="lxrx-20200331.xsd#CollaborationandLicenseAgreements"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/CollaborationandLicenseAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsTables" xlink:type="simple" xlink:href="lxrx-20200331.xsd#CollaborationandLicenseAgreementsTables"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" xlink:type="simple" xlink:href="lxrx-20200331.xsd#CollaborationandLicenseAgreementsDetails"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>lxrx-20200331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:b6c3a7dc-b64d-45d6-bfee-77eb11f000ac,g:4bb55044-54d9-4307-a743-01e703a924d5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="lxrx-20200331.xsd#DocumentandEntityInformation"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/DocumentandEntityInformation" xlink:type="extended" id="i91290a64b15d439aa7f8ebbcf752596a_ac9d3276-79cf-41ef-82b0-6ede3c0b8ed9"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="lxrx-20200331.xsd#ConsolidatedBalanceSheetsUnaudited"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="extended" id="i70612bc2232643068d7e651e6a416565_ebb373ce-b652-415e-becf-d2901e7e330b">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_acd41f62-ef14-4611-b86b-8120a3a023f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_73a89eac-3c14-4ae2-95d2-db1497832790" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_acd41f62-ef14-4611-b86b-8120a3a023f3" xlink:to="loc_us-gaap_AssetsCurrentAbstract_73a89eac-3c14-4ae2-95d2-db1497832790" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c7381589-297b-45f4-b278-e91151b350cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_73a89eac-3c14-4ae2-95d2-db1497832790" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c7381589-297b-45f4-b278-e91151b350cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_1656c999-9c55-483a-aed3-01eac292733b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_73a89eac-3c14-4ae2-95d2-db1497832790" xlink:to="loc_us-gaap_ShortTermInvestments_1656c999-9c55-483a-aed3-01eac292733b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_3ebe6b84-1bb0-4591-99b6-0f51314a973c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_73a89eac-3c14-4ae2-95d2-db1497832790" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_3ebe6b84-1bb0-4591-99b6-0f51314a973c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_b91c6447-0e19-4108-b61a-25a4b6f72ccb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_73a89eac-3c14-4ae2-95d2-db1497832790" xlink:to="loc_us-gaap_InventoryNet_b91c6447-0e19-4108-b61a-25a4b6f72ccb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_5a20615e-b3cf-4c0e-9957-9b11a50df236" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_73a89eac-3c14-4ae2-95d2-db1497832790" xlink:to="loc_us-gaap_OtherAssetsCurrent_5a20615e-b3cf-4c0e-9957-9b11a50df236" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f41b3826-ae8b-4b88-a2bf-adb30e7e256e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_73a89eac-3c14-4ae2-95d2-db1497832790" xlink:to="loc_us-gaap_AssetsCurrent_f41b3826-ae8b-4b88-a2bf-adb30e7e256e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c88a9819-69f7-4a76-97de-155e4426c8a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_acd41f62-ef14-4611-b86b-8120a3a023f3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c88a9819-69f7-4a76-97de-155e4426c8a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_67197895-9867-4ce9-9668-4d310f26221a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_acd41f62-ef14-4611-b86b-8120a3a023f3" xlink:to="loc_us-gaap_Goodwill_67197895-9867-4ce9-9668-4d310f26221a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5ebcba0f-eae7-49f8-b657-e0ba4205ffb7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_acd41f62-ef14-4611-b86b-8120a3a023f3" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5ebcba0f-eae7-49f8-b657-e0ba4205ffb7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ad8f28b0-4554-4606-9c8d-6dff483982c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_acd41f62-ef14-4611-b86b-8120a3a023f3" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ad8f28b0-4554-4606-9c8d-6dff483982c0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b97bbaf9-e6d0-4bf2-a55d-905e32a848ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_acd41f62-ef14-4611-b86b-8120a3a023f3" xlink:to="loc_us-gaap_Assets_b97bbaf9-e6d0-4bf2-a55d-905e32a848ec" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_4d5247f7-1b80-4a4b-bfd3-8011de27f464" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_acd41f62-ef14-4611-b86b-8120a3a023f3" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_4d5247f7-1b80-4a4b-bfd3-8011de27f464" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_3c132d60-4b7f-4354-aa5f-791017c9f2e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4d5247f7-1b80-4a4b-bfd3-8011de27f464" xlink:to="loc_us-gaap_AccountsPayableCurrent_3c132d60-4b7f-4354-aa5f-791017c9f2e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_08c8a79d-5ee8-4700-b307-63aa5b5987aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4d5247f7-1b80-4a4b-bfd3-8011de27f464" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_08c8a79d-5ee8-4700-b307-63aa5b5987aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_9417a559-cb0d-4be4-9edc-4b5789e8f713" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4d5247f7-1b80-4a4b-bfd3-8011de27f464" xlink:to="loc_us-gaap_LongTermDebtCurrent_9417a559-cb0d-4be4-9edc-4b5789e8f713" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d1621c19-b20c-410f-b564-c33d58436261" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4d5247f7-1b80-4a4b-bfd3-8011de27f464" xlink:to="loc_us-gaap_LiabilitiesCurrent_d1621c19-b20c-410f-b564-c33d58436261" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_0d22bebf-0f00-4230-8a98-27d0c5a2f191" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_acd41f62-ef14-4611-b86b-8120a3a023f3" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_0d22bebf-0f00-4230-8a98-27d0c5a2f191" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_81a4d083-f349-448d-87a0-e4a7175e099d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_acd41f62-ef14-4611-b86b-8120a3a023f3" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_81a4d083-f349-448d-87a0-e4a7175e099d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6b549fb1-41f2-403a-8be2-d55bb0944fc6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_acd41f62-ef14-4611-b86b-8120a3a023f3" xlink:to="loc_us-gaap_Liabilities_6b549fb1-41f2-403a-8be2-d55bb0944fc6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_a4efa5d4-2755-492b-92d5-dfc36f564f11" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_acd41f62-ef14-4611-b86b-8120a3a023f3" xlink:to="loc_us-gaap_CommitmentsAndContingencies_a4efa5d4-2755-492b-92d5-dfc36f564f11" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e9a9c57f-aa5a-48f0-9ea6-a48a88634017" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_acd41f62-ef14-4611-b86b-8120a3a023f3" xlink:to="loc_us-gaap_EquityAbstract_e9a9c57f-aa5a-48f0-9ea6-a48a88634017" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_7834f04b-1713-4e6f-987b-1c9ebea753e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_e9a9c57f-aa5a-48f0-9ea6-a48a88634017" xlink:to="loc_us-gaap_PreferredStockValue_7834f04b-1713-4e6f-987b-1c9ebea753e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_41b1b73c-eb87-418c-8ee9-704dd8d9fdfd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_e9a9c57f-aa5a-48f0-9ea6-a48a88634017" xlink:to="loc_us-gaap_CommonStockValue_41b1b73c-eb87-418c-8ee9-704dd8d9fdfd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_c8fef810-adb6-4b2d-b327-bf03abb8fc67" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_e9a9c57f-aa5a-48f0-9ea6-a48a88634017" xlink:to="loc_us-gaap_AdditionalPaidInCapital_c8fef810-adb6-4b2d-b327-bf03abb8fc67" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c24e6bb5-06f3-41db-9360-c80a4a21e37b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_e9a9c57f-aa5a-48f0-9ea6-a48a88634017" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c24e6bb5-06f3-41db-9360-c80a4a21e37b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6b4ea127-9367-4d2a-99db-0c669c81f6a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_e9a9c57f-aa5a-48f0-9ea6-a48a88634017" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6b4ea127-9367-4d2a-99db-0c669c81f6a9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_76986153-65d1-4bf4-b526-740434520c37" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_e9a9c57f-aa5a-48f0-9ea6-a48a88634017" xlink:to="loc_us-gaap_TreasuryStockValue_76986153-65d1-4bf4-b526-740434520c37" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a7286416-b02a-4ccc-9af9-2a43976c72da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_e9a9c57f-aa5a-48f0-9ea6-a48a88634017" xlink:to="loc_us-gaap_StockholdersEquity_a7286416-b02a-4ccc-9af9-2a43976c72da" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_4b8ba583-655b-4815-af6e-2babecbdb947" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_acd41f62-ef14-4611-b86b-8120a3a023f3" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_4b8ba583-655b-4815-af6e-2babecbdb947" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6a078597-bc7d-498b-85d9-611435f6e19f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_acd41f62-ef14-4611-b86b-8120a3a023f3" xlink:to="loc_us-gaap_StatementTable_6a078597-bc7d-498b-85d9-611435f6e19f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_163a29fd-8483-40da-8f4f-1ee621e07f3e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6a078597-bc7d-498b-85d9-611435f6e19f" xlink:to="loc_srt_StatementScenarioAxis_163a29fd-8483-40da-8f4f-1ee621e07f3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_163a29fd-8483-40da-8f4f-1ee621e07f3e_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_163a29fd-8483-40da-8f4f-1ee621e07f3e" xlink:to="loc_srt_ScenarioUnspecifiedDomain_163a29fd-8483-40da-8f4f-1ee621e07f3e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_d53e6b40-7f75-4f35-8c4a-5c3bea128601" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_163a29fd-8483-40da-8f4f-1ee621e07f3e" xlink:to="loc_srt_ScenarioUnspecifiedDomain_d53e6b40-7f75-4f35-8c4a-5c3bea128601" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_d9196aec-d986-42eb-8553-de1ae4b47bc2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6a078597-bc7d-498b-85d9-611435f6e19f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_d9196aec-d986-42eb-8553-de1ae4b47bc2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d9196aec-d986-42eb-8553-de1ae4b47bc2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d9196aec-d986-42eb-8553-de1ae4b47bc2" xlink:to="loc_us-gaap_ClassOfStockDomain_d9196aec-d986-42eb-8553-de1ae4b47bc2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_62230abd-6935-48c1-bcd7-1305d7fa7d02" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d9196aec-d986-42eb-8553-de1ae4b47bc2" xlink:to="loc_us-gaap_ClassOfStockDomain_62230abd-6935-48c1-bcd7-1305d7fa7d02" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals" xlink:type="simple" xlink:href="lxrx-20200331.xsd#ConsolidatedBalanceSheetsParentheticals"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals" xlink:type="extended" id="id5773a4487c94f17b483e9e779ac3627_e27f6799-176c-411b-b721-954dc3160bae"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="simple" xlink:href="lxrx-20200331.xsd#ConsolidatedStatementsofComprehensiveLossUnaudited"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="extended" id="i442030d2066f43b6b43a6b60d1eb6523_0f7f2107-825b-4682-9f28-885c3b8ce27d">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_214efdaa-4111-4eab-ab89-1aa2ea27c166" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_45013f18-cb38-4756-a59b-bf842df4a6c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_214efdaa-4111-4eab-ab89-1aa2ea27c166" xlink:to="loc_us-gaap_RevenuesAbstract_45013f18-cb38-4756-a59b-bf842df4a6c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Netproductrevenue_e488c217-ef66-4641-b4e2-0aae752035bc" xlink:href="lxrx-20200331.xsd#lxrx_Netproductrevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_45013f18-cb38-4756-a59b-bf842df4a6c7" xlink:to="loc_lxrx_Netproductrevenue_e488c217-ef66-4641-b4e2-0aae752035bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4b293e65-4e13-469b-bd8e-2839de85994f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_45013f18-cb38-4756-a59b-bf842df4a6c7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4b293e65-4e13-469b-bd8e-2839de85994f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating_fc913091-185b-4e68-8eef-219f8753270f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_45013f18-cb38-4756-a59b-bf842df4a6c7" xlink:to="loc_us-gaap_RoyaltyIncomeNonoperating_fc913091-185b-4e68-8eef-219f8753270f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_96c68afe-79a2-4b5c-94f4-35b2a57df906" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_45013f18-cb38-4756-a59b-bf842df4a6c7" xlink:to="loc_us-gaap_Revenues_96c68afe-79a2-4b5c-94f4-35b2a57df906" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_51598531-829f-4234-b124-cc13e4e024e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_214efdaa-4111-4eab-ab89-1aa2ea27c166" xlink:to="loc_us-gaap_OperatingExpensesAbstract_51598531-829f-4234-b124-cc13e4e024e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_2e01ce0c-f5f3-472c-9049-97b32add6d35" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_51598531-829f-4234-b124-cc13e4e024e1" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_2e01ce0c-f5f3-472c-9049-97b32add6d35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0cba5bc3-8de5-4ed0-bf79-64dbbd02c52f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_51598531-829f-4234-b124-cc13e4e024e1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0cba5bc3-8de5-4ed0-bf79-64dbbd02c52f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Sellinggeneralandadministrativeexpenses_06d4ca07-89c5-4910-ac03-fabd63a2795b" xlink:href="lxrx-20200331.xsd#lxrx_Sellinggeneralandadministrativeexpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_51598531-829f-4234-b124-cc13e4e024e1" xlink:to="loc_lxrx_Sellinggeneralandadministrativeexpenses_06d4ca07-89c5-4910-ac03-fabd63a2795b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_0c23a3f7-e5b6-4d04-b63b-c70e20cdd237" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_51598531-829f-4234-b124-cc13e4e024e1" xlink:to="loc_us-gaap_OperatingExpenses_0c23a3f7-e5b6-4d04-b63b-c70e20cdd237" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_7ebac876-d714-4369-8dd7-ca9433cfce16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_214efdaa-4111-4eab-ab89-1aa2ea27c166" xlink:to="loc_us-gaap_OperatingIncomeLoss_7ebac876-d714-4369-8dd7-ca9433cfce16" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_c51c62a1-41be-43dc-be6d-3930de24a657" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_214efdaa-4111-4eab-ab89-1aa2ea27c166" xlink:to="loc_us-gaap_InterestExpense_c51c62a1-41be-43dc-be6d-3930de24a657" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_66c863a4-6700-4890-8a54-b8b0fa38168c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_214efdaa-4111-4eab-ab89-1aa2ea27c166" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_66c863a4-6700-4890-8a54-b8b0fa38168c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c7b338e1-6852-44ca-a194-695e063c1880" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_214efdaa-4111-4eab-ab89-1aa2ea27c166" xlink:to="loc_us-gaap_NetIncomeLoss_c7b338e1-6852-44ca-a194-695e063c1880" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_c4fffd3a-c5ca-4b8a-aac8-f52854b2b71c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_214efdaa-4111-4eab-ab89-1aa2ea27c166" xlink:to="loc_us-gaap_EarningsPerShareBasic_c4fffd3a-c5ca-4b8a-aac8-f52854b2b71c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9eff9d76-ecdc-4de9-b981-acdeeed66802" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_214efdaa-4111-4eab-ab89-1aa2ea27c166" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9eff9d76-ecdc-4de9-b981-acdeeed66802" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_51e21d2c-f959-43bf-a715-063e187f3732" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_214efdaa-4111-4eab-ab89-1aa2ea27c166" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_51e21d2c-f959-43bf-a715-063e187f3732" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_619119c8-7821-45ee-a9ef-82cfc8a943db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_214efdaa-4111-4eab-ab89-1aa2ea27c166" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_619119c8-7821-45ee-a9ef-82cfc8a943db" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_34472268-fc3b-412d-ae8d-cffa09bc677c" xlink:href="lxrx-20200331.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_214efdaa-4111-4eab-ab89-1aa2ea27c166" xlink:to="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_34472268-fc3b-412d-ae8d-cffa09bc677c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense_8f13aa5b-c753-4dcf-8ae6-f56830b5029e" xlink:href="lxrx-20200331.xsd#lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_214efdaa-4111-4eab-ab89-1aa2ea27c166" xlink:to="loc_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense_8f13aa5b-c753-4dcf-8ae6-f56830b5029e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_196d45c2-25ff-4068-8b2b-a9f982dd183f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_214efdaa-4111-4eab-ab89-1aa2ea27c166" xlink:to="loc_us-gaap_StatementTable_196d45c2-25ff-4068-8b2b-a9f982dd183f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_cc608597-c812-4910-9fb0-823d1d73d894" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_196d45c2-25ff-4068-8b2b-a9f982dd183f" xlink:to="loc_srt_StatementScenarioAxis_cc608597-c812-4910-9fb0-823d1d73d894" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_cc608597-c812-4910-9fb0-823d1d73d894_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_cc608597-c812-4910-9fb0-823d1d73d894" xlink:to="loc_srt_ScenarioUnspecifiedDomain_cc608597-c812-4910-9fb0-823d1d73d894_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_8a62e5b3-96ef-4282-867c-bea43e925cc7" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_cc608597-c812-4910-9fb0-823d1d73d894" xlink:to="loc_srt_ScenarioUnspecifiedDomain_8a62e5b3-96ef-4282-867c-bea43e925cc7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals" xlink:type="simple" xlink:href="lxrx-20200331.xsd#ConsolidatedStatementsofComprehensiveLossParentheticals"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals" xlink:type="extended" id="i012a40e8ee5f49c9ada718c8e0948c63_be884f1c-17cd-487e-9a96-1f7d3bd26ae0"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" xlink:type="simple" xlink:href="lxrx-20200331.xsd#ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" xlink:type="extended" id="i4f244f38b7fb4998866451d06b8c329e_81cf600e-bf2b-409c-ab8b-587eaccf3170">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3c37f293-0208-4fe5-abd7-9f59a6ec218c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_f8c5289d-acc1-4ae5-85d8-a01f84dd20bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3c37f293-0208-4fe5-abd7-9f59a6ec218c" xlink:to="loc_us-gaap_CommonStockSharesIssued_f8c5289d-acc1-4ae5-85d8-a01f84dd20bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_59c804e9-6114-4171-8c54-6dd2bea756ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3c37f293-0208-4fe5-abd7-9f59a6ec218c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_59c804e9-6114-4171-8c54-6dd2bea756ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b881d6a9-388a-4f74-afe9-a15060ae37ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3c37f293-0208-4fe5-abd7-9f59a6ec218c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b881d6a9-388a-4f74-afe9-a15060ae37ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1605d3af-22af-4bdd-96b4-4e44017fb1db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3c37f293-0208-4fe5-abd7-9f59a6ec218c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1605d3af-22af-4bdd-96b4-4e44017fb1db" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e5ddf382-dd8f-4dfd-81d0-32bc44aada0e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3c37f293-0208-4fe5-abd7-9f59a6ec218c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e5ddf382-dd8f-4dfd-81d0-32bc44aada0e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_feec8090-8032-4f44-b69d-04e2abdb38d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3c37f293-0208-4fe5-abd7-9f59a6ec218c" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_feec8090-8032-4f44-b69d-04e2abdb38d9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_649b4b24-cbe0-429d-b135-9e575df06dc9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3c37f293-0208-4fe5-abd7-9f59a6ec218c" xlink:to="loc_us-gaap_NetIncomeLoss_649b4b24-cbe0-429d-b135-9e575df06dc9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_e5ea9e2c-b8c6-4f05-80a1-b82d0c0deb15" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3c37f293-0208-4fe5-abd7-9f59a6ec218c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_e5ea9e2c-b8c6-4f05-80a1-b82d0c0deb15" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_ffc5b17b-3756-40d5-956d-43e8d93bffa3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_089b54c9-ebb9-41b0-a8e8-30dfa32d98fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1512b3ba-8ba6-46e6-8c1b-f5f00f44302c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3c37f293-0208-4fe5-abd7-9f59a6ec218c" xlink:to="loc_us-gaap_StatementTable_1512b3ba-8ba6-46e6-8c1b-f5f00f44302c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_fac3dfa3-32a0-4ac6-801b-3f4aeba86b3f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1512b3ba-8ba6-46e6-8c1b-f5f00f44302c" xlink:to="loc_srt_StatementScenarioAxis_fac3dfa3-32a0-4ac6-801b-3f4aeba86b3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_fac3dfa3-32a0-4ac6-801b-3f4aeba86b3f_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_fac3dfa3-32a0-4ac6-801b-3f4aeba86b3f" xlink:to="loc_srt_ScenarioUnspecifiedDomain_fac3dfa3-32a0-4ac6-801b-3f4aeba86b3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_0ea65a33-2d06-437a-bbf5-a26f49a88f88" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_fac3dfa3-32a0-4ac6-801b-3f4aeba86b3f" xlink:to="loc_srt_ScenarioUnspecifiedDomain_0ea65a33-2d06-437a-bbf5-a26f49a88f88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_cff05e01-ef8b-40f0-8a9e-c6eba65fc6d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1512b3ba-8ba6-46e6-8c1b-f5f00f44302c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_cff05e01-ef8b-40f0-8a9e-c6eba65fc6d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_cff05e01-ef8b-40f0-8a9e-c6eba65fc6d6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cff05e01-ef8b-40f0-8a9e-c6eba65fc6d6" xlink:to="loc_us-gaap_EquityComponentDomain_cff05e01-ef8b-40f0-8a9e-c6eba65fc6d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a34d246e-bfd0-4e9e-99d2-b1e986b2ce12" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cff05e01-ef8b-40f0-8a9e-c6eba65fc6d6" xlink:to="loc_us-gaap_EquityComponentDomain_a34d246e-bfd0-4e9e-99d2-b1e986b2ce12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ab014a94-d8af-4b99-be2f-ad59e9baa71a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a34d246e-bfd0-4e9e-99d2-b1e986b2ce12" xlink:to="loc_us-gaap_CommonStockMember_ab014a94-d8af-4b99-be2f-ad59e9baa71a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_7757dd24-caf5-4cdd-9c0a-161af390fd31" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a34d246e-bfd0-4e9e-99d2-b1e986b2ce12" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_7757dd24-caf5-4cdd-9c0a-161af390fd31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d7d049cf-70f2-4eea-b16b-8124778e77c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a34d246e-bfd0-4e9e-99d2-b1e986b2ce12" xlink:to="loc_us-gaap_RetainedEarningsMember_d7d049cf-70f2-4eea-b16b-8124778e77c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e0a2bcfb-908b-4f8c-9e3b-1a4e8e35bad0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a34d246e-bfd0-4e9e-99d2-b1e986b2ce12" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e0a2bcfb-908b-4f8c-9e3b-1a4e8e35bad0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_fa0c1d0e-7b33-4c14-b65d-17c59c146865" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a34d246e-bfd0-4e9e-99d2-b1e986b2ce12" xlink:to="loc_us-gaap_TreasuryStockMember_fa0c1d0e-7b33-4c14-b65d-17c59c146865" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_719b2df6-1fee-40b7-84c2-6fe2d438eecf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1512b3ba-8ba6-46e6-8c1b-f5f00f44302c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_719b2df6-1fee-40b7-84c2-6fe2d438eecf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_719b2df6-1fee-40b7-84c2-6fe2d438eecf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_719b2df6-1fee-40b7-84c2-6fe2d438eecf" xlink:to="loc_us-gaap_ClassOfStockDomain_719b2df6-1fee-40b7-84c2-6fe2d438eecf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ecd188a3-4ad3-4606-866d-e95f7b9b4e30" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_719b2df6-1fee-40b7-84c2-6fe2d438eecf" xlink:to="loc_us-gaap_ClassOfStockDomain_ecd188a3-4ad3-4606-866d-e95f7b9b4e30" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="lxrx-20200331.xsd#ConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended" id="i8f397283db6e40ada0fca2d65ca392c7_2769698b-dffa-45f9-af67-e8fa5509d69a">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1e626afe-f0d9-420a-8313-6cf8787f3635" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0b38f419-5a31-44d8-898f-f4f9724eb644" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1e626afe-f0d9-420a-8313-6cf8787f3635" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0b38f419-5a31-44d8-898f-f4f9724eb644" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2a3344c5-d549-4c22-b597-24d4e91b40ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0b38f419-5a31-44d8-898f-f4f9724eb644" xlink:to="loc_us-gaap_NetIncomeLoss_2a3344c5-d549-4c22-b597-24d4e91b40ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3d0ffbf2-415c-4fa9-9b8f-88f831244472" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0b38f419-5a31-44d8-898f-f4f9724eb644" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3d0ffbf2-415c-4fa9-9b8f-88f831244472" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_39b92d2c-d990-46f1-8d47-8e0f0ddc2a8c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3d0ffbf2-415c-4fa9-9b8f-88f831244472" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_39b92d2c-d990-46f1-8d47-8e0f0ddc2a8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_0247649d-96f1-4392-8b29-a8ed8d52685e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3d0ffbf2-415c-4fa9-9b8f-88f831244472" xlink:to="loc_us-gaap_ShareBasedCompensation_0247649d-96f1-4392-8b29-a8ed8d52685e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_ea0d8b97-3d86-4cab-885d-e012a88e5023" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3d0ffbf2-415c-4fa9-9b8f-88f831244472" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_ea0d8b97-3d86-4cab-885d-e012a88e5023" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f6ffc65d-c8bf-4f04-83af-71288136674e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3d0ffbf2-415c-4fa9-9b8f-88f831244472" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f6ffc65d-c8bf-4f04-83af-71288136674e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8365b1e0-c71c-4970-aec8-b963e31dedcc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f6ffc65d-c8bf-4f04-83af-71288136674e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8365b1e0-c71c-4970-aec8-b963e31dedcc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_6e12c1be-d0df-4529-9fbc-6f01af7c1135" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f6ffc65d-c8bf-4f04-83af-71288136674e" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_6e12c1be-d0df-4529-9fbc-6f01af7c1135" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4f451708-9e27-43a8-af91-040d0c45d6ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f6ffc65d-c8bf-4f04-83af-71288136674e" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4f451708-9e27-43a8-af91-040d0c45d6ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_92aebdd2-7aac-4168-af9f-ab91a790bdfe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f6ffc65d-c8bf-4f04-83af-71288136674e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_92aebdd2-7aac-4168-af9f-ab91a790bdfe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_b63b4d37-8396-4bd5-86be-08603c2a495f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f6ffc65d-c8bf-4f04-83af-71288136674e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_b63b4d37-8396-4bd5-86be-08603c2a495f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_3dca1ebe-add4-48e0-bcd7-1cf99b0ed433" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f6ffc65d-c8bf-4f04-83af-71288136674e" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_3dca1ebe-add4-48e0-bcd7-1cf99b0ed433" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ba2a8980-da23-416d-b626-d941437c4f7f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0b38f419-5a31-44d8-898f-f4f9724eb644" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ba2a8980-da23-416d-b626-d941437c4f7f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e984e9c8-b269-46bd-b639-0c0770cb8024" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1e626afe-f0d9-420a-8313-6cf8787f3635" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e984e9c8-b269-46bd-b639-0c0770cb8024" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2b9d37bf-e939-4b1f-b3e9-0c08cae6be9a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e984e9c8-b269-46bd-b639-0c0770cb8024" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2b9d37bf-e939-4b1f-b3e9-0c08cae6be9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_9d17bc8d-e56b-4143-acd5-6087078d1dac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e984e9c8-b269-46bd-b639-0c0770cb8024" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_9d17bc8d-e56b-4143-acd5-6087078d1dac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_3b7855aa-f229-442b-9f45-9448af8cad23" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e984e9c8-b269-46bd-b639-0c0770cb8024" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_3b7855aa-f229-442b-9f45-9448af8cad23" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6d059029-2d4d-4258-a583-c5cf1ffbb072" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e984e9c8-b269-46bd-b639-0c0770cb8024" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6d059029-2d4d-4258-a583-c5cf1ffbb072" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_86ccf290-b653-4cb0-97bf-abfe18da633b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1e626afe-f0d9-420a-8313-6cf8787f3635" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_86ccf290-b653-4cb0-97bf-abfe18da633b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_e02a6eb9-b40f-41a1-bc8f-c81c7a44e706" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_86ccf290-b653-4cb0-97bf-abfe18da633b" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_e02a6eb9-b40f-41a1-bc8f-c81c7a44e706" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_d7af816b-d4c7-42dd-bf9d-08fd7673e726" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_86ccf290-b653-4cb0-97bf-abfe18da633b" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_d7af816b-d4c7-42dd-bf9d-08fd7673e726" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_309ca1df-b424-4b83-af23-50b6940d8f88" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_86ccf290-b653-4cb0-97bf-abfe18da633b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_309ca1df-b424-4b83-af23-50b6940d8f88" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_c7079c14-aea2-4475-b055-6536489adc1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1e626afe-f0d9-420a-8313-6cf8787f3635" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_c7079c14-aea2-4475-b055-6536489adc1d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_dc99c137-e8d9-44bb-9cfb-3404b0572aed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1e626afe-f0d9-420a-8313-6cf8787f3635" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_dc99c137-e8d9-44bb-9cfb-3404b0572aed" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_dd25fdb3-854f-40e4-bb9a-b799474fd448" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_7adee890-a3d8-49a8-821b-609aa489294b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1e626afe-f0d9-420a-8313-6cf8787f3635" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_7adee890-a3d8-49a8-821b-609aa489294b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_bf2a4d10-ad1d-49e8-93fd-7975869bceff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7adee890-a3d8-49a8-821b-609aa489294b" xlink:to="loc_us-gaap_InterestPaidNet_bf2a4d10-ad1d-49e8-93fd-7975869bceff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d75b825f-26fa-45ff-889b-d0ade3cda7ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1e626afe-f0d9-420a-8313-6cf8787f3635" xlink:to="loc_us-gaap_StatementTable_d75b825f-26fa-45ff-889b-d0ade3cda7ff" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_68e6e049-1d4a-46c4-9053-083b90e862c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d75b825f-26fa-45ff-889b-d0ade3cda7ff" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_68e6e049-1d4a-46c4-9053-083b90e862c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_68e6e049-1d4a-46c4-9053-083b90e862c6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_68e6e049-1d4a-46c4-9053-083b90e862c6" xlink:to="loc_us-gaap_EquityComponentDomain_68e6e049-1d4a-46c4-9053-083b90e862c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2fd978db-bb97-49f7-b891-ed8330bc1358" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_68e6e049-1d4a-46c4-9053-083b90e862c6" xlink:to="loc_us-gaap_EquityComponentDomain_2fd978db-bb97-49f7-b891-ed8330bc1358" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_54102839-e8b0-4c64-b2bc-634b86e6fc2d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d75b825f-26fa-45ff-889b-d0ade3cda7ff" xlink:to="loc_srt_StatementScenarioAxis_54102839-e8b0-4c64-b2bc-634b86e6fc2d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_54102839-e8b0-4c64-b2bc-634b86e6fc2d_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_54102839-e8b0-4c64-b2bc-634b86e6fc2d" xlink:to="loc_srt_ScenarioUnspecifiedDomain_54102839-e8b0-4c64-b2bc-634b86e6fc2d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_12e6a0a4-7aac-40d6-93ae-8efaed999d5d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_54102839-e8b0-4c64-b2bc-634b86e6fc2d" xlink:to="loc_srt_ScenarioUnspecifiedDomain_12e6a0a4-7aac-40d6-93ae-8efaed999d5d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes" xlink:type="simple" xlink:href="lxrx-20200331.xsd#SummaryofSignificantAccountingPoliciesNotes"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes" xlink:type="extended" id="i166997e97c2a4c6a8bee48391724daf6_febbd999-4299-438a-8fb3-a97a1d60355b"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="lxrx-20200331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="ic15daaf000aa4ce4962e9b78496743b1_1b64a3fa-e37c-4b76-8f70-cffa6d2652a1"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="lxrx-20200331.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended" id="ia48bfb03be1649158fc19b1b6c369edf_2d552351-4468-4ecd-a7fd-0a59009308df"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables" xlink:type="simple" xlink:href="lxrx-20200331.xsd#SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables" xlink:type="extended" id="i65981e9f6473497282e26bbe3ede6d98_ed6a9b98-6b9c-4670-a536-cb7911ac554d"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails" xlink:type="simple" xlink:href="lxrx-20200331.xsd#SummaryofSignificantAccountingPoliciesInventoryDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails" xlink:type="extended" id="id5ef2d7519c942cb9724bfca19af85b4_d003e9e4-5f35-4dd9-a397-03b9bb8efab4">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_ec1deff6-0838-4e04-97ca-3db085ccd373" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_0bc89263-b9d7-4079-843c-b6de14ca3013" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_ec1deff6-0838-4e04-97ca-3db085ccd373" xlink:to="loc_us-gaap_InventoryRawMaterials_0bc89263-b9d7-4079-843c-b6de14ca3013" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_93a0eab1-e62e-41b7-b05d-ec46d640b1d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_ec1deff6-0838-4e04-97ca-3db085ccd373" xlink:to="loc_us-gaap_InventoryWorkInProcess_93a0eab1-e62e-41b7-b05d-ec46d640b1d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_c482fbc3-4039-40d6-9cc8-9c6b1836a578" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_ec1deff6-0838-4e04-97ca-3db085ccd373" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_c482fbc3-4039-40d6-9cc8-9c6b1836a578" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_d76abbd2-9e6f-4e27-9448-f398fe935d06" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_ec1deff6-0838-4e04-97ca-3db085ccd373" xlink:to="loc_us-gaap_InventoryFinishedGoods_d76abbd2-9e6f-4e27-9448-f398fe935d06" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_e87339ff-300c-4427-94e1-c1897925f617" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_ec1deff6-0838-4e04-97ca-3db085ccd373" xlink:to="loc_us-gaap_InventoryGross_e87339ff-300c-4427-94e1-c1897925f617" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_5312e4cc-d0bb-4bf2-b83f-3c146b7d7591" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_ec1deff6-0838-4e04-97ca-3db085ccd373" xlink:to="loc_us-gaap_InventoryCurrentTable_5312e4cc-d0bb-4bf2-b83f-3c146b7d7591" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_e77592eb-f669-4056-a5e5-198572affb3c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_5312e4cc-d0bb-4bf2-b83f-3c146b7d7591" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_e77592eb-f669-4056-a5e5-198572affb3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_e77592eb-f669-4056-a5e5-198572affb3c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_e77592eb-f669-4056-a5e5-198572affb3c" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_e77592eb-f669-4056-a5e5-198572affb3c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_120cc813-b4d3-4982-a614-c8d934cf7471" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_e77592eb-f669-4056-a5e5-198572affb3c" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_120cc813-b4d3-4982-a614-c8d934cf7471" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" xlink:type="simple" xlink:href="lxrx-20200331.xsd#SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" xlink:type="extended" id="i29b0b6ef7f9a44248c0e6fe526336cfa_fb5ea587-9802-47a8-9e2d-8b65f998ea6a">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac94f69c-fd06-4835-8700-244e4cf10a78" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_b1cdd1d3-4391-4723-86f3-971aca84b0cc" xlink:href="lxrx-20200331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac94f69c-fd06-4835-8700-244e4cf10a78" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_b1cdd1d3-4391-4723-86f3-971aca84b0cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_d69feb02-7c60-4387-a655-875fa6d3e64d" xlink:href="lxrx-20200331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac94f69c-fd06-4835-8700-244e4cf10a78" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_d69feb02-7c60-4387-a655-875fa6d3e64d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_4b8bb087-475d-48cf-a43c-bba581a12a0b" xlink:href="lxrx-20200331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac94f69c-fd06-4835-8700-244e4cf10a78" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_4b8bb087-475d-48cf-a43c-bba581a12a0b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_557670aa-40d4-402a-ad86-2a6b3f3155fe" xlink:href="lxrx-20200331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac94f69c-fd06-4835-8700-244e4cf10a78" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_557670aa-40d4-402a-ad86-2a6b3f3155fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_e7f13efa-f763-41d4-b26e-7485f387bb44" xlink:href="lxrx-20200331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac94f69c-fd06-4835-8700-244e4cf10a78" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_e7f13efa-f763-41d4-b26e-7485f387bb44" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_6a94b13f-1191-4a57-aee3-1d68c7452924" xlink:href="lxrx-20200331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac94f69c-fd06-4835-8700-244e4cf10a78" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_6a94b13f-1191-4a57-aee3-1d68c7452924" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_899b3b6a-b44e-4cf8-8da7-3945673f29f4" xlink:href="lxrx-20200331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac94f69c-fd06-4835-8700-244e4cf10a78" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_899b3b6a-b44e-4cf8-8da7-3945673f29f4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_09ddfedb-09cc-4081-b51b-4a6de298884b" xlink:href="lxrx-20200331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac94f69c-fd06-4835-8700-244e4cf10a78" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_09ddfedb-09cc-4081-b51b-4a6de298884b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f371bf13-0336-495f-97f5-c657d90d7bb5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac94f69c-fd06-4835-8700-244e4cf10a78" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f371bf13-0336-495f-97f5-c657d90d7bb5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_ce334015-f304-4474-bbf1-9072b0e2bfa0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f371bf13-0336-495f-97f5-c657d90d7bb5" xlink:to="loc_us-gaap_PlanNameAxis_ce334015-f304-4474-bbf1-9072b0e2bfa0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ce334015-f304-4474-bbf1-9072b0e2bfa0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_ce334015-f304-4474-bbf1-9072b0e2bfa0" xlink:to="loc_us-gaap_PlanNameDomain_ce334015-f304-4474-bbf1-9072b0e2bfa0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a813748f-7547-45b8-9e31-c28ad1c1ef0e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_ce334015-f304-4474-bbf1-9072b0e2bfa0" xlink:to="loc_us-gaap_PlanNameDomain_a813748f-7547-45b8-9e31-c28ad1c1ef0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_4e13f14d-2a80-4d74-9f4d-312861c4c3ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f371bf13-0336-495f-97f5-c657d90d7bb5" xlink:to="loc_us-gaap_AwardDateAxis_4e13f14d-2a80-4d74-9f4d-312861c4c3ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_4e13f14d-2a80-4d74-9f4d-312861c4c3ab_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardDateAxis_4e13f14d-2a80-4d74-9f4d-312861c4c3ab" xlink:to="loc_us-gaap_AwardDateDomain_4e13f14d-2a80-4d74-9f4d-312861c4c3ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_0795ade6-097c-47b3-bd17-f3eeb602c552" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardDateAxis_4e13f14d-2a80-4d74-9f4d-312861c4c3ab" xlink:to="loc_us-gaap_AwardDateDomain_0795ade6-097c-47b3-bd17-f3eeb602c552" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f6a3db60-c967-407a-a8ff-a80777d8edd2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f371bf13-0336-495f-97f5-c657d90d7bb5" xlink:to="loc_us-gaap_AwardTypeAxis_f6a3db60-c967-407a-a8ff-a80777d8edd2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f6a3db60-c967-407a-a8ff-a80777d8edd2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f6a3db60-c967-407a-a8ff-a80777d8edd2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f6a3db60-c967-407a-a8ff-a80777d8edd2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fa34e95e-b5b9-43fe-997e-df464adfe031" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f6a3db60-c967-407a-a8ff-a80777d8edd2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fa34e95e-b5b9-43fe-997e-df464adfe031" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_a29a7421-a123-42af-894c-bcbbee4af3b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fa34e95e-b5b9-43fe-997e-df464adfe031" xlink:to="loc_us-gaap_StockOptionMember_a29a7421-a123-42af-894c-bcbbee4af3b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_da53f784-d135-4ae0-bea2-4ecfa8e39ed8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f371bf13-0336-495f-97f5-c657d90d7bb5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_da53f784-d135-4ae0-bea2-4ecfa8e39ed8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_da53f784-d135-4ae0-bea2-4ecfa8e39ed8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_da53f784-d135-4ae0-bea2-4ecfa8e39ed8" xlink:to="loc_us-gaap_ClassOfStockDomain_da53f784-d135-4ae0-bea2-4ecfa8e39ed8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3b101392-7d3b-463e-ba08-38ec6ac1dd2b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_da53f784-d135-4ae0-bea2-4ecfa8e39ed8" xlink:to="loc_us-gaap_ClassOfStockDomain_3b101392-7d3b-463e-ba08-38ec6ac1dd2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_85bac312-a2b9-4551-b802-8856104d4d5d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f371bf13-0336-495f-97f5-c657d90d7bb5" xlink:to="loc_srt_RangeAxis_85bac312-a2b9-4551-b802-8856104d4d5d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_85bac312-a2b9-4551-b802-8856104d4d5d_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_85bac312-a2b9-4551-b802-8856104d4d5d" xlink:to="loc_srt_RangeMember_85bac312-a2b9-4551-b802-8856104d4d5d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0cd51b47-d870-42e2-b5c2-def8257c5a0e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_85bac312-a2b9-4551-b802-8856104d4d5d" xlink:to="loc_srt_RangeMember_0cd51b47-d870-42e2-b5c2-def8257c5a0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_8c4d7337-e880-46d8-8082-ce57d1aab835" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f371bf13-0336-495f-97f5-c657d90d7bb5" xlink:to="loc_us-gaap_VestingAxis_8c4d7337-e880-46d8-8082-ce57d1aab835" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_8c4d7337-e880-46d8-8082-ce57d1aab835_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_8c4d7337-e880-46d8-8082-ce57d1aab835" xlink:to="loc_us-gaap_VestingDomain_8c4d7337-e880-46d8-8082-ce57d1aab835_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_06f9154f-9ed6-404e-99c8-cfcee0949d9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_8c4d7337-e880-46d8-8082-ce57d1aab835" xlink:to="loc_us-gaap_VestingDomain_06f9154f-9ed6-404e-99c8-cfcee0949d9f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" xlink:type="simple" xlink:href="lxrx-20200331.xsd#SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" xlink:type="extended" id="if417479ddb5b4c7abde4cab3da708c44_8d873c5e-dc66-46eb-9a1d-4d9d7f3c8abd">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60548cd-546f-476a-a917-e98498745ee7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_db3f13ae-4d20-4a16-a930-6b7e44549d55" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60548cd-546f-476a-a917-e98498745ee7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_db3f13ae-4d20-4a16-a930-6b7e44549d55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_946416a0-90a6-4dc9-bd7e-9a5991977b79" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60548cd-546f-476a-a917-e98498745ee7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_946416a0-90a6-4dc9-bd7e-9a5991977b79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_8eb2bf9b-d6ed-4261-862e-e4c0755a8811" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60548cd-546f-476a-a917-e98498745ee7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_8eb2bf9b-d6ed-4261-862e-e4c0755a8811" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_83debb2e-bb86-4929-a22c-4cb029239182" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60548cd-546f-476a-a917-e98498745ee7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_83debb2e-bb86-4929-a22c-4cb029239182" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_5fa23587-5f40-4f11-9dde-6f72597da5d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60548cd-546f-476a-a917-e98498745ee7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_5fa23587-5f40-4f11-9dde-6f72597da5d9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_6636d9b3-00f3-4718-b7c7-55f0aa0d0299" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60548cd-546f-476a-a917-e98498745ee7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_6636d9b3-00f3-4718-b7c7-55f0aa0d0299" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_31929d81-8fab-46e6-b525-b1d8390c819f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60548cd-546f-476a-a917-e98498745ee7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_31929d81-8fab-46e6-b525-b1d8390c819f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4b82c82f-ea71-40c9-90f4-40db7eb3b66b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60548cd-546f-476a-a917-e98498745ee7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4b82c82f-ea71-40c9-90f4-40db7eb3b66b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c27e31b0-f5ac-4969-9141-034052102b75" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60548cd-546f-476a-a917-e98498745ee7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c27e31b0-f5ac-4969-9141-034052102b75" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_06cbdd66-c808-445c-810a-7b11c9b7abb9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60548cd-546f-476a-a917-e98498745ee7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_06cbdd66-c808-445c-810a-7b11c9b7abb9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a90c9c36-2979-4315-a00c-9513094efd36" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60548cd-546f-476a-a917-e98498745ee7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a90c9c36-2979-4315-a00c-9513094efd36" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f9d593e1-0be9-485c-8451-28f818ec35ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60548cd-546f-476a-a917-e98498745ee7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f9d593e1-0be9-485c-8451-28f818ec35ac" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7bb01ef3-79c8-4f27-95df-ccf5419bdf0a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60548cd-546f-476a-a917-e98498745ee7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7bb01ef3-79c8-4f27-95df-ccf5419bdf0a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fdb2272d-2ae2-4413-b5a2-e7f32facf462" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60548cd-546f-476a-a917-e98498745ee7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fdb2272d-2ae2-4413-b5a2-e7f32facf462" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1bf21ef2-aeaf-4f67-94d4-ca958dc0b03e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60548cd-546f-476a-a917-e98498745ee7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1bf21ef2-aeaf-4f67-94d4-ca958dc0b03e" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f6a5f727-418f-4273-a367-a61a02dad066" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60548cd-546f-476a-a917-e98498745ee7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f6a5f727-418f-4273-a367-a61a02dad066" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_192d3078-fd6f-4858-8dbb-d26150101fcb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60548cd-546f-476a-a917-e98498745ee7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_192d3078-fd6f-4858-8dbb-d26150101fcb" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d04c03c3-d91d-4e9f-90da-2c8f6b146b46" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60548cd-546f-476a-a917-e98498745ee7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d04c03c3-d91d-4e9f-90da-2c8f6b146b46" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e799cdf2-f6ac-4602-88e8-e37164600451" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60548cd-546f-476a-a917-e98498745ee7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e799cdf2-f6ac-4602-88e8-e37164600451" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_4bceb6f4-00de-420e-b4ef-bf897f97ea82" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e799cdf2-f6ac-4602-88e8-e37164600451" xlink:to="loc_us-gaap_PlanNameAxis_4bceb6f4-00de-420e-b4ef-bf897f97ea82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4bceb6f4-00de-420e-b4ef-bf897f97ea82_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_4bceb6f4-00de-420e-b4ef-bf897f97ea82" xlink:to="loc_us-gaap_PlanNameDomain_4bceb6f4-00de-420e-b4ef-bf897f97ea82_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_458e25f3-96e0-4028-9dba-bb46e27eb3fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_4bceb6f4-00de-420e-b4ef-bf897f97ea82" xlink:to="loc_us-gaap_PlanNameDomain_458e25f3-96e0-4028-9dba-bb46e27eb3fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_3a73c2b9-4e4e-43d7-9a0f-4d0bb710d765" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e799cdf2-f6ac-4602-88e8-e37164600451" xlink:to="loc_us-gaap_AwardDateAxis_3a73c2b9-4e4e-43d7-9a0f-4d0bb710d765" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_3a73c2b9-4e4e-43d7-9a0f-4d0bb710d765_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardDateAxis_3a73c2b9-4e4e-43d7-9a0f-4d0bb710d765" xlink:to="loc_us-gaap_AwardDateDomain_3a73c2b9-4e4e-43d7-9a0f-4d0bb710d765_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_0bf95dae-fa26-4590-8bde-139048a7383b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardDateAxis_3a73c2b9-4e4e-43d7-9a0f-4d0bb710d765" xlink:to="loc_us-gaap_AwardDateDomain_0bf95dae-fa26-4590-8bde-139048a7383b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bed7f46d-64fe-4189-b6bb-c2ce1382b150" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e799cdf2-f6ac-4602-88e8-e37164600451" xlink:to="loc_us-gaap_AwardTypeAxis_bed7f46d-64fe-4189-b6bb-c2ce1382b150" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bed7f46d-64fe-4189-b6bb-c2ce1382b150_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_bed7f46d-64fe-4189-b6bb-c2ce1382b150" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bed7f46d-64fe-4189-b6bb-c2ce1382b150_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b611d449-fadd-4023-aebe-b495fca42bb1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_bed7f46d-64fe-4189-b6bb-c2ce1382b150" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b611d449-fadd-4023-aebe-b495fca42bb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_df2480f1-b94e-477c-9214-2bb8c664e8ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b611d449-fadd-4023-aebe-b495fca42bb1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_df2480f1-b94e-477c-9214-2bb8c664e8ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4f1189ae-418e-4276-abed-53783e00c7a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b611d449-fadd-4023-aebe-b495fca42bb1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4f1189ae-418e-4276-abed-53783e00c7a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6d41fb2c-b146-45f3-b58b-b3814bf3cec3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e799cdf2-f6ac-4602-88e8-e37164600451" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6d41fb2c-b146-45f3-b58b-b3814bf3cec3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6d41fb2c-b146-45f3-b58b-b3814bf3cec3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6d41fb2c-b146-45f3-b58b-b3814bf3cec3" xlink:to="loc_us-gaap_ClassOfStockDomain_6d41fb2c-b146-45f3-b58b-b3814bf3cec3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9be6d4ec-8262-4549-ae37-6c056b9405d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6d41fb2c-b146-45f3-b58b-b3814bf3cec3" xlink:to="loc_us-gaap_ClassOfStockDomain_9be6d4ec-8262-4549-ae37-6c056b9405d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_717c1d68-a364-40f0-8d05-200a6ffb843a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e799cdf2-f6ac-4602-88e8-e37164600451" xlink:to="loc_srt_RangeAxis_717c1d68-a364-40f0-8d05-200a6ffb843a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_717c1d68-a364-40f0-8d05-200a6ffb843a_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_717c1d68-a364-40f0-8d05-200a6ffb843a" xlink:to="loc_srt_RangeMember_717c1d68-a364-40f0-8d05-200a6ffb843a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2c9d2183-d28c-4cd9-a4e2-10ba7d9fc4d2" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_717c1d68-a364-40f0-8d05-200a6ffb843a" xlink:to="loc_srt_RangeMember_2c9d2183-d28c-4cd9-a4e2-10ba7d9fc4d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_0c88d029-0f30-4143-9c23-f75e85531769" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e799cdf2-f6ac-4602-88e8-e37164600451" xlink:to="loc_us-gaap_VestingAxis_0c88d029-0f30-4143-9c23-f75e85531769" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_0c88d029-0f30-4143-9c23-f75e85531769_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_0c88d029-0f30-4143-9c23-f75e85531769" xlink:to="loc_us-gaap_VestingDomain_0c88d029-0f30-4143-9c23-f75e85531769_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_e3c534e8-a90b-464d-ad2f-280504d640c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_0c88d029-0f30-4143-9c23-f75e85531769" xlink:to="loc_us-gaap_VestingDomain_e3c534e8-a90b-464d-ad2f-280504d640c2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2" xlink:type="simple" xlink:href="lxrx-20200331.xsd#SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2" xlink:type="extended" id="i140e62c7625b49f2b9892962e526e58c_063d37f9-55c0-4db2-a26c-18b513b5199b">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d42bd232-9f0c-47c1-bc64-c2ace0824238" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7ebb575-2f94-47cd-b252-ea0c3142c2af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d42bd232-9f0c-47c1-bc64-c2ace0824238" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7ebb575-2f94-47cd-b252-ea0c3142c2af" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_f3730984-cc40-405c-9243-e3d429ef81e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7ebb575-2f94-47cd-b252-ea0c3142c2af" xlink:to="loc_us-gaap_PlanNameAxis_f3730984-cc40-405c-9243-e3d429ef81e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f3730984-cc40-405c-9243-e3d429ef81e6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_f3730984-cc40-405c-9243-e3d429ef81e6" xlink:to="loc_us-gaap_PlanNameDomain_f3730984-cc40-405c-9243-e3d429ef81e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_688deff8-fa9a-429e-bfff-b9af361585cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_f3730984-cc40-405c-9243-e3d429ef81e6" xlink:to="loc_us-gaap_PlanNameDomain_688deff8-fa9a-429e-bfff-b9af361585cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9d31ffb8-fc72-460c-a39f-7b5364adc27c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7ebb575-2f94-47cd-b252-ea0c3142c2af" xlink:to="loc_us-gaap_AwardTypeAxis_9d31ffb8-fc72-460c-a39f-7b5364adc27c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9d31ffb8-fc72-460c-a39f-7b5364adc27c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9d31ffb8-fc72-460c-a39f-7b5364adc27c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9d31ffb8-fc72-460c-a39f-7b5364adc27c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e07257cd-8ab0-41e1-b6c0-4891b1081e0e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9d31ffb8-fc72-460c-a39f-7b5364adc27c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e07257cd-8ab0-41e1-b6c0-4891b1081e0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4fc1b15d-23fa-4fc1-8899-cad1f12ae3b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7ebb575-2f94-47cd-b252-ea0c3142c2af" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4fc1b15d-23fa-4fc1-8899-cad1f12ae3b3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4fc1b15d-23fa-4fc1-8899-cad1f12ae3b3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4fc1b15d-23fa-4fc1-8899-cad1f12ae3b3" xlink:to="loc_us-gaap_ClassOfStockDomain_4fc1b15d-23fa-4fc1-8899-cad1f12ae3b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_176922bd-fdf0-4c38-a6f7-5f72ff14cfe2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4fc1b15d-23fa-4fc1-8899-cad1f12ae3b3" xlink:to="loc_us-gaap_ClassOfStockDomain_176922bd-fdf0-4c38-a6f7-5f72ff14cfe2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5b9767dc-aad8-4cb6-9958-362698979d54" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7ebb575-2f94-47cd-b252-ea0c3142c2af" xlink:to="loc_srt_RangeAxis_5b9767dc-aad8-4cb6-9958-362698979d54" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5b9767dc-aad8-4cb6-9958-362698979d54_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5b9767dc-aad8-4cb6-9958-362698979d54" xlink:to="loc_srt_RangeMember_5b9767dc-aad8-4cb6-9958-362698979d54_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_654c23f0-2a25-4c43-9082-e052a107d73e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5b9767dc-aad8-4cb6-9958-362698979d54" xlink:to="loc_srt_RangeMember_654c23f0-2a25-4c43-9082-e052a107d73e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes" xlink:type="simple" xlink:href="lxrx-20200331.xsd#RecentAccountingPronouncementsLevel1Notes"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes" xlink:type="extended" id="icf443b8069174cf2b374086fd4d06160_f48fa418-ee3a-4862-9736-d1b50e015c47"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails" xlink:type="simple" xlink:href="lxrx-20200331.xsd#RecentAccountingPronouncementsDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails" xlink:type="extended" id="ia2880a58b1df4e0f8dc5283d21053e34_dbc2ea3e-3c26-47ff-9b17-511871c7d634"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments" xlink:type="simple" xlink:href="lxrx-20200331.xsd#CashandCashEquivalentsandInvestments"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments" xlink:type="extended" id="i0e167f6cfb8846809e326661e0d8b8eb_56eeb9f0-b374-464c-a415-d32f0c000669"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables" xlink:type="simple" xlink:href="lxrx-20200331.xsd#CashandCashEquivalentsandInvestmentsTables"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables" xlink:type="extended" id="i4a0d2df4f6dc48c6904c4e8c57f75efe_af11dd5b-d498-4d19-9643-d417f045e29d"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1" xlink:type="simple" xlink:href="lxrx-20200331.xsd#CashandCashEquivalentsandInvestmentsDetails1"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1" xlink:type="extended" id="i91fa7e8fbc6141b1b30f498ef23aec4b_5804ce3a-51a5-4e6b-aeb6-1414bcd3b85a">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_897a7188-ceba-40ba-b169-d1c2e34fcf90" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_6c8f11c0-69c8-4fff-a6de-117acd852fd5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_897a7188-ceba-40ba-b169-d1c2e34fcf90" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_6c8f11c0-69c8-4fff-a6de-117acd852fd5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0c154f0f-451b-4a90-b5c6-eaf00ff82e4f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_897a7188-ceba-40ba-b169-d1c2e34fcf90" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0c154f0f-451b-4a90-b5c6-eaf00ff82e4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c9161220-f2cb-4654-aa75-140e820e3bde" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_897a7188-ceba-40ba-b169-d1c2e34fcf90" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c9161220-f2cb-4654-aa75-140e820e3bde" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_e25f001d-d721-481c-b71f-8d5b21bafafb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_897a7188-ceba-40ba-b169-d1c2e34fcf90" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_e25f001d-d721-481c-b71f-8d5b21bafafb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_3215492b-133b-4553-9955-83579e6c8c41" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_897a7188-ceba-40ba-b169-d1c2e34fcf90" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_3215492b-133b-4553-9955-83579e6c8c41" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_a45f35b6-9e1d-4928-8506-1b2cab0e98ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_3215492b-133b-4553-9955-83579e6c8c41" xlink:to="loc_us-gaap_InvestmentTypeAxis_a45f35b6-9e1d-4928-8506-1b2cab0e98ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_a45f35b6-9e1d-4928-8506-1b2cab0e98ea_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_a45f35b6-9e1d-4928-8506-1b2cab0e98ea" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_a45f35b6-9e1d-4928-8506-1b2cab0e98ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_6eebcbae-7877-483a-9bcc-37dbb7537095" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_a45f35b6-9e1d-4928-8506-1b2cab0e98ea" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_6eebcbae-7877-483a-9bcc-37dbb7537095" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_e9f1954e-9328-42ab-a1c7-4f552a1f676a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_6eebcbae-7877-483a-9bcc-37dbb7537095" xlink:to="loc_us-gaap_CashMember_e9f1954e-9328-42ab-a1c7-4f552a1f676a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_948f86c9-5aea-46b6-8a34-5db269487669" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_6eebcbae-7877-483a-9bcc-37dbb7537095" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_948f86c9-5aea-46b6-8a34-5db269487669" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_5027c1f5-f90c-4a16-8aa7-0673e84d0271" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_6eebcbae-7877-483a-9bcc-37dbb7537095" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_5027c1f5-f90c-4a16-8aa7-0673e84d0271" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_95836705-deb9-4810-9bdb-04a1fe33af6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_6eebcbae-7877-483a-9bcc-37dbb7537095" xlink:to="loc_us-gaap_InvestmentsMember_95836705-deb9-4810-9bdb-04a1fe33af6c" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2" xlink:type="simple" xlink:href="lxrx-20200331.xsd#CashandCashEquivalentsandInvestmentsDetails2"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2" xlink:type="extended" id="i83360d15a79d4604a023b4a4168ef9c1_f1a4dbb6-f9af-4833-be15-11cc4fb75c0b">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_33580f6c-b350-454d-a7e3-642818580329" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_bd81dfd4-e96e-49b5-831c-7dc0b87e6267" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_33580f6c-b350-454d-a7e3-642818580329" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_bd81dfd4-e96e-49b5-831c-7dc0b87e6267" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_95c75504-1eb7-4d10-bc89-7c1b4dbdb720" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_33580f6c-b350-454d-a7e3-642818580329" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_95c75504-1eb7-4d10-bc89-7c1b4dbdb720" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingActivityByTypeAxis_7e85357c-69dd-4ab1-b300-7121e024d5ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TradingActivityByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_95c75504-1eb7-4d10-bc89-7c1b4dbdb720" xlink:to="loc_us-gaap_TradingActivityByTypeAxis_7e85357c-69dd-4ab1-b300-7121e024d5ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingActivityByTypeDomain_7e85357c-69dd-4ab1-b300-7121e024d5ee_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TradingActivityByTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TradingActivityByTypeAxis_7e85357c-69dd-4ab1-b300-7121e024d5ee" xlink:to="loc_us-gaap_TradingActivityByTypeDomain_7e85357c-69dd-4ab1-b300-7121e024d5ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingActivityByTypeDomain_b73b36dc-df2a-40df-a8ad-ccc5674598cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TradingActivityByTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TradingActivityByTypeAxis_7e85357c-69dd-4ab1-b300-7121e024d5ee" xlink:to="loc_us-gaap_TradingActivityByTypeDomain_b73b36dc-df2a-40df-a8ad-ccc5674598cb" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="lxrx-20200331.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurements" xlink:type="extended" id="i41ca3a3c38044cb4b41f4f3dc9882d6f_72a60e04-7e1b-4dfb-94c2-025b569db24c"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="lxrx-20200331.xsd#FairValueMeasurementsTables"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsTables" xlink:type="extended" id="i6dc30a35a39f42a39f5f4ed3e81eaf5c_88436b14-382c-49a1-b409-6c4c7936f729"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:type="simple" xlink:href="lxrx-20200331.xsd#FairValueMeasurementsDetails1"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:type="extended" id="i8b96aa2d01c14c00ae969a9d9fd9f104_a2783a84-779e-4fd6-8286-aeb6749759f2">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7753a026-49d1-4a93-880d-6e8274266b55" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_47bae650-c128-4dce-887a-5f324b8f0527" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7753a026-49d1-4a93-880d-6e8274266b55" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_47bae650-c128-4dce-887a-5f324b8f0527" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecurities_981df2b7-db92-4ad2-9d96-fa29a0db9b14" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7753a026-49d1-4a93-880d-6e8274266b55" xlink:to="loc_us-gaap_AvailableForSaleSecurities_981df2b7-db92-4ad2-9d96-fa29a0db9b14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_79acc44c-8e6e-4776-83a7-ef3c969cdaa9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7753a026-49d1-4a93-880d-6e8274266b55" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_79acc44c-8e6e-4776-83a7-ef3c969cdaa9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_83318631-8c69-4b95-be18-8722c4517228" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7753a026-49d1-4a93-880d-6e8274266b55" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_83318631-8c69-4b95-be18-8722c4517228" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_74b32fa2-e81b-4490-bb14-1e9e5c9e89ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_83318631-8c69-4b95-be18-8722c4517228" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_74b32fa2-e81b-4490-bb14-1e9e5c9e89ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_74b32fa2-e81b-4490-bb14-1e9e5c9e89ec_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_74b32fa2-e81b-4490-bb14-1e9e5c9e89ec" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_74b32fa2-e81b-4490-bb14-1e9e5c9e89ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1489b30c-02e3-4345-b88d-30c04d9618d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_74b32fa2-e81b-4490-bb14-1e9e5c9e89ec" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1489b30c-02e3-4345-b88d-30c04d9618d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_b3d43cb5-205a-4b4a-9d0a-b74c0fdeb42e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1489b30c-02e3-4345-b88d-30c04d9618d6" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_b3d43cb5-205a-4b4a-9d0a-b74c0fdeb42e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_7a120bd4-3499-4543-9a92-a5738a276283" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1489b30c-02e3-4345-b88d-30c04d9618d6" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_7a120bd4-3499-4543-9a92-a5738a276283" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_c56fe132-03d7-40d2-a10a-fe500d0e3ba9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1489b30c-02e3-4345-b88d-30c04d9618d6" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_c56fe132-03d7-40d2-a10a-fe500d0e3ba9" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligations" xlink:type="simple" xlink:href="lxrx-20200331.xsd#DebtObligations"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/DebtObligations" xlink:type="extended" id="i2d421a9f365d457997b82163f29a4627_913aa7e9-3fdc-4ec9-8b94-aad872bd1394"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsTables" xlink:type="simple" xlink:href="lxrx-20200331.xsd#DebtObligationsTables"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/DebtObligationsTables" xlink:type="extended" id="i1e717a7f3d3c4bf0ab7878eba328c237_d056a62d-b345-45f0-91c1-423b2ea07296"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsDetails" xlink:type="simple" xlink:href="lxrx-20200331.xsd#DebtObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/DebtObligationsDetails" xlink:type="extended" id="ie1a2374543214960b1f27c4515b7c3a0_73c6ede3-8d77-4bcd-b716-f1dc79e73f56">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_f3ef174c-0d81-4855-b5c4-7f2df6e4e864" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_e7b35372-297a-43a6-aa1c-db1a6ec53e53" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f3ef174c-0d81-4855-b5c4-7f2df6e4e864" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_e7b35372-297a-43a6-aa1c-db1a6ec53e53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_b85b07bf-7bf6-42df-a405-5a57e5fda761" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f3ef174c-0d81-4855-b5c4-7f2df6e4e864" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_b85b07bf-7bf6-42df-a405-5a57e5fda761" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_24ae8cf2-673e-4bb6-8a98-d43b9af8625f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f3ef174c-0d81-4855-b5c4-7f2df6e4e864" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_24ae8cf2-673e-4bb6-8a98-d43b9af8625f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvDebtInstrumentInterestRateStatedPercentage_83ec12a4-9a83-432c-8ff1-12c3b081addc" xlink:href="lxrx-20200331.xsd#lxrx_ConvDebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f3ef174c-0d81-4855-b5c4-7f2df6e4e864" xlink:to="loc_lxrx_ConvDebtInstrumentInterestRateStatedPercentage_83ec12a4-9a83-432c-8ff1-12c3b081addc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_d38042b3-9075-41bf-965a-07413be5419e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f3ef174c-0d81-4855-b5c4-7f2df6e4e864" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_d38042b3-9075-41bf-965a-07413be5419e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_0ce76b94-de20-4441-af43-8d32d9457d81" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f3ef174c-0d81-4855-b5c4-7f2df6e4e864" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_0ce76b94-de20-4441-af43-8d32d9457d81" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_b16c7f21-f341-4446-a3d5-cc92e6ed5704" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f3ef174c-0d81-4855-b5c4-7f2df6e4e864" xlink:to="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_b16c7f21-f341-4446-a3d5-cc92e6ed5704" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_468c4d3f-5be0-44d0-bd10-6333acd92935" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f3ef174c-0d81-4855-b5c4-7f2df6e4e864" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_468c4d3f-5be0-44d0-bd10-6333acd92935" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_feee3577-60e7-4827-9ee4-8a43fc0ec28c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f3ef174c-0d81-4855-b5c4-7f2df6e4e864" xlink:to="loc_us-gaap_DebtInstrumentFairValue_feee3577-60e7-4827-9ee4-8a43fc0ec28c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInstrument_Revere_LXRX_8c46a4e3-62ca-475b-8559-0fb93348a662" xlink:href="lxrx-20200331.xsd#lxrx_MortgageDebtInstrument_Revere_LXRX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f3ef174c-0d81-4855-b5c4-7f2df6e4e864" xlink:to="loc_lxrx_MortgageDebtInstrument_Revere_LXRX_8c46a4e3-62ca-475b-8559-0fb93348a662" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX_4ea22dad-0e7d-4589-84cb-d41fa8a60eac" xlink:href="lxrx-20200331.xsd#lxrx_MortgageDebtInterestRate_Base_Revere_LXRX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f3ef174c-0d81-4855-b5c4-7f2df6e4e864" xlink:to="loc_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX_4ea22dad-0e7d-4589-84cb-d41fa8a60eac" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX_a08cdb56-11c4-492c-9402-78e9dfc88af7" xlink:href="lxrx-20200331.xsd#lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f3ef174c-0d81-4855-b5c4-7f2df6e4e864" xlink:to="loc_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX_a08cdb56-11c4-492c-9402-78e9dfc88af7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtBalloonPayment_LXRX_5b01253f-de99-49b2-874d-43ee818ec21c" xlink:href="lxrx-20200331.xsd#lxrx_MortgageDebtBalloonPayment_LXRX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f3ef174c-0d81-4855-b5c4-7f2df6e4e864" xlink:to="loc_lxrx_MortgageDebtBalloonPayment_LXRX_5b01253f-de99-49b2-874d-43ee818ec21c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtIssueCosts_Revere_LXRX_02811b32-359e-4ffd-a409-c96648f9a586" xlink:href="lxrx-20200331.xsd#lxrx_MortgageDebtIssueCosts_Revere_LXRX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f3ef174c-0d81-4855-b5c4-7f2df6e4e864" xlink:to="loc_lxrx_MortgageDebtIssueCosts_Revere_LXRX_02811b32-359e-4ffd-a409-c96648f9a586" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_BuildingsCollateral_a41c7e47-d523-49d4-9c78-695f9764d37c" xlink:href="lxrx-20200331.xsd#lxrx_BuildingsCollateral"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f3ef174c-0d81-4855-b5c4-7f2df6e4e864" xlink:to="loc_lxrx_BuildingsCollateral_a41c7e47-d523-49d4-9c78-695f9764d37c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LandCollateral_b4fbc43b-79b6-4100-a805-9af97ebc57a6" xlink:href="lxrx-20200331.xsd#lxrx_LandCollateral"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f3ef174c-0d81-4855-b5c4-7f2df6e4e864" xlink:to="loc_lxrx_LandCollateral_b4fbc43b-79b6-4100-a805-9af97ebc57a6" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c8c4aa58-d674-4922-8d2f-3142337d0da3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f3ef174c-0d81-4855-b5c4-7f2df6e4e864" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c8c4aa58-d674-4922-8d2f-3142337d0da3" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_78ff585a-0e6c-40f3-84b7-546f963f19e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f3ef174c-0d81-4855-b5c4-7f2df6e4e864" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_78ff585a-0e6c-40f3-84b7-546f963f19e0" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_3319cae7-3151-4da5-9a2a-92965101bb3c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f3ef174c-0d81-4855-b5c4-7f2df6e4e864" xlink:to="loc_us-gaap_DebtInstrumentTable_3319cae7-3151-4da5-9a2a-92965101bb3c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_8d406ca3-f716-44d6-bdae-f4eb9fd55a56" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3319cae7-3151-4da5-9a2a-92965101bb3c" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_8d406ca3-f716-44d6-bdae-f4eb9fd55a56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8d406ca3-f716-44d6-bdae-f4eb9fd55a56_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8d406ca3-f716-44d6-bdae-f4eb9fd55a56" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8d406ca3-f716-44d6-bdae-f4eb9fd55a56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6d8f2663-25ed-42c5-aec9-94ce5f4b83ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8d406ca3-f716-44d6-bdae-f4eb9fd55a56" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6d8f2663-25ed-42c5-aec9-94ce5f4b83ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d00837e1-21a4-42b0-b182-3d66ee0c4a37" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3319cae7-3151-4da5-9a2a-92965101bb3c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d00837e1-21a4-42b0-b182-3d66ee0c4a37" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d00837e1-21a4-42b0-b182-3d66ee0c4a37_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d00837e1-21a4-42b0-b182-3d66ee0c4a37" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d00837e1-21a4-42b0-b182-3d66ee0c4a37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_719f7980-e0e1-4a0f-a1c7-d04b7ed90467" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d00837e1-21a4-42b0-b182-3d66ee0c4a37" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_719f7980-e0e1-4a0f-a1c7-d04b7ed90467" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_49fd944d-31f7-46d6-87b1-5f29bdbc59d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3319cae7-3151-4da5-9a2a-92965101bb3c" xlink:to="loc_us-gaap_DebtInstrumentAxis_49fd944d-31f7-46d6-87b1-5f29bdbc59d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_49fd944d-31f7-46d6-87b1-5f29bdbc59d3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_49fd944d-31f7-46d6-87b1-5f29bdbc59d3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_49fd944d-31f7-46d6-87b1-5f29bdbc59d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fed1a37f-9d7b-4c2d-bcac-05443980874f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_49fd944d-31f7-46d6-87b1-5f29bdbc59d3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fed1a37f-9d7b-4c2d-bcac-05443980874f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="lxrx-20200331.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CommitmentsandContingencies" xlink:type="extended" id="ia9f1d1ad0edc4dffa24d306886f5725c_2f4b3835-1695-40d7-9fda-2a298c5c0e3f"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreements" xlink:type="simple" xlink:href="lxrx-20200331.xsd#CollaborationandLicenseAgreements"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CollaborationandLicenseAgreements" xlink:type="extended" id="i0d94637be114410ab1357aa90f0c46be_e8811f70-1d46-4e29-bcb6-a8480b476bdb"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsTables" xlink:type="simple" xlink:href="lxrx-20200331.xsd#CollaborationandLicenseAgreementsTables"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsTables" xlink:type="extended" id="i6eea85cbc3db4638bf4d2907673a71d3_7af01c27-6c64-44ae-9cd0-8c95dde548f7"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" xlink:type="simple" xlink:href="lxrx-20200331.xsd#CollaborationandLicenseAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" xlink:type="extended" id="i3f96a4c559a34a2fbe89cc2e16bd03f4_6a4056fe-cd55-47ca-ad70-cc1b03c591d8"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>lxrx-20200331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:b6c3a7dc-b64d-45d6-bfee-77eb11f000ac,g:4bb55044-54d9-4307-a743-01e703a924d5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_604f3ccc-d84f-42e7-b201-309cb6da83e7_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, value</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d58c5fae-2820-4fbb-83d1-34f276315d46_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, value</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_033302b3-cb3b-4964-af86-c2104ea9bd5d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_9c39e562-ff4b-460e-89ee-07fbeb102dc5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_ec735f11-5491-4604-8d8f-893763f0e751_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0bd80e5b-99b7-4a2b-a39d-194685146c8d_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0b291cd2-a6f0-43c0-80fc-e8e4b452e203_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Increase) decrease in prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_6b09cfe8-e125-4c43-bb44-0b2748786a9f_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_d2297857-521f-4db8-a745-24556ea8b36b_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net of accumulated amortization of $5,444 and $5,003, respectively</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_bfe329d1-6297-4653-b804-11f446033f69_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_DebtObligationsAbstract_728b1948-708a-4a0b-80e1-a4e3af334021_terseLabel_en-US" xlink:label="lab_lxrx_DebtObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Obligations [Abstract]</link:label>
    <link:label id="lab_lxrx_DebtObligationsAbstract_label_en-US" xlink:label="lab_lxrx_DebtObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Obligations [Abstract]</link:label>
    <link:label id="lab_lxrx_DebtObligationsAbstract_documentation_en-US" xlink:label="lab_lxrx_DebtObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Obligations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DebtObligationsAbstract" xlink:href="lxrx-20200331.xsd#lxrx_DebtObligationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DebtObligationsAbstract" xlink:to="lab_lxrx_DebtObligationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_bdfa6a00-1e41-4951-8505-8e3239d3e18b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_68d6f30f-307b-467f-a183-3704129d3b58_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_15cb271e-9c26-464a-953b-f6a4024f5eb1_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e569264e-7805-4669-9f4e-8401c7967e15_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_7667b209-9fba-48d9-9ea6-000a0f8912a4_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents Disclosure</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_120204ee-7c1b-47d5-881e-3763dcaff09a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2dbaaf63-125f-4cc6-bdf1-3cfcda8afeef_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardDateAxis_9606b18d-c535-4dea-a330-d432912f1c62_terseLabel_en-US" xlink:label="lab_us-gaap_AwardDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardDateAxis_label_en-US" xlink:label="lab_us-gaap_AwardDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardDateAxis" xlink:to="lab_us-gaap_AwardDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_a21c1f18-c112-4ce6-a38b-9b41dccad94d_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales (including finite-lived intangible asset amortization)</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_45af9fd4-2417-46f9-91dd-d251bd037456_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_34a44b44-26ad-4f62-995f-0c9c695825c6_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_BuildingsCollateral_1342f379-5cd3-4ec0-9f02-327bf248601d_terseLabel_en-US" xlink:label="lab_lxrx_BuildingsCollateral" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings Collateral</link:label>
    <link:label id="lab_lxrx_BuildingsCollateral_label_en-US" xlink:label="lab_lxrx_BuildingsCollateral" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings Collateral</link:label>
    <link:label id="lab_lxrx_BuildingsCollateral_documentation_en-US" xlink:label="lab_lxrx_BuildingsCollateral" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The buildings that serve as collateral for Lexicon's mortgage loan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_BuildingsCollateral" xlink:href="lxrx-20200331.xsd#lxrx_BuildingsCollateral"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_BuildingsCollateral" xlink:to="lab_lxrx_BuildingsCollateral" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_fe742b73-01fd-434c-80a9-88c07133441d_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_36efe815-b67d-415a-bb8a-09d7b5ddb1fd_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value per share</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_FairValueMeasurementsAbstract_3ab205df-bf26-44c1-a8cd-aaa0634e2482_terseLabel_en-US" xlink:label="lab_lxrx_FairValueMeasurementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements [Abstract]</link:label>
    <link:label id="lab_lxrx_FairValueMeasurementsAbstract_label_en-US" xlink:label="lab_lxrx_FairValueMeasurementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements [Abstract]</link:label>
    <link:label id="lab_lxrx_FairValueMeasurementsAbstract_documentation_en-US" xlink:label="lab_lxrx_FairValueMeasurementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FairValueMeasurementsAbstract" xlink:href="lxrx-20200331.xsd#lxrx_FairValueMeasurementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_FairValueMeasurementsAbstract" xlink:to="lab_lxrx_FairValueMeasurementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_c64cee9c-afb7-445a-9168-2918761bc1f5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_25f84a56-e23e-421f-b95f-c9d3d3f5522b_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the officers' and non-employee directors' option's term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:href="lxrx-20200331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_bdbc2a0b-ff6a-47b1-bbcd-d32bc6c5f6de_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_Sellinggeneralandadministrativeexpenses_3f2c5d0f-2fe2-4a19-a1cb-e67dfe6ff6a2_terseLabel_en-US" xlink:label="lab_lxrx_Sellinggeneralandadministrativeexpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses, included stock-based compensation of $2,256 and $1,643, respectively</link:label>
    <link:label id="lab_lxrx_Sellinggeneralandadministrativeexpenses_label_en-US" xlink:label="lab_lxrx_Sellinggeneralandadministrativeexpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_lxrx_Sellinggeneralandadministrativeexpenses_documentation_en-US" xlink:label="lab_lxrx_Sellinggeneralandadministrativeexpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses - the expenses related to selling Lexicon's product as well as general and administrative costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Sellinggeneralandadministrativeexpenses" xlink:href="lxrx-20200331.xsd#lxrx_Sellinggeneralandadministrativeexpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_Sellinggeneralandadministrativeexpenses" xlink:to="lab_lxrx_Sellinggeneralandadministrativeexpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_bb20cad0-69e7-42ff-af86-7d6f070b922a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_34be7a00-5d01-4e44-b194-a9a3e3e5dedf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_e53b7234-2594-4112-a86e-b2c328cc617b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under Equity Incentive Plans, value</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_b46b40e3-53a4-45bc-969b-5a114788d4d7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of cash and cash equivalents and investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_26fb3528-bdb5-4775-8f07-2338d1554960_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cbecb9d9-92a3-4404-8426-452eb1359356_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_0dee8fe7-aafb-438d-ba40-93abd61088f4_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract_4f8d9ef8-fa83-44d5-9a7e-bb54d4101635_terseLabel_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Operations [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract_label_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Operations [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract_documentation_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:href="lxrx-20200331.xsd#lxrx_ConsolidatedStatementsOfOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:to="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_e8e0b92e-ce75-4018-a851-282ad69505ce_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_c5b829a1-f2db-48be-a300-7ccb617cc4d7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net of accumulated depreciation and amortization of $61,302 and $61,741, respectively</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_09dd49a8-2204-4937-bdba-f38f3d9e73f4_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2cbccde6-4781-44ee-8334-93793008226e_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_93bb0220-d6da-4489-b2ae-fd73aec765df_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_65334642-b8c1-4e0c-b49a-c6564f19c867_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenMaximumSalesMilestones_7113c90e-df9e-4ffa-9398-3e11bc2f886b_terseLabel_en-US" xlink:label="lab_lxrx_IpsenMaximumSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Maximum Sales Milestones</link:label>
    <link:label id="lab_lxrx_IpsenMaximumSalesMilestones_label_en-US" xlink:label="lab_lxrx_IpsenMaximumSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Maximum Sales Milestones</link:label>
    <link:label id="lab_lxrx_IpsenMaximumSalesMilestones_documentation_en-US" xlink:label="lab_lxrx_IpsenMaximumSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the maximum sales milestones payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMaximumSalesMilestones" xlink:href="lxrx-20200331.xsd#lxrx_IpsenMaximumSalesMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenMaximumSalesMilestones" xlink:to="lab_lxrx_IpsenMaximumSalesMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_630bc5b1-66a5-43cd-827c-3835592d625c_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_4e782a07-c5d5-4ae2-8156-09ad7bb70c7d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Inputs, Disclosure</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_cca549b0-0d9e-471a-b8e1-e86ae8989350_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX_a7b9a716-feb6-4673-a8c3-fc534fb5136a_terseLabel_en-US" xlink:label="lab_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Interest Rate BasePlus_Revere_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX_label_en-US" xlink:label="lab_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Interest Rate BasePlus_Revere_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX_documentation_en-US" xlink:label="lab_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Interest Rate BasePlus_Revere_LXRX - represents a base for the range of the interest rate that will be charged on the Revere loan. Interest charged will be greater of 30-day LIBOR plus 5.5% or 7.5%</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX" xlink:href="lxrx-20200331.xsd#lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX" xlink:to="lab_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_eeb5bc73-d623-4fe0-800d-5839f65cd52c_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of debt borrowings, net of fees</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_136f278b-1fae-449d-a995-8ae54c23a23c_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_1995517b-cf5a-4be7-a14b-5fda199bc5d3_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_1bbd0653-3faa-4999-a073-0a24986539e4_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">For officers and non-employee directors, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:href="lxrx-20200331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_84af57d0-2a4b-4ef0-83e5-142381d5fe61_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Increase) decrease in accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_61717a1a-d62b-4793-bec2-4716249bf351_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_4d95b3ac-62f3-447f-8634-dcaf54fd46e1_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_d7522d12-4ab0-4a84-901a-dde6426d55a7_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_ec0ad14c-d3f2-479a-b5d8-e7c10b9af9f3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradingActivityByTypeDomain_cedc748d-0faa-47ca-b863-9b6c2a55afa5_terseLabel_en-US" xlink:label="lab_us-gaap_TradingActivityByTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Activity, by Type [Domain]</link:label>
    <link:label id="lab_us-gaap_TradingActivityByTypeDomain_label_en-US" xlink:label="lab_us-gaap_TradingActivityByTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Activity, by Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingActivityByTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TradingActivityByTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradingActivityByTypeDomain" xlink:to="lab_us-gaap_TradingActivityByTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_eeb798a3-3a85-468e-89fd-ee3b234adcfe_terseLabel_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Investment Gains (Losses)</link:label>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_label_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Investment Gains (Losses)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:to="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_17659989-5fde-4b64-9e6b-685fe032f21f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_7717df26-450d-4075-aeef-f35705d8de52_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradingActivityByTypeAxis_9d3197ae-188d-4875-8721-f395c18daa7e_terseLabel_en-US" xlink:label="lab_us-gaap_TradingActivityByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Activity, by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_TradingActivityByTypeAxis_label_en-US" xlink:label="lab_us-gaap_TradingActivityByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Activity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingActivityByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TradingActivityByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradingActivityByTypeAxis" xlink:to="lab_us-gaap_TradingActivityByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_InventoryAbstract_693314bf-48ba-44dd-b207-96eea5a33508_terseLabel_en-US" xlink:label="lab_lxrx_InventoryAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Abstract]</link:label>
    <link:label id="lab_lxrx_InventoryAbstract_label_en-US" xlink:label="lab_lxrx_InventoryAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Abstract]</link:label>
    <link:label id="lab_lxrx_InventoryAbstract_documentation_en-US" xlink:label="lab_lxrx_InventoryAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_InventoryAbstract" xlink:href="lxrx-20200331.xsd#lxrx_InventoryAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_InventoryAbstract" xlink:to="lab_lxrx_InventoryAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_f83472b6-8811-4caf-bcf9-3217cf3c1b99_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryMajorClassesPolicy_63ef4826-f959-447c-b0ee-d452065d8d9c_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryMajorClassesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Major Classes, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_InventoryMajorClassesPolicy_label_en-US" xlink:label="lab_us-gaap_InventoryMajorClassesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Major Classes, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryMajorClassesPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryMajorClassesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryMajorClassesPolicy" xlink:to="lab_us-gaap_InventoryMajorClassesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_aa8b05c8-77f6-4742-b286-6d37579d4161_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_a67c202c-32fd-4ba5-ae77-e242344dc505_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The expected term assumption that is used in valuing an option on its own shares for officers and non-employee directors.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:href="lxrx-20200331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_047efc80-8081-4861-943b-e6022893cdf0_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:to="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_fa4182f9-3ede-42a7-b55d-711b6bf0305f_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_cfcf07be-8111-4a0a-9c0b-778fdd27b6a5_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_1cf20579-1ac1-4e0d-8550-e413709896dd_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable_450fd112-45f2-4fd4-a0f4-301f147f158a_terseLabel_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Allocated to License Deliverable</link:label>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable_label_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Allocated to License Deliverable</link:label>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable_documentation_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the amount of the upfront payment allocated to the license deliverable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable" xlink:href="lxrx-20200331.xsd#lxrx_IpsenRevenueAllocatedtoLicenseDeliverable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable" xlink:to="lab_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_be1ed2ed-1d79-4689-978c-b597ab614b1d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract_0addfbe8-cd5a-4270-8685-39472b916364_terseLabel_en-US" xlink:label="lab_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]</link:label>
    <link:label id="lab_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract_label_en-US" xlink:label="lab_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]</link:label>
    <link:label id="lab_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract_documentation_en-US" xlink:label="lab_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract" xlink:href="lxrx-20200331.xsd#lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract" xlink:to="lab_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_c67ac217-7957-4bc0-a81a-b44e8473ee46_terseLabel_en-US" xlink:label="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense associated with research and development expense</link:label>
    <link:label id="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense associated with research and development expense</link:label>
    <link:label id="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_documentation_en-US" xlink:label="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense included in research and development expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:href="lxrx-20200331.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:to="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_022aed52-5e9b-468a-8beb-1f594ac4716a_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_ff616589-a263-451b-acfa-ab5f6258dde8_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_7ed4d857-b4f0-4a86-881c-ec819176ed78_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2c6c19f0-3ef2-42fd-9ec3-f97e5b90d028_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_2187ce99-ae6a-41c7-aa4d-0e983f40c7ec_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_3f29d988-4d9c-43fd-a378-f1fc1be01d96_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5fe26603-8760-42af-87fb-761ddc097fd0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated intangible assets amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_1fdbad6a-a378-449b-883a-42fbea6585cf_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_86f61400-253c-458d-ab58-45656bfecec3_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2ac92d2d-df0c-49c1-b297-fac0b13fecf1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_3da9ce24-6c9f-4125-9e9c-115383654fa3_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7c1c25fb-973e-4872-b613-9dae5548ae3f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenRevenueRecognized_272b10e3-f1d1-4e6f-865d-03c2c463d52a_terseLabel_en-US" xlink:label="lab_lxrx_IpsenRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Recognized</link:label>
    <link:label id="lab_lxrx_IpsenRevenueRecognized_label_en-US" xlink:label="lab_lxrx_IpsenRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Recognized</link:label>
    <link:label id="lab_lxrx_IpsenRevenueRecognized_documentation_en-US" xlink:label="lab_lxrx_IpsenRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the revenue recognized in the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueRecognized" xlink:href="lxrx-20200331.xsd#lxrx_IpsenRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenRevenueRecognized" xlink:to="lab_lxrx_IpsenRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_ebf92e06-d3ea-4c2e-9749-5ef75a168a4f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenMilestonePayment_40fef703-7485-4947-9423-e25ef3998876_terseLabel_en-US" xlink:label="lab_lxrx_IpsenMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Milestone Payment</link:label>
    <link:label id="lab_lxrx_IpsenMilestonePayment_label_en-US" xlink:label="lab_lxrx_IpsenMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Milestone Payment</link:label>
    <link:label id="lab_lxrx_IpsenMilestonePayment_documentation_en-US" xlink:label="lab_lxrx_IpsenMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl. This represents the milestone payments received under the agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMilestonePayment" xlink:href="lxrx-20200331.xsd#lxrx_IpsenMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenMilestonePayment" xlink:to="lab_lxrx_IpsenMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_d727720e-a2d0-412b-80cb-84478d6e18b0_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_71b1b8e9-e35a-4871-8e3b-1f1637bef4f9_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of deferred issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_ee14e9bf-e889-4387-a593-d5084fef1cff_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_ee903175-73a0-4893-9f21-d513f0ae195d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_6a8396e8-6749-4a23-964c-5394e5c4846f_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_86ea3078-c3d4-419c-a79e-875f7b2e12b2_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost, 741 and 407 shares, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_a42306f9-b9fd-4977-a010-49f190416823_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, ExpectedVolatilityRate, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, ExpectedVolatilityRate, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">For employees, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:href="lxrx-20200331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_80a41e9a-d9e7-42ed-8171-c8375eed266d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_b2d8467c-4127-44e9-a551-182f5c9c472e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ad099765-2cff-4c1b-a91f-a162a1a77d49_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e93d6b80-3062-40c4-ad3a-99ea5838a153_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract_3695913f-fef5-4ece-adb9-bd7cf6d4bb83_terseLabel_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Cash Flows [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract_label_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Cash Flows [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract_documentation_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfCashFlowsAbstract" xlink:href="lxrx-20200331.xsd#lxrx_ConsolidatedStatementsOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConsolidatedStatementsOfCashFlowsAbstract" xlink:to="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_77553230-25a1-46da-8b0e-8e90c99e3ef5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_44ac90af-ab7c-4163-9a8d-41b92efef911_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_LandCollateral_878c6eb3-348d-4854-afa3-095cdeca4fd7_terseLabel_en-US" xlink:label="lab_lxrx_LandCollateral" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land Collateral</link:label>
    <link:label id="lab_lxrx_LandCollateral_label_en-US" xlink:label="lab_lxrx_LandCollateral" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land Collateral</link:label>
    <link:label id="lab_lxrx_LandCollateral_documentation_en-US" xlink:label="lab_lxrx_LandCollateral" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The land that serves as collateral for Lexicon's mortgage loan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LandCollateral" xlink:href="lxrx-20200331.xsd#lxrx_LandCollateral"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_LandCollateral" xlink:to="lab_lxrx_LandCollateral" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_e2bf7f5a-c45e-4874-b6c2-da7d33ba2b22_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_db1450ca-280d-418d-9fe1-7877ffea80d1_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_fa3bc15a-4523-4a62-b419-013b1ffa8016_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_e0ae005a-746c-46f0-a9e2-5eb5a2c14043_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_d0b820bb-cae8-47bc-b89b-11ff0c02a853_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_282093ca-3fcb-42bc-a62e-8d8c2b6c25ed_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0e2487d4-091e-45bb-b62d-675c518686f2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreements</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_8d07d67d-6258-463d-a695-5f891d941f9c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_e6a18eba-30ea-462e-801d-2c65dea8424d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share, Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eb59f1d5-4757-46d2-83b3-e330373ba75c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_2efdf8e0-656d-4aa9-b542-a04e8ecd7542_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b013a3af-544d-4827-9e6f-475fe50149ab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_bccf0300-6df4-4fb9-abeb-181e2fa6c7e9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_940a5cd1-b5a8-48fc-80f4-0cfdb2859e54_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in accounts payable and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_d1459b0f-f242-42b4-877a-35026f86b698_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_f60cc0db-0894-4472-a842-569860157f03_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_93645d45-0ecd-4c0a-9339-3f219d0dc3d5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_163eaabe-c2c9-4153-aa5b-0532b549ca3e_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_93676e9c-d277-49f1-aacf-5f6f637833b5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_28d6147d-f8d7-46cd-a386-edeba789a55e_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardDateDomain_9c9a10a6-6f46-4beb-b58f-fa2ec1b9e095_terseLabel_en-US" xlink:label="lab_us-gaap_AwardDateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Domain]</link:label>
    <link:label id="lab_us-gaap_AwardDateDomain_label_en-US" xlink:label="lab_us-gaap_AwardDateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardDateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardDateDomain" xlink:to="lab_us-gaap_AwardDateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_43bbe7f4-d28d-4e87-b056-25d63d4e8ef8_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_145c8d7f-2139-4860-aa76-e81bf7860e48_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense_c511d921-9055-40b3-83a3-3c2cc308c3a1_terseLabel_en-US" xlink:label="lab_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense associated with selling, general and administrative expense</link:label>
    <link:label id="lab_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense_label_en-US" xlink:label="lab_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense associated with selling, general and administrative expense</link:label>
    <link:label id="lab_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense_documentation_en-US" xlink:label="lab_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense associated with selling, general and administrative expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" xlink:href="lxrx-20200331.xsd#lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" xlink:to="lab_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_4074d4a4-f133-4bf7-a261-1dfea53a6924_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_949e6d0a-dde7-4707-bbb5-18a043730d1c_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_733acc58-b645-43bc-9b3d-c8ca23c31f11_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConsolidatedBalanceSheetsAbstract_29d9ff61-9c54-4cf4-8114-31bd1233e43d_terseLabel_en-US" xlink:label="lab_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Balance Sheets [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedBalanceSheetsAbstract_label_en-US" xlink:label="lab_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Balance Sheets [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedBalanceSheetsAbstract_documentation_en-US" xlink:label="lab_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Balance Sheets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:href="lxrx-20200331.xsd#lxrx_ConsolidatedBalanceSheetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:to="lab_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_f0e76f9e-ad7b-44e3-83db-36d98d25567b_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_501cf12a-1335-4eff-9abb-1d6dd514f240_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_61b0526e-9716-4446-aa3d-9e3df873b465_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_bfe7125f-610a-4685-8d5b-1063b3788b65_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_cd74c480-7497-4081-98f4-3843adc5484f_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_8c4a0406-40b7-4308-b618-9b1802797cad_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_ef10c541-0223-48d3-ac24-784da34a7d21_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_39a8d6a3-b986-4f0a-b807-41f5bf5290a8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_d237cd46-6bf5-4036-8ebe-c4cba0b0d053_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsMember_3c008dee-f6a7-4e84-9f82-5ec85486e243_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Cash and Cash Equivalents and Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsMember_label_en-US" xlink:label="lab_us-gaap_InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsMember" xlink:to="lab_us-gaap_InvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_MortgageDebtIssueCosts_Revere_LXRX_04d93c03-793c-48b0-a141-f3224e64c5fe_terseLabel_en-US" xlink:label="lab_lxrx_MortgageDebtIssueCosts_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Issue Costs_Revere_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtIssueCosts_Revere_LXRX_label_en-US" xlink:label="lab_lxrx_MortgageDebtIssueCosts_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Issue Costs_Revere_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtIssueCosts_Revere_LXRX_documentation_en-US" xlink:label="lab_lxrx_MortgageDebtIssueCosts_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Issue Costs_Revere_LXRX - represents the total debt issue costs incurred in connection with the Revere debt agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtIssueCosts_Revere_LXRX" xlink:href="lxrx-20200331.xsd#lxrx_MortgageDebtIssueCosts_Revere_LXRX"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_MortgageDebtIssueCosts_Revere_LXRX" xlink:to="lab_lxrx_MortgageDebtIssueCosts_Revere_LXRX" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_f8e55f3d-0b35-4567-aeab-312b3c96858e_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Cash and Cash Equivalents and Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_be4f5824-3d0f-4881-a5e7-11bcacdad298_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenTotalPayments_62db6d52-03fc-462c-a131-032228203379_terseLabel_en-US" xlink:label="lab_lxrx_IpsenTotalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Total Payments</link:label>
    <link:label id="lab_lxrx_IpsenTotalPayments_label_en-US" xlink:label="lab_lxrx_IpsenTotalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Total Payments</link:label>
    <link:label id="lab_lxrx_IpsenTotalPayments_documentation_en-US" xlink:label="lab_lxrx_IpsenTotalPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl. This represents the total payments received to date under the agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenTotalPayments" xlink:href="lxrx-20200331.xsd#lxrx_IpsenTotalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenTotalPayments" xlink:to="lab_lxrx_IpsenTotalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_1c9cdf2f-a62f-4c13-b121-c90bff914770_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_aebefecd-a962-4a14-9378-ef779586879b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_e52b30ed-0f6b-4bf6-aac5-1dce109b53b0_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1a0f478b-1f13-4a69-8741-da3ffb9128e0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_63765aef-7921-4f91-b1d7-8d89a82906d7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_272094da-0a5b-4751-b800-e38007cd2c37_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_4a68bc14-823f-439e-946f-560b9bc7a936_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_7debc90c-a77f-4f17-8b14-c8e71e1646d9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_e12036c5-3d56-49a8-9b99-9f77dc8c36f3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_344ec9a8-6d63-48ed-8c0e-d9e4ff3115e1_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_7c45879c-e76b-4105-97b5-f4d9fccab1b7_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_15de2c63-3899-45ed-90da-18da8d7706f3_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury Securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_630ed0fb-c258-4fb6-8f29-90205b686e3d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_aecd59df-3c85-4c57-aaa1-8991ffcd5e2e_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_e4179fa5-42fe-4043-a2dd-5cb6fefbdf9e_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_12f0f2fc-76e6-4c61-b85a-b40ca5027eb9_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Short-term Investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_f576778a-fcb1-4395-9d92-6eba28f5360f_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_db84d7d9-380a-44f6-b618-327cf31a5c3a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_MortgageDebtInstrument_Revere_LXRX_cf64c01c-943f-4394-8e8d-fb8e8d58f2f8_terseLabel_en-US" xlink:label="lab_lxrx_MortgageDebtInstrument_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Instrument_Revere_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtInstrument_Revere_LXRX_label_en-US" xlink:label="lab_lxrx_MortgageDebtInstrument_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Instrument_Revere_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtInstrument_Revere_LXRX_documentation_en-US" xlink:label="lab_lxrx_MortgageDebtInstrument_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Instrument_Revere_LXRX - Principal loan amount borrowed, using Woodlands Campus as collateral</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInstrument_Revere_LXRX" xlink:href="lxrx-20200331.xsd#lxrx_MortgageDebtInstrument_Revere_LXRX"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_MortgageDebtInstrument_Revere_LXRX" xlink:to="lab_lxrx_MortgageDebtInstrument_Revere_LXRX" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_06fb4e68-7f9b-4efc-85fe-19429ed0d042_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_5fd03cae-41a4-4414-b5fb-85d235303292_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa6d6edb-b39c-4b0d-bd48-1436ca43b7f6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_1cf87823-a63d-446d-9fef-456a690cf136_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_493471ba-6b9e-4379-b8ed-84ce074537b9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_6e1f16e7-6b14-4cd1-8d2a-b99ebddec539_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_b91e6bf7-6223-4334-8f5b-b94f428393d8_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_ed41a909-fab3-484d-afd8-2d07860406dc_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d269a6a2-351a-4722-ad4d-767e8a37bb54_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_3379eb8c-c103-491d-bcf4-a3cbd0e2be0f_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement, Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_90f6dcff-d9bf-41b1-8ae7-4c4e87b454a1_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_86e1e4cb-ec94-4cc0-9ab5-5380a121484a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_2c4b573a-82bb-4924-86eb-9627ea7ffa0e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_5e24432b-3858-4d79-9011-965e4bce0a5c_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_0576fe60-2a1d-454c-9052-ae06d568076c_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_342bacfe-c678-43ea-9da5-b97bfdca5620_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_a5f87da2-1a9d-4397-8b66-45c43515f1aa_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value per share</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenTotalUpfrontPayments_6b99b7ae-c3af-4f69-b6fa-6af2da232439_terseLabel_en-US" xlink:label="lab_lxrx_IpsenTotalUpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Total Upfront Payments</link:label>
    <link:label id="lab_lxrx_IpsenTotalUpfrontPayments_label_en-US" xlink:label="lab_lxrx_IpsenTotalUpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Total Upfront Payments</link:label>
    <link:label id="lab_lxrx_IpsenTotalUpfrontPayments_documentation_en-US" xlink:label="lab_lxrx_IpsenTotalUpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the total of the upfront payments under the agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenTotalUpfrontPayments" xlink:href="lxrx-20200331.xsd#lxrx_IpsenTotalUpfrontPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenTotalUpfrontPayments" xlink:to="lab_lxrx_IpsenTotalUpfrontPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_6265a141-dee4-4955-b3f4-c052594c65a7_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_a1aa3b67-ee82-408c-995d-c9621889ba32_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_14524733-fa12-4892-86e4-8a31d67574ce_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_a1c0a0a0-b8f9-45ac-8d00-f1af0cc54ef0_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_5c00ec03-3a2b-40d9-bdaf-cff76374a66b_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_20d8f3df-d048-48b6-9321-73b816b7cf95_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_074e4919-6fa7-4cce-9425-63a1b682078c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_a7d8e380-eacc-4468-a7b1-b127ff5df054_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The expected term assumption that is used in valuing an option on its own shares for employees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:href="lxrx-20200331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_1034f0f5-4677-4fa5-b02e-7dfd09c3a711_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt, net of deferred issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_d3d922bd-c18a-4b04-a220-fa691196ec64_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2d8a08e8-01d1-4aab-bdc3-d8903193d3b7_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation and amortization, property and equipment</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b3f7d62c-8501-437e-8a5c-3fa05f7390bd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_ca9ba1de-6f57-4768-85bd-7d3c188873fd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0469938d-ea93-4ab6-9417-5242db47bdaf_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_acbfcca9-d737-40de-8443-98a59fe55c47_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_802c9a85-39e6-4358-aa26-f1ce0d8cfa20_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_a9816da1-3301-4855-8ae7-11b42e3c4e96_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_f82865af-0722-468c-8397-09fcbde73f18_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_34968b4f-fd83-4a00-9925-7a0886e3f238_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_Lxrx_Sanofiterminationcashpayment_31c7ec04-2978-4ce0-a021-9fb8372bc0e8_terseLabel_en-US" xlink:label="lab_lxrx_Lxrx_Sanofiterminationcashpayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi termination cash payment</link:label>
    <link:label id="lab_lxrx_Lxrx_Sanofiterminationcashpayment_label_en-US" xlink:label="lab_lxrx_Lxrx_Sanofiterminationcashpayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">lxrx_Sanofi termination cash payment</link:label>
    <link:label id="lab_lxrx_Lxrx_Sanofiterminationcashpayment_documentation_en-US" xlink:label="lab_lxrx_Lxrx_Sanofiterminationcashpayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">lxrx_Sanofi termination cash payment - represents the cash payment from Sanofi to terminate the collaboration alliance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Lxrx_Sanofiterminationcashpayment" xlink:href="lxrx-20200331.xsd#lxrx_Lxrx_Sanofiterminationcashpayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_Lxrx_Sanofiterminationcashpayment" xlink:to="lab_lxrx_Lxrx_Sanofiterminationcashpayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_37571037-0921-4370-bc57-3ee62365370d_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_15d157c6-2387-4e76-8257-59578155dca1_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the employees' option's term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:href="lxrx-20200331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_81cdc4ad-5c09-4c9d-a235-ea3d72ff9bf2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under Equity Incentive Plans, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_21be97b2-0b37-47e1-82e1-a171fb4fb2a7_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_9c7e56b1-eab6-40e6-bfa3-f3a09895e439_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_a937c8fd-98cb-43ce-9f25-44c51189b19b_terseLabel_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Allocated to Development Deliverable</link:label>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_label_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Allocated to Development Deliverable</link:label>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_documentation_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the amount of the upfront payment allocated to the development services deliverable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:href="lxrx-20200331.xsd#lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:to="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_0627efcf-9f52-4408-bf92-81a809096cef_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_5f2185e9-4705-4976-af59-0d8df30574d1_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_99e87c8c-1315-4eb1-914f-627612bb6d4f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX_f9b445c2-aaba-47a8-a1ac-7d837fed0d19_terseLabel_en-US" xlink:label="lab_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Interest Rate_Base_Revere_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX_label_en-US" xlink:label="lab_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Interest Rate_Base_Revere_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX_documentation_en-US" xlink:label="lab_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Interest Rate_Base_Revere_LXRX - interest rate in Revere loan agreement is 30-day LIBOR plus 5.5% as base rate. Interest charged is the greater of base or 7.5%</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX" xlink:href="lxrx-20200331.xsd#lxrx_MortgageDebtInterestRate_Base_Revere_LXRX"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX" xlink:to="lab_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_a04f1f58-a95b-48ee-94ae-4f935dfe4c38_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_0fe7216b-7472-41d5-987d-78ef9f9abce3_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_262bd9ec-db31-419c-b6e6-c1df7107a36b_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_272c587c-e45e-4a0b-9552-e52bac77a57a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $.001 par value; 225,000 shares authorized; 107,711 and 106,679 shares issued, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_f2cb4f05-ad33-4f55-a39a-988b695753ac_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development, including stock-based compensation of $2,176 and $1,768, respectively</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_a7236ecc-cafd-41ca-a548-011c11da3839_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_8f87bcd4-ab6e-4eff-a8b9-b32d6352ac15_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_a10e3965-e038-4945-8b58-941945822011_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_RecentAccountingPronouncementsAbstract_1a21b3c0-f121-480b-ae39-1ef71acc105c_terseLabel_en-US" xlink:label="lab_lxrx_RecentAccountingPronouncementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements [Abstract]</link:label>
    <link:label id="lab_lxrx_RecentAccountingPronouncementsAbstract_label_en-US" xlink:label="lab_lxrx_RecentAccountingPronouncementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements [Abstract]</link:label>
    <link:label id="lab_lxrx_RecentAccountingPronouncementsAbstract_documentation_en-US" xlink:label="lab_lxrx_RecentAccountingPronouncementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RecentAccountingPronouncementsAbstract" xlink:href="lxrx-20200331.xsd#lxrx_RecentAccountingPronouncementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_RecentAccountingPronouncementsAbstract" xlink:to="lab_lxrx_RecentAccountingPronouncementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_c890e5f6-5e2f-4b27-b246-d8b0f6b66cf1_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The risk-free interest rate assumption that is used in valuing an option on its own shares for employees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:href="lxrx-20200331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_674f037f-386e-43d7-a787-96ce51816a42_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_acbc1fbe-c1ed-454d-90d1-bc58a3cfe3d3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Increase) decrease in inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenMilestonePaymentReceived_fafb7115-5ad2-4439-9484-c289a044be15_terseLabel_en-US" xlink:label="lab_lxrx_IpsenMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Milestone Payment Received</link:label>
    <link:label id="lab_lxrx_IpsenMilestonePaymentReceived_label_en-US" xlink:label="lab_lxrx_IpsenMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Milestone Payment Received</link:label>
    <link:label id="lab_lxrx_IpsenMilestonePaymentReceived_documentation_en-US" xlink:label="lab_lxrx_IpsenMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the amount of milestone payments earned during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMilestonePaymentReceived" xlink:href="lxrx-20200331.xsd#lxrx_IpsenMilestonePaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenMilestonePaymentReceived" xlink:to="lab_lxrx_IpsenMilestonePaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_CollaborationAndLicenseAgreementsAbstract_29e1142a-a5f5-4ed3-ba5f-83d47b372800_terseLabel_en-US" xlink:label="lab_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:label id="lab_lxrx_CollaborationAndLicenseAgreementsAbstract_label_en-US" xlink:label="lab_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:label id="lab_lxrx_CollaborationAndLicenseAgreementsAbstract_documentation_en-US" xlink:label="lab_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:href="lxrx-20200331.xsd#lxrx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:to="lab_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_90e5044c-d1e5-4686-ab1b-39eb89ec9d97_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_f58fe883-a40a-42af-8fa8-7dc03ff8fdaf_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9c1e4712-6b5d-4b5b-98f8-e044d7d56820_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_16b5265b-4f50-4d0b-b935-203eec22881d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_664202c5-e5ab-40bc-9dce-71130d84ce9a_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_9dcaed37-4d8b-4bfb-be55-ae85816622a0_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_42f1cc97-d043-45c6-80a2-370cf3329962_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in computing net loss per common share, Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_3c93d7a0-9c85-443c-9617-3fe9363b6b86_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_b2b30b24-edf3-4f43-b30c-08137230e943_terseLabel_en-US" xlink:label="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents and Investments [Abstract]</link:label>
    <link:label id="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_label_en-US" xlink:label="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents and Investments [Abstract]</link:label>
    <link:label id="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_documentation_en-US" xlink:label="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents and Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:href="lxrx-20200331.xsd#lxrx_CashAndCashEquivalentsAndInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:to="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_13725d83-f27c-485f-8f20-1e185ac84263_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_2d5de2c7-f3fb-4bcb-8153-b3364a4a0258_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_bee2c029-b9e8-4be3-b02b-0c95fef18097_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_4c241020-4f03-4965-9c61-4465aa80d2d6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_4b0d1936-11fe-43a5-b441-2545fc05b8f2_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_4de79205-419b-44ae-93c1-1a625e6afeb1_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholder's equity (deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_ef4608ab-0453-400b-a44a-b976b632c520_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash, Cash Equivalents and Short-term Investments [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_00f69e2b-5238-44a7-935d-b76d954811dc_terseLabel_en-US" xlink:label="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:label id="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_label_en-US" xlink:label="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:label id="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_documentation_en-US" xlink:label="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:href="lxrx-20200331.xsd#lxrx_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a89329af-8ed6-49d4-9f67-117f2c24e481_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConvDebtInstrumentInterestRateStatedPercentage_270d94a1-c148-4877-8a30-a856f497d1d0_terseLabel_en-US" xlink:label="lab_lxrx_ConvDebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conv Debt Instrument Interest Rate Stated Percentage</link:label>
    <link:label id="lab_lxrx_ConvDebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_lxrx_ConvDebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conv Debt Instrument Interest Rate Stated Percentage</link:label>
    <link:label id="lab_lxrx_ConvDebtInstrumentInterestRateStatedPercentage_documentation_en-US" xlink:label="lab_lxrx_ConvDebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conv Debt Instrument Interest Rate Stated Percentage - contractual interest rate for convertible debt bonds under the debt agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvDebtInstrumentInterestRateStatedPercentage" xlink:href="lxrx-20200331.xsd#lxrx_ConvDebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConvDebtInstrumentInterestRateStatedPercentage" xlink:to="lab_lxrx_ConvDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1267b0a2-4660-4fee-83ae-5e4a0c03d8fb_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_Lxrx_sanofiInitialCashPayment_583dd2f8-7a53-451a-a821-a2a1b4debaa4_terseLabel_en-US" xlink:label="lab_lxrx_Lxrx_sanofiInitialCashPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">lxrx_sanofi initial cash payment</link:label>
    <link:label id="lab_lxrx_Lxrx_sanofiInitialCashPayment_label_en-US" xlink:label="lab_lxrx_Lxrx_sanofiInitialCashPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">lxrx_sanofi initial cash payment</link:label>
    <link:label id="lab_lxrx_Lxrx_sanofiInitialCashPayment_documentation_en-US" xlink:label="lab_lxrx_Lxrx_sanofiInitialCashPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">lxrx_sanofi initial cash payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Lxrx_sanofiInitialCashPayment" xlink:href="lxrx-20200331.xsd#lxrx_Lxrx_sanofiInitialCashPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_Lxrx_sanofiInitialCashPayment" xlink:to="lab_lxrx_Lxrx_sanofiInitialCashPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones_1a827104-2949-477b-b09f-04e72954c82c_terseLabel_en-US" xlink:label="lab_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Maximum Regulatory And Commercial Milestones</link:label>
    <link:label id="lab_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones_label_en-US" xlink:label="lab_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Maximum Regulatory And Commercial Milestones</link:label>
    <link:label id="lab_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones_documentation_en-US" xlink:label="lab_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the maximum regulatory and commercial launch milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones" xlink:href="lxrx-20200331.xsd#lxrx_IpsenMaximumRegulatoryAndCommercialMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones" xlink:to="lab_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_fea16d5a-79ed-4159-82f7-fc4896c76453_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyIncomeNonoperating_c1217d46-69cc-449e-8166-8193879cf53b_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties and other revenue</link:label>
    <link:label id="lab_us-gaap_RoyaltyIncomeNonoperating_label_en-US" xlink:label="lab_us-gaap_RoyaltyIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Income, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyIncomeNonoperating" xlink:to="lab_us-gaap_RoyaltyIncomeNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_Lxrx_sanofifuturecashpayment_cca1fc71-5483-419c-ab66-219069ee29d6_terseLabel_en-US" xlink:label="lab_lxrx_Lxrx_sanofifuturecashpayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi future cash payment</link:label>
    <link:label id="lab_lxrx_Lxrx_sanofifuturecashpayment_label_en-US" xlink:label="lab_lxrx_Lxrx_sanofifuturecashpayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">lxrx_sanofi future cash payment</link:label>
    <link:label id="lab_lxrx_Lxrx_sanofifuturecashpayment_documentation_en-US" xlink:label="lab_lxrx_Lxrx_sanofifuturecashpayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">lxrx_sanofi future cash payment - represents the future cash payment to be made by Sanofi as part of the termination of the alliance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Lxrx_sanofifuturecashpayment" xlink:href="lxrx-20200331.xsd#lxrx_Lxrx_sanofifuturecashpayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_Lxrx_sanofifuturecashpayment" xlink:to="lab_lxrx_Lxrx_sanofifuturecashpayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_3d080b87-cb22-41bc-9812-31ba75c225bc_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_3768c918-0c93-49fa-a3de-12330f4a547b_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_d1025bf8-718c-4d17-bcf4-634c2c3f0711_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_ae707dab-28c9-40a9-a7eb-ab54900923f3_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_f3d958e6-7d6b-4a54-b0f3-68c00d524a58_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $.01 par value; 5,000 shares authorized; no shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f4a7ea63-85d5-487b-964e-0fa0adda0889_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_fb4bb459-72ee-4bff-9050-a3dcebde03e5_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_fdbc4c4f-58c7-43f4-8ea6-88e378352667_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_45d1603b-8788-49ea-8bde-ffe9d3137aa2_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_Netproductrevenue_0408700c-a6dc-4723-972c-9907b7dcbb12_terseLabel_en-US" xlink:label="lab_lxrx_Netproductrevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenue</link:label>
    <link:label id="lab_lxrx_Netproductrevenue_label_en-US" xlink:label="lab_lxrx_Netproductrevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenue</link:label>
    <link:label id="lab_lxrx_Netproductrevenue_documentation_en-US" xlink:label="lab_lxrx_Netproductrevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenue - amount of revenue recognized from product sales, net of discounts. Sales process constitutes an earnings process.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Netproductrevenue" xlink:href="lxrx-20200331.xsd#lxrx_Netproductrevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_Netproductrevenue" xlink:to="lab_lxrx_Netproductrevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_1d15b76a-2a0d-4c06-a8a1-107e5152f3c1_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_74265d75-cab2-4f43-95fc-35ec4b2edb1d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_0d9117c4-44de-487f-9c79-b96217c640f5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f88f7eec-787d-4668-a1c7-ad017230c1ac_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_e3240855-cf2c-468a-9ec1-9486b7b39bf0_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SanofiRevenueRecognized_bbc7bcd1-3948-476a-b16e-b1af2641335d_terseLabel_en-US" xlink:label="lab_lxrx_SanofiRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Revenue Recognized</link:label>
    <link:label id="lab_lxrx_SanofiRevenueRecognized_label_en-US" xlink:label="lab_lxrx_SanofiRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Revenue Recognized</link:label>
    <link:label id="lab_lxrx_SanofiRevenueRecognized_documentation_en-US" xlink:label="lab_lxrx_SanofiRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the revenue recognized in the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiRevenueRecognized" xlink:href="lxrx-20200331.xsd#lxrx_SanofiRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiRevenueRecognized" xlink:to="lab_lxrx_SanofiRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_12024a5a-7165-4deb-9e99-544cdda30f20_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_40becc10-3b94-4704-bcce-3866714eb541_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_b8f120d9-4195-4b6d-8f90-d88810f485ef_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_a179bcaa-682b-462c-954e-ad4fa9c2d43b_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_1767fe21-755a-488a-9905-83c36c488f5f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_00e1735d-21c4-44d9-9a5c-f266744f1008_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_857e6087-2d9e-45a3-a9be-5e2880b90955_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_4c1f4adc-20b7-4d94-88b7-2cd61d94d895_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_045a8c48-707e-4d5a-babb-8798c5f0aedc_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_59e5c63e-f000-4a7f-b078-1e87bd40296a_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The risk-free interest rate assumption that is used in valuing an option on its own shares for officers and non-employee directors.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:href="lxrx-20200331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_2468febc-eddf-4428-aec9-a889f767831f_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2f51d94e-0348-41e8-bf38-c597de9d2e4b_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_a5ccfe31-66d4-446f-8ae3-0b5a89af5a98_terseLabel_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Stockholders&#8217; Equity [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Stockholders&#8217; Equity [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_documentation_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Stockholders&#8217; Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:href="lxrx-20200331.xsd#lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:to="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_82269bab-786d-417a-ae8d-dd3cc3f02a14_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_aa60a7c6-56ce-4391-91f4-a3553ae7d527_terseLabel_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized Debt Issuance Expense</link:label>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_label_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized Debt Issuance Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_07c0d7fb-ec3c-4657-afb6-6ec7560ca70c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_MortgageDebtBalloonPayment_LXRX_372b64af-1d38-4e96-bf46-b25a1b8e74b3_terseLabel_en-US" xlink:label="lab_lxrx_MortgageDebtBalloonPayment_LXRX" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Balloon Payment_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtBalloonPayment_LXRX_label_en-US" xlink:label="lab_lxrx_MortgageDebtBalloonPayment_LXRX" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Balloon Payment_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtBalloonPayment_LXRX_documentation_en-US" xlink:label="lab_lxrx_MortgageDebtBalloonPayment_LXRX" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Balloon Payment_LXRX - Balloon payment due at the end of the 2-year maturity date of mortgage loan with Revere.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtBalloonPayment_LXRX" xlink:href="lxrx-20200331.xsd#lxrx_MortgageDebtBalloonPayment_LXRX"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_MortgageDebtBalloonPayment_LXRX" xlink:to="lab_lxrx_MortgageDebtBalloonPayment_LXRX" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_a41de513-b866-4093-96c2-79ebfce2c59d_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Cost</link:label>
    <link:label id="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of Financing and Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_4e2d60de-1c28-42e6-888b-286a13101554_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable_80188d3e-c220-403d-b819-5c30c2ce371b_terseLabel_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Allocated to Committee Deliverable</link:label>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable_label_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Allocated to Committee Deliverable</link:label>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable_documentation_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This is the amount of the upfront payment allocated to the committee participation deliverable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable" xlink:href="lxrx-20200331.xsd#lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable" xlink:to="lab_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>lxrx-20200331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:b6c3a7dc-b64d-45d6-bfee-77eb11f000ac,g:4bb55044-54d9-4307-a743-01e703a924d5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lexpharma.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="lxrx-20200331.xsd#DocumentandEntityInformation"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/DocumentandEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_72ab99a5-5fdd-4603-8a65-1f8dc666c732" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_357334c7-e3c2-475a-945d-51c18f0ecfa1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_72ab99a5-5fdd-4603-8a65-1f8dc666c732" xlink:to="loc_dei_DocumentType_357334c7-e3c2-475a-945d-51c18f0ecfa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_b1e4adc8-de4e-41a0-a4ce-f0dda64fb105" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_72ab99a5-5fdd-4603-8a65-1f8dc666c732" xlink:to="loc_dei_DocumentFiscalPeriodFocus_b1e4adc8-de4e-41a0-a4ce-f0dda64fb105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_3317517a-b833-457a-98eb-a8970e661304" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_72ab99a5-5fdd-4603-8a65-1f8dc666c732" xlink:to="loc_dei_DocumentQuarterlyReport_3317517a-b833-457a-98eb-a8970e661304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_7ea78380-7c6a-496a-b953-ce48819392f2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_72ab99a5-5fdd-4603-8a65-1f8dc666c732" xlink:to="loc_dei_DocumentPeriodEndDate_7ea78380-7c6a-496a-b953-ce48819392f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_242b6bcf-a2b8-41bf-a4ad-b6342ff9ff9a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_72ab99a5-5fdd-4603-8a65-1f8dc666c732" xlink:to="loc_dei_DocumentTransitionReport_242b6bcf-a2b8-41bf-a4ad-b6342ff9ff9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_b81f2f77-b0dd-49d0-ba2c-578ba92538e0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_72ab99a5-5fdd-4603-8a65-1f8dc666c732" xlink:to="loc_dei_AmendmentFlag_b81f2f77-b0dd-49d0-ba2c-578ba92538e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_fbe0ddbf-7f5b-4776-aa40-f3866140d11d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_72ab99a5-5fdd-4603-8a65-1f8dc666c732" xlink:to="loc_dei_DocumentFiscalYearFocus_fbe0ddbf-7f5b-4776-aa40-f3866140d11d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_feee7197-10b7-4261-9083-6ed40ff2dd59" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_72ab99a5-5fdd-4603-8a65-1f8dc666c732" xlink:to="loc_dei_CurrentFiscalYearEndDate_feee7197-10b7-4261-9083-6ed40ff2dd59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_7d3cdc02-e5b6-4221-a950-e8efc27bc933" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_72ab99a5-5fdd-4603-8a65-1f8dc666c732" xlink:to="loc_dei_EntityFileNumber_7d3cdc02-e5b6-4221-a950-e8efc27bc933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_c9bc7e25-84b3-4829-a2bd-014ed2b93af4" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_72ab99a5-5fdd-4603-8a65-1f8dc666c732" xlink:to="loc_dei_EntityRegistrantName_c9bc7e25-84b3-4829-a2bd-014ed2b93af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_51621048-e45c-4fd3-9d7e-c8d85f7f0208" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_72ab99a5-5fdd-4603-8a65-1f8dc666c732" xlink:to="loc_dei_EntityCentralIndexKey_51621048-e45c-4fd3-9d7e-c8d85f7f0208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_3ae55d49-dd46-4b0e-9a76-759da0745341" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_72ab99a5-5fdd-4603-8a65-1f8dc666c732" xlink:to="loc_dei_EntityIncorporationStateCountryCode_3ae55d49-dd46-4b0e-9a76-759da0745341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d80d642e-3c6f-42e0-9da8-fa32b1d8cafb" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_72ab99a5-5fdd-4603-8a65-1f8dc666c732" xlink:to="loc_dei_EntityTaxIdentificationNumber_d80d642e-3c6f-42e0-9da8-fa32b1d8cafb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_d986a7df-69b8-4a5c-9f6d-7f8127f610f9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_72ab99a5-5fdd-4603-8a65-1f8dc666c732" xlink:to="loc_dei_EntityAddressAddressLine1_d986a7df-69b8-4a5c-9f6d-7f8127f610f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_3b3ca1c7-68d6-4d46-8119-0f39a91da180" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_72ab99a5-5fdd-4603-8a65-1f8dc666c732" xlink:to="loc_dei_EntityAddressCityOrTown_3b3ca1c7-68d6-4d46-8119-0f39a91da180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_63c5a404-f3a1-46ef-b025-f8984d77df13" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_72ab99a5-5fdd-4603-8a65-1f8dc666c732" xlink:to="loc_dei_EntityAddressStateOrProvince_63c5a404-f3a1-46ef-b025-f8984d77df13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_ec6d8ea7-5111-4110-9be7-c72dcfe05e78" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_72ab99a5-5fdd-4603-8a65-1f8dc666c732" xlink:to="loc_dei_EntityAddressPostalZipCode_ec6d8ea7-5111-4110-9be7-c72dcfe05e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_30a2373a-5056-454e-bac1-5eb06e67a542" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_72ab99a5-5fdd-4603-8a65-1f8dc666c732" xlink:to="loc_dei_CityAreaCode_30a2373a-5056-454e-bac1-5eb06e67a542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_7688974a-6f1b-4a78-b3f1-081c34905b98" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_72ab99a5-5fdd-4603-8a65-1f8dc666c732" xlink:to="loc_dei_LocalPhoneNumber_7688974a-6f1b-4a78-b3f1-081c34905b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_b812b125-cbf6-4e9d-8f26-f3f994f2eed3" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_72ab99a5-5fdd-4603-8a65-1f8dc666c732" xlink:to="loc_dei_Security12bTitle_b812b125-cbf6-4e9d-8f26-f3f994f2eed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_e82bb7e1-45b5-42cf-881a-7a5cf9da0df1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_72ab99a5-5fdd-4603-8a65-1f8dc666c732" xlink:to="loc_dei_TradingSymbol_e82bb7e1-45b5-42cf-881a-7a5cf9da0df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_a4973ccb-8650-4500-98bd-cd59add18619" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_72ab99a5-5fdd-4603-8a65-1f8dc666c732" xlink:to="loc_dei_SecurityExchangeName_a4973ccb-8650-4500-98bd-cd59add18619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_0fbfbff2-bd69-46ef-9aa0-c837c9fa86be" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_72ab99a5-5fdd-4603-8a65-1f8dc666c732" xlink:to="loc_dei_EntityCurrentReportingStatus_0fbfbff2-bd69-46ef-9aa0-c837c9fa86be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_f56dddc4-c296-44bb-bc93-c9971ef5a5d3" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_72ab99a5-5fdd-4603-8a65-1f8dc666c732" xlink:to="loc_dei_EntityInteractiveDataCurrent_f56dddc4-c296-44bb-bc93-c9971ef5a5d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_32072b32-6865-41a9-a995-9acedb0e2bf7" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_72ab99a5-5fdd-4603-8a65-1f8dc666c732" xlink:to="loc_dei_EntityFilerCategory_32072b32-6865-41a9-a995-9acedb0e2bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_4d078cb7-81b9-48bf-ba7f-5631ccfea0d1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_72ab99a5-5fdd-4603-8a65-1f8dc666c732" xlink:to="loc_dei_EntitySmallBusiness_4d078cb7-81b9-48bf-ba7f-5631ccfea0d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_f1d36be7-ad8d-4c64-b9c8-f85f3ce21b1f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_72ab99a5-5fdd-4603-8a65-1f8dc666c732" xlink:to="loc_dei_EntityEmergingGrowthCompany_f1d36be7-ad8d-4c64-b9c8-f85f3ce21b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_ca938df3-4d83-42b4-a760-2ec0f8998bd6" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_72ab99a5-5fdd-4603-8a65-1f8dc666c732" xlink:to="loc_dei_EntityShellCompany_ca938df3-4d83-42b4-a760-2ec0f8998bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_6a470d61-bfb4-4736-99ff-6e2e54f50504" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_72ab99a5-5fdd-4603-8a65-1f8dc666c732" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_6a470d61-bfb4-4736-99ff-6e2e54f50504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="lxrx-20200331.xsd#ConsolidatedBalanceSheetsUnaudited"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedBalanceSheetsAbstract_4f27b2a7-f88f-4c3f-9524-bd362275f460" xlink:href="lxrx-20200331.xsd#lxrx_ConsolidatedBalanceSheetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6a078597-bc7d-498b-85d9-611435f6e19f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_4f27b2a7-f88f-4c3f-9524-bd362275f460" xlink:to="loc_us-gaap_StatementTable_6a078597-bc7d-498b-85d9-611435f6e19f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_163a29fd-8483-40da-8f4f-1ee621e07f3e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6a078597-bc7d-498b-85d9-611435f6e19f" xlink:to="loc_srt_StatementScenarioAxis_163a29fd-8483-40da-8f4f-1ee621e07f3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_d53e6b40-7f75-4f35-8c4a-5c3bea128601" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_163a29fd-8483-40da-8f4f-1ee621e07f3e" xlink:to="loc_srt_ScenarioUnspecifiedDomain_d53e6b40-7f75-4f35-8c4a-5c3bea128601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_d9196aec-d986-42eb-8553-de1ae4b47bc2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6a078597-bc7d-498b-85d9-611435f6e19f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_d9196aec-d986-42eb-8553-de1ae4b47bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_62230abd-6935-48c1-bcd7-1305d7fa7d02" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d9196aec-d986-42eb-8553-de1ae4b47bc2" xlink:to="loc_us-gaap_ClassOfStockDomain_62230abd-6935-48c1-bcd7-1305d7fa7d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_acd41f62-ef14-4611-b86b-8120a3a023f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6a078597-bc7d-498b-85d9-611435f6e19f" xlink:to="loc_us-gaap_StatementLineItems_acd41f62-ef14-4611-b86b-8120a3a023f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_73a89eac-3c14-4ae2-95d2-db1497832790" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_acd41f62-ef14-4611-b86b-8120a3a023f3" xlink:to="loc_us-gaap_AssetsCurrentAbstract_73a89eac-3c14-4ae2-95d2-db1497832790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c7381589-297b-45f4-b278-e91151b350cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_73a89eac-3c14-4ae2-95d2-db1497832790" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c7381589-297b-45f4-b278-e91151b350cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_1656c999-9c55-483a-aed3-01eac292733b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_73a89eac-3c14-4ae2-95d2-db1497832790" xlink:to="loc_us-gaap_ShortTermInvestments_1656c999-9c55-483a-aed3-01eac292733b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_3ebe6b84-1bb0-4591-99b6-0f51314a973c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_73a89eac-3c14-4ae2-95d2-db1497832790" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_3ebe6b84-1bb0-4591-99b6-0f51314a973c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_b91c6447-0e19-4108-b61a-25a4b6f72ccb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_73a89eac-3c14-4ae2-95d2-db1497832790" xlink:to="loc_us-gaap_InventoryNet_b91c6447-0e19-4108-b61a-25a4b6f72ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_5a20615e-b3cf-4c0e-9957-9b11a50df236" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_73a89eac-3c14-4ae2-95d2-db1497832790" xlink:to="loc_us-gaap_OtherAssetsCurrent_5a20615e-b3cf-4c0e-9957-9b11a50df236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f41b3826-ae8b-4b88-a2bf-adb30e7e256e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_73a89eac-3c14-4ae2-95d2-db1497832790" xlink:to="loc_us-gaap_AssetsCurrent_f41b3826-ae8b-4b88-a2bf-adb30e7e256e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c88a9819-69f7-4a76-97de-155e4426c8a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_acd41f62-ef14-4611-b86b-8120a3a023f3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c88a9819-69f7-4a76-97de-155e4426c8a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_67197895-9867-4ce9-9668-4d310f26221a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_acd41f62-ef14-4611-b86b-8120a3a023f3" xlink:to="loc_us-gaap_Goodwill_67197895-9867-4ce9-9668-4d310f26221a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5ebcba0f-eae7-49f8-b657-e0ba4205ffb7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_acd41f62-ef14-4611-b86b-8120a3a023f3" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5ebcba0f-eae7-49f8-b657-e0ba4205ffb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ad8f28b0-4554-4606-9c8d-6dff483982c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_acd41f62-ef14-4611-b86b-8120a3a023f3" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ad8f28b0-4554-4606-9c8d-6dff483982c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b97bbaf9-e6d0-4bf2-a55d-905e32a848ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_acd41f62-ef14-4611-b86b-8120a3a023f3" xlink:to="loc_us-gaap_Assets_b97bbaf9-e6d0-4bf2-a55d-905e32a848ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_4d5247f7-1b80-4a4b-bfd3-8011de27f464" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_acd41f62-ef14-4611-b86b-8120a3a023f3" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_4d5247f7-1b80-4a4b-bfd3-8011de27f464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_3c132d60-4b7f-4354-aa5f-791017c9f2e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4d5247f7-1b80-4a4b-bfd3-8011de27f464" xlink:to="loc_us-gaap_AccountsPayableCurrent_3c132d60-4b7f-4354-aa5f-791017c9f2e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_08c8a79d-5ee8-4700-b307-63aa5b5987aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4d5247f7-1b80-4a4b-bfd3-8011de27f464" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_08c8a79d-5ee8-4700-b307-63aa5b5987aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_9417a559-cb0d-4be4-9edc-4b5789e8f713" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4d5247f7-1b80-4a4b-bfd3-8011de27f464" xlink:to="loc_us-gaap_LongTermDebtCurrent_9417a559-cb0d-4be4-9edc-4b5789e8f713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d1621c19-b20c-410f-b564-c33d58436261" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4d5247f7-1b80-4a4b-bfd3-8011de27f464" xlink:to="loc_us-gaap_LiabilitiesCurrent_d1621c19-b20c-410f-b564-c33d58436261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_0d22bebf-0f00-4230-8a98-27d0c5a2f191" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_acd41f62-ef14-4611-b86b-8120a3a023f3" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_0d22bebf-0f00-4230-8a98-27d0c5a2f191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_81a4d083-f349-448d-87a0-e4a7175e099d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_acd41f62-ef14-4611-b86b-8120a3a023f3" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_81a4d083-f349-448d-87a0-e4a7175e099d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6b549fb1-41f2-403a-8be2-d55bb0944fc6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_acd41f62-ef14-4611-b86b-8120a3a023f3" xlink:to="loc_us-gaap_Liabilities_6b549fb1-41f2-403a-8be2-d55bb0944fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_a4efa5d4-2755-492b-92d5-dfc36f564f11" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_acd41f62-ef14-4611-b86b-8120a3a023f3" xlink:to="loc_us-gaap_CommitmentsAndContingencies_a4efa5d4-2755-492b-92d5-dfc36f564f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e9a9c57f-aa5a-48f0-9ea6-a48a88634017" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_acd41f62-ef14-4611-b86b-8120a3a023f3" xlink:to="loc_us-gaap_EquityAbstract_e9a9c57f-aa5a-48f0-9ea6-a48a88634017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_7834f04b-1713-4e6f-987b-1c9ebea753e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e9a9c57f-aa5a-48f0-9ea6-a48a88634017" xlink:to="loc_us-gaap_PreferredStockValue_7834f04b-1713-4e6f-987b-1c9ebea753e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_41b1b73c-eb87-418c-8ee9-704dd8d9fdfd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e9a9c57f-aa5a-48f0-9ea6-a48a88634017" xlink:to="loc_us-gaap_CommonStockValue_41b1b73c-eb87-418c-8ee9-704dd8d9fdfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_c8fef810-adb6-4b2d-b327-bf03abb8fc67" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e9a9c57f-aa5a-48f0-9ea6-a48a88634017" xlink:to="loc_us-gaap_AdditionalPaidInCapital_c8fef810-adb6-4b2d-b327-bf03abb8fc67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c24e6bb5-06f3-41db-9360-c80a4a21e37b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e9a9c57f-aa5a-48f0-9ea6-a48a88634017" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c24e6bb5-06f3-41db-9360-c80a4a21e37b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6b4ea127-9367-4d2a-99db-0c669c81f6a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e9a9c57f-aa5a-48f0-9ea6-a48a88634017" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6b4ea127-9367-4d2a-99db-0c669c81f6a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_76986153-65d1-4bf4-b526-740434520c37" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e9a9c57f-aa5a-48f0-9ea6-a48a88634017" xlink:to="loc_us-gaap_TreasuryStockValue_76986153-65d1-4bf4-b526-740434520c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a7286416-b02a-4ccc-9af9-2a43976c72da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e9a9c57f-aa5a-48f0-9ea6-a48a88634017" xlink:to="loc_us-gaap_StockholdersEquity_a7286416-b02a-4ccc-9af9-2a43976c72da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_4b8ba583-655b-4815-af6e-2babecbdb947" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_acd41f62-ef14-4611-b86b-8120a3a023f3" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_4b8ba583-655b-4815-af6e-2babecbdb947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals" xlink:type="simple" xlink:href="lxrx-20200331.xsd#ConsolidatedBalanceSheetsParentheticals"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedBalanceSheetsAbstract_df2c441b-24bf-4510-b06a-0e8a09333ed1" xlink:href="lxrx-20200331.xsd#lxrx_ConsolidatedBalanceSheetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0887f522-d534-48ba-ae0c-853af414788f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_df2c441b-24bf-4510-b06a-0e8a09333ed1" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0887f522-d534-48ba-ae0c-853af414788f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0a64295a-cd6d-43d3-a95d-c9baa0e5762f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_df2c441b-24bf-4510-b06a-0e8a09333ed1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0a64295a-cd6d-43d3-a95d-c9baa0e5762f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3509f83e-a3a0-40bc-8092-86e1197223a7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_df2c441b-24bf-4510-b06a-0e8a09333ed1" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3509f83e-a3a0-40bc-8092-86e1197223a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_c03620b6-3be3-4221-afce-da63d64af61d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_df2c441b-24bf-4510-b06a-0e8a09333ed1" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_c03620b6-3be3-4221-afce-da63d64af61d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_e5882c24-79ec-4c05-99cd-57524b5ab4ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_df2c441b-24bf-4510-b06a-0e8a09333ed1" xlink:to="loc_us-gaap_PreferredStockSharesIssued_e5882c24-79ec-4c05-99cd-57524b5ab4ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_a11d06db-e62d-40a0-80f9-9b870fcf3064" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_df2c441b-24bf-4510-b06a-0e8a09333ed1" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_a11d06db-e62d-40a0-80f9-9b870fcf3064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_cfdfd5ad-9849-4f8a-aa87-575090b5bac0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_df2c441b-24bf-4510-b06a-0e8a09333ed1" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_cfdfd5ad-9849-4f8a-aa87-575090b5bac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_cc9a8186-ad29-40ed-9286-77b4d206058c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_df2c441b-24bf-4510-b06a-0e8a09333ed1" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_cc9a8186-ad29-40ed-9286-77b4d206058c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_6751f9c7-8ce9-4786-b6a3-fe144085f8cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_df2c441b-24bf-4510-b06a-0e8a09333ed1" xlink:to="loc_us-gaap_CommonStockSharesIssued_6751f9c7-8ce9-4786-b6a3-fe144085f8cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_1ba3b2ca-8960-4b21-95a9-b7ddda540d73" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_df2c441b-24bf-4510-b06a-0e8a09333ed1" xlink:to="loc_us-gaap_TreasuryStockShares_1ba3b2ca-8960-4b21-95a9-b7ddda540d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="simple" xlink:href="lxrx-20200331.xsd#ConsolidatedStatementsofComprehensiveLossUnaudited"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract_a6208d83-d4bc-41ec-bf7f-cd528e8e15b5" xlink:href="lxrx-20200331.xsd#lxrx_ConsolidatedStatementsOfOperationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_196d45c2-25ff-4068-8b2b-a9f982dd183f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract_a6208d83-d4bc-41ec-bf7f-cd528e8e15b5" xlink:to="loc_us-gaap_StatementTable_196d45c2-25ff-4068-8b2b-a9f982dd183f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_cc608597-c812-4910-9fb0-823d1d73d894" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_196d45c2-25ff-4068-8b2b-a9f982dd183f" xlink:to="loc_srt_StatementScenarioAxis_cc608597-c812-4910-9fb0-823d1d73d894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_8a62e5b3-96ef-4282-867c-bea43e925cc7" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_cc608597-c812-4910-9fb0-823d1d73d894" xlink:to="loc_srt_ScenarioUnspecifiedDomain_8a62e5b3-96ef-4282-867c-bea43e925cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_214efdaa-4111-4eab-ab89-1aa2ea27c166" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_196d45c2-25ff-4068-8b2b-a9f982dd183f" xlink:to="loc_us-gaap_StatementLineItems_214efdaa-4111-4eab-ab89-1aa2ea27c166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_45013f18-cb38-4756-a59b-bf842df4a6c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_214efdaa-4111-4eab-ab89-1aa2ea27c166" xlink:to="loc_us-gaap_RevenuesAbstract_45013f18-cb38-4756-a59b-bf842df4a6c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Netproductrevenue_e488c217-ef66-4641-b4e2-0aae752035bc" xlink:href="lxrx-20200331.xsd#lxrx_Netproductrevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_45013f18-cb38-4756-a59b-bf842df4a6c7" xlink:to="loc_lxrx_Netproductrevenue_e488c217-ef66-4641-b4e2-0aae752035bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4b293e65-4e13-469b-bd8e-2839de85994f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_45013f18-cb38-4756-a59b-bf842df4a6c7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4b293e65-4e13-469b-bd8e-2839de85994f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating_fc913091-185b-4e68-8eef-219f8753270f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_45013f18-cb38-4756-a59b-bf842df4a6c7" xlink:to="loc_us-gaap_RoyaltyIncomeNonoperating_fc913091-185b-4e68-8eef-219f8753270f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_96c68afe-79a2-4b5c-94f4-35b2a57df906" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_45013f18-cb38-4756-a59b-bf842df4a6c7" xlink:to="loc_us-gaap_Revenues_96c68afe-79a2-4b5c-94f4-35b2a57df906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_51598531-829f-4234-b124-cc13e4e024e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_214efdaa-4111-4eab-ab89-1aa2ea27c166" xlink:to="loc_us-gaap_OperatingExpensesAbstract_51598531-829f-4234-b124-cc13e4e024e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_2e01ce0c-f5f3-472c-9049-97b32add6d35" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_51598531-829f-4234-b124-cc13e4e024e1" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_2e01ce0c-f5f3-472c-9049-97b32add6d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0cba5bc3-8de5-4ed0-bf79-64dbbd02c52f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_51598531-829f-4234-b124-cc13e4e024e1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0cba5bc3-8de5-4ed0-bf79-64dbbd02c52f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Sellinggeneralandadministrativeexpenses_06d4ca07-89c5-4910-ac03-fabd63a2795b" xlink:href="lxrx-20200331.xsd#lxrx_Sellinggeneralandadministrativeexpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_51598531-829f-4234-b124-cc13e4e024e1" xlink:to="loc_lxrx_Sellinggeneralandadministrativeexpenses_06d4ca07-89c5-4910-ac03-fabd63a2795b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_0c23a3f7-e5b6-4d04-b63b-c70e20cdd237" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_51598531-829f-4234-b124-cc13e4e024e1" xlink:to="loc_us-gaap_OperatingExpenses_0c23a3f7-e5b6-4d04-b63b-c70e20cdd237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_7ebac876-d714-4369-8dd7-ca9433cfce16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_214efdaa-4111-4eab-ab89-1aa2ea27c166" xlink:to="loc_us-gaap_OperatingIncomeLoss_7ebac876-d714-4369-8dd7-ca9433cfce16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_c51c62a1-41be-43dc-be6d-3930de24a657" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_214efdaa-4111-4eab-ab89-1aa2ea27c166" xlink:to="loc_us-gaap_InterestExpense_c51c62a1-41be-43dc-be6d-3930de24a657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_66c863a4-6700-4890-8a54-b8b0fa38168c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_214efdaa-4111-4eab-ab89-1aa2ea27c166" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_66c863a4-6700-4890-8a54-b8b0fa38168c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c7b338e1-6852-44ca-a194-695e063c1880" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_214efdaa-4111-4eab-ab89-1aa2ea27c166" xlink:to="loc_us-gaap_NetIncomeLoss_c7b338e1-6852-44ca-a194-695e063c1880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_c4fffd3a-c5ca-4b8a-aac8-f52854b2b71c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_214efdaa-4111-4eab-ab89-1aa2ea27c166" xlink:to="loc_us-gaap_EarningsPerShareBasic_c4fffd3a-c5ca-4b8a-aac8-f52854b2b71c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9eff9d76-ecdc-4de9-b981-acdeeed66802" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_214efdaa-4111-4eab-ab89-1aa2ea27c166" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9eff9d76-ecdc-4de9-b981-acdeeed66802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_51e21d2c-f959-43bf-a715-063e187f3732" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_214efdaa-4111-4eab-ab89-1aa2ea27c166" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_51e21d2c-f959-43bf-a715-063e187f3732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_619119c8-7821-45ee-a9ef-82cfc8a943db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_214efdaa-4111-4eab-ab89-1aa2ea27c166" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_619119c8-7821-45ee-a9ef-82cfc8a943db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_34472268-fc3b-412d-ae8d-cffa09bc677c" xlink:href="lxrx-20200331.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_214efdaa-4111-4eab-ab89-1aa2ea27c166" xlink:to="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_34472268-fc3b-412d-ae8d-cffa09bc677c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense_8f13aa5b-c753-4dcf-8ae6-f56830b5029e" xlink:href="lxrx-20200331.xsd#lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_214efdaa-4111-4eab-ab89-1aa2ea27c166" xlink:to="loc_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense_8f13aa5b-c753-4dcf-8ae6-f56830b5029e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals" xlink:type="simple" xlink:href="lxrx-20200331.xsd#ConsolidatedStatementsofComprehensiveLossParentheticals"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract_8f98d559-ecf7-4630-b862-f74303567216" xlink:href="lxrx-20200331.xsd#lxrx_ConsolidatedStatementsOfOperationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_c9e3e73a-ade5-46c6-8e13-d4c47c5f894b" xlink:href="lxrx-20200331.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract_8f98d559-ecf7-4630-b862-f74303567216" xlink:to="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_c9e3e73a-ade5-46c6-8e13-d4c47c5f894b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense_74ac3888-c31e-4902-bd36-07b379d6ae15" xlink:href="lxrx-20200331.xsd#lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract_8f98d559-ecf7-4630-b862-f74303567216" xlink:to="loc_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense_74ac3888-c31e-4902-bd36-07b379d6ae15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" xlink:type="simple" xlink:href="lxrx-20200331.xsd#ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_28a6efd3-28dd-405f-8a77-e6ce8743d7f4" xlink:href="lxrx-20200331.xsd#lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1512b3ba-8ba6-46e6-8c1b-f5f00f44302c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_28a6efd3-28dd-405f-8a77-e6ce8743d7f4" xlink:to="loc_us-gaap_StatementTable_1512b3ba-8ba6-46e6-8c1b-f5f00f44302c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_fac3dfa3-32a0-4ac6-801b-3f4aeba86b3f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1512b3ba-8ba6-46e6-8c1b-f5f00f44302c" xlink:to="loc_srt_StatementScenarioAxis_fac3dfa3-32a0-4ac6-801b-3f4aeba86b3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_0ea65a33-2d06-437a-bbf5-a26f49a88f88" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_fac3dfa3-32a0-4ac6-801b-3f4aeba86b3f" xlink:to="loc_srt_ScenarioUnspecifiedDomain_0ea65a33-2d06-437a-bbf5-a26f49a88f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_cff05e01-ef8b-40f0-8a9e-c6eba65fc6d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1512b3ba-8ba6-46e6-8c1b-f5f00f44302c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_cff05e01-ef8b-40f0-8a9e-c6eba65fc6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a34d246e-bfd0-4e9e-99d2-b1e986b2ce12" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cff05e01-ef8b-40f0-8a9e-c6eba65fc6d6" xlink:to="loc_us-gaap_EquityComponentDomain_a34d246e-bfd0-4e9e-99d2-b1e986b2ce12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ab014a94-d8af-4b99-be2f-ad59e9baa71a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a34d246e-bfd0-4e9e-99d2-b1e986b2ce12" xlink:to="loc_us-gaap_CommonStockMember_ab014a94-d8af-4b99-be2f-ad59e9baa71a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_7757dd24-caf5-4cdd-9c0a-161af390fd31" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a34d246e-bfd0-4e9e-99d2-b1e986b2ce12" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_7757dd24-caf5-4cdd-9c0a-161af390fd31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d7d049cf-70f2-4eea-b16b-8124778e77c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a34d246e-bfd0-4e9e-99d2-b1e986b2ce12" xlink:to="loc_us-gaap_RetainedEarningsMember_d7d049cf-70f2-4eea-b16b-8124778e77c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e0a2bcfb-908b-4f8c-9e3b-1a4e8e35bad0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a34d246e-bfd0-4e9e-99d2-b1e986b2ce12" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e0a2bcfb-908b-4f8c-9e3b-1a4e8e35bad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_fa0c1d0e-7b33-4c14-b65d-17c59c146865" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a34d246e-bfd0-4e9e-99d2-b1e986b2ce12" xlink:to="loc_us-gaap_TreasuryStockMember_fa0c1d0e-7b33-4c14-b65d-17c59c146865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_719b2df6-1fee-40b7-84c2-6fe2d438eecf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1512b3ba-8ba6-46e6-8c1b-f5f00f44302c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_719b2df6-1fee-40b7-84c2-6fe2d438eecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ecd188a3-4ad3-4606-866d-e95f7b9b4e30" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_719b2df6-1fee-40b7-84c2-6fe2d438eecf" xlink:to="loc_us-gaap_ClassOfStockDomain_ecd188a3-4ad3-4606-866d-e95f7b9b4e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3c37f293-0208-4fe5-abd7-9f59a6ec218c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1512b3ba-8ba6-46e6-8c1b-f5f00f44302c" xlink:to="loc_us-gaap_StatementLineItems_3c37f293-0208-4fe5-abd7-9f59a6ec218c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_f8c5289d-acc1-4ae5-85d8-a01f84dd20bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3c37f293-0208-4fe5-abd7-9f59a6ec218c" xlink:to="loc_us-gaap_CommonStockSharesIssued_f8c5289d-acc1-4ae5-85d8-a01f84dd20bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_59c804e9-6114-4171-8c54-6dd2bea756ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3c37f293-0208-4fe5-abd7-9f59a6ec218c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_59c804e9-6114-4171-8c54-6dd2bea756ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b881d6a9-388a-4f74-afe9-a15060ae37ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3c37f293-0208-4fe5-abd7-9f59a6ec218c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b881d6a9-388a-4f74-afe9-a15060ae37ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1605d3af-22af-4bdd-96b4-4e44017fb1db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3c37f293-0208-4fe5-abd7-9f59a6ec218c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1605d3af-22af-4bdd-96b4-4e44017fb1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e5ddf382-dd8f-4dfd-81d0-32bc44aada0e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3c37f293-0208-4fe5-abd7-9f59a6ec218c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e5ddf382-dd8f-4dfd-81d0-32bc44aada0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_feec8090-8032-4f44-b69d-04e2abdb38d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3c37f293-0208-4fe5-abd7-9f59a6ec218c" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_feec8090-8032-4f44-b69d-04e2abdb38d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_649b4b24-cbe0-429d-b135-9e575df06dc9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3c37f293-0208-4fe5-abd7-9f59a6ec218c" xlink:to="loc_us-gaap_NetIncomeLoss_649b4b24-cbe0-429d-b135-9e575df06dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_e5ea9e2c-b8c6-4f05-80a1-b82d0c0deb15" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3c37f293-0208-4fe5-abd7-9f59a6ec218c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_e5ea9e2c-b8c6-4f05-80a1-b82d0c0deb15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_ffc5b17b-3756-40d5-956d-43e8d93bffa3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3c37f293-0208-4fe5-abd7-9f59a6ec218c" xlink:to="loc_us-gaap_CommonStockSharesIssued_ffc5b17b-3756-40d5-956d-43e8d93bffa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_089b54c9-ebb9-41b0-a8e8-30dfa32d98fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3c37f293-0208-4fe5-abd7-9f59a6ec218c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_089b54c9-ebb9-41b0-a8e8-30dfa32d98fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="lxrx-20200331.xsd#ConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfCashFlowsAbstract_420b2a7e-e778-4be3-8b53-5f90e2906707" xlink:href="lxrx-20200331.xsd#lxrx_ConsolidatedStatementsOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d75b825f-26fa-45ff-889b-d0ade3cda7ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedStatementsOfCashFlowsAbstract_420b2a7e-e778-4be3-8b53-5f90e2906707" xlink:to="loc_us-gaap_StatementTable_d75b825f-26fa-45ff-889b-d0ade3cda7ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_68e6e049-1d4a-46c4-9053-083b90e862c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d75b825f-26fa-45ff-889b-d0ade3cda7ff" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_68e6e049-1d4a-46c4-9053-083b90e862c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2fd978db-bb97-49f7-b891-ed8330bc1358" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_68e6e049-1d4a-46c4-9053-083b90e862c6" xlink:to="loc_us-gaap_EquityComponentDomain_2fd978db-bb97-49f7-b891-ed8330bc1358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_54102839-e8b0-4c64-b2bc-634b86e6fc2d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d75b825f-26fa-45ff-889b-d0ade3cda7ff" xlink:to="loc_srt_StatementScenarioAxis_54102839-e8b0-4c64-b2bc-634b86e6fc2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_12e6a0a4-7aac-40d6-93ae-8efaed999d5d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_54102839-e8b0-4c64-b2bc-634b86e6fc2d" xlink:to="loc_srt_ScenarioUnspecifiedDomain_12e6a0a4-7aac-40d6-93ae-8efaed999d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1e626afe-f0d9-420a-8313-6cf8787f3635" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d75b825f-26fa-45ff-889b-d0ade3cda7ff" xlink:to="loc_us-gaap_StatementLineItems_1e626afe-f0d9-420a-8313-6cf8787f3635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0b38f419-5a31-44d8-898f-f4f9724eb644" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1e626afe-f0d9-420a-8313-6cf8787f3635" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0b38f419-5a31-44d8-898f-f4f9724eb644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2a3344c5-d549-4c22-b597-24d4e91b40ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0b38f419-5a31-44d8-898f-f4f9724eb644" xlink:to="loc_us-gaap_NetIncomeLoss_2a3344c5-d549-4c22-b597-24d4e91b40ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3d0ffbf2-415c-4fa9-9b8f-88f831244472" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0b38f419-5a31-44d8-898f-f4f9724eb644" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3d0ffbf2-415c-4fa9-9b8f-88f831244472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_39b92d2c-d990-46f1-8d47-8e0f0ddc2a8c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3d0ffbf2-415c-4fa9-9b8f-88f831244472" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_39b92d2c-d990-46f1-8d47-8e0f0ddc2a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_0247649d-96f1-4392-8b29-a8ed8d52685e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3d0ffbf2-415c-4fa9-9b8f-88f831244472" xlink:to="loc_us-gaap_ShareBasedCompensation_0247649d-96f1-4392-8b29-a8ed8d52685e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_ea0d8b97-3d86-4cab-885d-e012a88e5023" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3d0ffbf2-415c-4fa9-9b8f-88f831244472" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_ea0d8b97-3d86-4cab-885d-e012a88e5023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f6ffc65d-c8bf-4f04-83af-71288136674e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3d0ffbf2-415c-4fa9-9b8f-88f831244472" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f6ffc65d-c8bf-4f04-83af-71288136674e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8365b1e0-c71c-4970-aec8-b963e31dedcc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f6ffc65d-c8bf-4f04-83af-71288136674e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8365b1e0-c71c-4970-aec8-b963e31dedcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_6e12c1be-d0df-4529-9fbc-6f01af7c1135" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f6ffc65d-c8bf-4f04-83af-71288136674e" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_6e12c1be-d0df-4529-9fbc-6f01af7c1135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4f451708-9e27-43a8-af91-040d0c45d6ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f6ffc65d-c8bf-4f04-83af-71288136674e" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4f451708-9e27-43a8-af91-040d0c45d6ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_92aebdd2-7aac-4168-af9f-ab91a790bdfe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f6ffc65d-c8bf-4f04-83af-71288136674e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_92aebdd2-7aac-4168-af9f-ab91a790bdfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_b63b4d37-8396-4bd5-86be-08603c2a495f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f6ffc65d-c8bf-4f04-83af-71288136674e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_b63b4d37-8396-4bd5-86be-08603c2a495f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_3dca1ebe-add4-48e0-bcd7-1cf99b0ed433" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f6ffc65d-c8bf-4f04-83af-71288136674e" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_3dca1ebe-add4-48e0-bcd7-1cf99b0ed433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ba2a8980-da23-416d-b626-d941437c4f7f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0b38f419-5a31-44d8-898f-f4f9724eb644" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ba2a8980-da23-416d-b626-d941437c4f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e984e9c8-b269-46bd-b639-0c0770cb8024" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1e626afe-f0d9-420a-8313-6cf8787f3635" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e984e9c8-b269-46bd-b639-0c0770cb8024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2b9d37bf-e939-4b1f-b3e9-0c08cae6be9a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e984e9c8-b269-46bd-b639-0c0770cb8024" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2b9d37bf-e939-4b1f-b3e9-0c08cae6be9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_9d17bc8d-e56b-4143-acd5-6087078d1dac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e984e9c8-b269-46bd-b639-0c0770cb8024" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_9d17bc8d-e56b-4143-acd5-6087078d1dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_3b7855aa-f229-442b-9f45-9448af8cad23" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e984e9c8-b269-46bd-b639-0c0770cb8024" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_3b7855aa-f229-442b-9f45-9448af8cad23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6d059029-2d4d-4258-a583-c5cf1ffbb072" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e984e9c8-b269-46bd-b639-0c0770cb8024" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6d059029-2d4d-4258-a583-c5cf1ffbb072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_86ccf290-b653-4cb0-97bf-abfe18da633b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1e626afe-f0d9-420a-8313-6cf8787f3635" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_86ccf290-b653-4cb0-97bf-abfe18da633b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_e02a6eb9-b40f-41a1-bc8f-c81c7a44e706" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_86ccf290-b653-4cb0-97bf-abfe18da633b" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_e02a6eb9-b40f-41a1-bc8f-c81c7a44e706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_d7af816b-d4c7-42dd-bf9d-08fd7673e726" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_86ccf290-b653-4cb0-97bf-abfe18da633b" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_d7af816b-d4c7-42dd-bf9d-08fd7673e726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_309ca1df-b424-4b83-af23-50b6940d8f88" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_86ccf290-b653-4cb0-97bf-abfe18da633b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_309ca1df-b424-4b83-af23-50b6940d8f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_c7079c14-aea2-4475-b055-6536489adc1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1e626afe-f0d9-420a-8313-6cf8787f3635" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_c7079c14-aea2-4475-b055-6536489adc1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_dc99c137-e8d9-44bb-9cfb-3404b0572aed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1e626afe-f0d9-420a-8313-6cf8787f3635" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_dc99c137-e8d9-44bb-9cfb-3404b0572aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_dd25fdb3-854f-40e4-bb9a-b799474fd448" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1e626afe-f0d9-420a-8313-6cf8787f3635" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_dd25fdb3-854f-40e4-bb9a-b799474fd448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_7adee890-a3d8-49a8-821b-609aa489294b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1e626afe-f0d9-420a-8313-6cf8787f3635" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_7adee890-a3d8-49a8-821b-609aa489294b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_bf2a4d10-ad1d-49e8-93fd-7975869bceff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7adee890-a3d8-49a8-821b-609aa489294b" xlink:to="loc_us-gaap_InterestPaidNet_bf2a4d10-ad1d-49e8-93fd-7975869bceff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes" xlink:type="simple" xlink:href="lxrx-20200331.xsd#SummaryofSignificantAccountingPoliciesNotes"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_e099bcdf-24d9-4ce7-a6ec-78967ae427a9" xlink:href="lxrx-20200331.xsd#lxrx_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1d89f141-b843-4c36-bfb7-41a1c929e7db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_e099bcdf-24d9-4ce7-a6ec-78967ae427a9" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1d89f141-b843-4c36-bfb7-41a1c929e7db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="lxrx-20200331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_61e4e91d-afab-43c8-b9ea-bad4576fe795" xlink:href="lxrx-20200331.xsd#lxrx_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_d4b8b4cf-ac81-4411-aab0-f120456dec5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_61e4e91d-afab-43c8-b9ea-bad4576fe795" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_d4b8b4cf-ac81-4411-aab0-f120456dec5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_9309ee30-34ee-4c67-8aa1-7272d267993f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_61e4e91d-afab-43c8-b9ea-bad4576fe795" xlink:to="loc_us-gaap_UseOfEstimates_9309ee30-34ee-4c67-8aa1-7272d267993f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_18a19ef7-15ae-4b85-94b3-2edba92ebeb8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_61e4e91d-afab-43c8-b9ea-bad4576fe795" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_18a19ef7-15ae-4b85-94b3-2edba92ebeb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_efca7cf6-3b0d-4227-b250-8a5ec879666a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_61e4e91d-afab-43c8-b9ea-bad4576fe795" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_efca7cf6-3b0d-4227-b250-8a5ec879666a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_7b1f9841-f5c2-4ff9-92d6-5556092447a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_61e4e91d-afab-43c8-b9ea-bad4576fe795" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_7b1f9841-f5c2-4ff9-92d6-5556092447a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_207bb3ab-2cef-4955-b70c-ab963020e918" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_61e4e91d-afab-43c8-b9ea-bad4576fe795" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_207bb3ab-2cef-4955-b70c-ab963020e918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_7e1be1e2-b051-427d-82a4-2945c9983afa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_61e4e91d-afab-43c8-b9ea-bad4576fe795" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_7e1be1e2-b051-427d-82a4-2945c9983afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_a1b40160-a346-482f-9ea7-f7955885058f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_61e4e91d-afab-43c8-b9ea-bad4576fe795" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_a1b40160-a346-482f-9ea7-f7955885058f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_7ed74dea-bc39-4355-8177-7e79ec949b19" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_61e4e91d-afab-43c8-b9ea-bad4576fe795" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_7ed74dea-bc39-4355-8177-7e79ec949b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_7659c57f-6b18-48a5-9017-7bc04e5e54da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_61e4e91d-afab-43c8-b9ea-bad4576fe795" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_7659c57f-6b18-48a5-9017-7bc04e5e54da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="lxrx-20200331.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_6f021b0c-0b59-413e-8093-20419086c7be" xlink:href="lxrx-20200331.xsd#lxrx_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryMajorClassesPolicy_438f50af-beb1-4c3d-9605-df5e91b59511" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryMajorClassesPolicy"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_6f021b0c-0b59-413e-8093-20419086c7be" xlink:to="loc_us-gaap_InventoryMajorClassesPolicy_438f50af-beb1-4c3d-9605-df5e91b59511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables" xlink:type="simple" xlink:href="lxrx-20200331.xsd#SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract_26636ee6-2038-4a79-830e-03155071dec4" xlink:href="lxrx-20200331.xsd#lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5ae13da5-2aae-4edb-81bb-79f83a9735b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract_26636ee6-2038-4a79-830e-03155071dec4" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5ae13da5-2aae-4edb-81bb-79f83a9735b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f023af11-4b80-40b9-a104-76eeb364ea72" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract_26636ee6-2038-4a79-830e-03155071dec4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f023af11-4b80-40b9-a104-76eeb364ea72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_3f174f61-e664-484a-a8a7-5d83785a06ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract_26636ee6-2038-4a79-830e-03155071dec4" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_3f174f61-e664-484a-a8a7-5d83785a06ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails" xlink:type="simple" xlink:href="lxrx-20200331.xsd#SummaryofSignificantAccountingPoliciesInventoryDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_InventoryAbstract_6dc3e95a-b4c1-4828-b23a-4da49ee97bdc" xlink:href="lxrx-20200331.xsd#lxrx_InventoryAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_5312e4cc-d0bb-4bf2-b83f-3c146b7d7591" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_InventoryAbstract_6dc3e95a-b4c1-4828-b23a-4da49ee97bdc" xlink:to="loc_us-gaap_InventoryCurrentTable_5312e4cc-d0bb-4bf2-b83f-3c146b7d7591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_e77592eb-f669-4056-a5e5-198572affb3c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_5312e4cc-d0bb-4bf2-b83f-3c146b7d7591" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_e77592eb-f669-4056-a5e5-198572affb3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_120cc813-b4d3-4982-a614-c8d934cf7471" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_e77592eb-f669-4056-a5e5-198572affb3c" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_120cc813-b4d3-4982-a614-c8d934cf7471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_ec1deff6-0838-4e04-97ca-3db085ccd373" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_5312e4cc-d0bb-4bf2-b83f-3c146b7d7591" xlink:to="loc_us-gaap_InventoryLineItems_ec1deff6-0838-4e04-97ca-3db085ccd373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_0bc89263-b9d7-4079-843c-b6de14ca3013" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_ec1deff6-0838-4e04-97ca-3db085ccd373" xlink:to="loc_us-gaap_InventoryRawMaterials_0bc89263-b9d7-4079-843c-b6de14ca3013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_93a0eab1-e62e-41b7-b05d-ec46d640b1d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_ec1deff6-0838-4e04-97ca-3db085ccd373" xlink:to="loc_us-gaap_InventoryWorkInProcess_93a0eab1-e62e-41b7-b05d-ec46d640b1d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_c482fbc3-4039-40d6-9cc8-9c6b1836a578" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_ec1deff6-0838-4e04-97ca-3db085ccd373" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_c482fbc3-4039-40d6-9cc8-9c6b1836a578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_d76abbd2-9e6f-4e27-9448-f398fe935d06" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_ec1deff6-0838-4e04-97ca-3db085ccd373" xlink:to="loc_us-gaap_InventoryFinishedGoods_d76abbd2-9e6f-4e27-9448-f398fe935d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_e87339ff-300c-4427-94e1-c1897925f617" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_ec1deff6-0838-4e04-97ca-3db085ccd373" xlink:to="loc_us-gaap_InventoryGross_e87339ff-300c-4427-94e1-c1897925f617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" xlink:type="simple" xlink:href="lxrx-20200331.xsd#SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_9dec468e-e7a4-4196-973a-c3a972f07c08" xlink:href="lxrx-20200331.xsd#lxrx_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f371bf13-0336-495f-97f5-c657d90d7bb5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_9dec468e-e7a4-4196-973a-c3a972f07c08" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f371bf13-0336-495f-97f5-c657d90d7bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_ce334015-f304-4474-bbf1-9072b0e2bfa0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f371bf13-0336-495f-97f5-c657d90d7bb5" xlink:to="loc_us-gaap_PlanNameAxis_ce334015-f304-4474-bbf1-9072b0e2bfa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a813748f-7547-45b8-9e31-c28ad1c1ef0e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_ce334015-f304-4474-bbf1-9072b0e2bfa0" xlink:to="loc_us-gaap_PlanNameDomain_a813748f-7547-45b8-9e31-c28ad1c1ef0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_4e13f14d-2a80-4d74-9f4d-312861c4c3ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardDateAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f371bf13-0336-495f-97f5-c657d90d7bb5" xlink:to="loc_us-gaap_AwardDateAxis_4e13f14d-2a80-4d74-9f4d-312861c4c3ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_0795ade6-097c-47b3-bd17-f3eeb602c552" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardDateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateAxis_4e13f14d-2a80-4d74-9f4d-312861c4c3ab" xlink:to="loc_us-gaap_AwardDateDomain_0795ade6-097c-47b3-bd17-f3eeb602c552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f6a3db60-c967-407a-a8ff-a80777d8edd2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f371bf13-0336-495f-97f5-c657d90d7bb5" xlink:to="loc_us-gaap_AwardTypeAxis_f6a3db60-c967-407a-a8ff-a80777d8edd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fa34e95e-b5b9-43fe-997e-df464adfe031" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f6a3db60-c967-407a-a8ff-a80777d8edd2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fa34e95e-b5b9-43fe-997e-df464adfe031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_a29a7421-a123-42af-894c-bcbbee4af3b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fa34e95e-b5b9-43fe-997e-df464adfe031" xlink:to="loc_us-gaap_StockOptionMember_a29a7421-a123-42af-894c-bcbbee4af3b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_da53f784-d135-4ae0-bea2-4ecfa8e39ed8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f371bf13-0336-495f-97f5-c657d90d7bb5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_da53f784-d135-4ae0-bea2-4ecfa8e39ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3b101392-7d3b-463e-ba08-38ec6ac1dd2b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_da53f784-d135-4ae0-bea2-4ecfa8e39ed8" xlink:to="loc_us-gaap_ClassOfStockDomain_3b101392-7d3b-463e-ba08-38ec6ac1dd2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_85bac312-a2b9-4551-b802-8856104d4d5d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f371bf13-0336-495f-97f5-c657d90d7bb5" xlink:to="loc_srt_RangeAxis_85bac312-a2b9-4551-b802-8856104d4d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0cd51b47-d870-42e2-b5c2-def8257c5a0e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_85bac312-a2b9-4551-b802-8856104d4d5d" xlink:to="loc_srt_RangeMember_0cd51b47-d870-42e2-b5c2-def8257c5a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_8c4d7337-e880-46d8-8082-ce57d1aab835" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f371bf13-0336-495f-97f5-c657d90d7bb5" xlink:to="loc_us-gaap_VestingAxis_8c4d7337-e880-46d8-8082-ce57d1aab835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_06f9154f-9ed6-404e-99c8-cfcee0949d9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_8c4d7337-e880-46d8-8082-ce57d1aab835" xlink:to="loc_us-gaap_VestingDomain_06f9154f-9ed6-404e-99c8-cfcee0949d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac94f69c-fd06-4835-8700-244e4cf10a78" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f371bf13-0336-495f-97f5-c657d90d7bb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac94f69c-fd06-4835-8700-244e4cf10a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_b1cdd1d3-4391-4723-86f3-971aca84b0cc" xlink:href="lxrx-20200331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac94f69c-fd06-4835-8700-244e4cf10a78" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_b1cdd1d3-4391-4723-86f3-971aca84b0cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_d69feb02-7c60-4387-a655-875fa6d3e64d" xlink:href="lxrx-20200331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac94f69c-fd06-4835-8700-244e4cf10a78" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_d69feb02-7c60-4387-a655-875fa6d3e64d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_4b8bb087-475d-48cf-a43c-bba581a12a0b" xlink:href="lxrx-20200331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac94f69c-fd06-4835-8700-244e4cf10a78" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_4b8bb087-475d-48cf-a43c-bba581a12a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_557670aa-40d4-402a-ad86-2a6b3f3155fe" xlink:href="lxrx-20200331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac94f69c-fd06-4835-8700-244e4cf10a78" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_557670aa-40d4-402a-ad86-2a6b3f3155fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_e7f13efa-f763-41d4-b26e-7485f387bb44" xlink:href="lxrx-20200331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac94f69c-fd06-4835-8700-244e4cf10a78" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_e7f13efa-f763-41d4-b26e-7485f387bb44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_6a94b13f-1191-4a57-aee3-1d68c7452924" xlink:href="lxrx-20200331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac94f69c-fd06-4835-8700-244e4cf10a78" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_6a94b13f-1191-4a57-aee3-1d68c7452924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_899b3b6a-b44e-4cf8-8da7-3945673f29f4" xlink:href="lxrx-20200331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac94f69c-fd06-4835-8700-244e4cf10a78" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_899b3b6a-b44e-4cf8-8da7-3945673f29f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_09ddfedb-09cc-4081-b51b-4a6de298884b" xlink:href="lxrx-20200331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac94f69c-fd06-4835-8700-244e4cf10a78" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_09ddfedb-09cc-4081-b51b-4a6de298884b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" xlink:type="simple" xlink:href="lxrx-20200331.xsd#SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_cccdc92a-ea9b-4711-88fe-3f8b8a8b4334" xlink:href="lxrx-20200331.xsd#lxrx_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e799cdf2-f6ac-4602-88e8-e37164600451" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_cccdc92a-ea9b-4711-88fe-3f8b8a8b4334" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e799cdf2-f6ac-4602-88e8-e37164600451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_4bceb6f4-00de-420e-b4ef-bf897f97ea82" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e799cdf2-f6ac-4602-88e8-e37164600451" xlink:to="loc_us-gaap_PlanNameAxis_4bceb6f4-00de-420e-b4ef-bf897f97ea82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_458e25f3-96e0-4028-9dba-bb46e27eb3fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_4bceb6f4-00de-420e-b4ef-bf897f97ea82" xlink:to="loc_us-gaap_PlanNameDomain_458e25f3-96e0-4028-9dba-bb46e27eb3fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_3a73c2b9-4e4e-43d7-9a0f-4d0bb710d765" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardDateAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e799cdf2-f6ac-4602-88e8-e37164600451" xlink:to="loc_us-gaap_AwardDateAxis_3a73c2b9-4e4e-43d7-9a0f-4d0bb710d765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_0bf95dae-fa26-4590-8bde-139048a7383b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardDateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateAxis_3a73c2b9-4e4e-43d7-9a0f-4d0bb710d765" xlink:to="loc_us-gaap_AwardDateDomain_0bf95dae-fa26-4590-8bde-139048a7383b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bed7f46d-64fe-4189-b6bb-c2ce1382b150" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e799cdf2-f6ac-4602-88e8-e37164600451" xlink:to="loc_us-gaap_AwardTypeAxis_bed7f46d-64fe-4189-b6bb-c2ce1382b150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b611d449-fadd-4023-aebe-b495fca42bb1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_bed7f46d-64fe-4189-b6bb-c2ce1382b150" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b611d449-fadd-4023-aebe-b495fca42bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_df2480f1-b94e-477c-9214-2bb8c664e8ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b611d449-fadd-4023-aebe-b495fca42bb1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_df2480f1-b94e-477c-9214-2bb8c664e8ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4f1189ae-418e-4276-abed-53783e00c7a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b611d449-fadd-4023-aebe-b495fca42bb1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4f1189ae-418e-4276-abed-53783e00c7a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6d41fb2c-b146-45f3-b58b-b3814bf3cec3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e799cdf2-f6ac-4602-88e8-e37164600451" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6d41fb2c-b146-45f3-b58b-b3814bf3cec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9be6d4ec-8262-4549-ae37-6c056b9405d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6d41fb2c-b146-45f3-b58b-b3814bf3cec3" xlink:to="loc_us-gaap_ClassOfStockDomain_9be6d4ec-8262-4549-ae37-6c056b9405d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_717c1d68-a364-40f0-8d05-200a6ffb843a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e799cdf2-f6ac-4602-88e8-e37164600451" xlink:to="loc_srt_RangeAxis_717c1d68-a364-40f0-8d05-200a6ffb843a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2c9d2183-d28c-4cd9-a4e2-10ba7d9fc4d2" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_717c1d68-a364-40f0-8d05-200a6ffb843a" xlink:to="loc_srt_RangeMember_2c9d2183-d28c-4cd9-a4e2-10ba7d9fc4d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_0c88d029-0f30-4143-9c23-f75e85531769" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e799cdf2-f6ac-4602-88e8-e37164600451" xlink:to="loc_us-gaap_VestingAxis_0c88d029-0f30-4143-9c23-f75e85531769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_e3c534e8-a90b-464d-ad2f-280504d640c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_0c88d029-0f30-4143-9c23-f75e85531769" xlink:to="loc_us-gaap_VestingDomain_e3c534e8-a90b-464d-ad2f-280504d640c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60548cd-546f-476a-a917-e98498745ee7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e799cdf2-f6ac-4602-88e8-e37164600451" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60548cd-546f-476a-a917-e98498745ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_db3f13ae-4d20-4a16-a930-6b7e44549d55" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60548cd-546f-476a-a917-e98498745ee7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_db3f13ae-4d20-4a16-a930-6b7e44549d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_946416a0-90a6-4dc9-bd7e-9a5991977b79" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60548cd-546f-476a-a917-e98498745ee7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_946416a0-90a6-4dc9-bd7e-9a5991977b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_8eb2bf9b-d6ed-4261-862e-e4c0755a8811" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60548cd-546f-476a-a917-e98498745ee7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_8eb2bf9b-d6ed-4261-862e-e4c0755a8811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_83debb2e-bb86-4929-a22c-4cb029239182" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60548cd-546f-476a-a917-e98498745ee7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_83debb2e-bb86-4929-a22c-4cb029239182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_5fa23587-5f40-4f11-9dde-6f72597da5d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60548cd-546f-476a-a917-e98498745ee7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_5fa23587-5f40-4f11-9dde-6f72597da5d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_6636d9b3-00f3-4718-b7c7-55f0aa0d0299" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60548cd-546f-476a-a917-e98498745ee7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_6636d9b3-00f3-4718-b7c7-55f0aa0d0299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_31929d81-8fab-46e6-b525-b1d8390c819f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60548cd-546f-476a-a917-e98498745ee7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_31929d81-8fab-46e6-b525-b1d8390c819f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4b82c82f-ea71-40c9-90f4-40db7eb3b66b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60548cd-546f-476a-a917-e98498745ee7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4b82c82f-ea71-40c9-90f4-40db7eb3b66b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c27e31b0-f5ac-4969-9141-034052102b75" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60548cd-546f-476a-a917-e98498745ee7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c27e31b0-f5ac-4969-9141-034052102b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_06cbdd66-c808-445c-810a-7b11c9b7abb9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60548cd-546f-476a-a917-e98498745ee7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_06cbdd66-c808-445c-810a-7b11c9b7abb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a90c9c36-2979-4315-a00c-9513094efd36" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60548cd-546f-476a-a917-e98498745ee7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a90c9c36-2979-4315-a00c-9513094efd36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f9d593e1-0be9-485c-8451-28f818ec35ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60548cd-546f-476a-a917-e98498745ee7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f9d593e1-0be9-485c-8451-28f818ec35ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7bb01ef3-79c8-4f27-95df-ccf5419bdf0a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60548cd-546f-476a-a917-e98498745ee7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7bb01ef3-79c8-4f27-95df-ccf5419bdf0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fdb2272d-2ae2-4413-b5a2-e7f32facf462" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60548cd-546f-476a-a917-e98498745ee7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fdb2272d-2ae2-4413-b5a2-e7f32facf462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1bf21ef2-aeaf-4f67-94d4-ca958dc0b03e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60548cd-546f-476a-a917-e98498745ee7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1bf21ef2-aeaf-4f67-94d4-ca958dc0b03e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f6a5f727-418f-4273-a367-a61a02dad066" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60548cd-546f-476a-a917-e98498745ee7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f6a5f727-418f-4273-a367-a61a02dad066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_192d3078-fd6f-4858-8dbb-d26150101fcb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60548cd-546f-476a-a917-e98498745ee7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_192d3078-fd6f-4858-8dbb-d26150101fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d04c03c3-d91d-4e9f-90da-2c8f6b146b46" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e60548cd-546f-476a-a917-e98498745ee7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d04c03c3-d91d-4e9f-90da-2c8f6b146b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2" xlink:type="simple" xlink:href="lxrx-20200331.xsd#SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_583b8dee-31eb-4186-b34f-94c4bb8ad587" xlink:href="lxrx-20200331.xsd#lxrx_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7ebb575-2f94-47cd-b252-ea0c3142c2af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_583b8dee-31eb-4186-b34f-94c4bb8ad587" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7ebb575-2f94-47cd-b252-ea0c3142c2af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_f3730984-cc40-405c-9243-e3d429ef81e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7ebb575-2f94-47cd-b252-ea0c3142c2af" xlink:to="loc_us-gaap_PlanNameAxis_f3730984-cc40-405c-9243-e3d429ef81e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_688deff8-fa9a-429e-bfff-b9af361585cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_f3730984-cc40-405c-9243-e3d429ef81e6" xlink:to="loc_us-gaap_PlanNameDomain_688deff8-fa9a-429e-bfff-b9af361585cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9d31ffb8-fc72-460c-a39f-7b5364adc27c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7ebb575-2f94-47cd-b252-ea0c3142c2af" xlink:to="loc_us-gaap_AwardTypeAxis_9d31ffb8-fc72-460c-a39f-7b5364adc27c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e07257cd-8ab0-41e1-b6c0-4891b1081e0e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9d31ffb8-fc72-460c-a39f-7b5364adc27c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e07257cd-8ab0-41e1-b6c0-4891b1081e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4fc1b15d-23fa-4fc1-8899-cad1f12ae3b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7ebb575-2f94-47cd-b252-ea0c3142c2af" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4fc1b15d-23fa-4fc1-8899-cad1f12ae3b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_176922bd-fdf0-4c38-a6f7-5f72ff14cfe2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4fc1b15d-23fa-4fc1-8899-cad1f12ae3b3" xlink:to="loc_us-gaap_ClassOfStockDomain_176922bd-fdf0-4c38-a6f7-5f72ff14cfe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5b9767dc-aad8-4cb6-9958-362698979d54" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7ebb575-2f94-47cd-b252-ea0c3142c2af" xlink:to="loc_srt_RangeAxis_5b9767dc-aad8-4cb6-9958-362698979d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_654c23f0-2a25-4c43-9082-e052a107d73e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5b9767dc-aad8-4cb6-9958-362698979d54" xlink:to="loc_srt_RangeMember_654c23f0-2a25-4c43-9082-e052a107d73e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d42bd232-9f0c-47c1-bc64-c2ace0824238" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7ebb575-2f94-47cd-b252-ea0c3142c2af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d42bd232-9f0c-47c1-bc64-c2ace0824238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes" xlink:type="simple" xlink:href="lxrx-20200331.xsd#RecentAccountingPronouncementsLevel1Notes"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RecentAccountingPronouncementsAbstract_43f99d67-4394-4443-8c53-f524bbb54d0d" xlink:href="lxrx-20200331.xsd#lxrx_RecentAccountingPronouncementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3d8f5ebc-1d24-44a8-a71a-77e4b0aca4fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_RecentAccountingPronouncementsAbstract_43f99d67-4394-4443-8c53-f524bbb54d0d" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3d8f5ebc-1d24-44a8-a71a-77e4b0aca4fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails" xlink:type="simple" xlink:href="lxrx-20200331.xsd#RecentAccountingPronouncementsDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RecentAccountingPronouncementsAbstract_bb1cffa2-5349-4d06-99e9-8980ea054465" xlink:href="lxrx-20200331.xsd#lxrx_RecentAccountingPronouncementsAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments" xlink:type="simple" xlink:href="lxrx-20200331.xsd#CashandCashEquivalentsandInvestments"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_87514077-7708-4515-bbe2-e456ba171b53" xlink:href="lxrx-20200331.xsd#lxrx_CashAndCashEquivalentsAndInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_9cba3c92-3763-43bb-a5fd-a50b6270ca8c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_87514077-7708-4515-bbe2-e456ba171b53" xlink:to="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_9cba3c92-3763-43bb-a5fd-a50b6270ca8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables" xlink:type="simple" xlink:href="lxrx-20200331.xsd#CashandCashEquivalentsandInvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_03e7c139-7c57-4230-a389-6e374ed7e0c5" xlink:href="lxrx-20200331.xsd#lxrx_CashAndCashEquivalentsAndInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_5d00e1a9-4748-438a-a388-14a30b6bc531" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_03e7c139-7c57-4230-a389-6e374ed7e0c5" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_5d00e1a9-4748-438a-a388-14a30b6bc531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1" xlink:type="simple" xlink:href="lxrx-20200331.xsd#CashandCashEquivalentsandInvestmentsDetails1"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_b498f67e-fca4-43ac-acb3-baeb397b8530" xlink:href="lxrx-20200331.xsd#lxrx_CashAndCashEquivalentsAndInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_3215492b-133b-4553-9955-83579e6c8c41" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_b498f67e-fca4-43ac-acb3-baeb397b8530" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_3215492b-133b-4553-9955-83579e6c8c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_a45f35b6-9e1d-4928-8506-1b2cab0e98ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_3215492b-133b-4553-9955-83579e6c8c41" xlink:to="loc_us-gaap_InvestmentTypeAxis_a45f35b6-9e1d-4928-8506-1b2cab0e98ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_6eebcbae-7877-483a-9bcc-37dbb7537095" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_a45f35b6-9e1d-4928-8506-1b2cab0e98ea" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_6eebcbae-7877-483a-9bcc-37dbb7537095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_e9f1954e-9328-42ab-a1c7-4f552a1f676a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_6eebcbae-7877-483a-9bcc-37dbb7537095" xlink:to="loc_us-gaap_CashMember_e9f1954e-9328-42ab-a1c7-4f552a1f676a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_948f86c9-5aea-46b6-8a34-5db269487669" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_6eebcbae-7877-483a-9bcc-37dbb7537095" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_948f86c9-5aea-46b6-8a34-5db269487669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_5027c1f5-f90c-4a16-8aa7-0673e84d0271" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_6eebcbae-7877-483a-9bcc-37dbb7537095" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_5027c1f5-f90c-4a16-8aa7-0673e84d0271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_95836705-deb9-4810-9bdb-04a1fe33af6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_6eebcbae-7877-483a-9bcc-37dbb7537095" xlink:to="loc_us-gaap_InvestmentsMember_95836705-deb9-4810-9bdb-04a1fe33af6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_897a7188-ceba-40ba-b169-d1c2e34fcf90" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_3215492b-133b-4553-9955-83579e6c8c41" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_897a7188-ceba-40ba-b169-d1c2e34fcf90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_6c8f11c0-69c8-4fff-a6de-117acd852fd5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_897a7188-ceba-40ba-b169-d1c2e34fcf90" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_6c8f11c0-69c8-4fff-a6de-117acd852fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0c154f0f-451b-4a90-b5c6-eaf00ff82e4f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_897a7188-ceba-40ba-b169-d1c2e34fcf90" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0c154f0f-451b-4a90-b5c6-eaf00ff82e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c9161220-f2cb-4654-aa75-140e820e3bde" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_897a7188-ceba-40ba-b169-d1c2e34fcf90" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c9161220-f2cb-4654-aa75-140e820e3bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_e25f001d-d721-481c-b71f-8d5b21bafafb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_897a7188-ceba-40ba-b169-d1c2e34fcf90" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_e25f001d-d721-481c-b71f-8d5b21bafafb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2" xlink:type="simple" xlink:href="lxrx-20200331.xsd#CashandCashEquivalentsandInvestmentsDetails2"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_1f67a950-9f13-4926-83f5-5931e19920b8" xlink:href="lxrx-20200331.xsd#lxrx_CashAndCashEquivalentsAndInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_95c75504-1eb7-4d10-bc89-7c1b4dbdb720" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_1f67a950-9f13-4926-83f5-5931e19920b8" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_95c75504-1eb7-4d10-bc89-7c1b4dbdb720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingActivityByTypeAxis_7e85357c-69dd-4ab1-b300-7121e024d5ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TradingActivityByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_95c75504-1eb7-4d10-bc89-7c1b4dbdb720" xlink:to="loc_us-gaap_TradingActivityByTypeAxis_7e85357c-69dd-4ab1-b300-7121e024d5ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingActivityByTypeDomain_b73b36dc-df2a-40df-a8ad-ccc5674598cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TradingActivityByTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TradingActivityByTypeAxis_7e85357c-69dd-4ab1-b300-7121e024d5ee" xlink:to="loc_us-gaap_TradingActivityByTypeDomain_b73b36dc-df2a-40df-a8ad-ccc5674598cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_33580f6c-b350-454d-a7e3-642818580329" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_95c75504-1eb7-4d10-bc89-7c1b4dbdb720" xlink:to="loc_us-gaap_ScheduleOfInvestmentsLineItems_33580f6c-b350-454d-a7e3-642818580329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_bd81dfd4-e96e-49b5-831c-7dc0b87e6267" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_33580f6c-b350-454d-a7e3-642818580329" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_bd81dfd4-e96e-49b5-831c-7dc0b87e6267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="lxrx-20200331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FairValueMeasurementsAbstract_f2310602-7945-4717-9a6b-97acb728217d" xlink:href="lxrx-20200331.xsd#lxrx_FairValueMeasurementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_a481e690-5245-4589-b186-5904d06f2eae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_FairValueMeasurementsAbstract_f2310602-7945-4717-9a6b-97acb728217d" xlink:to="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_a481e690-5245-4589-b186-5904d06f2eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="lxrx-20200331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FairValueMeasurementsAbstract_34f9c98c-26a9-47db-9964-35c6b8384b55" xlink:href="lxrx-20200331.xsd#lxrx_FairValueMeasurementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_b9bd9a27-74ef-4f9f-b925-e7578facbdff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_FairValueMeasurementsAbstract_34f9c98c-26a9-47db-9964-35c6b8384b55" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_b9bd9a27-74ef-4f9f-b925-e7578facbdff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:type="simple" xlink:href="lxrx-20200331.xsd#FairValueMeasurementsDetails1"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FairValueMeasurementsAbstract_72f89cb2-2f41-4c7e-8659-c64a73ec8f1f" xlink:href="lxrx-20200331.xsd#lxrx_FairValueMeasurementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_83318631-8c69-4b95-be18-8722c4517228" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_FairValueMeasurementsAbstract_72f89cb2-2f41-4c7e-8659-c64a73ec8f1f" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_83318631-8c69-4b95-be18-8722c4517228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_74b32fa2-e81b-4490-bb14-1e9e5c9e89ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_83318631-8c69-4b95-be18-8722c4517228" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_74b32fa2-e81b-4490-bb14-1e9e5c9e89ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1489b30c-02e3-4345-b88d-30c04d9618d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_74b32fa2-e81b-4490-bb14-1e9e5c9e89ec" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1489b30c-02e3-4345-b88d-30c04d9618d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_b3d43cb5-205a-4b4a-9d0a-b74c0fdeb42e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1489b30c-02e3-4345-b88d-30c04d9618d6" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_b3d43cb5-205a-4b4a-9d0a-b74c0fdeb42e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_7a120bd4-3499-4543-9a92-a5738a276283" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1489b30c-02e3-4345-b88d-30c04d9618d6" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_7a120bd4-3499-4543-9a92-a5738a276283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_c56fe132-03d7-40d2-a10a-fe500d0e3ba9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1489b30c-02e3-4345-b88d-30c04d9618d6" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_c56fe132-03d7-40d2-a10a-fe500d0e3ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7753a026-49d1-4a93-880d-6e8274266b55" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_83318631-8c69-4b95-be18-8722c4517228" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7753a026-49d1-4a93-880d-6e8274266b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_47bae650-c128-4dce-887a-5f324b8f0527" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7753a026-49d1-4a93-880d-6e8274266b55" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_47bae650-c128-4dce-887a-5f324b8f0527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecurities_981df2b7-db92-4ad2-9d96-fa29a0db9b14" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7753a026-49d1-4a93-880d-6e8274266b55" xlink:to="loc_us-gaap_AvailableForSaleSecurities_981df2b7-db92-4ad2-9d96-fa29a0db9b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_79acc44c-8e6e-4776-83a7-ef3c969cdaa9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7753a026-49d1-4a93-880d-6e8274266b55" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_79acc44c-8e6e-4776-83a7-ef3c969cdaa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligations" xlink:type="simple" xlink:href="lxrx-20200331.xsd#DebtObligations"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/DebtObligations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DebtObligationsAbstract_4e65a447-d52b-45e0-ab05-21b7102b7267" xlink:href="lxrx-20200331.xsd#lxrx_DebtObligationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_959d22a7-2cc1-4d73-aeaa-62e28d19575e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DebtObligationsAbstract_4e65a447-d52b-45e0-ab05-21b7102b7267" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_959d22a7-2cc1-4d73-aeaa-62e28d19575e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsTables" xlink:type="simple" xlink:href="lxrx-20200331.xsd#DebtObligationsTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/DebtObligationsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsDetails" xlink:type="simple" xlink:href="lxrx-20200331.xsd#DebtObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/DebtObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DebtObligationsAbstract_f21081ff-50be-48cc-9526-4b8797078e46" xlink:href="lxrx-20200331.xsd#lxrx_DebtObligationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_3319cae7-3151-4da5-9a2a-92965101bb3c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DebtObligationsAbstract_f21081ff-50be-48cc-9526-4b8797078e46" xlink:to="loc_us-gaap_DebtInstrumentTable_3319cae7-3151-4da5-9a2a-92965101bb3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_8d406ca3-f716-44d6-bdae-f4eb9fd55a56" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3319cae7-3151-4da5-9a2a-92965101bb3c" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_8d406ca3-f716-44d6-bdae-f4eb9fd55a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6d8f2663-25ed-42c5-aec9-94ce5f4b83ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8d406ca3-f716-44d6-bdae-f4eb9fd55a56" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6d8f2663-25ed-42c5-aec9-94ce5f4b83ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d00837e1-21a4-42b0-b182-3d66ee0c4a37" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3319cae7-3151-4da5-9a2a-92965101bb3c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d00837e1-21a4-42b0-b182-3d66ee0c4a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_719f7980-e0e1-4a0f-a1c7-d04b7ed90467" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d00837e1-21a4-42b0-b182-3d66ee0c4a37" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_719f7980-e0e1-4a0f-a1c7-d04b7ed90467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_49fd944d-31f7-46d6-87b1-5f29bdbc59d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3319cae7-3151-4da5-9a2a-92965101bb3c" xlink:to="loc_us-gaap_DebtInstrumentAxis_49fd944d-31f7-46d6-87b1-5f29bdbc59d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fed1a37f-9d7b-4c2d-bcac-05443980874f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_49fd944d-31f7-46d6-87b1-5f29bdbc59d3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fed1a37f-9d7b-4c2d-bcac-05443980874f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_f3ef174c-0d81-4855-b5c4-7f2df6e4e864" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3319cae7-3151-4da5-9a2a-92965101bb3c" xlink:to="loc_us-gaap_DebtInstrumentLineItems_f3ef174c-0d81-4855-b5c4-7f2df6e4e864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_e7b35372-297a-43a6-aa1c-db1a6ec53e53" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f3ef174c-0d81-4855-b5c4-7f2df6e4e864" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_e7b35372-297a-43a6-aa1c-db1a6ec53e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_b85b07bf-7bf6-42df-a405-5a57e5fda761" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f3ef174c-0d81-4855-b5c4-7f2df6e4e864" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_b85b07bf-7bf6-42df-a405-5a57e5fda761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_24ae8cf2-673e-4bb6-8a98-d43b9af8625f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f3ef174c-0d81-4855-b5c4-7f2df6e4e864" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_24ae8cf2-673e-4bb6-8a98-d43b9af8625f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvDebtInstrumentInterestRateStatedPercentage_83ec12a4-9a83-432c-8ff1-12c3b081addc" xlink:href="lxrx-20200331.xsd#lxrx_ConvDebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f3ef174c-0d81-4855-b5c4-7f2df6e4e864" xlink:to="loc_lxrx_ConvDebtInstrumentInterestRateStatedPercentage_83ec12a4-9a83-432c-8ff1-12c3b081addc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_d38042b3-9075-41bf-965a-07413be5419e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f3ef174c-0d81-4855-b5c4-7f2df6e4e864" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_d38042b3-9075-41bf-965a-07413be5419e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_0ce76b94-de20-4441-af43-8d32d9457d81" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f3ef174c-0d81-4855-b5c4-7f2df6e4e864" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_0ce76b94-de20-4441-af43-8d32d9457d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_b16c7f21-f341-4446-a3d5-cc92e6ed5704" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f3ef174c-0d81-4855-b5c4-7f2df6e4e864" xlink:to="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_b16c7f21-f341-4446-a3d5-cc92e6ed5704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_468c4d3f-5be0-44d0-bd10-6333acd92935" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f3ef174c-0d81-4855-b5c4-7f2df6e4e864" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_468c4d3f-5be0-44d0-bd10-6333acd92935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_feee3577-60e7-4827-9ee4-8a43fc0ec28c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f3ef174c-0d81-4855-b5c4-7f2df6e4e864" xlink:to="loc_us-gaap_DebtInstrumentFairValue_feee3577-60e7-4827-9ee4-8a43fc0ec28c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInstrument_Revere_LXRX_8c46a4e3-62ca-475b-8559-0fb93348a662" xlink:href="lxrx-20200331.xsd#lxrx_MortgageDebtInstrument_Revere_LXRX"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f3ef174c-0d81-4855-b5c4-7f2df6e4e864" xlink:to="loc_lxrx_MortgageDebtInstrument_Revere_LXRX_8c46a4e3-62ca-475b-8559-0fb93348a662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX_4ea22dad-0e7d-4589-84cb-d41fa8a60eac" xlink:href="lxrx-20200331.xsd#lxrx_MortgageDebtInterestRate_Base_Revere_LXRX"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f3ef174c-0d81-4855-b5c4-7f2df6e4e864" xlink:to="loc_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX_4ea22dad-0e7d-4589-84cb-d41fa8a60eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX_a08cdb56-11c4-492c-9402-78e9dfc88af7" xlink:href="lxrx-20200331.xsd#lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f3ef174c-0d81-4855-b5c4-7f2df6e4e864" xlink:to="loc_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX_a08cdb56-11c4-492c-9402-78e9dfc88af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtBalloonPayment_LXRX_5b01253f-de99-49b2-874d-43ee818ec21c" xlink:href="lxrx-20200331.xsd#lxrx_MortgageDebtBalloonPayment_LXRX"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f3ef174c-0d81-4855-b5c4-7f2df6e4e864" xlink:to="loc_lxrx_MortgageDebtBalloonPayment_LXRX_5b01253f-de99-49b2-874d-43ee818ec21c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtIssueCosts_Revere_LXRX_02811b32-359e-4ffd-a409-c96648f9a586" xlink:href="lxrx-20200331.xsd#lxrx_MortgageDebtIssueCosts_Revere_LXRX"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f3ef174c-0d81-4855-b5c4-7f2df6e4e864" xlink:to="loc_lxrx_MortgageDebtIssueCosts_Revere_LXRX_02811b32-359e-4ffd-a409-c96648f9a586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_BuildingsCollateral_a41c7e47-d523-49d4-9c78-695f9764d37c" xlink:href="lxrx-20200331.xsd#lxrx_BuildingsCollateral"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f3ef174c-0d81-4855-b5c4-7f2df6e4e864" xlink:to="loc_lxrx_BuildingsCollateral_a41c7e47-d523-49d4-9c78-695f9764d37c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LandCollateral_b4fbc43b-79b6-4100-a805-9af97ebc57a6" xlink:href="lxrx-20200331.xsd#lxrx_LandCollateral"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f3ef174c-0d81-4855-b5c4-7f2df6e4e864" xlink:to="loc_lxrx_LandCollateral_b4fbc43b-79b6-4100-a805-9af97ebc57a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c8c4aa58-d674-4922-8d2f-3142337d0da3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f3ef174c-0d81-4855-b5c4-7f2df6e4e864" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c8c4aa58-d674-4922-8d2f-3142337d0da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_78ff585a-0e6c-40f3-84b7-546f963f19e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f3ef174c-0d81-4855-b5c4-7f2df6e4e864" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_78ff585a-0e6c-40f3-84b7-546f963f19e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="lxrx-20200331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e27d09ce-ef7b-4d13-b5ba-b705f8a2cdff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8e4e2cb6-d517-497e-80b8-59a5525d8721" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e27d09ce-ef7b-4d13-b5ba-b705f8a2cdff" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8e4e2cb6-d517-497e-80b8-59a5525d8721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreements" xlink:type="simple" xlink:href="lxrx-20200331.xsd#CollaborationandLicenseAgreements"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CollaborationandLicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_45a4e8a5-dc5c-4916-8a67-b924ebdc7226" xlink:href="lxrx-20200331.xsd#lxrx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_3c97957b-33e6-4ea5-8f31-8cd4dc3cc501" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_45a4e8a5-dc5c-4916-8a67-b924ebdc7226" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_3c97957b-33e6-4ea5-8f31-8cd4dc3cc501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsTables" xlink:type="simple" xlink:href="lxrx-20200331.xsd#CollaborationandLicenseAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" xlink:type="simple" xlink:href="lxrx-20200331.xsd#CollaborationandLicenseAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_9eec9d5d-c815-46ea-b989-45cd933587ab" xlink:href="lxrx-20200331.xsd#lxrx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Lxrx_Sanofiterminationcashpayment_cef71901-f1e8-484f-b0fd-9556c1dcb75f" xlink:href="lxrx-20200331.xsd#lxrx_Lxrx_Sanofiterminationcashpayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_9eec9d5d-c815-46ea-b989-45cd933587ab" xlink:to="loc_lxrx_Lxrx_Sanofiterminationcashpayment_cef71901-f1e8-484f-b0fd-9556c1dcb75f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Lxrx_sanofifuturecashpayment_b5e92c3a-34c6-45a5-ba58-6e68948cf43b" xlink:href="lxrx-20200331.xsd#lxrx_Lxrx_sanofifuturecashpayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_9eec9d5d-c815-46ea-b989-45cd933587ab" xlink:to="loc_lxrx_Lxrx_sanofifuturecashpayment_b5e92c3a-34c6-45a5-ba58-6e68948cf43b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiRevenueRecognized_175f9183-cd33-4c51-9006-c3902e8a057e" xlink:href="lxrx-20200331.xsd#lxrx_SanofiRevenueRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_9eec9d5d-c815-46ea-b989-45cd933587ab" xlink:to="loc_lxrx_SanofiRevenueRecognized_175f9183-cd33-4c51-9006-c3902e8a057e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenTotalPayments_aa0b5e48-e4b4-4f69-a777-710a469d8331" xlink:href="lxrx-20200331.xsd#lxrx_IpsenTotalPayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_9eec9d5d-c815-46ea-b989-45cd933587ab" xlink:to="loc_lxrx_IpsenTotalPayments_aa0b5e48-e4b4-4f69-a777-710a469d8331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones_9cb705a4-7727-4176-9307-ca712b45a853" xlink:href="lxrx-20200331.xsd#lxrx_IpsenMaximumRegulatoryAndCommercialMilestones"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_9eec9d5d-c815-46ea-b989-45cd933587ab" xlink:to="loc_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones_9cb705a4-7727-4176-9307-ca712b45a853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMaximumSalesMilestones_a6218f2d-70da-4c64-ad1c-4232907f8f6b" xlink:href="lxrx-20200331.xsd#lxrx_IpsenMaximumSalesMilestones"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_9eec9d5d-c815-46ea-b989-45cd933587ab" xlink:to="loc_lxrx_IpsenMaximumSalesMilestones_a6218f2d-70da-4c64-ad1c-4232907f8f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenTotalUpfrontPayments_84e1736c-dc72-40fa-8a3e-1a22fb0998a0" xlink:href="lxrx-20200331.xsd#lxrx_IpsenTotalUpfrontPayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_9eec9d5d-c815-46ea-b989-45cd933587ab" xlink:to="loc_lxrx_IpsenTotalUpfrontPayments_84e1736c-dc72-40fa-8a3e-1a22fb0998a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMilestonePayment_533ea080-3316-4a85-8ae8-f00a7f4f049c" xlink:href="lxrx-20200331.xsd#lxrx_IpsenMilestonePayment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_9eec9d5d-c815-46ea-b989-45cd933587ab" xlink:to="loc_lxrx_IpsenMilestonePayment_533ea080-3316-4a85-8ae8-f00a7f4f049c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMilestonePaymentReceived_f68a84a3-6a42-47ce-a930-8335a7f775b5" xlink:href="lxrx-20200331.xsd#lxrx_IpsenMilestonePaymentReceived"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_9eec9d5d-c815-46ea-b989-45cd933587ab" xlink:to="loc_lxrx_IpsenMilestonePaymentReceived_f68a84a3-6a42-47ce-a930-8335a7f775b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable_102350ca-9ba8-40f9-a520-e1639b7b4242" xlink:href="lxrx-20200331.xsd#lxrx_IpsenRevenueAllocatedtoLicenseDeliverable"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_9eec9d5d-c815-46ea-b989-45cd933587ab" xlink:to="loc_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable_102350ca-9ba8-40f9-a520-e1639b7b4242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_f8af5278-3eb9-406f-a5f7-d10393574890" xlink:href="lxrx-20200331.xsd#lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_9eec9d5d-c815-46ea-b989-45cd933587ab" xlink:to="loc_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_f8af5278-3eb9-406f-a5f7-d10393574890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable_ce63bbfe-c1b6-45e4-b289-01ba10c19302" xlink:href="lxrx-20200331.xsd#lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_9eec9d5d-c815-46ea-b989-45cd933587ab" xlink:to="loc_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable_ce63bbfe-c1b6-45e4-b289-01ba10c19302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueRecognized_b01814b2-7afa-4a99-9a50-c62807ad8387" xlink:href="lxrx-20200331.xsd#lxrx_IpsenRevenueRecognized"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_9eec9d5d-c815-46ea-b989-45cd933587ab" xlink:to="loc_lxrx_IpsenRevenueRecognized_b01814b2-7afa-4a99-9a50-c62807ad8387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Lxrx_sanofiInitialCashPayment_2139d3f6-48e1-4d8b-957f-c2e343fcab5f" xlink:href="lxrx-20200331.xsd#lxrx_Lxrx_sanofiInitialCashPayment"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_9eec9d5d-c815-46ea-b989-45cd933587ab" xlink:to="loc_lxrx_Lxrx_sanofiInitialCashPayment_2139d3f6-48e1-4d8b-957f-c2e343fcab5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6773899904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents and Investments (Details 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Realized Investment Gains (Losses)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net realized gains or losses on investments during the period, not including gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.3(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6654620448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Inventory (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Inventory, Raw Materials, Gross</a></td>
<td class="nump">$ 2,218,000<span></span>
</td>
<td class="nump">$ 3,182,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Inventory, Work in Process, Gross</a></td>
<td class="nump">1,117,000<span></span>
</td>
<td class="nump">153,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Inventory, Finished Goods, Net of Reserves</a></td>
<td class="nump">812,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Inventory, Finished Goods, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">908,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory, Gross</a></td>
<td class="nump">$ 4,147,000<span></span>
</td>
<td class="nump">$ 4,243,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>lxrx-20200331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:lxrx="http://www.lexpharma.com/20200331"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="lxrx-20200331.xsd" xlink:type="simple"/>
    <context id="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id2404fdeff6740faada8a1fcc2da1bf3_I20200423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2020-04-23</instant>
        </period>
    </context>
    <context id="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i363fbff4bcfa49938a12d82839eb6a03_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6e1705cc437a4623985876b0a6850cd4_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ia7a2afb94e3d47888a4f5fb5cbad1728_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i4d1fdae96a904b22b9d37b0de77588fb_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6bd9c5bf42c248cd9bf25b6dea04bd1a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7bc51fbc5bfc475ea508dad359524362_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i5b7022476157494398816b99471e0697_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ifb01c97139de4c7da87be444c5833141_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ibcb21aab8fb742a4b472651ad313d600_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ie9b975fc81164d7cbff5a2763c95ef28_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ifa015c4922754b5d91743371bfe8a576_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ib455b101c4484d4c8d9f69a783226edd_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i9a9b6cf9115b4d328637e78789aa34f1_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="if43ffe172d1f4c68b5844235ee4289f7_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i8f6a44ebc0994be5a7cef652c7d2857e_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i6910b93f33e4481fb289ea612c84f3ae_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i593c8c0affe34641adbf79593094ac0b_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ie255744bc9f3477ba151d4eaa2718fe1_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="if2014f01922b408fa97848ffdeb88941_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iba79016389514c5ebe72f001f7acf420_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia1a8986ec8894a469fbd46f3df2dc202_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2c9621fa321f4e9195d6603061f89e2f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i846c9d455edf4f1cb3d7646d362b3a11_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1112901d3eee474b98585e70b151f858_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i3d8f640e99d948e59de6f191b2509423_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i8f1459fd243c427791a12f208909ef19_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie225ba400e5842d2896152f546aedab5_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iaac8e8918b3b48de8027ed5b977e799b_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4f1cd0ed4c754265b45c85c1bc69396f_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="if4f4eb4f717648a1807ac159d3543e2c_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i3daccec285f3488c8d44f5dc7865d44e_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i92dc246d5c4e4b13a56fd11a7345454e_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i9cd8c8c5263c421b8fa978b95f7cd714_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i3f18a324e14b49309846f18ff6f8c0bc_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i71615d600ea045f8b04f0104cca32e8c_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i0feb9d4ec8584f3ba002dca3b78ba1a4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9befb60474ef4d338b2be4e84a752c34_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i006d636778dc433599008ebda0fae643_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i208e16ef59a04b3c8182732d53d1e2eb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icb6eab599353423faf94057d3a06d361_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6d895ee7aef1499d98cd6729af5ed070_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i5874757311014de880a5b19a0ef172e9_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ic70d1635899243dcae62140e9324e2e5_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i9fe1a3b2255e409c8e58bbc860ad020d_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i2ec309d5c8d74374add6eb8f7da20570_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ic774c47684e0435aa7c3af7fdf7fe3fd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie0f70c6928fb4964a9779e08a7863739_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7833aa4e5e984d3dba5516f674a6a6fd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5690a7970c9142c1b8c462b80f0e2ba2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6a4c4a7f94924e29a9ae0e9f3ffd742f_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ie20916e42c934ea59584c72016a49665_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i0b10f1125ee94d22854381cfc60caac9_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ib827aa338f2c4aca8a2d4e234b9f0078_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icc19c78530d54ec0a70b9d2bdd0a9db7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic3d4c113ca4e4166a72c7baa6566b202_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibd4832dfa32a43a6b0d3e7ac775c2680_D20141101-20141130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2014-11-01</startDate>
            <endDate>2014-11-30</endDate>
        </period>
    </context>
    <context id="i7a726c0e01c741f09f3d21d85cd63800_I20141120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2014-11-20</instant>
        </period>
    </context>
    <context id="id80805ff25ba4c6c9ddb0b2c60375c8a_I20180830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2018-08-30</instant>
        </period>
    </context>
    <context id="i65c277c002ca41af9214fb16de22bcb8_I20171218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2017-12-18</instant>
        </period>
    </context>
    <context id="i723e1df096a74ef3a7ed1c4ee79e00cb_D20150301-20150331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2015-03-01</startDate>
            <endDate>2015-03-31</endDate>
        </period>
    </context>
    <context id="if2f0442e8e3949d2acab519802cd9a7a_D20160701-20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2016-07-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="i9f3132da0556457c978c3721090d9425_D20170701-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2017-07-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="i949545145223492aa3a8472aa5f75d6c_D20171001-20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="icb75b1b2778741648129edca9c77b0d1_D20171101-20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="i41e7bc56d8f44697acef137f70b02cef_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i9940e83a99be4c0db47b16062f8cf74e_D20190201-20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="iace247b45bbe4d50be1b8046b7cf2019_D20141001-20141031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2014-10-01</startDate>
            <endDate>2014-10-31</endDate>
        </period>
    </context>
    <context id="i2eee5e8c4bdb4710a81e6835c783b093_D20150101-20150630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-06-30</endDate>
        </period>
    </context>
    <context id="ic1c464c977e64590a82ac8d115d0d92c_D20160101-20160630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-06-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <dei:DocumentFiscalPeriodFocus
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80L2ZyYWc6NDZjNjc0YjdiODgxNDdkNGEyNzcyMGFhNjVhNDExZjAvdGFibGU6NjZlZjEzNzJhZGU4NGNlNTg3NjhhNWVhZGYzNzIzMjQvdGFibGVyYW5nZTo2NmVmMTM3MmFkZTg0Y2U1ODc2OGE1ZWFkZjM3MjMyNF81LTMtMS0xLTQwOQ_38e6f152-88d3-4167-8625-ed15634d6c43">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80L2ZyYWc6NDZjNjc0YjdiODgxNDdkNGEyNzcyMGFhNjVhNDExZjAvdGFibGU6NjZlZjEzNzJhZGU4NGNlNTg3NjhhNWVhZGYzNzIzMjQvdGFibGVyYW5nZTo2NmVmMTM3MmFkZTg0Y2U1ODc2OGE1ZWFkZjM3MjMyNF85LTMtMS0xLTQ0MA_9bd7b305-d67b-4f25-9789-5e8f3bc28c10">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80L2ZyYWc6NDZjNjc0YjdiODgxNDdkNGEyNzcyMGFhNjVhNDExZjAvdGFibGU6NjZlZjEzNzJhZGU4NGNlNTg3NjhhNWVhZGYzNzIzMjQvdGFibGVyYW5nZTo2NmVmMTM3MmFkZTg0Y2U1ODc2OGE1ZWFkZjM3MjMyNF8xMC0zLTEtMS00NDA_9021772b-ace6-48e9-ac17-676341bd9018">2020</dei:DocumentFiscalYearFocus>
    <dei:CurrentFiscalYearEndDate
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80L2ZyYWc6NDZjNjc0YjdiODgxNDdkNGEyNzcyMGFhNjVhNDExZjAvdGFibGU6NjZlZjEzNzJhZGU4NGNlNTg3NjhhNWVhZGYzNzIzMjQvdGFibGVyYW5nZTo2NmVmMTM3MmFkZTg0Y2U1ODc2OGE1ZWFkZjM3MjMyNF8xMS0zLTEtMS00Mzc_ba168edf-152e-4d53-9c4f-008f0623711a">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityRegistrantName
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80L2ZyYWc6NDZjNjc0YjdiODgxNDdkNGEyNzcyMGFhNjVhNDExZjAvdGFibGU6NjZlZjEzNzJhZGU4NGNlNTg3NjhhNWVhZGYzNzIzMjQvdGFibGVyYW5nZTo2NmVmMTM3MmFkZTg0Y2U1ODc2OGE1ZWFkZjM3MjMyNF8xMy0zLTEtMS00NDA_f2058429-c706-4206-b258-33ad60c21b73">LEXICON PHARMACEUTICALS, INC./DE</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80L2ZyYWc6NDZjNjc0YjdiODgxNDdkNGEyNzcyMGFhNjVhNDExZjAvdGFibGU6NjZlZjEzNzJhZGU4NGNlNTg3NjhhNWVhZGYzNzIzMjQvdGFibGVyYW5nZTo2NmVmMTM3MmFkZTg0Y2U1ODc2OGE1ZWFkZjM3MjMyNF8xNC0zLTEtMS00NDA_c1ee6fd0-a87a-45a8-9808-17fff4d48ef2">0001062822</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xL2ZyYWc6MGJiNDQwZTdkYmY1NGQ1ZDg2M2M2Y2I2YzM0MjhiMTQvdGV4dHJlZ2lvbjowYmI0NDBlN2RiZjU0ZDVkODYzYzZjYjZjMzQyOGIxNF8zODQ4MjkwNjk5NDg5_5900730a-9864-4c83-b9dc-8783a3ff5a31">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xL2ZyYWc6MGJiNDQwZTdkYmY1NGQ1ZDg2M2M2Y2I2YzM0MjhiMTQvdGFibGU6MGUyMWJmNDhlN2U4NDU0N2FmNTc1YWExNDhiZTAyYTYvdGFibGVyYW5nZTowZTIxYmY0OGU3ZTg0NTQ3YWY1NzVhYTE0OGJlMDJhNl8wLTAtMS0xLTQyMA_ec9bbd15-c0e7-45e0-833c-bcd943aaf937">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xL2ZyYWc6MGJiNDQwZTdkYmY1NGQ1ZDg2M2M2Y2I2YzM0MjhiMTQvdGV4dHJlZ2lvbjowYmI0NDBlN2RiZjU0ZDVkODYzYzZjYjZjMzQyOGIxNF8zODQ4MjkwNjk5NDg2_48b2298e-4883-43c1-848b-955787a285e2">2020-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xL2ZyYWc6MGJiNDQwZTdkYmY1NGQ1ZDg2M2M2Y2I2YzM0MjhiMTQvdGFibGU6MDViMWIzM2Q3NjQxNDc5OWExZGJlODhjYTkyMzcyMmMvdGFibGVyYW5nZTowNWIxYjMzZDc2NDE0Nzk5YTFkYmU4OGNhOTIzNzIyY18wLTAtMS0xLTQzMQ_a50e18b4-a582-46ae-95ce-5ebb5c4ed36d">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xL2ZyYWc6MGJiNDQwZTdkYmY1NGQ1ZDg2M2M2Y2I2YzM0MjhiMTQvdGV4dHJlZ2lvbjowYmI0NDBlN2RiZjU0ZDVkODYzYzZjYjZjMzQyOGIxNF8zODQ4MjkwNjk5NTMy_64963127-913a-4982-8290-4796f9ae9c9f">000-30111</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xL2ZyYWc6MGJiNDQwZTdkYmY1NGQ1ZDg2M2M2Y2I2YzM0MjhiMTQvdGFibGU6MDUxMWVhZGQwMzQwNGMyOWJkZGQ3M2JmNGQwMWJkYjAvdGFibGVyYW5nZTowNTExZWFkZDAzNDA0YzI5YmRkZDczYmY0ZDAxYmRiMF8wLTAtMS0xLTQ2Mw_ed445a3e-b02f-4a6c-b02f-582f0a51eda3">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xL2ZyYWc6MGJiNDQwZTdkYmY1NGQ1ZDg2M2M2Y2I2YzM0MjhiMTQvdGFibGU6MDUxMWVhZGQwMzQwNGMyOWJkZGQ3M2JmNGQwMWJkYjAvdGFibGVyYW5nZTowNTExZWFkZDAzNDA0YzI5YmRkZDczYmY0ZDAxYmRiMF8wLTEtMS0xLTQ3NA_bf0d9ffb-eac0-4401-857d-59eb625c2a55">76-0474169</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xL2ZyYWc6MGJiNDQwZTdkYmY1NGQ1ZDg2M2M2Y2I2YzM0MjhiMTQvdGV4dHJlZ2lvbjowYmI0NDBlN2RiZjU0ZDVkODYzYzZjYjZjMzQyOGIxNF8zODQ4MjkwNjk5NTY0_2070fd33-fcd0-4d93-b727-726f268abcf6">8800 Technology Forest Place</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xL2ZyYWc6MGJiNDQwZTdkYmY1NGQ1ZDg2M2M2Y2I2YzM0MjhiMTQvdGV4dHJlZ2lvbjowYmI0NDBlN2RiZjU0ZDVkODYzYzZjYjZjMzQyOGIxNF8zODQ4MjkwNjk5NTc5_9ccbca5f-f29e-48be-8319-d0392b35361b">The Woodlands</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xL2ZyYWc6MGJiNDQwZTdkYmY1NGQ1ZDg2M2M2Y2I2YzM0MjhiMTQvdGV4dHJlZ2lvbjowYmI0NDBlN2RiZjU0ZDVkODYzYzZjYjZjMzQyOGIxNF8zODQ4MjkwNjk5NTg2_78710e08-3020-47c8-badc-69802b961eac">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xL2ZyYWc6MGJiNDQwZTdkYmY1NGQ1ZDg2M2M2Y2I2YzM0MjhiMTQvdGV4dHJlZ2lvbjowYmI0NDBlN2RiZjU0ZDVkODYzYzZjYjZjMzQyOGIxNF8zODQ4MjkwNjk5NTkz_b065f455-0630-426d-b79f-0fc0eba1d22d">77381</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xL2ZyYWc6MGJiNDQwZTdkYmY1NGQ1ZDg2M2M2Y2I2YzM0MjhiMTQvdGV4dHJlZ2lvbjowYmI0NDBlN2RiZjU0ZDVkODYzYzZjYjZjMzQyOGIxNF8zODQ4MjkwNjk5NTk4_fa3886dc-8d9a-4f36-917e-f9e9ec665762">281</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xL2ZyYWc6MGJiNDQwZTdkYmY1NGQ1ZDg2M2M2Y2I2YzM0MjhiMTQvdGV4dHJlZ2lvbjowYmI0NDBlN2RiZjU0ZDVkODYzYzZjYjZjMzQyOGIxNF8zODQ4MjkwNjk5NjA4_6ada45dc-6aec-429d-bc25-1726fbf38d60">863-3000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xL2ZyYWc6MGJiNDQwZTdkYmY1NGQ1ZDg2M2M2Y2I2YzM0MjhiMTQvdGFibGU6OTQ1YzJmMmVjMWM1NDBmZjlkZWExMGIyZDkyNTBlYmIvdGFibGVyYW5nZTo5NDVjMmYyZWMxYzU0MGZmOWRlYTEwYjJkOTI1MGViYl8xLTAtMS0xLTYwNw_2c00f7d5-eca3-42c7-b5df-46cfc02a9bf4">Common Stock, par value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xL2ZyYWc6MGJiNDQwZTdkYmY1NGQ1ZDg2M2M2Y2I2YzM0MjhiMTQvdGFibGU6OTQ1YzJmMmVjMWM1NDBmZjlkZWExMGIyZDkyNTBlYmIvdGFibGVyYW5nZTo5NDVjMmYyZWMxYzU0MGZmOWRlYTEwYjJkOTI1MGViYl8xLTEtMS0xLTYxMg_05af65cb-5bf3-4c1e-a712-d18de0a30930">LXRX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xL2ZyYWc6MGJiNDQwZTdkYmY1NGQ1ZDg2M2M2Y2I2YzM0MjhiMTQvdGFibGU6OTQ1YzJmMmVjMWM1NDBmZjlkZWExMGIyZDkyNTBlYmIvdGFibGVyYW5nZTo5NDVjMmYyZWMxYzU0MGZmOWRlYTEwYjJkOTI1MGViYl8xLTItMS0xLTYxNg_73d0278b-a6c6-4b52-bf58-a28000cb6449">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xL2ZyYWc6MGJiNDQwZTdkYmY1NGQ1ZDg2M2M2Y2I2YzM0MjhiMTQvdGFibGU6NzcxZWE5MzlkMWFjNDc4NWJmOWQ3MzRkYzM0YWYwZWYvdGFibGVyYW5nZTo3NzFlYTkzOWQxYWM0Nzg1YmY5ZDczNGRjMzRhZjBlZl8wLTAtMS0xLTUwMA_04f25efa-555c-4780-abf1-63cbe8cf746b">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xL2ZyYWc6MGJiNDQwZTdkYmY1NGQ1ZDg2M2M2Y2I2YzM0MjhiMTQvdGFibGU6ZTJjMmVkYWQ4NmE3NDQ1MmIyNTRjNTg2NmZlODM3ZDEvdGFibGVyYW5nZTplMmMyZWRhZDg2YTc0NDUyYjI1NGM1ODY2ZmU4MzdkMV8wLTAtMS0xLTA_b8eb8bd2-1627-464e-a739-e1d8a332c482">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xL2ZyYWc6MGJiNDQwZTdkYmY1NGQ1ZDg2M2M2Y2I2YzM0MjhiMTQvdGV4dHJlZ2lvbjowYmI0NDBlN2RiZjU0ZDVkODYzYzZjYjZjMzQyOGIxNF8zODQ4MjkwNjk5NjI5_3ca07447-611c-467e-970a-6c0cd0be1cf8">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xL2ZyYWc6MGJiNDQwZTdkYmY1NGQ1ZDg2M2M2Y2I2YzM0MjhiMTQvdGV4dHJlZ2lvbjowYmI0NDBlN2RiZjU0ZDVkODYzYzZjYjZjMzQyOGIxNF8xMDk5NTExNjMwMjgy_53fb5f83-0bac-4ca8-ba8a-7dc018302ede">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xL2ZyYWc6MGJiNDQwZTdkYmY1NGQ1ZDg2M2M2Y2I2YzM0MjhiMTQvdGV4dHJlZ2lvbjowYmI0NDBlN2RiZjU0ZDVkODYzYzZjYjZjMzQyOGIxNF8xMDk5NTExNjMwMjc2_c9c9a2b7-91de-4bfb-aa9d-b7e555fd8b17">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xL2ZyYWc6MGJiNDQwZTdkYmY1NGQ1ZDg2M2M2Y2I2YzM0MjhiMTQvdGFibGU6Zjg0OWZkYTQ2MTNjNDZjZGJmNDBkMDNiMDJhZGE0MjQvdGFibGVyYW5nZTpmODQ5ZmRhNDYxM2M0NmNkYmY0MGQwM2IwMmFkYTQyNF8wLTEtMS0xLTI2Mzc_f34f3f9c-60f2-44d4-adae-9b20eeedb841">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="id2404fdeff6740faada8a1fcc2da1bf3_I20200423"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xL2ZyYWc6MGJiNDQwZTdkYmY1NGQ1ZDg2M2M2Y2I2YzM0MjhiMTQvdGV4dHJlZ2lvbjowYmI0NDBlN2RiZjU0ZDVkODYzYzZjYjZjMzQyOGIxNF8yMTM3_892d7be4-240a-48e4-bb6b-0207bb6e7525"
      unitRef="shares">106969973</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfNC0yLTEtMS0w_689e64e5-6b70-4a70-a03a-09c855cccf06"
      unitRef="usd">55592000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfNC00LTEtMS0w_98d2b4e5-073c-495f-8ed3-1d5548c5f360"
      unitRef="usd">36112000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfNS0yLTEtMS0w_934992ab-10b7-432d-9f12-7386666c6346"
      unitRef="usd">193545000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfNS00LTEtMS0w_85f34df9-324b-4345-b789-ec4779f652b6"
      unitRef="usd">235547000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfNi0yLTEtMS0w_ba43fddf-8fac-417c-a014-1ca7f5b45e10"
      unitRef="usd">30135000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfNi00LTEtMS0w_27ceab8c-3b5f-493b-aad1-82e144e3be5b"
      unitRef="usd">56532000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfOC0yLTEtMS0w_d561675f-04f0-4c96-a4c9-0ef10b2e3b96"
      unitRef="usd">4147000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfOC00LTEtMS0w_be235262-209c-4835-b70c-0556e35e44a7"
      unitRef="usd">4243000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfOS0yLTEtMS0w_da5ac5e1-e0f5-4236-91aa-56039fb84976"
      unitRef="usd">8195000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfOS00LTEtMS0w_aef4036a-9ec3-4532-842e-a58eb48c851d"
      unitRef="usd">5320000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMTAtMi0xLTEtMA_8e1f0dc2-b7a3-4bc4-9ba0-de28fc3afb88"
      unitRef="usd">291614000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMTAtNC0xLTEtMA_e080dbd1-42eb-4e2d-9f22-7118fddee500"
      unitRef="usd">337754000</us-gaap:AssetsCurrent>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMTEtMC0xLTEtMC90ZXh0cmVnaW9uOjFhMjAzNjkyMTJjZDQ1NTU4YWY1NmY0OTQ4NWNjYjk1XzEwOTk1MTE2Mjc4OTY_9e24c66e-476b-4e96-9acd-da9496bd3545"
      unitRef="usd">61302000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i6e1705cc437a4623985876b0a6850cd4_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMTEtMC0xLTEtMC90ZXh0cmVnaW9uOjFhMjAzNjkyMTJjZDQ1NTU4YWY1NmY0OTQ4NWNjYjk1XzEwOTk1MTE2Mjc5MDY_94f013fa-fdd6-4ac9-90d4-1f2223052794"
      unitRef="usd">61741000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMTEtMi0xLTEtMA_39acbc28-7170-4569-bdf2-ab07a250f7cb"
      unitRef="usd">13582000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMTEtNC0xLTEtMA_c9e2ff82-e8e3-4bc2-9ce2-149194141e3f"
      unitRef="usd">14047000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMTItMi0xLTEtMA_7e212510-6cf5-4644-a868-37bae3555c5d"
      unitRef="usd">44543000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMTItNC0xLTEtMA_d5c50fce-53ab-49f7-bdc8-cdad760e6786"
      unitRef="usd">44543000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMTMtMC0xLTEtMC90ZXh0cmVnaW9uOjViOTAxMzIyMWE3MTRhZjViMGVkOTdhYWYwNzU3NGE2XzEwOTk1MTE2Mjc4NzE_9de30d0b-f988-4672-a040-62b9e8ffcf15"
      unitRef="usd">5444000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6e1705cc437a4623985876b0a6850cd4_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMTMtMC0xLTEtMC90ZXh0cmVnaW9uOjViOTAxMzIyMWE3MTRhZjViMGVkOTdhYWYwNzU3NGE2XzEwOTk1MTE2Mjc4ODA_efdca08c-f570-4b46-b56f-06bbd02d8a75"
      unitRef="usd">5003000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMTMtMi0xLTEtMA_863b4990-f46d-431a-b601-269886643baa"
      unitRef="usd">19275000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMTMtNC0xLTEtMA_349355d9-9383-4b02-8073-305f98f8be30"
      unitRef="usd">19716000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMTQtMi0xLTEtMA_53b49b20-7088-40ca-b00d-0146512ab7a0"
      unitRef="usd">1553000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMTQtNC0xLTEtMA_91ccbd08-a183-4231-afa3-20613a48442d"
      unitRef="usd">1655000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMTUtMi0xLTEtMA_d2bca3b7-9648-42f4-a4f1-b52a10c83a04"
      unitRef="usd">370567000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMTUtNC0xLTEtMA_66be56d0-d117-4f86-8190-9fd8244cfd54"
      unitRef="usd">417715000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMTgtMi0xLTEtMA_bcf5e249-89f9-407b-b434-ad335ef4638e"
      unitRef="usd">18236000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMTgtNC0xLTEtMA_2b8fe24e-9948-4051-b068-01233a5b1a37"
      unitRef="usd">12178000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMTktMi0xLTEtMA_f6e3e991-339f-4c03-aa98-bf8b40c406b5"
      unitRef="usd">51349000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMTktNC0xLTEtMA_5222011e-6f65-4329-959f-82ef09ab2924"
      unitRef="usd">42151000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMjEtMi0xLTEtMA_9a249cf1-a7f9-4eb6-9e17-d837dc78dedd"
      unitRef="usd">10734000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMjEtNC0xLTEtMA_d6543030-2f7a-4fa8-bfe3-04836dc8e2a9"
      unitRef="usd">11012000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMjItMi0xLTEtMA_e197da08-5d6f-45ba-8de5-24a4b5bf7d30"
      unitRef="usd">80319000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMjItNC0xLTEtMA_2f7eba51-75ba-4938-89ed-ffa27bd72012"
      unitRef="usd">65341000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMjQtMi0xLTEtMA_3a0a1e76-78e2-4e2b-94d1-0ab33b9882b5"
      unitRef="usd">234488000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMjQtNC0xLTEtMA_460739b5-9db7-4b7c-8bdc-a2240a1925ba"
      unitRef="usd">234171000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMjYtMi0xLTEtMA_c782b84e-6245-4182-83fb-8f4e3acf3266"
      unitRef="usd">983000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMjYtNC0xLTEtMA_20cdedb0-07d8-49a0-a210-9cdd70493d30"
      unitRef="usd">1102000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMjctMi0xLTEtMA_0aad4ad9-3284-407c-a165-d313f7ed7346"
      unitRef="usd">315790000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMjctNC0xLTEtMA_c13d5730-fb4a-42a8-b276-eb4f9850dca2"
      unitRef="usd">300614000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMjgtMi0xLTEtMA_ed67e6fd-8191-4ea5-a532-8f7071642463"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMjgtNC0xLTEtMA_1a6b29e0-148b-41dd-88f4-0533fa8ce647"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i6e1705cc437a4623985876b0a6850cd4_I20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzAtMC0xLTEtMjUxMi90ZXh0cmVnaW9uOmIxOGYxMWM5YWIxYTRiMjI5ZTVmMmY5N2M4OGUwNjUwXzEwOTk1MTE2Mjc4NzU_545d4705-f391-4920-b14b-ffc6de4ae80e"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzAtMC0xLTEtMjUxMi90ZXh0cmVnaW9uOmIxOGYxMWM5YWIxYTRiMjI5ZTVmMmY5N2M4OGUwNjUwXzEwOTk1MTE2Mjc4NzU_63987c78-f6ba-45d4-95f8-a29d760a8ebd"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzAtMC0xLTEtMjUxMi90ZXh0cmVnaW9uOmIxOGYxMWM5YWIxYTRiMjI5ZTVmMmY5N2M4OGUwNjUwXzEwOTk1MTE2Mjc4ODQ_87fbd2b5-4429-4193-8794-b0942f61763f"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i6e1705cc437a4623985876b0a6850cd4_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzAtMC0xLTEtMjUxMi90ZXh0cmVnaW9uOmIxOGYxMWM5YWIxYTRiMjI5ZTVmMmY5N2M4OGUwNjUwXzEwOTk1MTE2Mjc4ODQ_ed94fcba-d1bd-47c1-ad20-08643a85c97d"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzAtMC0xLTEtMjUxMi90ZXh0cmVnaW9uOmIxOGYxMWM5YWIxYTRiMjI5ZTVmMmY5N2M4OGUwNjUwXzEwOTk1MTE2Mjc4ODg_2f8ec445-ce3d-482e-9061-f990db6a485e"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i6e1705cc437a4623985876b0a6850cd4_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzAtMC0xLTEtMjUxMi90ZXh0cmVnaW9uOmIxOGYxMWM5YWIxYTRiMjI5ZTVmMmY5N2M4OGUwNjUwXzEwOTk1MTE2Mjc4ODg_639bcf51-efc3-4be7-a37d-3ca4b39f8419"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i6e1705cc437a4623985876b0a6850cd4_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzAtMC0xLTEtMjUxMi90ZXh0cmVnaW9uOmIxOGYxMWM5YWIxYTRiMjI5ZTVmMmY5N2M4OGUwNjUwXzEwOTk1MTE2Mjc4ODg_dad046b8-0e98-46f5-b400-fb6f04837791"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzAtMC0xLTEtMjUxMi90ZXh0cmVnaW9uOmIxOGYxMWM5YWIxYTRiMjI5ZTVmMmY5N2M4OGUwNjUwXzEwOTk1MTE2Mjc4ODg_f32801b3-dbda-4074-a2d1-49a82d20a81a"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzAtMi0xLTEtMA_f1b9c80b-845a-4d1d-a3e9-ee2416e64a8b"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzAtNC0xLTEtMA_76a63a28-7b39-4e4d-aefa-ed9cca664ab1"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i6e1705cc437a4623985876b0a6850cd4_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmZhNDU1NmM2YTFkZTRlMWM5NWE2OWI2MjIxZGY4NDRhXzEwOTk1MTE2Mjc4OTA_70f4657f-5b3d-4ff6-ae20-83f7780e2e60"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmZhNDU1NmM2YTFkZTRlMWM5NWE2OWI2MjIxZGY4NDRhXzEwOTk1MTE2Mjc4OTA_94e6d1f7-fec6-410c-9fe2-1d5045d69e3f"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i6e1705cc437a4623985876b0a6850cd4_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmZhNDU1NmM2YTFkZTRlMWM5NWE2OWI2MjIxZGY4NDRhXzEwOTk1MTE2Mjc5MDA_71d3a7a3-9087-43bb-aa6b-2b174b8c68e7"
      unitRef="shares">225000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmZhNDU1NmM2YTFkZTRlMWM5NWE2OWI2MjIxZGY4NDRhXzEwOTk1MTE2Mjc5MDA_cc78fe79-e278-4017-9149-31052455dc59"
      unitRef="shares">225000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmZhNDU1NmM2YTFkZTRlMWM5NWE2OWI2MjIxZGY4NDRhXzEwOTk1MTE2Mjc5MDk_5055e18e-ffbc-4e4a-b904-4b0326142c0d"
      unitRef="shares">107711000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i6e1705cc437a4623985876b0a6850cd4_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmZhNDU1NmM2YTFkZTRlMWM5NWE2OWI2MjIxZGY4NDRhXzEwOTk1MTE2Mjc5MTg_fe7c9c68-0e32-48c1-bf0f-c1b5fd604c7a"
      unitRef="shares">106679000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzEtMi0xLTEtMA_dee62d2c-52c1-430f-a7df-44b493f28014"
      unitRef="usd">108000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzEtNC0xLTEtMA_bd2ea142-8598-4146-b1f6-a1e41caa94a5"
      unitRef="usd">106000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzItMi0xLTEtMA_f301a9ec-ec60-4d13-8942-37e545133bb3"
      unitRef="usd">1466604000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzItNC0xLTEtMA_73ce01a5-2585-414b-8098-42da147cfda8"
      unitRef="usd">1462172000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzMtMi0xLTEtMA_d4dbf238-9f17-450f-83d0-30bf45f13497"
      unitRef="usd">-1408055000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzMtNC0xLTEtMA_a9589ae4-474a-46b0-92aa-953a0186a85b"
      unitRef="usd">-1341444000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzQtMi0xLTEtMA_ee649ae7-0998-48ff-97b7-5634c658a3a4"
      unitRef="usd">860000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzQtNC0xLTEtMA_c0bc4462-b968-4965-93bb-2299b69c5022"
      unitRef="usd">84000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TreasuryStockShares
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjQ4OGMxMDNkN2NkODQyYTVhNjc3YjAzMjg3YTlmNmY0XzEwOTk1MTE2Mjc4NDA_f884ba01-ac08-452c-8968-410dc58a697d"
      unitRef="shares">741000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="i6e1705cc437a4623985876b0a6850cd4_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjQ4OGMxMDNkN2NkODQyYTVhNjc3YjAzMjg3YTlmNmY0XzEwOTk1MTE2Mjc4NDU_94d166fb-95fd-4ee0-83e1-bd8e7b912548"
      unitRef="shares">407000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzUtMi0xLTEtMA_d9ac5401-5100-4a52-a57d-3f29101b7582"
      unitRef="usd">4740000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzUtNC0xLTEtMA_6271097f-ea77-460c-8fe1-d8ce5792f19e"
      unitRef="usd">3817000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzYtMi0xLTEtMA_6dbcd67b-1d96-40d4-be23-a417626f45f9"
      unitRef="usd">54777000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzYtNC0xLTEtMA_6acdf108-34be-40e4-a808-3471881906b9"
      unitRef="usd">117101000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzctMi0xLTEtMA_fb03cded-d57d-4a6f-bd7f-e069de3a7500"
      unitRef="usd">370567000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8xOS9mcmFnOmMzMzcyYzc1YThjYjRjNWE4ZjM2MGE0OWY2M2UxNTc3L3RhYmxlOmZhYWYyYjYyZmIxMzQ2YTE5NGEwMWU5ZTcyMmRlOTAxL3RhYmxlcmFuZ2U6ZmFhZjJiNjJmYjEzNDZhMTk0YTAxZTllNzIyZGU5MDFfMzctNC0xLTEtMA_1693783b-e3af-4848-be27-10f2b3255eda"
      unitRef="usd">417715000</us-gaap:LiabilitiesAndStockholdersEquity>
    <lxrx:Netproductrevenue
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfMy0yLTEtMS0w_f631b02d-bbfb-41a1-8706-6df4350b75cf"
      unitRef="usd">7877000</lxrx:Netproductrevenue>
    <lxrx:Netproductrevenue
      contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfMy00LTEtMS0w_77714aae-fa66-42a0-9719-cc4c6f692cdd"
      unitRef="usd">6740000</lxrx:Netproductrevenue>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfNC0yLTEtMS0w_460dbade-964f-4dfa-a72a-67367cdfe49d"
      unitRef="usd">8000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfNC00LTEtMS0w_a3b1d1ea-c190-422c-9657-2c1dc1669d65"
      unitRef="usd">2439000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfNS0yLTEtMS0w_48c8d54f-7ae7-425f-88e0-12955cfac74e"
      unitRef="usd">114000</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfNS00LTEtMS0w_d4bce01d-4e76-4b8c-a009-469956003735"
      unitRef="usd">37000</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:Revenues
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfNi0yLTEtMS0w_6e1ee496-6ab9-40d6-bdcd-bb16c1b59153"
      unitRef="usd">7999000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfNi00LTEtMS0w_e1111dbb-bd01-4747-97cf-9d32c9f9f606"
      unitRef="usd">9216000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfOC0yLTEtMS0w_df4be9f3-dc18-45e0-a658-73442523be62"
      unitRef="usd">568000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfOC00LTEtMS0w_12d0c3a3-58ae-466e-8f92-905929338577"
      unitRef="usd">553000</us-gaap:CostOfGoodsAndServicesSold>
    <lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfOS0wLTEtMS0wL3RleHRyZWdpb246NjVlN2U2NjlhNDhiNGU2MWE3NTQyYTNlYjhmOGVmYWVfMTA5OTUxMTYyNzg4MQ_a56f6a6c-6091-41d5-a48f-9bb5dd770ca1"
      unitRef="usd">2176000</lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense>
    <lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
      contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfOS0wLTEtMS0wL3RleHRyZWdpb246NjVlN2U2NjlhNDhiNGU2MWE3NTQyYTNlYjhmOGVmYWVfMTA5OTUxMTYyNzg5MA_4baa3628-931a-40ae-8cd4-d7851c87400b"
      unitRef="usd">1768000</lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfOS0yLTEtMS0w_c65413a8-0b86-4951-9fc4-130caa88ca6e"
      unitRef="usd">55181000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfOS00LTEtMS0w_06004b37-390d-46e6-8c4b-0aa02b51142c"
      unitRef="usd">12022000</us-gaap:ResearchAndDevelopmentExpense>
    <lxrx:Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfMTEtMC0xLTEtMC90ZXh0cmVnaW9uOjE4MDQxNDA1ZDg3YjQ3OGY5NWFmNzliMjg1YTc5MmJiXzEwOTk1MTE2Mjc4OTI_c3c947d4-9a32-4e43-85d5-7a57d6bdaa2c"
      unitRef="usd">2256000</lxrx:Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense>
    <lxrx:Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense
      contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfMTEtMC0xLTEtMC90ZXh0cmVnaW9uOjE4MDQxNDA1ZDg3YjQ3OGY5NWFmNzliMjg1YTc5MmJiXzEwOTk1MTE2Mjc5MDE_34d16177-059b-42f4-b640-4a211b1d01ac"
      unitRef="usd">1643000</lxrx:Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense>
    <lxrx:Sellinggeneralandadministrativeexpenses
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfMTEtMi0xLTEtMA_30de8d93-5d0d-4e28-ac9a-c11442451668"
      unitRef="usd">14688000</lxrx:Sellinggeneralandadministrativeexpenses>
    <lxrx:Sellinggeneralandadministrativeexpenses
      contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfMTEtNC0xLTEtMA_5de6819b-e7b3-407d-876e-cafe06d6097c"
      unitRef="usd">14110000</lxrx:Sellinggeneralandadministrativeexpenses>
    <us-gaap:OperatingExpenses
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfMTMtMi0xLTEtMA_6c0229f0-5b5a-4280-9ee7-3a50063a79b3"
      unitRef="usd">70437000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfMTMtNC0xLTEtMA_559bdcaa-0696-42a1-a8b9-4def9e2136d2"
      unitRef="usd">26685000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfMTQtMi0xLTEtMA_af368696-08ac-414f-8e03-23636fa4649a"
      unitRef="usd">-62438000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfMTQtNC0xLTEtMA_f5486c51-995c-4730-b644-5ed14fed9773"
      unitRef="usd">-17469000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfMTYtMi0xLTEtMA_f5479ddd-433e-4c2f-be61-c6bbcb7f11de"
      unitRef="usd">5131000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfMTYtNC0xLTEtMA_2c6cc2cd-3539-4a8a-a22b-6828112e70ec"
      unitRef="usd">5117000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfMTctMi0xLTEtMA_92889f34-e875-4d48-8c0a-305cc7f4750c"
      unitRef="usd">958000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfMTctNC0xLTEtMA_8e0d828b-8289-48ea-b7ee-8f6fd4278e2e"
      unitRef="usd">789000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfMjAtMi0xLTEtMA_3cfa9bad-625f-4ba4-a7dd-22350909857a"
      unitRef="usd">-66611000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfMjAtNC0xLTEtMA_846c77e1-e40d-43e8-b864-89650a48e40c"
      unitRef="usd">-21797000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfMjEtMi0xLTEtMA_65291304-4a93-48ad-aaea-0af9f1f6b4b8"
      unitRef="usdPerShare">-0.63</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfMjEtNC0xLTEtMA_d311b46a-b756-488b-966a-ce910125bae7"
      unitRef="usdPerShare">-0.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfMjQtMi0xLTEtMA_266adef1-31eb-4825-a225-16a2e0c3ca81"
      unitRef="shares">106536000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfMjQtNC0xLTEtMA_76015721-7d0b-4d79-93a6-461e28fc51c7"
      unitRef="shares">106054000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfMjgtMi0xLTEtMA_6422c48b-eff7-425e-a94d-e4eb08d676fe"
      unitRef="usd">776000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfMjgtNC0xLTEtMA_d78fbb2e-2469-43b4-b489-ef2c10e839b1"
      unitRef="usd">45000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfMjktMi0xLTEtMA_a863fa24-3582-45cd-b833-37e12ea18bfc"
      unitRef="usd">-65835000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8yNS9mcmFnOmUxMzEwMTFhYzljZTRkZWNiYTYwZmFmODA0YjYyZWQ4L3RhYmxlOmMyOGMxNjczMjRiNTQ0MDFhMTliZTIxODdiMTk4YzAwL3RhYmxlcmFuZ2U6YzI4YzE2NzMyNGI1NDQwMWExOWJlMjE4N2IxOThjMDBfMjktNC0xLTEtMA_359a4abd-2635-49e7-8bbd-5902e8e0b39e"
      unitRef="usd">-21752000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="ia7a2afb94e3d47888a4f5fb5cbad1728_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfMi0yLTEtMS0xODY4_190af5a5-3d91-4045-be66-d5c701b6dae1"
      unitRef="shares">106162000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia7a2afb94e3d47888a4f5fb5cbad1728_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfMi00LTEtMS0xODY4_286bad70-403b-4388-a13e-a47fb5043827"
      unitRef="usd">106000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4d1fdae96a904b22b9d37b0de77588fb_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfMi02LTEtMS0xODY4_f0b6ebe5-3866-471c-aefd-f26dc79f6d47"
      unitRef="usd">1447954000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6bd9c5bf42c248cd9bf25b6dea04bd1a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfMi04LTEtMS0xODY4_e754f991-b06d-4a65-a174-99d9e0a7b9b9"
      unitRef="usd">-1471577000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7bc51fbc5bfc475ea508dad359524362_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfMi0xMC0xLTEtMTg2OA_665dd37b-a47d-48e2-80b1-06f15dab7da1"
      unitRef="usd">-12000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5b7022476157494398816b99471e0697_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfMi0xMi0xLTEtMTg2OA_6960d531-ce41-4e73-aa16-ae8493ca3c7f"
      unitRef="usd">-2876000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifb01c97139de4c7da87be444c5833141_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfMi0xNC0xLTEtMTg2OA_d5d5b785-1779-4421-8b09-f844d5c522a6"
      unitRef="usd">-26405000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ibcb21aab8fb742a4b472651ad313d600_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfNS00LTEtMS0xODY4_a14645aa-120a-41e6-9cf5-df1be37615be"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie9b975fc81164d7cbff5a2763c95ef28_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfNS02LTEtMS0xODY4_661f6963-a699-4cbe-bbc3-1c3ac2ca8819"
      unitRef="usd">3411000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ifa015c4922754b5d91743371bfe8a576_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfNS04LTEtMS0xODY4_cb89294c-60f2-42d9-9493-59e4f724685f"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib455b101c4484d4c8d9f69a783226edd_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfNS0xMC0xLTEtMTg2OA_9f9b7195-7bf2-4923-9df8-00154ccec4ae"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9a9b6cf9115b4d328637e78789aa34f1_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfNS0xMi0xLTEtMTg2OA_21f91f43-2a78-4517-ad33-dbfd92c6b8f7"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfNS0xNC0xLTEtMTg2OA_f4b13187-4367-42e3-9f34-b4d72c30103f"
      unitRef="usd">3411000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ibcb21aab8fb742a4b472651ad313d600_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfNi0yLTEtMS0xODY4_084008e1-2407-475a-ac12-c9ec42135243"
      unitRef="shares">517000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ibcb21aab8fb742a4b472651ad313d600_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfNi00LTEtMS0xODY4_00896b00-0079-4d8b-b513-cee2c0250278"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ie9b975fc81164d7cbff5a2763c95ef28_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfNi02LTEtMS0xODY4_ec3b7bde-796d-4a1c-a79a-e5be2ba5c858"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ifa015c4922754b5d91743371bfe8a576_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfNi04LTEtMS0xODY4_4ec62a80-8a57-4b1f-b6da-b1a3d0ecc8ec"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib455b101c4484d4c8d9f69a783226edd_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfNi0xMC0xLTEtMTg2OA_eaae4370-b498-4174-867d-f6ed07391a65"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i9a9b6cf9115b4d328637e78789aa34f1_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfNi0xMi0xLTEtMTg2OA_aa74fd8c-d253-4d33-a0a9-5f6163ff00bc"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfNi0xNC0xLTEtMTg2OA_395916b2-3df9-44f5-a454-20ba0da0c51a"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ibcb21aab8fb742a4b472651ad313d600_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfOC00LTEtMS0xODY4_dcbe4b55-8bc4-46c7-9ac6-b6f8ad4de291"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ie9b975fc81164d7cbff5a2763c95ef28_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfOC02LTEtMS0xODY4_7a8cf25b-8688-4ba9-ad98-37e08f9d1067"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ifa015c4922754b5d91743371bfe8a576_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfOC04LTEtMS0xODY4_58c77f0d-cf3e-4371-b775-9119fc574eb1"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ib455b101c4484d4c8d9f69a783226edd_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfOC0xMC0xLTEtMTg2OA_5257743a-1c30-471d-bfbd-850b5a450353"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i9a9b6cf9115b4d328637e78789aa34f1_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfOC0xMi0xLTEtMTg2OA_1e52387a-070f-46b1-8515-3d5d59a5d85e"
      unitRef="usd">941000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfOC0xNC0xLTEtMTg2OA_447fbdfc-b2d3-4836-aee6-73a49f44fab0"
      unitRef="usd">941000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:NetIncomeLoss
      contextRef="ibcb21aab8fb742a4b472651ad313d600_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfOS00LTEtMS0xODY4_f11bf1eb-4860-4c43-9b5c-f9e81f7604d0"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie9b975fc81164d7cbff5a2763c95ef28_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfOS02LTEtMS0xODY4_f89cc261-25c6-4dda-b3f4-c9fefa7ac7e7"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifa015c4922754b5d91743371bfe8a576_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfOS04LTEtMS0xODY4_9710988d-3b8a-4da3-b7bd-f8a389cb8948"
      unitRef="usd">-21797000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib455b101c4484d4c8d9f69a783226edd_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfOS0xMC0xLTEtMTg2OA_6edb9789-1159-4c62-a8e4-44380203d894"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9a9b6cf9115b4d328637e78789aa34f1_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfOS0xMi0xLTEtMTg2OA_43f9de6b-4f18-4463-989e-66e41281c4b7"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifa015c4922754b5d91743371bfe8a576_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfOS0xNC0xLTEtMTg2OA_5b6dd330-2a3d-45a3-b1cd-df611c4a125a"
      unitRef="usd">-21797000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ibcb21aab8fb742a4b472651ad313d600_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfMTAtNC0xLTEtMTg2OA_3500cea9-5f86-49f4-a96a-09b8d9ba0657"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ie9b975fc81164d7cbff5a2763c95ef28_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfMTAtNi0xLTEtMTg2OA_134d36be-be2c-446c-a833-a4e0ac1a05bd"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ifa015c4922754b5d91743371bfe8a576_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfMTAtOC0xLTEtMTg2OA_928a5684-aa51-4f9c-bec6-204cfbf100ac"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ib455b101c4484d4c8d9f69a783226edd_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfMTAtMTAtMS0xLTE4Njg_559d5605-bef0-4201-8ad9-a632cb2ab628"
      unitRef="usd">45000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i9a9b6cf9115b4d328637e78789aa34f1_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfMTAtMTItMS0xLTE4Njg_f6513c8b-dcfe-461c-ad1a-9f71c59bdc13"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfMTAtMTQtMS0xLTE4Njg_0fbbbed0-1960-47ea-94aa-ff05d10fcdb4"
      unitRef="usd">45000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="if43ffe172d1f4c68b5844235ee4289f7_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfMTItMi0xLTEtMTg2OA_b40137ea-6327-4947-b9cc-a35d5c4b2465"
      unitRef="shares">106679000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if43ffe172d1f4c68b5844235ee4289f7_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfMTItNC0xLTEtMTg2OA_25d598b2-b919-474b-b33e-7b54ec98f96b"
      unitRef="usd">106000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8f6a44ebc0994be5a7cef652c7d2857e_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfMTItNi0xLTEtMTg2OA_f0aa1725-092f-411b-abc3-b4fa09aef006"
      unitRef="usd">1451365000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6910b93f33e4481fb289ea612c84f3ae_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfMTItOC0xLTEtMTg2OA_d3a6202d-4f98-4e3e-84b5-058afceb35b2"
      unitRef="usd">-1493374000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i593c8c0affe34641adbf79593094ac0b_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfMTItMTAtMS0xLTE4Njg_505984e7-3cee-4f35-8ee5-ab702f7b885e"
      unitRef="usd">33000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie255744bc9f3477ba151d4eaa2718fe1_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfMTItMTItMS0xLTE4Njg_3849ed20-ead9-4e26-9d3f-74b46d7579ef"
      unitRef="usd">-3817000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6e1705cc437a4623985876b0a6850cd4_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjliNjI1MDY4ZTFhZDRjYTg4MWM2NDEzNWRlMTJmNzFjL3RhYmxlcmFuZ2U6OWI2MjUwNjhlMWFkNGNhODgxYzY0MTM1ZGUxMmY3MWNfMTItMTQtMS0xLTE4Njg_6b685ef7-0981-45d2-97bf-d78aeec3304f"
      unitRef="usd">-45687000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="if2014f01922b408fa97848ffdeb88941_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfMi0yLTEtMS0w_bf4f3ff0-875d-4073-aa4a-5d02b474b098"
      unitRef="shares">106679000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if2014f01922b408fa97848ffdeb88941_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfMi00LTEtMS0w_1e516a6a-74a7-410e-8fe0-ba099aca1b5f"
      unitRef="usd">106000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iba79016389514c5ebe72f001f7acf420_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfMi02LTEtMS0w_ca83e4b9-d147-4446-af92-487668bc009a"
      unitRef="usd">1462172000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia1a8986ec8894a469fbd46f3df2dc202_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfMi04LTEtMS0w_06cf67f6-7822-458d-89a0-a9a1c46e7e5e"
      unitRef="usd">-1341444000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2c9621fa321f4e9195d6603061f89e2f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfMi0xMC0xLTEtMA_aad4fc2d-84c9-4680-96f9-4f9b27010402"
      unitRef="usd">84000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i846c9d455edf4f1cb3d7646d362b3a11_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfMi0xMi0xLTEtMA_71fe86e3-695c-4519-ae6e-cfc7d6a94072"
      unitRef="usd">-3817000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfMi0xNC0xLTEtMA_adcd153d-47ff-4da1-9a2a-5c06a65974d7"
      unitRef="usd">117101000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1112901d3eee474b98585e70b151f858_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfNC00LTEtMS0w_3b690daa-d54f-4ccd-a0a7-26746570c5b9"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3d8f640e99d948e59de6f191b2509423_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfNC02LTEtMS0w_4b68d85b-7bc9-4db4-a244-9322de10daf5"
      unitRef="usd">4432000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8f1459fd243c427791a12f208909ef19_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfNC04LTEtMS0w_e823b55b-f446-4b10-bce4-0306109d6035"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie225ba400e5842d2896152f546aedab5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfNC0xMC0xLTEtMA_0565faf0-e1eb-4f8e-8439-9ea991ec7c21"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iaac8e8918b3b48de8027ed5b977e799b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfNC0xMi0xLTEtMA_d8ad0fe8-5aa6-4c72-960b-720557e100e8"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfNC0xNC0xLTEtMA_0f09821c-4cf4-4499-8dba-57deaa0946dd"
      unitRef="usd">4432000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i1112901d3eee474b98585e70b151f858_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfNS0yLTEtMS0w_b756c506-17f1-47ca-8b6b-8071bb71be8b"
      unitRef="shares">1032000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i1112901d3eee474b98585e70b151f858_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfNS00LTEtMS0w_a2297fc8-c035-4bfe-a7f1-99af85d877af"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i3d8f640e99d948e59de6f191b2509423_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfNS02LTEtMS0w_d43f4228-1b54-47d5-b853-d14c9368e7f0"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i8f1459fd243c427791a12f208909ef19_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfNS04LTEtMS0w_27694e58-ddfa-45ca-a2ec-2df5886b5ec3"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ie225ba400e5842d2896152f546aedab5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfNS0xMC0xLTEtMA_fa7e1749-0dd7-4de0-b047-54da3d1447b0"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="iaac8e8918b3b48de8027ed5b977e799b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfNS0xMi0xLTEtMA_3e2607d5-00f9-4118-967f-a6f840167e28"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfNS0xNC0xLTEtMA_23e4831a-68e2-4570-8429-79e6384e813d"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i1112901d3eee474b98585e70b151f858_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfNy00LTEtMS0w_47d4bc40-e118-4565-b5a3-4c6b587a9045"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i3d8f640e99d948e59de6f191b2509423_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfNy02LTEtMS0w_7d2dd6fd-ace0-4ec7-8c00-375f64906304"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i8f1459fd243c427791a12f208909ef19_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfNy04LTEtMS0w_fd9ea4ea-f699-49e4-bf93-a467c3bfe306"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ie225ba400e5842d2896152f546aedab5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfNy0xMC0xLTEtMA_de7899f8-be26-4d52-88ac-0f9eedb9afeb"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="iaac8e8918b3b48de8027ed5b977e799b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfNy0xMi0xLTEtMA_2478d44c-8dd9-4308-a2fd-10621fc60665"
      unitRef="usd">923000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfNy0xNC0xLTEtMA_99b53118-46be-4661-a065-8157ce3b325c"
      unitRef="usd">923000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:NetIncomeLoss
      contextRef="i1112901d3eee474b98585e70b151f858_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfOC00LTEtMS0w_19534256-5605-4afd-9fe5-48f4e0c57e93"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3d8f640e99d948e59de6f191b2509423_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfOC02LTEtMS0w_e6f9dfc7-b76c-431e-90d0-996f961cb692"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8f1459fd243c427791a12f208909ef19_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfOC04LTEtMS0w_1d7ed101-b715-47b7-9a76-10161fc91cb5"
      unitRef="usd">-66611000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie225ba400e5842d2896152f546aedab5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfOC0xMC0xLTEtMA_8b9e95c6-d5c9-4ff7-bb45-8d009b8faa3f"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iaac8e8918b3b48de8027ed5b977e799b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfOC0xMi0xLTEtMA_860a2528-86ca-46d2-b042-804af66e6d04"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8f1459fd243c427791a12f208909ef19_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfOC0xNC0xLTEtMA_5ccbb156-42e6-48a4-8ced-a13bfb3ee154"
      unitRef="usd">-66611000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i1112901d3eee474b98585e70b151f858_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfOS00LTEtMS0w_b2c3304d-1ac2-4092-8926-55b6249e5aa8"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i3d8f640e99d948e59de6f191b2509423_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfOS02LTEtMS0w_26441351-f23a-4fa1-a1ef-f589ed296bf3"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i8f1459fd243c427791a12f208909ef19_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfOS04LTEtMS0w_101e1089-93c9-4bd9-9ce8-ae5035d8df57"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ie225ba400e5842d2896152f546aedab5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfOS0xMC0xLTEtMA_00bfb920-4133-4cd6-a3a7-5ccfb7f7c474"
      unitRef="usd">776000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="iaac8e8918b3b48de8027ed5b977e799b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfOS0xMi0xLTEtMA_8bcca751-91aa-49e9-8add-b9bd14bc1cad"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfOS0xNC0xLTEtMA_59b03450-d98e-4997-804b-5c034774c28c"
      unitRef="usd">776000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="i4f1cd0ed4c754265b45c85c1bc69396f_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfMTEtMi0xLTEtMA_407658d8-3d14-43f8-bf15-6d2f0f4d4cc5"
      unitRef="shares">107711000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4f1cd0ed4c754265b45c85c1bc69396f_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfMTEtNC0xLTEtMA_d344a527-4320-4f88-bb9a-264f76a006f3"
      unitRef="usd">108000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if4f4eb4f717648a1807ac159d3543e2c_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfMTEtNi0xLTEtMA_5acd83ac-62c4-462f-b37a-a6b207275bf4"
      unitRef="usd">1466604000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3daccec285f3488c8d44f5dc7865d44e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfMTEtOC0xLTEtMA_43b03278-b4f7-4f0d-8b5d-46c74ad82244"
      unitRef="usd">-1408055000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i92dc246d5c4e4b13a56fd11a7345454e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfMTEtMTAtMS0xLTA_472f0ec0-1269-4b42-908a-cdd868aaa621"
      unitRef="usd">860000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9cd8c8c5263c421b8fa978b95f7cd714_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfMTEtMTItMS0xLTA_134d19de-fe2d-4086-83b4-86f8fb2f6984"
      unitRef="usd">-4740000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zMS9mcmFnOmNlZjNkNTY3ZGUzODQ0MmNiOGJiM2Y1MGU5NzczNmZkL3RhYmxlOjkyZjM5N2JiMTlmMjRjZWNiMGU2MTYxNThlZjI2NmIxL3RhYmxlcmFuZ2U6OTJmMzk3YmIxOWYyNGNlY2IwZTYxNjE1OGVmMjY2YjFfMTEtMTQtMS0xLTA_fc2b59b2-6b39-44a2-9575-694cf950865a"
      unitRef="usd">54777000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMy0yLTEtMS0w_3252e041-f837-46a5-9669-bc200c25a663"
      unitRef="usd">-66611000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMy00LTEtMS0w_8982abbb-0d7c-4afa-9b5b-7718d3a80b7b"
      unitRef="usd">-21797000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfNS0yLTEtMS0w_64204879-17d3-4644-9dfd-20a9e89a2366"
      unitRef="usd">906000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfNS00LTEtMS0w_92891195-f077-4957-a9b0-857399797fd2"
      unitRef="usd">901000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfNy0yLTEtMS0w_2bc11876-53df-4491-8074-23be18bcbb9f"
      unitRef="usd">4432000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfNy00LTEtMS0w_01c78543-80be-48d7-b835-500444363282"
      unitRef="usd">3411000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfOC0yLTEtMS0w_55c92998-3cc8-4ad7-ada9-ba2ff1176237"
      unitRef="usd">362000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfOC00LTEtMS0w_a4cd6a63-a8da-4384-8465-02fe3342f8ed"
      unitRef="usd">346000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMTItMi0xLTEtMA_24a6707a-7814-4338-b5a5-2f9a7eaad61f"
      unitRef="usd">-26397000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMTItNC0xLTEtMA_545a1cfe-fb8b-43f0-91c6-1f8e393a72e0"
      unitRef="usd">-1534000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMTMtMi0xLTEtMA_67262b3f-04b3-4a75-ad77-44ef68077513"
      unitRef="usd">-96000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMTMtNC0xLTEtMA_cf5132b1-1122-4aea-81c6-4070b1c0cb27"
      unitRef="usd">-74000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMTQtMi0xLTEtMA_e2b5ec9b-7870-4880-b226-651423c49d7c"
      unitRef="usd">2875000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMTQtNC0xLTEtMA_05f00341-8bce-40b4-ba58-ea47875b03e4"
      unitRef="usd">2018000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMTUtMi0xLTEtMA_cc77c298-0bd5-4fa4-af10-1156077a9b7a"
      unitRef="usd">-102000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMTUtNC0xLTEtMA_4b896e64-43c9-49f6-834f-1bc479463932"
      unitRef="usd">-91000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMTYtMi0xLTEtMA_154f4b54-bd9f-430f-b154-3cd5e0b88ea7"
      unitRef="usd">15137000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMTYtNC0xLTEtMA_2ee8f2cc-ab5d-4896-9db3-b00caa5389b3"
      unitRef="usd">-8171000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMTctMi0xLTEtMA_0b1a1537-fa0e-4f55-be0c-4c1439ef3674"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMTctNC0xLTEtMA_79325fd0-649c-49a9-93e5-51c69ef5ffc3"
      unitRef="usd">9000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMTgtMi0xLTEtMA_1ec9bad0-68d5-46f9-9271-23d88d098818"
      unitRef="usd">-22054000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMTgtNC0xLTEtMA_55e6b6a2-fb23-41fc-8efa-b08186c8223c"
      unitRef="usd">-25620000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMjAtMi0xLTEtMA_711ce673-b449-4de5-bf3a-d7c6a1577dd8"
      unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMjAtNC0xLTEtMA_c7e37486-21b9-4a46-8860-d3374576a6f6"
      unitRef="usd">70000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMjItMi0xLTEtMA_4e47380e-9ac2-4340-8d87-8dd5f22622cb"
      unitRef="usd">33222000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMjItNC0xLTEtMA_902b4aef-a7c9-4f90-bd6b-f48b41f0f112"
      unitRef="usd">87256000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMjMtMi0xLTEtMA_c955c724-c56c-4098-baa3-22fe821176e0"
      unitRef="usd">76000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMjMtNC0xLTEtMA_0bed98c4-fa5c-4f78-a5af-bc0941eeb9a9"
      unitRef="usd">79600000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMjQtMi0xLTEtMA_b1001308-ba9c-473b-b67e-e80dea296a55"
      unitRef="usd">42778000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMjQtNC0xLTEtMA_fe973dd0-4b1c-4706-956a-1a42c8ba1f5d"
      unitRef="usd">-7726000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMjctMi0xLTEtMA_b96e5557-cf22-454e-bce3-72342c530cd7"
      unitRef="usd">923000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMjctNC0xLTEtMA_85caca17-9d30-4a43-9cd1-91b5bd7cec33"
      unitRef="usd">941000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMjktMi0xLTEtMA_404ba0c2-4a42-4f15-a88b-c28f2ab5c45d"
      unitRef="usd">321000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMjktNC0xLTEtMA_c30485a8-7e41-418d-bb65-adb64941b691"
      unitRef="usd">321000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMzEtMi0xLTEtMA_d9a14b92-d398-433f-852f-447d6c64182b"
      unitRef="usd">-1244000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMzEtNC0xLTEtMA_f7eb2a0e-14bb-4a34-9e47-d14de30ee820"
      unitRef="usd">-1262000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMzItMi0xLTEtMA_46be6666-13d2-47f3-8a41-6fafaf18fd0a"
      unitRef="usd">19480000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMzItNC0xLTEtMA_c38d75e8-f137-4c45-9a5c-0ba6dbed34e2"
      unitRef="usd">-34608000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMzMtMi0xLTEtMA_07bd24d0-453d-4396-80be-9153bd6fd3ef"
      unitRef="usd">36112000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ifb01c97139de4c7da87be444c5833141_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMzMtNC0xLTEtMA_b086110d-7a57-4008-9971-47a67e61bb4d"
      unitRef="usd">80386000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMzQtMi0xLTEtMA_2161500a-5835-43b7-aee7-8ada7bd9e110"
      unitRef="usd">55592000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6e1705cc437a4623985876b0a6850cd4_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMzQtNC0xLTEtMA_f17af563-4fd3-4824-a9db-8e01b0e24bd4"
      unitRef="usd">45778000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InterestPaidNet
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMzctMi0xLTEtMA_2fc63cc1-348a-437b-a152-7ed8a8fd1339"
      unitRef="usd">3658000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF8zNC9mcmFnOmY5NDUwMWYxZWRiNTQyYjZhNmZhNGQzYzM4MzllM2Q1L3RhYmxlOjI3N2RiOWI1ZThjMjQ0MWI5ZGM2MDI0YWQ0YzU5MjViL3RhYmxlcmFuZ2U6Mjc3ZGI5YjVlOGMyNDQxYjlkYzYwMjRhZDRjNTkyNWJfMzctNC0xLTEtMA_37c0d2fc-53fd-421b-a6e0-6e78c26b7f3c"
      unitRef="usd">3698000</us-gaap:InterestPaidNet>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RleHRyZWdpb246MDkyOWE5NjdiMTAwNDI5ZmIzOTljZGJkMWVhNTQxNTlfMTc4NzI_8c495c6d-ada6-4e21-9411-716913d0a105">Summary of Significant Accounting Policies&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Basis of Presentation:&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; The accompanying unaudited condensed consolidated financial statements of Lexicon Pharmaceuticals, Inc. (&#x201c;Lexicon&#x201d; or the &#x201c;Company&#x201d;) have been prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three-month period ended March&#160;31, 2020 are not necessarily indicative of the results that may be expected for the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying condensed consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries. Intercompany transactions and balances are eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For further information, refer to the financial statements and footnotes thereto included in Lexicon&#x2019;s annual report on Form 10-K for the year ended December&#160;31, 2019, as filed with the SEC.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Use of Estimates:&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; The preparation of financial statements in conformity with U. S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Cash, Cash Equivalents and Short-Term Investments:&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of March&#160;31, 2020 and December&#160;31, 2019, short-term investments consisted of U.S. treasury bills.  The Company&#x2019;s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security.&#160;&#160;Unrealized gains and losses on such securities are reported as a separate component of stockholders&#x2019; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Accounts Receivable:&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&#160;Lexicon records trade accounts receivable in the normal course of business related to the sale of products or services, net of an allowance for expected credit losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Inventory: &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; Inventory is comprised of the Company&#x2019;s approved product it is commercializing in the United States, XERMELO&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae; &lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;(telotristat ethyl).  Inventories are determined at the lower of cost or market value with cost determined under the specific identification method and may consist of raw materials, work in process and finished goods. Inventory consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:82.163%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:51.380%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.689%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:19.886%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.757%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:19.888%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Revenue Recognition:&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Product revenues consist of commercial sales of XERMELO in the United States and sales of bulk tablets of XERMELO to Ipsen Pharma SAS (&#x201c;Ipsen&#x201d;).  Product revenues are recognized when the customer obtains control of the Company&#x2019;s product, which occurs upon delivery to the customer.  The Company recognizes product revenue net of applicable reserves for variable consideration, including allowances for customer credits, estimated rebates, chargebacks, discounts, returns, distribution service fees, and government rebates, such as Medicare Part D coverage gap reimbursements in the U.S.  These estimates are based on the most likely amount method for relevant factors such as current contractual and statutory requirements, industry data and forecasted customer buying and payment patterns.  The Company&#x2019;s net product revenues reflect the Company&#x2019;s best estimates of the amounts of consideration to which it is entitled based on the terms of the respective underlying contracts.  Product shipping and handling costs are considered a fulfillment activity when control transfers to the Company&#x2019;s customers and such costs are included in cost of sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Collaborative Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenues under collaborative agreements include both license revenue and contract research revenue.  The Company performs the following five steps in determining the amount of revenue to recognize as it fulfills its performance obligations under each of its agreements:  (i) identify the contract(s) with a customer; (ii) identify the performance obligation in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation.  The Company applies this five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.  At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct.  The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.  The Company develops assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;At contract inception, the Company evaluates whether development milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.  If it is probable that a significant revenue reversal will not occur, the associated development milestone value is included in the transaction price.  Development milestones that are not within the control of the Company or the licensee, including those requiring regulatory approval, are not considered probable of being achieved until those approvals are received.  The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue when (or as) the performance obligation is satisfied.  At the end of each reporting period, the Company re-evaluates the probability of achievement of the development milestones and any related constraint, and if necessary, adjusts its estimates of the overall transaction price.  Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In agreements in which a license to the Company&#x2019;s intellectual property is determined distinct from other performance obligations identified in the agreement, the Company recognizes revenue when the license is transferred to the licensee and the licensee is able to use and benefit from the license.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For agreements that include sales-based royalties, including milestones based on a level of sales, the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company may receive payments from its licensees based on billing schedules established in each contract.  Up-front payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these agreements.  Amounts are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Cost of Sales: &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; Cost of sales consists of third-party manufacturing costs, freight and indirect overhead costs associated with sales of XERMELO. Product shipping and handling costs are included in cost of sales. Cost of sales also includes the amortization of the in-process research and development intangible asset for XERMELO using the straight-line method over the estimated useful life of 14 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Research and Development Expenses:&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#x2019;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company&#x2019;s estimates of the clinical study costs and costs to transition activities from Sanofi for development of sotagliflozin for type 2 diabetes, heart failure and chronic kidney disease, including the costs to close out those studies, were based on actual costs incurred for activities completed subsequent to the transition date and estimates of the services to be received and efforts to be expended pursuant to contracts with multiple vendors and the CRO that has conducted and managed and is now closing out the clinical studies on its behalf.  The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#x2019;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Stock-Based Compensation:&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&#160;The Company recognizes compensation expense in its condensed consolidated statements of comprehensive loss for share-based payments, including stock options and restricted stock units issued to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#x2019;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#x2019;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in a change in the assumptions used for expected option lives.&#160;&#160;Historical data is used to estimate the expected option life for each group.  Expected volatility is based on the historical volatility in the Company&#x2019;s stock price.&#160;&#160;The Company utilized the Black-Scholes valuation model for estimating the fair value of the stock option compensation granted, with the following weighted-average assumptions for options granted in the three months ended March&#160;31, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:50.422%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.069%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.719%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.838%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.016%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk-free Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Dividend&lt;br/&gt;Rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Officers and non-employee directors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2019:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Officers and non-employee directors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following is a summary of stock option activity under Lexicon&#x2019;s stock-based compensation plans for the three months ended March&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:66.035%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.929%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.570%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(202)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding at March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercisable at March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the three months ended March&#160;31, 2020, Lexicon granted its employees annual restricted stock units. Outstanding employee restricted stock units vest in three to four annual installments.  The following is a summary of restricted stock units activity under Lexicon&#x2019;s stock-based compensation plans for the three months ended March&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:65.008%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.929%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.597%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted Average Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,032)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding at March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;Net Loss per Common Share: Net loss per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with convertible debt, stock options and restricted stock units are not included because they are antidilutive.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RleHRyZWdpb246MDkyOWE5NjdiMTAwNDI5ZmIzOTljZGJkMWVhNTQxNTlfMTc5NDc_6d0a56d7-0ee1-4e4d-b4b1-ffb1835500c3">The accompanying condensed consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries. Intercompany transactions and balances are eliminated in consolidation.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RleHRyZWdpb246MDkyOWE5NjdiMTAwNDI5ZmIzOTljZGJkMWVhNTQxNTlfMTc4OTY_f2f34036-63f9-46ae-b309-5004f4b03245">&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Use of Estimates:&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; The preparation of financial statements in conformity with U. S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.&lt;/span&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RleHRyZWdpb246MDkyOWE5NjdiMTAwNDI5ZmIzOTljZGJkMWVhNTQxNTlfMTc5MzM_0be67a7d-56ce-4e91-9909-5293f0600d23">&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Cash, Cash Equivalents and Short-Term Investments:&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of March&#160;31, 2020 and December&#160;31, 2019, short-term investments consisted of U.S. treasury bills.  The Company&#x2019;s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security.&#160;&#160;Unrealized gains and losses on such securities are reported as a separate component of stockholders&#x2019; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.&lt;/span&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RleHRyZWdpb246MDkyOWE5NjdiMTAwNDI5ZmIzOTljZGJkMWVhNTQxNTlfMTc4ODM_f15338eb-3a05-438a-9e64-2df87765a5c0">&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Accounts Receivable:&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&#160;Lexicon records trade accounts receivable in the normal course of business related to the sale of products or services, net of an allowance for expected credit losses.&lt;/span&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RleHRyZWdpb246MDkyOWE5NjdiMTAwNDI5ZmIzOTljZGJkMWVhNTQxNTlfMTc4ODQ_ce351c3b-b2f4-4a5d-a29b-e6900342d046">&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Inventory: &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; Inventory is comprised of the Company&#x2019;s approved product it is commercializing in the United States, XERMELO&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae; &lt;/sup&gt;(telotristat ethyl).  Inventories are determined at the lower of cost or market value with cost determined under the specific identification method and may consist of raw materials, work in process and finished goods.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:InventoryMajorClassesPolicy
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RleHRyZWdpb246MDkyOWE5NjdiMTAwNDI5ZmIzOTljZGJkMWVhNTQxNTlfMTc5Mjk_8f785e75-c0ab-4154-be93-fe1041a56635">&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:82.163%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:51.380%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.689%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:19.886%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.757%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:19.888%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InventoryMajorClassesPolicy>
    <us-gaap:InventoryRawMaterials
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOmY2NjU0OWE0ZTNjMzQ2NDY5OWU1ZDcwMDQwNWU4YTQ0L3RhYmxlcmFuZ2U6ZjY2NTQ5YTRlM2MzNDY0Njk5ZTVkNzAwNDA1ZThhNDRfMy0yLTEtMS0w_ad719df1-43df-4e62-a2b9-2fe30fe6bfb4"
      unitRef="usd">2218000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOmY2NjU0OWE0ZTNjMzQ2NDY5OWU1ZDcwMDQwNWU4YTQ0L3RhYmxlcmFuZ2U6ZjY2NTQ5YTRlM2MzNDY0Njk5ZTVkNzAwNDA1ZThhNDRfMy00LTEtMS0w_23794b2d-3521-40bb-bcde-794dd1639a3e"
      unitRef="usd">3182000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOmY2NjU0OWE0ZTNjMzQ2NDY5OWU1ZDcwMDQwNWU4YTQ0L3RhYmxlcmFuZ2U6ZjY2NTQ5YTRlM2MzNDY0Njk5ZTVkNzAwNDA1ZThhNDRfNC0yLTEtMS0w_4aabdb6f-1d61-4e99-9161-6af108cd84b4"
      unitRef="usd">1117000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOmY2NjU0OWE0ZTNjMzQ2NDY5OWU1ZDcwMDQwNWU4YTQ0L3RhYmxlcmFuZ2U6ZjY2NTQ5YTRlM2MzNDY0Njk5ZTVkNzAwNDA1ZThhNDRfNC00LTEtMS0w_75da5ad9-abf2-44f3-a526-73de3af5fcd3"
      unitRef="usd">153000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOmY2NjU0OWE0ZTNjMzQ2NDY5OWU1ZDcwMDQwNWU4YTQ0L3RhYmxlcmFuZ2U6ZjY2NTQ5YTRlM2MzNDY0Njk5ZTVkNzAwNDA1ZThhNDRfNS0yLTEtMS0w_c1d6a042-2ef1-42c4-8c26-52465cf7bcfa"
      unitRef="usd">812000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoods
      contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOmY2NjU0OWE0ZTNjMzQ2NDY5OWU1ZDcwMDQwNWU4YTQ0L3RhYmxlcmFuZ2U6ZjY2NTQ5YTRlM2MzNDY0Njk5ZTVkNzAwNDA1ZThhNDRfNS00LTEtMS0w_1ac80397-bd65-4dcf-ac5c-429be1dc89a5"
      unitRef="usd">908000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOmY2NjU0OWE0ZTNjMzQ2NDY5OWU1ZDcwMDQwNWU4YTQ0L3RhYmxlcmFuZ2U6ZjY2NTQ5YTRlM2MzNDY0Njk5ZTVkNzAwNDA1ZThhNDRfNi0yLTEtMS0w_de53ccb2-9e9c-4c51-929b-ddbc8acffbab"
      unitRef="usd">4147000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOmY2NjU0OWE0ZTNjMzQ2NDY5OWU1ZDcwMDQwNWU4YTQ0L3RhYmxlcmFuZ2U6ZjY2NTQ5YTRlM2MzNDY0Njk5ZTVkNzAwNDA1ZThhNDRfNi00LTEtMS0w_025aa42a-dd61-4975-9f59-0bcf1c0b89c4"
      unitRef="usd">4243000</us-gaap:InventoryGross>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RleHRyZWdpb246MDkyOWE5NjdiMTAwNDI5ZmIzOTljZGJkMWVhNTQxNTlfMTc5MTA_123f812b-16b7-4807-9b40-d5ce58474a2a">&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Revenue Recognition:&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Product revenues consist of commercial sales of XERMELO in the United States and sales of bulk tablets of XERMELO to Ipsen Pharma SAS (&#x201c;Ipsen&#x201d;).  Product revenues are recognized when the customer obtains control of the Company&#x2019;s product, which occurs upon delivery to the customer.  The Company recognizes product revenue net of applicable reserves for variable consideration, including allowances for customer credits, estimated rebates, chargebacks, discounts, returns, distribution service fees, and government rebates, such as Medicare Part D coverage gap reimbursements in the U.S.  These estimates are based on the most likely amount method for relevant factors such as current contractual and statutory requirements, industry data and forecasted customer buying and payment patterns.  The Company&#x2019;s net product revenues reflect the Company&#x2019;s best estimates of the amounts of consideration to which it is entitled based on the terms of the respective underlying contracts.  Product shipping and handling costs are considered a fulfillment activity when control transfers to the Company&#x2019;s customers and such costs are included in cost of sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Collaborative Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenues under collaborative agreements include both license revenue and contract research revenue.  The Company performs the following five steps in determining the amount of revenue to recognize as it fulfills its performance obligations under each of its agreements:  (i) identify the contract(s) with a customer; (ii) identify the performance obligation in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation.  The Company applies this five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.  At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct.  The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.  The Company develops assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;At contract inception, the Company evaluates whether development milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.  If it is probable that a significant revenue reversal will not occur, the associated development milestone value is included in the transaction price.  Development milestones that are not within the control of the Company or the licensee, including those requiring regulatory approval, are not considered probable of being achieved until those approvals are received.  The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue when (or as) the performance obligation is satisfied.  At the end of each reporting period, the Company re-evaluates the probability of achievement of the development milestones and any related constraint, and if necessary, adjusts its estimates of the overall transaction price.  Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In agreements in which a license to the Company&#x2019;s intellectual property is determined distinct from other performance obligations identified in the agreement, the Company recognizes revenue when the license is transferred to the licensee and the licensee is able to use and benefit from the license.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For agreements that include sales-based royalties, including milestones based on a level of sales, the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/div&gt;The Company may receive payments from its licensees based on billing schedules established in each contract.  Up-front payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these agreements.  Amounts are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional.</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RleHRyZWdpb246MDkyOWE5NjdiMTAwNDI5ZmIzOTljZGJkMWVhNTQxNTlfMTc5NTE_e8080f24-a565-4940-a79a-d71b1a5157de">Cost of Sales:  Cost of sales consists of third-party manufacturing costs, freight and indirect overhead costs associated with sales of XERMELO. Product shipping and handling costs are included in cost of sales. Cost of sales also includes the amortization of the in-process research and development intangible asset for XERMELO using the straight-line method over the estimated useful life of 14 years.</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RleHRyZWdpb246MDkyOWE5NjdiMTAwNDI5ZmIzOTljZGJkMWVhNTQxNTlfMTc5MTg_4788584c-1703-4806-a735-98c58280231c">&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Research and Development Expenses:&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#x2019;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company&#x2019;s estimates of the clinical study costs and costs to transition activities from Sanofi for development of sotagliflozin for type 2 diabetes, heart failure and chronic kidney disease, including the costs to close out those studies, were based on actual costs incurred for activities completed subsequent to the transition date and estimates of the services to be received and efforts to be expended pursuant to contracts with multiple vendors and the CRO that has conducted and managed and is now closing out the clinical studies on its behalf.  The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#x2019;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.&lt;/span&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RleHRyZWdpb246MDkyOWE5NjdiMTAwNDI5ZmIzOTljZGJkMWVhNTQxNTlfMTc4ODA_aa95d882-3431-4414-8ed3-92478b579ee5">&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Stock-Based Compensation:&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&#160;The Company recognizes compensation expense in its condensed consolidated statements of comprehensive loss for share-based payments, including stock options and restricted stock units issued to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#x2019;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#x2019;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in a change in the assumptions used for expected option lives.&#160;&#160;Historical data is used to estimate the expected option life for each group.  Expected volatility is based on the historical volatility in the Company&#x2019;s stock price.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RleHRyZWdpb246MDkyOWE5NjdiMTAwNDI5ZmIzOTljZGJkMWVhNTQxNTlfMTc5MzE_4dd15fca-0c68-4e34-aaf4-ac6c644070c2">&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:50.422%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.069%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.719%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.838%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.016%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk-free Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Dividend&lt;br/&gt;Rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Officers and non-employee directors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2019:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Officers and non-employee directors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees
      contextRef="i3f18a324e14b49309846f18ff6f8c0bc_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjhhZDY3MDc5NGJhYTRlYTY4MWQxMGJmMjc2NWFjZmM5L3RhYmxlcmFuZ2U6OGFkNjcwNzk0YmFhNGVhNjgxZDEwYmYyNzY1YWNmYzlfMi0yLTEtMS0w_401d2936-6e7d-4500-aa3f-c83aaa673bb1"
      unitRef="number">0.89</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee
      contextRef="i3f18a324e14b49309846f18ff6f8c0bc_D20200101-20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjhhZDY3MDc5NGJhYTRlYTY4MWQxMGJmMjc2NWFjZmM5L3RhYmxlcmFuZ2U6OGFkNjcwNzk0YmFhNGVhNjgxZDEwYmYyNzY1YWNmYzlfMi00LTEtMS0w_836853ba-a9c5-4eca-9750-4f3f874f2722"
      unitRef="number">0.013</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees
      contextRef="i3f18a324e14b49309846f18ff6f8c0bc_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjhhZDY3MDc5NGJhYTRlYTY4MWQxMGJmMjc2NWFjZmM5L3RhYmxlcmFuZ2U6OGFkNjcwNzk0YmFhNGVhNjgxZDEwYmYyNzY1YWNmYzlfMi02LTEtMS0w_22177d64-cbf3-4e93-b7c2-81446f883b3c">P4Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees
      contextRef="i3f18a324e14b49309846f18ff6f8c0bc_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjhhZDY3MDc5NGJhYTRlYTY4MWQxMGJmMjc2NWFjZmM5L3RhYmxlcmFuZ2U6OGFkNjcwNzk0YmFhNGVhNjgxZDEwYmYyNzY1YWNmYzlfMi04LTEtMS0w_b26b58fa-83b0-4500-a795-31d915f95d19"
      unitRef="number">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors
      contextRef="i3f18a324e14b49309846f18ff6f8c0bc_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjhhZDY3MDc5NGJhYTRlYTY4MWQxMGJmMjc2NWFjZmM5L3RhYmxlcmFuZ2U6OGFkNjcwNzk0YmFhNGVhNjgxZDEwYmYyNzY1YWNmYzlfMy0yLTEtMS0w_9a4494ee-caa4-49ec-862c-6353904bd98c"
      unitRef="number">0.77</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors
      contextRef="i3f18a324e14b49309846f18ff6f8c0bc_D20200101-20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjhhZDY3MDc5NGJhYTRlYTY4MWQxMGJmMjc2NWFjZmM5L3RhYmxlcmFuZ2U6OGFkNjcwNzk0YmFhNGVhNjgxZDEwYmYyNzY1YWNmYzlfMy00LTEtMS0w_061e585c-5c3c-4efd-9a02-2bb38d67ae28"
      unitRef="number">0.014</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors
      contextRef="i3f18a324e14b49309846f18ff6f8c0bc_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjhhZDY3MDc5NGJhYTRlYTY4MWQxMGJmMjc2NWFjZmM5L3RhYmxlcmFuZ2U6OGFkNjcwNzk0YmFhNGVhNjgxZDEwYmYyNzY1YWNmYzlfMy02LTEtMS0w_91c88d6b-5868-4457-a2c6-18a2adac708c">P8Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors
      contextRef="i3f18a324e14b49309846f18ff6f8c0bc_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjhhZDY3MDc5NGJhYTRlYTY4MWQxMGJmMjc2NWFjZmM5L3RhYmxlcmFuZ2U6OGFkNjcwNzk0YmFhNGVhNjgxZDEwYmYyNzY1YWNmYzlfMy04LTEtMS0w_e8a5b58d-bf5d-484e-b6d9-f3b80372fd69"
      unitRef="number">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees
      contextRef="i71615d600ea045f8b04f0104cca32e8c_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjhhZDY3MDc5NGJhYTRlYTY4MWQxMGJmMjc2NWFjZmM5L3RhYmxlcmFuZ2U6OGFkNjcwNzk0YmFhNGVhNjgxZDEwYmYyNzY1YWNmYzlfNS0yLTEtMS0w_578075b1-195d-42e8-baad-7ab25781d003"
      unitRef="number">0.63</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee
      contextRef="i71615d600ea045f8b04f0104cca32e8c_D20190101-20190331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjhhZDY3MDc5NGJhYTRlYTY4MWQxMGJmMjc2NWFjZmM5L3RhYmxlcmFuZ2U6OGFkNjcwNzk0YmFhNGVhNjgxZDEwYmYyNzY1YWNmYzlfNS00LTEtMS0w_b0466e6e-54fb-4155-9c1c-e45edc898c35"
      unitRef="number">0.025</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees
      contextRef="i71615d600ea045f8b04f0104cca32e8c_D20190101-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjhhZDY3MDc5NGJhYTRlYTY4MWQxMGJmMjc2NWFjZmM5L3RhYmxlcmFuZ2U6OGFkNjcwNzk0YmFhNGVhNjgxZDEwYmYyNzY1YWNmYzlfNS02LTEtMS0w_84da0214-42c2-4cb5-9638-02f682eea092">P4Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees
      contextRef="i71615d600ea045f8b04f0104cca32e8c_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjhhZDY3MDc5NGJhYTRlYTY4MWQxMGJmMjc2NWFjZmM5L3RhYmxlcmFuZ2U6OGFkNjcwNzk0YmFhNGVhNjgxZDEwYmYyNzY1YWNmYzlfNS04LTEtMS0w_fc9069b9-cce5-4a07-b491-d96b34534168"
      unitRef="number">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors
      contextRef="i71615d600ea045f8b04f0104cca32e8c_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjhhZDY3MDc5NGJhYTRlYTY4MWQxMGJmMjc2NWFjZmM5L3RhYmxlcmFuZ2U6OGFkNjcwNzk0YmFhNGVhNjgxZDEwYmYyNzY1YWNmYzlfNi0yLTEtMS0w_4498effc-7f44-4c19-baf0-2de2750e4877"
      unitRef="number">0.63</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors
      contextRef="i71615d600ea045f8b04f0104cca32e8c_D20190101-20190331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjhhZDY3MDc5NGJhYTRlYTY4MWQxMGJmMjc2NWFjZmM5L3RhYmxlcmFuZ2U6OGFkNjcwNzk0YmFhNGVhNjgxZDEwYmYyNzY1YWNmYzlfNi00LTEtMS0w_c3b7758e-69e6-45b7-a6fb-559cd3d1d6b5"
      unitRef="number">0.026</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors
      contextRef="i71615d600ea045f8b04f0104cca32e8c_D20190101-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjhhZDY3MDc5NGJhYTRlYTY4MWQxMGJmMjc2NWFjZmM5L3RhYmxlcmFuZ2U6OGFkNjcwNzk0YmFhNGVhNjgxZDEwYmYyNzY1YWNmYzlfNi02LTEtMS0w_6b115799-8e88-40f6-866d-fe6406f475aa">P8Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors
      contextRef="i71615d600ea045f8b04f0104cca32e8c_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjhhZDY3MDc5NGJhYTRlYTY4MWQxMGJmMjc2NWFjZmM5L3RhYmxlcmFuZ2U6OGFkNjcwNzk0YmFhNGVhNjgxZDEwYmYyNzY1YWNmYzlfNi04LTEtMS0w_413973ec-5256-499a-9bd0-bc66c91643e4"
      unitRef="number">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RleHRyZWdpb246MDkyOWE5NjdiMTAwNDI5ZmIzOTljZGJkMWVhNTQxNTlfMTc5MDU_386e6624-aea5-4fe3-90bf-b7358362774f">&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:66.035%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.929%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.570%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(202)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding at March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercisable at March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i0feb9d4ec8584f3ba002dca3b78ba1a4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOmY0MTEzMDZiODllMTRmZjY4ZjMxOTcwMTc2YjRjMWUxL3RhYmxlcmFuZ2U6ZjQxMTMwNmI4OWUxNGZmNjhmMzE5NzAxNzZiNGMxZTFfMi0yLTEtMS0w_fc9f8645-8fce-4728-88b7-98c15e63db19"
      unitRef="shares">7695000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i0feb9d4ec8584f3ba002dca3b78ba1a4_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOmY0MTEzMDZiODllMTRmZjY4ZjMxOTcwMTc2YjRjMWUxL3RhYmxlcmFuZ2U6ZjQxMTMwNmI4OWUxNGZmNjhmMzE5NzAxNzZiNGMxZTFfMi00LTEtMS0w_792bf944-99a4-4620-9dbd-7ca8d83b5773"
      unitRef="usdPerShare">8.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i9befb60474ef4d338b2be4e84a752c34_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOmY0MTEzMDZiODllMTRmZjY4ZjMxOTcwMTc2YjRjMWUxL3RhYmxlcmFuZ2U6ZjQxMTMwNmI4OWUxNGZmNjhmMzE5NzAxNzZiNGMxZTFfMy0yLTEtMS0w_5c10c5ee-9943-45a7-934a-bd1be35c5353"
      unitRef="shares">3301000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i9befb60474ef4d338b2be4e84a752c34_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOmY0MTEzMDZiODllMTRmZjY4ZjMxOTcwMTc2YjRjMWUxL3RhYmxlcmFuZ2U6ZjQxMTMwNmI4OWUxNGZmNjhmMzE5NzAxNzZiNGMxZTFfMy00LTEtMS0w_e3a431e5-8e9c-495b-b3f9-6679e068b9a6"
      unitRef="usdPerShare">3.31</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i9befb60474ef4d338b2be4e84a752c34_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOmY0MTEzMDZiODllMTRmZjY4ZjMxOTcwMTc2YjRjMWUxL3RhYmxlcmFuZ2U6ZjQxMTMwNmI4OWUxNGZmNjhmMzE5NzAxNzZiNGMxZTFfNS0yLTEtMS0w_2498b368-4c12-4813-8aad-1d6569a25a88"
      unitRef="shares">202000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i9befb60474ef4d338b2be4e84a752c34_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOmY0MTEzMDZiODllMTRmZjY4ZjMxOTcwMTc2YjRjMWUxL3RhYmxlcmFuZ2U6ZjQxMTMwNmI4OWUxNGZmNjhmMzE5NzAxNzZiNGMxZTFfNS00LTEtMS0w_ff93eec8-4bc9-4892-9ffa-00bad066cb55"
      unitRef="usdPerShare">13.30</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i9befb60474ef4d338b2be4e84a752c34_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOmY0MTEzMDZiODllMTRmZjY4ZjMxOTcwMTc2YjRjMWUxL3RhYmxlcmFuZ2U6ZjQxMTMwNmI4OWUxNGZmNjhmMzE5NzAxNzZiNGMxZTFfNi0yLTEtMS0w_8f625790-fb5f-449d-ba0c-2e7398b45bd9"
      unitRef="shares">73000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i9befb60474ef4d338b2be4e84a752c34_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOmY0MTEzMDZiODllMTRmZjY4ZjMxOTcwMTc2YjRjMWUxL3RhYmxlcmFuZ2U6ZjQxMTMwNmI4OWUxNGZmNjhmMzE5NzAxNzZiNGMxZTFfNi00LTEtMS0w_8ceb3429-ce82-4ab1-94a7-d999475fcb4b"
      unitRef="usdPerShare">11.10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i006d636778dc433599008ebda0fae643_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOmY0MTEzMDZiODllMTRmZjY4ZjMxOTcwMTc2YjRjMWUxL3RhYmxlcmFuZ2U6ZjQxMTMwNmI4OWUxNGZmNjhmMzE5NzAxNzZiNGMxZTFfNy0yLTEtMS0w_ce626104-e8d0-46b6-873e-5fe0d16a57e7"
      unitRef="shares">10721000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i006d636778dc433599008ebda0fae643_I20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOmY0MTEzMDZiODllMTRmZjY4ZjMxOTcwMTc2YjRjMWUxL3RhYmxlcmFuZ2U6ZjQxMTMwNmI4OWUxNGZmNjhmMzE5NzAxNzZiNGMxZTFfNy00LTEtMS0w_214b2091-52d8-4dde-8da8-568945f82c2e"
      unitRef="usdPerShare">7.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i006d636778dc433599008ebda0fae643_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOmY0MTEzMDZiODllMTRmZjY4ZjMxOTcwMTc2YjRjMWUxL3RhYmxlcmFuZ2U6ZjQxMTMwNmI4OWUxNGZmNjhmMzE5NzAxNzZiNGMxZTFfOC0yLTEtMS0w_63e0900c-9b09-4e1d-a47e-774325ef1d00"
      unitRef="shares">4731000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i006d636778dc433599008ebda0fae643_I20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOmY0MTEzMDZiODllMTRmZjY4ZjMxOTcwMTc2YjRjMWUxL3RhYmxlcmFuZ2U6ZjQxMTMwNmI4OWUxNGZmNjhmMzE5NzAxNzZiNGMxZTFfOC00LTEtMS0w_e936fa32-9876-4a7f-98ac-015168971a7c"
      unitRef="usdPerShare">9.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RleHRyZWdpb246MDkyOWE5NjdiMTAwNDI5ZmIzOTljZGJkMWVhNTQxNTlfMTc4ODE_8ae9e864-d22d-4520-92ad-fade43d98a11">&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:65.008%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.929%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.597%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted Average Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,032)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding at March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i208e16ef59a04b3c8182732d53d1e2eb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjk1MGMxNWZhNjMwNzQ3NTU4NDlkZWQ3YTY4ZWM5NWZmL3RhYmxlcmFuZ2U6OTUwYzE1ZmE2MzA3NDc1NTg0OWRlZDdhNjhlYzk1ZmZfMi0yLTEtMS0w_af81c9e5-12eb-40f1-97aa-3e93c83c0e2d"
      unitRef="shares">2830000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i208e16ef59a04b3c8182732d53d1e2eb_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjk1MGMxNWZhNjMwNzQ3NTU4NDlkZWQ3YTY4ZWM5NWZmL3RhYmxlcmFuZ2U6OTUwYzE1ZmE2MzA3NDc1NTg0OWRlZDdhNjhlYzk1ZmZfMi00LTEtMS0w_5cfb66c8-dc4e-4bd8-a827-5dd02fa47ead"
      unitRef="usdPerShare">6.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="icb6eab599353423faf94057d3a06d361_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjk1MGMxNWZhNjMwNzQ3NTU4NDlkZWQ3YTY4ZWM5NWZmL3RhYmxlcmFuZ2U6OTUwYzE1ZmE2MzA3NDc1NTg0OWRlZDdhNjhlYzk1ZmZfMy0yLTEtMS0w_5dfb87bd-75b9-47c4-a303-d4273c4c4922"
      unitRef="shares">3060000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="icb6eab599353423faf94057d3a06d361_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjk1MGMxNWZhNjMwNzQ3NTU4NDlkZWQ3YTY4ZWM5NWZmL3RhYmxlcmFuZ2U6OTUwYzE1ZmE2MzA3NDc1NTg0OWRlZDdhNjhlYzk1ZmZfMy00LTEtMS0w_34c1cb1f-b6e0-40c7-bdae-1361b31ae321"
      unitRef="usdPerShare">3.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="icb6eab599353423faf94057d3a06d361_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjk1MGMxNWZhNjMwNzQ3NTU4NDlkZWQ3YTY4ZWM5NWZmL3RhYmxlcmFuZ2U6OTUwYzE1ZmE2MzA3NDc1NTg0OWRlZDdhNjhlYzk1ZmZfNC0yLTEtMS0w_6701bb4c-d140-44f7-94ea-4992a51309d7"
      unitRef="shares">1032000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="icb6eab599353423faf94057d3a06d361_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjk1MGMxNWZhNjMwNzQ3NTU4NDlkZWQ3YTY4ZWM5NWZmL3RhYmxlcmFuZ2U6OTUwYzE1ZmE2MzA3NDc1NTg0OWRlZDdhNjhlYzk1ZmZfNC00LTEtMS0w_f1553bb3-af1d-4c19-85a2-e396eb24b9c3"
      unitRef="usdPerShare">7.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="icb6eab599353423faf94057d3a06d361_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjk1MGMxNWZhNjMwNzQ3NTU4NDlkZWQ3YTY4ZWM5NWZmL3RhYmxlcmFuZ2U6OTUwYzE1ZmE2MzA3NDc1NTg0OWRlZDdhNjhlYzk1ZmZfNS0yLTEtMS0w_1c3a4d11-fa1a-4ba0-bef9-9130bc76c0ea"
      unitRef="shares">34000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="icb6eab599353423faf94057d3a06d361_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjk1MGMxNWZhNjMwNzQ3NTU4NDlkZWQ3YTY4ZWM5NWZmL3RhYmxlcmFuZ2U6OTUwYzE1ZmE2MzA3NDc1NTg0OWRlZDdhNjhlYzk1ZmZfNS00LTEtMS0w_64c85938-6964-4c01-bfee-b72c964d84f6"
      unitRef="usdPerShare">5.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i6d895ee7aef1499d98cd6729af5ed070_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjk1MGMxNWZhNjMwNzQ3NTU4NDlkZWQ3YTY4ZWM5NWZmL3RhYmxlcmFuZ2U6OTUwYzE1ZmE2MzA3NDc1NTg0OWRlZDdhNjhlYzk1ZmZfNi0yLTEtMS0w_d7df2984-67c4-4456-bb5e-2114ddded7da"
      unitRef="shares">4824000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i6d895ee7aef1499d98cd6729af5ed070_I20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RhYmxlOjk1MGMxNWZhNjMwNzQ3NTU4NDlkZWQ3YTY4ZWM5NWZmL3RhYmxlcmFuZ2U6OTUwYzE1ZmE2MzA3NDc1NTg0OWRlZDdhNjhlYzk1ZmZfNi00LTEtMS0w_e81f69b6-fbb0-4d48-81da-6d41e93f8123"
      unitRef="usdPerShare">4.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80MC9mcmFnOjA5MjlhOTY3YjEwMDQyOWZiMzk5Y2RiZDFlYTU0MTU5L3RleHRyZWdpb246MDkyOWE5NjdiMTAwNDI5ZmIzOTljZGJkMWVhNTQxNTlfMTc5MjM_dfb27d8b-dbc6-4a1d-8d59-38ec9078ec9a">Net Loss per Common Share: Net loss per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with convertible debt, stock options and restricted stock units are not included because they are antidilutive.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80Ni9mcmFnOmZjNjYwOWZmODdmMDRlNzI4YTYwMTEzMDUyZTU5ODcyL3RleHRyZWdpb246ZmM2NjA5ZmY4N2YwNGU3MjhhNjAxMTMwNTJlNTk4NzJfMTA5OTUxMTYzMjY1Nw_5f1b624b-37b9-4ff6-adbc-966fcea8041d">Recent Accounting Pronouncements&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In November 2018, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606.  This targeted amendment to Topic 808 clarifies that certain transactions resulting from a collaborative agreement should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer for a good or service that is a distinct unit-of-account.  This amendment is effective for fiscal years, and interim periods within years presented, beginning after December 15, 2019, and should be applied retrospectively to the date of initial application of Topic 606.  The Company has applied the provisions of Topic 606 to account for its transactions for collaboration arrangements, including recognition, measurement, presentation and disclosure requirement, and adoption of this ASU did not have a material impact on the condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In January 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and Other, which is intended to simplify the subsequent measurement of goodwill.  The pronouncement allows an entity, during its annual or interim goodwill impairment evaluation, to compare the fair value of a reporting unit with its carrying amount.  An impairment charge is immediately recognized by which the carrying amount exceeds the fair value.  This ASU is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019.  The adoption of this ASU did not have a material impact on the condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsDisclosureTextBlock
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RleHRyZWdpb246OGJkOWQ0MGY0MWJlNDYyM2IzZTk1Njk4Y2M1NDRjYmZfMzIw_115bdcf4-0cd1-4577-9c8e-7408cefbb948">Cash and Cash Equivalents and Investments&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of cash and cash equivalents and investments held at March&#160;31, 2020 and December&#160;31, 2019 are as follows:&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:51.147%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.980%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.980%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.980%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.985%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;55,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;55,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Securities maturing within one year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;192,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;193,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;192,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;193,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;248,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;249,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Securities maturing within one year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;235,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;235,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;235,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;235,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-18pt;padding-left:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;271,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;271,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;There were no realized losses during either of the three months ended March&#160;31, 2020 and 2019, respectively.  The cost of securities sold is based on the specific identification method.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RleHRyZWdpb246OGJkOWQ0MGY0MWJlNDYyM2IzZTk1Njk4Y2M1NDRjYmZfMzI2_1297cde6-8149-4226-99d2-578a4478bddf">&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:51.147%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.980%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.980%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.980%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.985%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;55,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;55,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Securities maturing within one year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;192,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;193,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;192,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;193,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;248,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;249,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Securities maturing within one year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;235,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;235,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;235,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;235,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-18pt;padding-left:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;271,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;271,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="i5874757311014de880a5b19a0ef172e9_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfMy0yLTEtMS0w_2249feaf-dd2d-43dd-a31e-4f6743cf800e"
      unitRef="usd">55592000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5874757311014de880a5b19a0ef172e9_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfMy00LTEtMS0w_7da65675-e4f5-4900-8e07-4ca67a6e7809"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5874757311014de880a5b19a0ef172e9_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfMy02LTEtMS0w_d040a3d0-2f7c-4d7a-b491-693f62b0685e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i5874757311014de880a5b19a0ef172e9_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfMy04LTEtMS0w_9d53ae3b-20bd-42c4-a992-8dd0e7bbca07"
      unitRef="usd">55592000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="ic70d1635899243dcae62140e9324e2e5_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfNS0yLTEtMS0w_2ab5255f-f91b-4178-9cfd-696226e38841"
      unitRef="usd">192685000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic70d1635899243dcae62140e9324e2e5_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfNS00LTEtMS0w_0aec86f7-f809-4ed0-b4cf-c0ea438f4428"
      unitRef="usd">860000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic70d1635899243dcae62140e9324e2e5_I20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfNS02LTEtMS0w_edd0e519-321b-4f7a-bb3b-7643ca43a4a0"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="ic70d1635899243dcae62140e9324e2e5_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfNS04LTEtMS0w_7611e858-d8f5-4098-895b-61510a78fa77"
      unitRef="usd">193545000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="i9fe1a3b2255e409c8e58bbc860ad020d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfNy0yLTEtMS0w_155e7c56-0020-4e8d-82cc-7769ea10c4f9"
      unitRef="usd">192685000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9fe1a3b2255e409c8e58bbc860ad020d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfNy00LTEtMS0w_e909d163-0b48-4cb6-8b97-c981d1a77cfe"
      unitRef="usd">860000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9fe1a3b2255e409c8e58bbc860ad020d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfNy02LTEtMS0w_b7ddbf48-2bf7-4f56-88e5-e136f7a7f3ed"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i9fe1a3b2255e409c8e58bbc860ad020d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfNy04LTEtMS0w_1e6d7e67-dcaf-42a7-ad15-f8d3bdb10b77"
      unitRef="usd">193545000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="i2ec309d5c8d74374add6eb8f7da20570_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfOC0yLTEtMS0w_e40b1244-ae77-4c56-8e0b-0b4b2ae0df40"
      unitRef="usd">248277000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2ec309d5c8d74374add6eb8f7da20570_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfOC00LTEtMS0w_9af8fac0-902c-4e3f-9813-54b3c9079db5"
      unitRef="usd">860000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2ec309d5c8d74374add6eb8f7da20570_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfOC02LTEtMS0w_86520240-343d-427a-b2cc-a098b6fc76f7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i2ec309d5c8d74374add6eb8f7da20570_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfOC04LTEtMS0w_cdf6b402-907f-4fa9-a2c5-6bcbd7896ae5"
      unitRef="usd">249137000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="ic774c47684e0435aa7c3af7fdf7fe3fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfMTMtMi0xLTEtMA_f90e3a41-1934-4952-807f-f3946b2728f7"
      unitRef="usd">36112000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic774c47684e0435aa7c3af7fdf7fe3fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfMTMtNC0xLTEtMA_01bf5c9b-2be0-4c26-84fd-c502b0f11f9c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic774c47684e0435aa7c3af7fdf7fe3fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfMTMtNi0xLTEtMA_437335bb-cfb5-42ec-8682-aaf4f9328355"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="ic774c47684e0435aa7c3af7fdf7fe3fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfMTMtOC0xLTEtMA_3e7d69be-ad9e-4a4f-a214-8d283d4d8062"
      unitRef="usd">36112000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="ie0f70c6928fb4964a9779e08a7863739_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfMTUtMi0xLTEtMA_87b8ec05-2f08-4ce8-a5df-d10bd3d0fb65"
      unitRef="usd">235463000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie0f70c6928fb4964a9779e08a7863739_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfMTUtNC0xLTEtMA_726d972c-d130-4e39-96bf-37f4e8457209"
      unitRef="usd">94000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie0f70c6928fb4964a9779e08a7863739_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfMTUtNi0xLTEtMA_47bbbda3-0423-45eb-972a-a9aadfb00246"
      unitRef="usd">10000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="ie0f70c6928fb4964a9779e08a7863739_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfMTUtOC0xLTEtMA_66c02517-10ba-4c05-a924-2f51087f3842"
      unitRef="usd">235547000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="i7833aa4e5e984d3dba5516f674a6a6fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfMTctMi0xLTEtMA_d8792a58-9a0a-432f-b733-7913bff8db49"
      unitRef="usd">235463000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7833aa4e5e984d3dba5516f674a6a6fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfMTctNC0xLTEtMA_cb58e9f7-9357-4271-ba36-6e5e10ab7c30"
      unitRef="usd">94000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7833aa4e5e984d3dba5516f674a6a6fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfMTctNi0xLTEtMA_0bbd31dd-bacf-4765-8fdc-007010d295f8"
      unitRef="usd">10000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i7833aa4e5e984d3dba5516f674a6a6fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfMTctOC0xLTEtMA_8162d845-f463-4d09-9345-c8c025bf5efc"
      unitRef="usd">235547000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="i5690a7970c9142c1b8c462b80f0e2ba2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfMTgtMi0xLTEtMA_2b77010e-c3c8-445a-927f-b5e81c4a4917"
      unitRef="usd">271575000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5690a7970c9142c1b8c462b80f0e2ba2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfMTgtNC0xLTEtMA_bd7b24b4-51c2-44d8-97da-a57f133e3f03"
      unitRef="usd">94000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5690a7970c9142c1b8c462b80f0e2ba2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfMTgtNi0xLTEtMA_faac951e-cc54-4a01-8ef7-2abc9f832f8a"
      unitRef="usd">10000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i5690a7970c9142c1b8c462b80f0e2ba2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RhYmxlOmU0MThjNDI3YzUxNzQ1ZWM5MGU0NmE3NTE2ZTA0MDI2L3RhYmxlcmFuZ2U6ZTQxOGM0MjdjNTE3NDVlYzkwZTQ2YTc1MTZlMDQwMjZfMTgtOC0xLTEtMA_56ca2f31-d194-4116-8104-3b66ade0b002"
      unitRef="usd">271659000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RleHRyZWdpb246OGJkOWQ0MGY0MWJlNDYyM2IzZTk1Njk4Y2M1NDRjYmZfMTYx_1eb59a67-51e3-4880-bc0c-d2952ce45ad3"
      unitRef="usd">0</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF80OS9mcmFnOjhiZDlkNDBmNDFiZTQ2MjNiM2U5NTY5OGNjNTQ0Y2JmL3RleHRyZWdpb246OGJkOWQ0MGY0MWJlNDYyM2IzZTk1Njk4Y2M1NDRjYmZfMTYx_928bfdd4-3a25-4cdd-ba30-b474813a7473"
      unitRef="usd">0</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:FairValueMeasurementInputsDisclosureTextBlock
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RleHRyZWdpb246MDlmYzc1YThiMTE2NGNlMTkyNDQ2ODM3ZWI4N2RlNzFfMTg0NA_b549da40-4666-4fa1-a08c-51e0ef0bd107">Fair Value Measurements&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis.  Assets and liabilities recorded at fair value in the condensed consolidated balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value.  The following levels are directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;Level 1 - quoted prices in active markets for identical investments, which include U.S. treasury securities &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;Level 2 - other significant observable inputs (including quoted prices for similar investments, market corroborated inputs, etc.), which includes corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;Level 3 - significant unobservable inputs &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The inputs or methodology used for valuing securities are not necessarily an indication of the credit risk associated with investing in those securities.  The following table provides the fair value measurements of applicable Company assets that are measured at fair value on a recurring basis according to the fair value levels defined above as of March&#160;31, 2020 and December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:45.723%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.334%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.334%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.334%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.339%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets and Liabilities at Fair Value as of March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;55,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;55,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;193,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;193,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;249,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;249,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:45.723%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.334%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.334%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.334%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.339%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets and Liabilities at Fair Value as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;235,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;235,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;271,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;271,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company did not have any Level 3 assets or liabilities as of March&#160;31, 2020 or December&#160;31, 2019. Transfers between levels are recognized at the actual date of circumstance that caused the transfer.  There were no transfers between Level 1 and Level 2 during the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company also has assets that under certain conditions are subject to measurement at fair value on a non-recurring basis.  These assets include goodwill associated with the acquisitions of Coelacanth Corporation in 2001 and Symphony Icon in 2010, and intangible assets associated with the acquisition of Symphony Icon in 2010. For these assets, measurement at fair value in periods subsequent to their initial recognition is applicable if one or more is determined to be impaired.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Refer to Note 5, Debt Obligations, for fair value measurements of debt obligations.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RleHRyZWdpb246MDlmYzc1YThiMTE2NGNlMTkyNDQ2ODM3ZWI4N2RlNzFfMTg1Nw_02c28e14-a22e-4221-8d4d-57611d8fb273">&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:45.723%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.334%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.334%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.334%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.339%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets and Liabilities at Fair Value as of March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;55,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;55,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;193,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;193,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;249,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;249,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:45.723%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.334%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.334%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.334%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.339%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets and Liabilities at Fair Value as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;235,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;235,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;271,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;271,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6a4c4a7f94924e29a9ae0e9f3ffd742f_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RhYmxlOmYxNDczOTNiNmFkMzQ5MGRiN2U4M2ZjZmFhNmVmNDUwL3RhYmxlcmFuZ2U6ZjE0NzM5M2I2YWQzNDkwZGI3ZTgzZmNmYWE2ZWY0NTBfNC0yLTEtMS0w_d696a02f-6065-492e-9252-15ce38d5ea68"
      unitRef="usd">55592000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie20916e42c934ea59584c72016a49665_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RhYmxlOmYxNDczOTNiNmFkMzQ5MGRiN2U4M2ZjZmFhNmVmNDUwL3RhYmxlcmFuZ2U6ZjE0NzM5M2I2YWQzNDkwZGI3ZTgzZmNmYWE2ZWY0NTBfNC00LTEtMS0w_4cb2c7d9-ddd8-4c18-8b7c-71a28f4a02e4"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0b10f1125ee94d22854381cfc60caac9_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RhYmxlOmYxNDczOTNiNmFkMzQ5MGRiN2U4M2ZjZmFhNmVmNDUwL3RhYmxlcmFuZ2U6ZjE0NzM5M2I2YWQzNDkwZGI3ZTgzZmNmYWE2ZWY0NTBfNC02LTEtMS0w_3f0a9162-f067-46af-93b5-693bca442381"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RhYmxlOmYxNDczOTNiNmFkMzQ5MGRiN2U4M2ZjZmFhNmVmNDUwL3RhYmxlcmFuZ2U6ZjE0NzM5M2I2YWQzNDkwZGI3ZTgzZmNmYWE2ZWY0NTBfNC04LTEtMS0w_e594f603-d992-4cbb-9013-5bed77ac58ac"
      unitRef="usd">55592000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecurities
      contextRef="i6a4c4a7f94924e29a9ae0e9f3ffd742f_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RhYmxlOmYxNDczOTNiNmFkMzQ5MGRiN2U4M2ZjZmFhNmVmNDUwL3RhYmxlcmFuZ2U6ZjE0NzM5M2I2YWQzNDkwZGI3ZTgzZmNmYWE2ZWY0NTBfNS0yLTEtMS0w_b80dadb9-91ba-4834-a182-92477108bb8e"
      unitRef="usd">193545000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="ie20916e42c934ea59584c72016a49665_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RhYmxlOmYxNDczOTNiNmFkMzQ5MGRiN2U4M2ZjZmFhNmVmNDUwL3RhYmxlcmFuZ2U6ZjE0NzM5M2I2YWQzNDkwZGI3ZTgzZmNmYWE2ZWY0NTBfNS00LTEtMS0w_ba2271f8-f5cc-444d-bfb6-af65dfe5e2ad"
      unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="i0b10f1125ee94d22854381cfc60caac9_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RhYmxlOmYxNDczOTNiNmFkMzQ5MGRiN2U4M2ZjZmFhNmVmNDUwL3RhYmxlcmFuZ2U6ZjE0NzM5M2I2YWQzNDkwZGI3ZTgzZmNmYWE2ZWY0NTBfNS02LTEtMS0w_76a2d618-f57d-49b4-97e2-717734721014"
      unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RhYmxlOmYxNDczOTNiNmFkMzQ5MGRiN2U4M2ZjZmFhNmVmNDUwL3RhYmxlcmFuZ2U6ZjE0NzM5M2I2YWQzNDkwZGI3ZTgzZmNmYWE2ZWY0NTBfNS04LTEtMS0w_f7da36d0-523f-4023-9722-c59c891cbe22"
      unitRef="usd">193545000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i6a4c4a7f94924e29a9ae0e9f3ffd742f_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RhYmxlOmYxNDczOTNiNmFkMzQ5MGRiN2U4M2ZjZmFhNmVmNDUwL3RhYmxlcmFuZ2U6ZjE0NzM5M2I2YWQzNDkwZGI3ZTgzZmNmYWE2ZWY0NTBfNi0yLTEtMS0w_47b13d47-33d5-4760-a4f6-62a348430525"
      unitRef="usd">249137000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ie20916e42c934ea59584c72016a49665_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RhYmxlOmYxNDczOTNiNmFkMzQ5MGRiN2U4M2ZjZmFhNmVmNDUwL3RhYmxlcmFuZ2U6ZjE0NzM5M2I2YWQzNDkwZGI3ZTgzZmNmYWE2ZWY0NTBfNi00LTEtMS0w_9fa78619-0418-4a77-85cf-4d180604d148"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i0b10f1125ee94d22854381cfc60caac9_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RhYmxlOmYxNDczOTNiNmFkMzQ5MGRiN2U4M2ZjZmFhNmVmNDUwL3RhYmxlcmFuZ2U6ZjE0NzM5M2I2YWQzNDkwZGI3ZTgzZmNmYWE2ZWY0NTBfNi02LTEtMS0w_a58c5ed6-5646-4c5e-a108-8c1af7cb7b9e"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RhYmxlOmYxNDczOTNiNmFkMzQ5MGRiN2U4M2ZjZmFhNmVmNDUwL3RhYmxlcmFuZ2U6ZjE0NzM5M2I2YWQzNDkwZGI3ZTgzZmNmYWE2ZWY0NTBfNi04LTEtMS0w_80df6cb6-50a8-4712-a001-2d265d4688a1"
      unitRef="usd">249137000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib827aa338f2c4aca8a2d4e234b9f0078_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RhYmxlOjNlMWZkZGY3NmZjOTQxYzVhNWRlYjRiODViMDY0YTU5L3RhYmxlcmFuZ2U6M2UxZmRkZjc2ZmM5NDFjNWE1ZGViNGI4NWIwNjRhNTlfNC0yLTEtMS0w_4bb80280-4f1b-48e0-9f71-272ac23d0803"
      unitRef="usd">36112000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="icc19c78530d54ec0a70b9d2bdd0a9db7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RhYmxlOjNlMWZkZGY3NmZjOTQxYzVhNWRlYjRiODViMDY0YTU5L3RhYmxlcmFuZ2U6M2UxZmRkZjc2ZmM5NDFjNWE1ZGViNGI4NWIwNjRhNTlfNC00LTEtMS0w_28670e5c-4e34-4732-a39b-e34d1519d1cb"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic3d4c113ca4e4166a72c7baa6566b202_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RhYmxlOjNlMWZkZGY3NmZjOTQxYzVhNWRlYjRiODViMDY0YTU5L3RhYmxlcmFuZ2U6M2UxZmRkZjc2ZmM5NDFjNWE1ZGViNGI4NWIwNjRhNTlfNC02LTEtMS0w_162e0ad8-4593-4b73-881f-90cad246f77b"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RhYmxlOjNlMWZkZGY3NmZjOTQxYzVhNWRlYjRiODViMDY0YTU5L3RhYmxlcmFuZ2U6M2UxZmRkZjc2ZmM5NDFjNWE1ZGViNGI4NWIwNjRhNTlfNC04LTEtMS0w_58a72c5c-a4ba-47dc-a526-72461b57c0e8"
      unitRef="usd">36112000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecurities
      contextRef="ib827aa338f2c4aca8a2d4e234b9f0078_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RhYmxlOjNlMWZkZGY3NmZjOTQxYzVhNWRlYjRiODViMDY0YTU5L3RhYmxlcmFuZ2U6M2UxZmRkZjc2ZmM5NDFjNWE1ZGViNGI4NWIwNjRhNTlfNS0yLTEtMS0w_4f6dc6bf-1386-4ba5-ab63-2d80b0228d6a"
      unitRef="usd">235547000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="icc19c78530d54ec0a70b9d2bdd0a9db7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RhYmxlOjNlMWZkZGY3NmZjOTQxYzVhNWRlYjRiODViMDY0YTU5L3RhYmxlcmFuZ2U6M2UxZmRkZjc2ZmM5NDFjNWE1ZGViNGI4NWIwNjRhNTlfNS00LTEtMS0w_2e9fd97c-d8fd-45c4-b6a5-30735b9db475"
      unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="ic3d4c113ca4e4166a72c7baa6566b202_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RhYmxlOjNlMWZkZGY3NmZjOTQxYzVhNWRlYjRiODViMDY0YTU5L3RhYmxlcmFuZ2U6M2UxZmRkZjc2ZmM5NDFjNWE1ZGViNGI4NWIwNjRhNTlfNS02LTEtMS0w_2b395af0-c6c2-4119-a12b-3a9fa9456388"
      unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RhYmxlOjNlMWZkZGY3NmZjOTQxYzVhNWRlYjRiODViMDY0YTU5L3RhYmxlcmFuZ2U6M2UxZmRkZjc2ZmM5NDFjNWE1ZGViNGI4NWIwNjRhNTlfNS04LTEtMS0w_f30dcb6c-1d12-47c6-acf0-e6bd1962854f"
      unitRef="usd">235547000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ib827aa338f2c4aca8a2d4e234b9f0078_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RhYmxlOjNlMWZkZGY3NmZjOTQxYzVhNWRlYjRiODViMDY0YTU5L3RhYmxlcmFuZ2U6M2UxZmRkZjc2ZmM5NDFjNWE1ZGViNGI4NWIwNjRhNTlfNi0yLTEtMS0w_7292a0d3-926f-431d-942a-efebe2fe6c83"
      unitRef="usd">271659000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="icc19c78530d54ec0a70b9d2bdd0a9db7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RhYmxlOjNlMWZkZGY3NmZjOTQxYzVhNWRlYjRiODViMDY0YTU5L3RhYmxlcmFuZ2U6M2UxZmRkZjc2ZmM5NDFjNWE1ZGViNGI4NWIwNjRhNTlfNi00LTEtMS0w_69e3c747-e734-4db1-8275-75fb6640050a"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ic3d4c113ca4e4166a72c7baa6566b202_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RhYmxlOjNlMWZkZGY3NmZjOTQxYzVhNWRlYjRiODViMDY0YTU5L3RhYmxlcmFuZ2U6M2UxZmRkZjc2ZmM5NDFjNWE1ZGViNGI4NWIwNjRhNTlfNi02LTEtMS0w_e8951fc9-7f30-4537-831e-abb825c4947b"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i363fbff4bcfa49938a12d82839eb6a03_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81NS9mcmFnOjA5ZmM3NWE4YjExNjRjZTE5MjQ0NjgzN2ViODdkZTcxL3RhYmxlOjNlMWZkZGY3NmZjOTQxYzVhNWRlYjRiODViMDY0YTU5L3RhYmxlcmFuZ2U6M2UxZmRkZjc2ZmM5NDFjNWE1ZGViNGI4NWIwNjRhNTlfNi04LTEtMS0w_d771d759-fb2b-4faa-822e-5101f83574e2"
      unitRef="usd">271659000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81OC9mcmFnOjAzNWRiOWFhYmMyYjQxZGE4MGVmZTAzZDdlZGJkODNlL3RleHRyZWdpb246MDM1ZGI5YWFiYzJiNDFkYTgwZWZlMDNkN2VkYmQ4M2VfNjk3Nw_17611cac-666c-48fa-ab24-755a2c0e0c9c">Debt Obligations&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Convertible Debt.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; In November 2014, Lexicon completed an offering of $87.5 million in aggregate principal amount of its 5.25% Convertible Senior Notes due 2021 (the &#x201c;Convertible Notes&#x201d;).  The conversion feature did not meet the criteria for bifurcation as required by generally accepted accounting principles and the entire principal amount was recorded as long-term debt on the Company&#x2019;s condensed consolidated balance sheets.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Convertible Notes are governed by an indenture (the &#x201c;Indenture&#x201d;), dated as of November&#160;26, 2014, between the Company and Wells Fargo Bank, N.A., as trustee.  The Convertible Notes bear interest at a rate of 5.25%&#160;per year, payable semiannually in arrears on June&#160;1 and December&#160;1 of each year, beginning on June&#160;1, 2015. The Convertible Notes mature on December&#160;1, 2021. The Company may not redeem the Convertible Notes prior to the maturity date, and no sinking fund is provided for the Convertible Notes.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Holders of the Convertible Notes may convert their Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, the Company will deliver for each $1,000 principal amount of converted Convertible Notes a number of shares of its common stock equal to the conversion rate, as described in the Indenture. The conversion rate is initially 118.4553 shares of common stock per $1,000 principal amount of Convertible Notes (equivalent to an initial conversion price of $8.442 per share of common stock). The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date, the Company will increase the conversion rate for a holder who elects to convert its Convertible Notes in connection with such a corporate event in certain circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;If the Company undergoes a fundamental change, holders may require the Company to repurchase for cash all or any portion of their Convertible Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In connection with the issuance of the Convertible Notes, the Company incurred $3.4 million of debt issuance costs.  The debt issuance costs are amortized as interest expense over the expected life of the Convertible Notes using the effective interest method.  The Company determined the expected life of the debt was equal to the seven-year term of the Convertible Notes.  As of March&#160;31, 2020, the balance of unamortized debt issuance costs was $0.8&#160;million, which offsets long-term debt on the condensed consolidated balance sheets.  As of March&#160;31, 2020, the carrying value of the Convertible Notes was $86.7 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of the Convertible Notes was $55.2&#160;million as of March&#160;31, 2020 and was determined using Level&#160;2 inputs based on the indicative pricing published by certain investment banks or trading levels of the Convertible Notes, which are not listed on any securities exchange or quoted on an inter-dealer automated quotation system.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Mortgage Loan.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&#160;In August 2018, a wholly owned subsidiary of Lexicon entered into a term loan and security agreement, refinancing the previously existing mortgage on its facilities in The Woodlands, Texas (the &#x201c;Property&#x201d;).  The loan agreement provides for a $12.9 million mortgage on the Property and has a two-year term with a 10-year amortization.  The mortgage loan bears interest at a rate per annum equal to the greater of (a) the 30-day LIBOR rate plus 5.5% and (b) 7.5% and provides for a balloon payment of $10.3 million due in August 2020.  Lexicon incurred $0.4 million of debt issuance costs in connection with the mortgage loan, which offsets the current portion of long-term debt on the condensed consolidated balance sheets and are amortized as interest expense over the two-year term of the loan agreement.  As of March&#160;31, 2020, the balance of unamortized debt issuance costs was $0.1 million.  The condensed consolidated balance sheet includes mortgage debt, the carrying value of the debt, of $10.7 million as of March&#160;31, 2020 and is included in current portion of long-term debt.  The buildings and land that serve as collateral for the mortgage loan are included in property and equipment at $59.2&#160;million and $2.7&#160;million, respectively, before accumulated depreciation, as of March&#160;31, 2020.  The fair value of the loan agreement approximates its carrying value.&#160;&#160;The fair value of the loan agreement was determined using Level&#160;2 inputs using discounted cash flow analysis, based on the Company&#x2019;s estimated current incremental borrowing rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In January 2020, Lexicon's wholly owned subsidiary entered into a real estate purchase and sale agreement under which Lexicon agreed to sell its facilities in The Woodlands, Texas.  Such sale is subject to normal and customary closing conditions, including a study period, which extends until June 8, 2020, during which the purchaser may conduct inspections, analyses and other studies of the property and may terminate the agreement in its discretion.  Such sale is also subject to the negotiation and execution by the parties of a leaseback agreement for a period of up to six months with respect to a portion of the property concurrently with closing.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;BioPharma Term Loan.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&#160;In December 2017, Lexicon entered into a loan agreement with BioPharma Credit PLC and BioPharma Credit Investments IV Sub LP under which $150.0 million was funded in December 2017 (the &#x201c;BioPharma Term Loan&#x201d;). The BioPharma Term Loan matures in December 2022, bears interest at 9% per year, subject to additional interest if an event of default occurs and is continuing, and is payable quarterly. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The BioPharma Term Loan is subject to mandatory prepayment provisions that require prepayment upon a change of control or receipt of proceeds from certain non-ordinary course transfers of assets.  The Company may prepay the BioPharma Term Loan in whole at its option at any time.  Any prepayment of the BioPharma Term Loan is subject to customary make-whole premiums and prepayment premiums.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s obligations under the BioPharma Term Loan are secured by a first lien security interest in substantially all of the assets of the Company and certain of its subsidiaries, other than its facilities in The Woodlands, Texas.  The loan agreement contains certain customary representations and warranties, affirmative and negative covenants and events of default applicable to the Company and certain of its subsidiaries, including among other things, covenants restricting dispositions, fundamental changes in the business, mergers or acquisitions, indebtedness, encumbrances, distributions, investments, transactions with affiliates and subordinated debt.  If an event of default occurs and is continuing, all amounts outstanding under the BioPharma Term Loan may be declared immediately due and payable.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In connection with the BioPharma Term Loan, the Company incurred $4.1 million of debt issuance costs.  The debt issuance costs are amortized as interest expense over the expected life of the BioPharma Term Loan using the effective interest method.  The Company determined the expected life of the debt was equal to the five-year term of the BioPharma Term Loan. As of March&#160;31, 2020, the balance of unamortized debt issuance costs was $2.2 million, which offsets long-term debt on the &lt;/span&gt;&lt;/div&gt;condensed consolidated balance sheets.  As of March&#160;31, 2020, the carrying value of the BioPharma Term Loan was $147.8 million.The fair value of the BioPharma Term Loan approximates its carrying value.  The fair value of the BioPharma Term Loan was determined using Level&#160;2 inputs using discounted cash flow analysis, based on the Company&#x2019;s estimated current incremental borrowing rate.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="ibd4832dfa32a43a6b0d3e7ac775c2680_D20141101-20141130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81OC9mcmFnOjAzNWRiOWFhYmMyYjQxZGE4MGVmZTAzZDdlZGJkODNlL3RleHRyZWdpb246MDM1ZGI5YWFiYzJiNDFkYTgwZWZlMDNkN2VkYmQ4M2VfOTQ_ca486937-201c-4c4c-8019-a96a56ec712d"
      unitRef="usd">87500000</us-gaap:ProceedsFromConvertibleDebt>
    <lxrx:ConvDebtInstrumentInterestRateStatedPercentage
      contextRef="i7a726c0e01c741f09f3d21d85cd63800_I20141120"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81OC9mcmFnOjAzNWRiOWFhYmMyYjQxZGE4MGVmZTAzZDdlZGJkODNlL3RleHRyZWdpb246MDM1ZGI5YWFiYzJiNDFkYTgwZWZlMDNkN2VkYmQ4M2VfMTM0_d3abe6d0-5787-42d6-aa5b-055174b78021"
      unitRef="number">0.0525</lxrx:ConvDebtInstrumentInterestRateStatedPercentage>
    <lxrx:ConvDebtInstrumentInterestRateStatedPercentage
      contextRef="i7a726c0e01c741f09f3d21d85cd63800_I20141120"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81OC9mcmFnOjAzNWRiOWFhYmMyYjQxZGE4MGVmZTAzZDdlZGJkODNlL3RleHRyZWdpb246MDM1ZGI5YWFiYzJiNDFkYTgwZWZlMDNkN2VkYmQ4M2VfNjUy_d3abe6d0-5787-42d6-aa5b-055174b78021"
      unitRef="number">0.0525</lxrx:ConvDebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="ibd4832dfa32a43a6b0d3e7ac775c2680_D20141101-20141130"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81OC9mcmFnOjAzNWRiOWFhYmMyYjQxZGE4MGVmZTAzZDdlZGJkODNlL3RleHRyZWdpb246MDM1ZGI5YWFiYzJiNDFkYTgwZWZlMDNkN2VkYmQ4M2VfMTM3OQ_a74980af-6b5b-4509-bfd4-b6ec39a5c45e"
      unitRef="number">118.4553</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i7a726c0e01c741f09f3d21d85cd63800_I20141120"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81OC9mcmFnOjAzNWRiOWFhYmMyYjQxZGE4MGVmZTAzZDdlZGJkODNlL3RleHRyZWdpb246MDM1ZGI5YWFiYzJiNDFkYTgwZWZlMDNkN2VkYmQ4M2VfMTUwMA_63aea6e2-6b5d-4a04-88cc-a614bfc36b90"
      unitRef="usdPerShare">8.442</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="ibd4832dfa32a43a6b0d3e7ac775c2680_D20141101-20141130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81OC9mcmFnOjAzNWRiOWFhYmMyYjQxZGE4MGVmZTAzZDdlZGJkODNlL3RleHRyZWdpb246MDM1ZGI5YWFiYzJiNDFkYTgwZWZlMDNkN2VkYmQ4M2VfMjM1Mw_5d06c895-5be9-465d-bcac-632c52de76e7"
      unitRef="usd">3400000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81OC9mcmFnOjAzNWRiOWFhYmMyYjQxZGE4MGVmZTAzZDdlZGJkODNlL3RleHRyZWdpb246MDM1ZGI5YWFiYzJiNDFkYTgwZWZlMDNkN2VkYmQ4M2VfMjY5OQ_bf329ce5-576f-4d49-8fc8-51e4f7c6db70"
      unitRef="usd">800000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81OC9mcmFnOjAzNWRiOWFhYmMyYjQxZGE4MGVmZTAzZDdlZGJkODNlL3RleHRyZWdpb246MDM1ZGI5YWFiYzJiNDFkYTgwZWZlMDNkN2VkYmQ4M2VfMjgyMg_4a33e44c-f93d-471c-b4b2-3c0d72adeace"
      unitRef="usd">55200000</us-gaap:DebtInstrumentFairValue>
    <lxrx:MortgageDebtInstrument_Revere_LXRX
      contextRef="id80805ff25ba4c6c9ddb0b2c60375c8a_I20180830"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81OC9mcmFnOjAzNWRiOWFhYmMyYjQxZGE4MGVmZTAzZDdlZGJkODNlL3RleHRyZWdpb246MDM1ZGI5YWFiYzJiNDFkYTgwZWZlMDNkN2VkYmQ4M2VfMzQ3MQ_97ffd612-d505-490a-bc7a-5505f23907a0"
      unitRef="usd">12900000</lxrx:MortgageDebtInstrument_Revere_LXRX>
    <lxrx:MortgageDebtInterestRate_Base_Revere_LXRX
      contextRef="id80805ff25ba4c6c9ddb0b2c60375c8a_I20180830"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81OC9mcmFnOjAzNWRiOWFhYmMyYjQxZGE4MGVmZTAzZDdlZGJkODNlL3RleHRyZWdpb246MDM1ZGI5YWFiYzJiNDFkYTgwZWZlMDNkN2VkYmQ4M2VfMzY2MQ_1eae08b7-56c1-437d-b3cd-a09875a3df94"
      unitRef="number">0.055</lxrx:MortgageDebtInterestRate_Base_Revere_LXRX>
    <lxrx:MortgageDebtInterestRateBasePlus_Revere_LXRX
      contextRef="id80805ff25ba4c6c9ddb0b2c60375c8a_I20180830"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81OC9mcmFnOjAzNWRiOWFhYmMyYjQxZGE4MGVmZTAzZDdlZGJkODNlL3RleHRyZWdpb246MDM1ZGI5YWFiYzJiNDFkYTgwZWZlMDNkN2VkYmQ4M2VfMzY3Mg_bb17b621-c61d-4df1-88b8-7e393d9938d2"
      unitRef="number">0.075</lxrx:MortgageDebtInterestRateBasePlus_Revere_LXRX>
    <lxrx:MortgageDebtBalloonPayment_LXRX
      contextRef="id80805ff25ba4c6c9ddb0b2c60375c8a_I20180830"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81OC9mcmFnOjAzNWRiOWFhYmMyYjQxZGE4MGVmZTAzZDdlZGJkODNlL3RleHRyZWdpb246MDM1ZGI5YWFiYzJiNDFkYTgwZWZlMDNkN2VkYmQ4M2VfMzcxMw_da39d526-f441-4e02-8859-33dd8a0e41d5"
      unitRef="usd">10300000</lxrx:MortgageDebtBalloonPayment_LXRX>
    <lxrx:MortgageDebtIssueCosts_Revere_LXRX
      contextRef="id80805ff25ba4c6c9ddb0b2c60375c8a_I20180830"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81OC9mcmFnOjAzNWRiOWFhYmMyYjQxZGE4MGVmZTAzZDdlZGJkODNlL3RleHRyZWdpb246MDM1ZGI5YWFiYzJiNDFkYTgwZWZlMDNkN2VkYmQ4M2VfMzc1NA_3bfa3612-272d-43c2-9b9e-aafc486cc9e5"
      unitRef="usd">400000</lxrx:MortgageDebtIssueCosts_Revere_LXRX>
    <lxrx:MortgageDebtIssueCosts_Revere_LXRX
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81OC9mcmFnOjAzNWRiOWFhYmMyYjQxZGE4MGVmZTAzZDdlZGJkODNlL3RleHRyZWdpb246MDM1ZGI5YWFiYzJiNDFkYTgwZWZlMDNkN2VkYmQ4M2VfNDAyOA_0820e636-713f-44be-aba4-0ab9e3388a39"
      unitRef="usd">100000</lxrx:MortgageDebtIssueCosts_Revere_LXRX>
    <lxrx:MortgageDebtInstrument_Revere_LXRX
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81OC9mcmFnOjAzNWRiOWFhYmMyYjQxZGE4MGVmZTAzZDdlZGJkODNlL3RleHRyZWdpb246MDM1ZGI5YWFiYzJiNDFkYTgwZWZlMDNkN2VkYmQ4M2VfNDEwMA_9e6f5324-87ce-4606-a6f5-bd18e4202389"
      unitRef="usd">10700000</lxrx:MortgageDebtInstrument_Revere_LXRX>
    <lxrx:BuildingsCollateral
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81OC9mcmFnOjAzNWRiOWFhYmMyYjQxZGE4MGVmZTAzZDdlZGJkODNlL3RleHRyZWdpb246MDM1ZGI5YWFiYzJiNDFkYTgwZWZlMDNkN2VkYmQ4M2VfNDI3OQ_8aeb2013-cfb2-4f8f-8897-854496b53343"
      unitRef="usd">59200000</lxrx:BuildingsCollateral>
    <lxrx:LandCollateral
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81OC9mcmFnOjAzNWRiOWFhYmMyYjQxZGE4MGVmZTAzZDdlZGJkODNlL3RleHRyZWdpb246MDM1ZGI5YWFiYzJiNDFkYTgwZWZlMDNkN2VkYmQ4M2VfNDI4Ng_5a484e7f-7006-4f19-ae7b-99b7d611f7c1"
      unitRef="usd">2700000</lxrx:LandCollateral>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i65c277c002ca41af9214fb16de22bcb8_I20171218"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81OC9mcmFnOjAzNWRiOWFhYmMyYjQxZGE4MGVmZTAzZDdlZGJkODNlL3RleHRyZWdpb246MDM1ZGI5YWFiYzJiNDFkYTgwZWZlMDNkN2VkYmQ4M2VfNDc1OA_b08922a2-89da-47d6-8bbd-fadb96984bc2"
      unitRef="usd">150000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81OC9mcmFnOjAzNWRiOWFhYmMyYjQxZGE4MGVmZTAzZDdlZGJkODNlL3RleHRyZWdpb246MDM1ZGI5YWFiYzJiNDFkYTgwZWZlMDNkN2VkYmQ4M2VfNDg4Ng_642e5ee6-fd56-41c2-86ac-318121124c13"
      unitRef="number">0.09</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i65c277c002ca41af9214fb16de22bcb8_I20171218"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81OC9mcmFnOjAzNWRiOWFhYmMyYjQxZGE4MGVmZTAzZDdlZGJkODNlL3RleHRyZWdpb246MDM1ZGI5YWFiYzJiNDFkYTgwZWZlMDNkN2VkYmQ4M2VfNjI4Mg_04739e8f-ab56-4eb5-b4fc-3e51bce9bb90"
      unitRef="usd">4100000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF81OC9mcmFnOjAzNWRiOWFhYmMyYjQxZGE4MGVmZTAzZDdlZGJkODNlL3RleHRyZWdpb246MDM1ZGI5YWFiYzJiNDFkYTgwZWZlMDNkN2VkYmQ4M2VfNjYzMA_275a6efc-49da-403a-9ac0-0f5b6ef1baaf"
      unitRef="usd">2200000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF82MS9mcmFnOjJjY2U0MmJjMWY4ZjQ1ZGI4MTkxYzgzMTJjY2M1MDQyL3RleHRyZWdpb246MmNjZTQyYmMxZjhmNDVkYjgxOTFjODMxMmNjYzUwNDJfMjc1NA_60d0079b-e864-43f9-99c4-1e5bbd50e86f">Commitments and Contingencies&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Legal Proceedings.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&#160;On January 28, 2019, a purported securities class action complaint captioned Daniel Manopla v. Lexicon Pharmaceuticals, Inc., Lonnel Coats, Jeffrey L. Wade and Pablo Lapuerta, M.D. was filed against the Company and certain of its officers in the U.S. District Court for the Southern District of Texas, Houston Division.  A first amended complaint was filed on July 30, 2019 and Lexicon filed a motion to dismiss such first amended complaint on September 30, 2019.  The plaintiff filed an opposition to Lexicon's motion to dismiss on November 14, 2019 and Lexicon filed a reply in support of its motion to dismiss on December 13, 2019.  The lawsuit purports to be a class action brought on behalf of purchasers of the Company&#x2019;s securities during the period from March&#160;11, 2016 through July 29, 2019.  The complaint alleges that the defendants violated federal securities laws by making materially false and misleading statements and/or omissions concerning data from its Phase 3 clinical trials of sotagliflozin in type 1 diabetes patients and the prospects of FDA approval of sotagliflozin for the treatment of type 1 diabetes.  The complaint purports to assert claims for violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.  The complaint seeks, on behalf of the purported class, an unspecified amount of monetary damages, interest, fees and expenses of attorneys and experts, and other relief.&lt;/span&gt;&lt;/div&gt;In addition, Lexicon is from time to time party to claims and legal proceedings that arise in the normal course of its business and that it believes will not have, individually or in the aggregate, a material adverse effect on its results of operations, financial condition or liquidity.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF82NC9mcmFnOjhlNjRhZTVhYWQ2MDQ3OTc5MDBlM2JhMDEzNmRlNzRhL3RleHRyZWdpb246OGU2NGFlNWFhZDYwNDc5NzkwMGUzYmEwMTM2ZGU3NGFfMTk2NDI_4f6dd749-b8ad-40fa-a144-f861f77baf7c">Collaboration and License Agreements&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Lexicon has derived substantially all of its revenues from drug discovery and development alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, product sales, government grants and contracts, technology licenses, subscriptions to its databases and compound library sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Ipsen.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;  In October 2014, Lexicon entered into a License and Collaboration Agreement, which was subsequently amended in March 2015 (collectively, the &#x201c;Ipsen Agreement&#x201d;), with Ipsen for the development and commercialization of XERMELO outside of the United States and Japan (the &#x201c;Licensed Territory&#x201d;).  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the Ipsen Agreement, Lexicon granted Ipsen an exclusive, royalty-bearing right and license under its patent rights and know-how to commercialize XERMELO in the Licensed Territory.  Ipsen is responsible for using diligent efforts to commercialize XERMELO in the Licensed Territory pursuant to a mutually approved commercialization plan.  Subject to certain exceptions, Lexicon was responsible for conducting clinical trials required to obtain regulatory approval for XERMELO for carcinoid syndrome in the European Union, including those contemplated by a mutually approved initial development plan, and has the first right to conduct most other clinical trials of XERMELO.  Lexicon was responsible for the costs of all clinical trials contemplated by the initial development plan. The costs of additional clinical trials will be allocated between the parties based on the nature of such clinical trials.  Under the Ipsen Agreement, Ipsen has paid Lexicon an aggregate of $47.2 million through March&#160;31, 2020, consisting of $24.5 million in upfront payments and a $6.4 million milestone payment upon the acceptance of the filing submitted by Ipsen to the European Medicines Agency for XERMELO as an adjunct to somatostatin analog therapy for the long-term treatment of carcinoid syndrome, a $5.1 million milestone upon Ipsen&#x2019;s receipt of approval from the European Commission for the marketing of XERMELO in all member states of the European Union, Norway and Iceland, a $3.8 million milestone upon Ipsen&#x2019;s first commercial sale in Germany, a $3.8 million milestone upon Ipsen&#x2019;s first commercial sale in the United Kingdom, a $1.3 million milestone upon Ipsen&#x2019;s receipt of approval from Health Canada and a $2.3 million milestone upon Ipsen&#x2019;s first commercial sale in Canada.  In addition, Lexicon is eligible to receive from Ipsen (a) up to an aggregate of approximately $9.6&#160;million upon the achievement of specified regulatory and commercial launch milestones and (b) up to an aggregate of &#x20ac;72&#160;million upon the achievement of specified sales milestones. Milestone payments that are contingent upon the achievement of a substantive milestone are deemed constrained.  Lexicon is also entitled to tiered, escalating royalties ranging from low twenties to mid-thirties percentages of net sales of XERMELO in the Licensed Territory, subject to a credit for amounts previously paid to Lexicon by Ipsen for the manufacture and supply of such units of XERMELO.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Lexicon and Ipsen have entered into a commercial supply agreement pursuant to which Lexicon will supply Ipsen&#x2019;s commercial requirements of XERMELO, and Ipsen pays an agreed upon transfer price for such commercial supply.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company considered the following as its performance obligations with respect to the revenue recognition of the $24.5&#160;million upfront payments: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-36pt;padding-left:72pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;"&gt;The exclusive license granted to Ipsen to develop and commercialize XERMELO in the Licensed Territory;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;"&gt;The development services Lexicon is performing for XERMELO;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-36pt;padding-left:72pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;"&gt;The obligation to participate in committees which govern the development of XERMELO until commercialization; and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;"&gt;The obligation to supply commercial supply of XERMELO, under a commercial supply agreement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company determined that the license had stand-alone value because it is an exclusive license that gives Ipsen the right to develop and commercialize XERMELO or to sublicense its rights.  In addition, at the time of the agreement, it would have been possible for Ipsen or another third party to conduct clinical trials without assistance from Lexicon.  As a result, the Company considers the license and the development services under the Ipsen Agreement to be separate performance obligations.  The Company recognized the portion of the transaction price allocated to the license immediately because Lexicon delivered the license and earned the revenue at the inception of the arrangement.  The Company recognized as revenue the amount allocated to the development services and the obligation to participate in committees over the period of time Lexicon performed the services, which was completed in 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company determined that the commercial supply agreement is a contingent deliverable at the onset of the Agreement.  There was inherent uncertainty in obtaining regulatory approval at the time of the agreement, thus, making the applicability of the commercial supply agreement outside the control of Lexicon and Ipsen.  As a result, the Company has determined the commercial supply agreement does not meet the definition of a performance obligation that needs to be accounted for at the inception of the arrangement.  The Company has also determined that there is no significant and incremental discount related to the commercial supply agreement that should be accounted for at the inception of the arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company determined that the initial transaction price was the $24.5&#160;million upfront payments because they were the only payments that were fixed and determinable at the inception of the arrangement.  There was considerable uncertainty at the date of the agreement as to whether Lexicon would earn milestone payments, royalty payments or payments for finished drug product.  As such, the Company did not include those payments in the transaction price.  The Company allocated the transaction price based on the relative best estimate of selling price of each performance obligation.  The Company estimated the selling price of the license deliverable by applying a probability-based income approach utilizing an appropriate discount rate.  The significant inputs the Company used to determine the projected income of the license included: estimated future product sales, estimated cost of goods sold, estimated operating expenses, income taxes, and an appropriate discount rate.  The Company estimated the selling price of the development services by using internal estimates of the cost to hire third parties to perform the services over the expected period to perform the development.  The Company estimated the selling price of the obligation to participate in committees by using internal estimates of the number of internal hours and salary and benefits costs to perform these services. &lt;/span&gt;&lt;/div&gt;As a result of the allocation, the Company recognized $21.2&#160;million of the $24.5&#160;million upfront payments for the license in 2014, and an additional $1.4&#160;million in 2015 upon entering into the amendment.  The Company recognized the $1.7&#160;million allocated to the development services performance obligation over the period of performance as development occurred, and recognized the $0.1&#160;million allocated to the committee participation performance obligation ratably over the period of performance.  Milestone payments that are contingent upon the achievement of a substantive milestone are deemed constrained.  If or when the constraint is determined to be resolved, the Company will re-evaluate the overall transaction price and recognize an adjustment on a cumulative catch-up basis in the period that the adjustment was evaluated.  Revenue recognized under the Agreement was $0.1&#160;million and $2.4 million for the three months ended March&#160;31, 2020 and 2019, respectively.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <lxrx:IpsenTotalPayments
      contextRef="i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF82NC9mcmFnOjhlNjRhZTVhYWQ2MDQ3OTc5MDBlM2JhMDEzNmRlNzRhL3RleHRyZWdpb246OGU2NGFlNWFhZDYwNDc5NzkwMGUzYmEwMTM2ZGU3NGFfMTMwOTg_c308680c-fc8f-4149-97b4-c106fa0a6454"
      unitRef="usd">47200000</lxrx:IpsenTotalPayments>
    <lxrx:IpsenTotalUpfrontPayments
      contextRef="i723e1df096a74ef3a7ed1c4ee79e00cb_D20150301-20150331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF82NC9mcmFnOjhlNjRhZTVhYWQ2MDQ3OTc5MDBlM2JhMDEzNmRlNzRhL3RleHRyZWdpb246OGU2NGFlNWFhZDYwNDc5NzkwMGUzYmEwMTM2ZGU3NGFfMTMxMjc_e4d9cde2-6244-4716-9383-d97f719ab439"
      unitRef="usd">24500000</lxrx:IpsenTotalUpfrontPayments>
    <lxrx:IpsenMilestonePayment
      contextRef="if2f0442e8e3949d2acab519802cd9a7a_D20160701-20160930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF82NC9mcmFnOjhlNjRhZTVhYWQ2MDQ3OTc5MDBlM2JhMDEzNmRlNzRhL3RleHRyZWdpb246OGU2NGFlNWFhZDYwNDc5NzkwMGUzYmEwMTM2ZGU3NGFfMTMxNTY_d98d939a-db39-4a6b-93ce-5434f92f1b2b"
      unitRef="usd">6400000</lxrx:IpsenMilestonePayment>
    <lxrx:IpsenMilestonePaymentReceived
      contextRef="i9f3132da0556457c978c3721090d9425_D20170701-20170930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF82NC9mcmFnOjhlNjRhZTVhYWQ2MDQ3OTc5MDBlM2JhMDEzNmRlNzRhL3RleHRyZWdpb246OGU2NGFlNWFhZDYwNDc5NzkwMGUzYmEwMTM2ZGU3NGFfMTMzNzM_0ff4595a-e98c-4b62-aa37-fd23c6b857b3"
      unitRef="usd">5100000</lxrx:IpsenMilestonePaymentReceived>
    <lxrx:IpsenMilestonePaymentReceived
      contextRef="i949545145223492aa3a8472aa5f75d6c_D20171001-20171031"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF82NC9mcmFnOjhlNjRhZTVhYWQ2MDQ3OTc5MDBlM2JhMDEzNmRlNzRhL3RleHRyZWdpb246OGU2NGFlNWFhZDYwNDc5NzkwMGUzYmEwMTM2ZGU3NGFfMTM1NDM_f94ab3b4-f2b2-40b1-a26c-933e1eb59f8b"
      unitRef="usd">3800000</lxrx:IpsenMilestonePaymentReceived>
    <lxrx:IpsenMilestonePaymentReceived
      contextRef="icb75b1b2778741648129edca9c77b0d1_D20171101-20171130"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF82NC9mcmFnOjhlNjRhZTVhYWQ2MDQ3OTc5MDBlM2JhMDEzNmRlNzRhL3RleHRyZWdpb246OGU2NGFlNWFhZDYwNDc5NzkwMGUzYmEwMTM2ZGU3NGFfMTM2MDU_9f118d8f-4ee4-4c26-b1d4-ec6d308f02c8"
      unitRef="usd">3800000</lxrx:IpsenMilestonePaymentReceived>
    <lxrx:IpsenMilestonePaymentReceived
      contextRef="i41e7bc56d8f44697acef137f70b02cef_D20190401-20190630"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF82NC9mcmFnOjhlNjRhZTVhYWQ2MDQ3OTc5MDBlM2JhMDEzNmRlNzRhL3RleHRyZWdpb246OGU2NGFlNWFhZDYwNDc5NzkwMGUzYmEwMTM2ZGU3NGFfMTM2Nzg_178fcb02-6b94-4d16-b0f7-818517ba1df0"
      unitRef="usd">1300000</lxrx:IpsenMilestonePaymentReceived>
    <lxrx:IpsenMilestonePaymentReceived
      contextRef="i9940e83a99be4c0db47b16062f8cf74e_D20190201-20190228"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF82NC9mcmFnOjhlNjRhZTVhYWQ2MDQ3OTc5MDBlM2JhMDEzNmRlNzRhL3RleHRyZWdpb246OGU2NGFlNWFhZDYwNDc5NzkwMGUzYmEwMTM2ZGU3NGFfMTM3NTc_4ad2fe41-f459-4649-90fb-9d4fc944d185"
      unitRef="usd">2300000</lxrx:IpsenMilestonePaymentReceived>
    <lxrx:IpsenMaximumRegulatoryAndCommercialMilestones
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF82NC9mcmFnOjhlNjRhZTVhYWQ2MDQ3OTc5MDBlM2JhMDEzNmRlNzRhL3RleHRyZWdpb246OGU2NGFlNWFhZDYwNDc5NzkwMGUzYmEwMTM2ZGU3NGFfMTM5MTI_27e79ba8-14e1-4124-b830-d354daa20c33"
      unitRef="usd">9600000</lxrx:IpsenMaximumRegulatoryAndCommercialMilestones>
    <lxrx:IpsenMaximumSalesMilestones
      contextRef="iace247b45bbe4d50be1b8046b7cf2019_D20141001-20141031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF82NC9mcmFnOjhlNjRhZTVhYWQ2MDQ3OTc5MDBlM2JhMDEzNmRlNzRhL3RleHRyZWdpb246OGU2NGFlNWFhZDYwNDc5NzkwMGUzYmEwMTM2ZGU3NGFfMTQwMjM_1d15da33-5671-4763-8098-b220a829d58d"
      unitRef="eur">72000000</lxrx:IpsenMaximumSalesMilestones>
    <lxrx:IpsenTotalUpfrontPayments
      contextRef="i723e1df096a74ef3a7ed1c4ee79e00cb_D20150301-20150331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF82NC9mcmFnOjhlNjRhZTVhYWQ2MDQ3OTc5MDBlM2JhMDEzNmRlNzRhL3RleHRyZWdpb246OGU2NGFlNWFhZDYwNDc5NzkwMGUzYmEwMTM2ZGU3NGFfMTQ4MTQ_e4d9cde2-6244-4716-9383-d97f719ab439"
      unitRef="usd">24500000</lxrx:IpsenTotalUpfrontPayments>
    <lxrx:IpsenTotalUpfrontPayments
      contextRef="i723e1df096a74ef3a7ed1c4ee79e00cb_D20150301-20150331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF82NC9mcmFnOjhlNjRhZTVhYWQ2MDQ3OTc5MDBlM2JhMDEzNmRlNzRhL3RleHRyZWdpb246OGU2NGFlNWFhZDYwNDc5NzkwMGUzYmEwMTM2ZGU3NGFfMTY4OTQ_e4d9cde2-6244-4716-9383-d97f719ab439"
      unitRef="usd">24500000</lxrx:IpsenTotalUpfrontPayments>
    <lxrx:IpsenRevenueAllocatedtoLicenseDeliverable
      contextRef="i2eee5e8c4bdb4710a81e6835c783b093_D20150101-20150630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF82NC9mcmFnOjhlNjRhZTVhYWQ2MDQ3OTc5MDBlM2JhMDEzNmRlNzRhL3RleHRyZWdpb246OGU2NGFlNWFhZDYwNDc5NzkwMGUzYmEwMTM2ZGU3NGFfMTgyNjc_ae2c8ba6-601d-4ff9-b803-20958cc82046"
      unitRef="usd">21200000</lxrx:IpsenRevenueAllocatedtoLicenseDeliverable>
    <lxrx:IpsenTotalUpfrontPayments
      contextRef="i723e1df096a74ef3a7ed1c4ee79e00cb_D20150301-20150331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF82NC9mcmFnOjhlNjRhZTVhYWQ2MDQ3OTc5MDBlM2JhMDEzNmRlNzRhL3RleHRyZWdpb246OGU2NGFlNWFhZDYwNDc5NzkwMGUzYmEwMTM2ZGU3NGFfMTgyNzc_e4d9cde2-6244-4716-9383-d97f719ab439"
      unitRef="usd">24500000</lxrx:IpsenTotalUpfrontPayments>
    <lxrx:IpsenRevenueAllocatedtoLicenseDeliverable
      contextRef="ic1c464c977e64590a82ac8d115d0d92c_D20160101-20160630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF82NC9mcmFnOjhlNjRhZTVhYWQ2MDQ3OTc5MDBlM2JhMDEzNmRlNzRhL3RleHRyZWdpb246OGU2NGFlNWFhZDYwNDc5NzkwMGUzYmEwMTM2ZGU3NGFfMTgzNDA_f5e10aed-16c7-4398-8774-15f8d762074e"
      unitRef="usd">1400000</lxrx:IpsenRevenueAllocatedtoLicenseDeliverable>
    <lxrx:IpsenRevenueAllocatedtoDevelopmentDeliverable
      contextRef="iace247b45bbe4d50be1b8046b7cf2019_D20141001-20141031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF82NC9mcmFnOjhlNjRhZTVhYWQ2MDQ3OTc5MDBlM2JhMDEzNmRlNzRhL3RleHRyZWdpb246OGU2NGFlNWFhZDYwNDc5NzkwMGUzYmEwMTM2ZGU3NGFfMTg0MTM_f09cf3a2-4375-42dd-88ec-e6d9c6231358"
      unitRef="usd">1700000</lxrx:IpsenRevenueAllocatedtoDevelopmentDeliverable>
    <lxrx:IpsenRevenueAllocatedtoCommitteeDeliverable
      contextRef="iace247b45bbe4d50be1b8046b7cf2019_D20141001-20141031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF82NC9mcmFnOjhlNjRhZTVhYWQ2MDQ3OTc5MDBlM2JhMDEzNmRlNzRhL3RleHRyZWdpb246OGU2NGFlNWFhZDYwNDc5NzkwMGUzYmEwMTM2ZGU3NGFfMTg1NTI_b354899c-c69d-44af-8819-50fa6e5d9780"
      unitRef="usd">100000</lxrx:IpsenRevenueAllocatedtoCommitteeDeliverable>
    <lxrx:IpsenRevenueRecognized
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF82NC9mcmFnOjhlNjRhZTVhYWQ2MDQ3OTc5MDBlM2JhMDEzNmRlNzRhL3RleHRyZWdpb246OGU2NGFlNWFhZDYwNDc5NzkwMGUzYmEwMTM2ZGU3NGFfMTkzNTA_8d7a2893-e77d-4703-9ea3-a43f52b3c343"
      unitRef="usd">100000</lxrx:IpsenRevenueRecognized>
    <lxrx:IpsenRevenueRecognized
      contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF82NC9mcmFnOjhlNjRhZTVhYWQ2MDQ3OTc5MDBlM2JhMDEzNmRlNzRhL3RleHRyZWdpb246OGU2NGFlNWFhZDYwNDc5NzkwMGUzYmEwMTM2ZGU3NGFfMTkzNTc_5406fef8-9e7c-4160-bd33-b25624113b07"
      unitRef="usd">2400000</lxrx:IpsenRevenueRecognized>
    <lxrx:Lxrx_Sanofiterminationcashpayment
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF82NC9mcmFnOjhlNjRhZTVhYWQ2MDQ3OTc5MDBlM2JhMDEzNmRlNzRhL3RleHRyZWdpb246OGU2NGFlNWFhZDYwNDc5NzkwMGUzYmEwMTM2ZGU3NGFfNjU5NzA2OTc4ODIxNQ_89149d9f-aa4f-485d-be70-f2a60dff369a"
      unitRef="usd">208000000</lxrx:Lxrx_Sanofiterminationcashpayment>
    <lxrx:Lxrx_sanofiInitialCashPayment
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF82NC9mcmFnOjhlNjRhZTVhYWQ2MDQ3OTc5MDBlM2JhMDEzNmRlNzRhL3RleHRyZWdpb246OGU2NGFlNWFhZDYwNDc5NzkwMGUzYmEwMTM2ZGU3NGFfNjU5NzA2OTc4ODIzNw_0d19cfc9-d660-48cf-8ea4-9a5d53e9e4e0"
      unitRef="usd">26000000</lxrx:Lxrx_sanofiInitialCashPayment>
    <lxrx:Lxrx_sanofifuturecashpayment
      contextRef="icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF82NC9mcmFnOjhlNjRhZTVhYWQ2MDQ3OTc5MDBlM2JhMDEzNmRlNzRhL3RleHRyZWdpb246OGU2NGFlNWFhZDYwNDc5NzkwMGUzYmEwMTM2ZGU3NGFfNjU5NzA2OTc4ODQ4MA_5e40d93c-ae84-47fd-876c-60196887e578"
      unitRef="usd">26000000</lxrx:Lxrx_sanofifuturecashpayment>
    <lxrx:SanofiRevenueRecognized
      contextRef="i9007b65119964d18952dc8bbfce46ea5_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlOGE2ZDg0ZTVlMjQxNTg4Mzk5YTBjZmQ0NjYwYzE4L3NlYzo0ZThhNmQ4NGU1ZTI0MTU4ODM5OWEwY2ZkNDY2MGMxOF82NC9mcmFnOjhlNjRhZTVhYWQ2MDQ3OTc5MDBlM2JhMDEzNmRlNzRhL3RleHRyZWdpb246OGU2NGFlNWFhZDYwNDc5NzkwMGUzYmEwMTM2ZGU3NGFfNjU5NzA2OTgwMDMzNQ_364c6289-e234-43e2-88f4-259aa2f6c62d"
      unitRef="usd">100000</lxrx:SanofiRevenueRecognized>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6784143216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets-Unaudited - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 55,592<span></span>
</td>
<td class="nump">$ 36,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">193,545<span></span>
</td>
<td class="nump">235,547<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">30,135<span></span>
</td>
<td class="nump">56,532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">4,147<span></span>
</td>
<td class="nump">4,243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">8,195<span></span>
</td>
<td class="nump">5,320<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">291,614<span></span>
</td>
<td class="nump">337,754<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation and amortization of $61,302 and $61,741, respectively</a></td>
<td class="nump">13,582<span></span>
</td>
<td class="nump">14,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">44,543<span></span>
</td>
<td class="nump">44,543<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net of accumulated amortization of $5,444 and $5,003, respectively</a></td>
<td class="nump">19,275<span></span>
</td>
<td class="nump">19,716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,553<span></span>
</td>
<td class="nump">1,655<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">370,567<span></span>
</td>
<td class="nump">417,715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">18,236<span></span>
</td>
<td class="nump">12,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">51,349<span></span>
</td>
<td class="nump">42,151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt, net of deferred issuance costs</a></td>
<td class="nump">10,734<span></span>
</td>
<td class="nump">11,012<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">80,319<span></span>
</td>
<td class="nump">65,341<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of deferred issuance costs</a></td>
<td class="nump">234,488<span></span>
</td>
<td class="nump">234,171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">983<span></span>
</td>
<td class="nump">1,102<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">315,790<span></span>
</td>
<td class="nump">300,614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $.01 par value; 5,000 shares authorized; no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $.001 par value; 225,000 shares authorized; 107,711 and 106,679 shares issued, respectively</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,466,604<span></span>
</td>
<td class="nump">1,462,172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,408,055)<span></span>
</td>
<td class="num">(1,341,444)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="nump">860<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost, 741 and 407 shares, respectively</a></td>
<td class="num">(4,740)<span></span>
</td>
<td class="num">(3,817)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholder's equity (deficit)</a></td>
<td class="nump">54,777<span></span>
</td>
<td class="nump">117,101<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 370,567<span></span>
</td>
<td class="nump">$ 417,715<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6783863408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity/Deficit-Unaudited - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Gain (Loss)</div></th>
<th class="th"><div>Treasury Stock</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance, shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, value at Dec. 31, 2018</a></td>
<td class="num">$ (26,405)<span></span>
</td>
<td class="nump">$ 106<span></span>
</td>
<td class="nump">$ 1,447,954<span></span>
</td>
<td class="num">$ (1,471,577)<span></span>
</td>
<td class="num">$ (12)<span></span>
</td>
<td class="num">$ (2,876)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">3,411<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">3,411<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under Equity Incentive Plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under Equity Incentive Plans, value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(941)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(941)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(21,797)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(21,797)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on investments</a></td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance, shares at Mar. 31, 2019</a></td>
<td class="nump">106,679<span></span>
</td>
<td class="nump">106,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, value at Mar. 31, 2019</a></td>
<td class="num">$ (45,687)<span></span>
</td>
<td class="nump">$ 106<span></span>
</td>
<td class="nump">1,451,365<span></span>
</td>
<td class="num">(1,493,374)<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="num">(3,817)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance, shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, value at Dec. 31, 2019</a></td>
<td class="nump">117,101<span></span>
</td>
<td class="nump">$ 106<span></span>
</td>
<td class="nump">1,462,172<span></span>
</td>
<td class="num">(1,341,444)<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="num">(3,817)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">4,432<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">4,432<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under Equity Incentive Plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under Equity Incentive Plans, value</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(923)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(923)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(66,611)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(66,611)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on investments</a></td>
<td class="nump">$ 776<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">776<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance, shares at Mar. 31, 2020</a></td>
<td class="nump">107,711<span></span>
</td>
<td class="nump">107,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, value at Mar. 31, 2020</a></td>
<td class="nump">$ 54,777<span></span>
</td>
<td class="nump">$ 108<span></span>
</td>
<td class="nump">$ 1,466,604<span></span>
</td>
<td class="num">$ (1,408,055)<span></span>
</td>
<td class="nump">$ 860<span></span>
</td>
<td class="num">$ (4,740)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6615199488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryMajorClassesPolicy', window );">Inventory, Major Classes, Policy [Policy Text Block]</a></td>
<td class="text"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:82.163%;"><tr><td style="width:1.0%;"/><td style="width:51.380%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.689%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:19.886%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.757%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:19.888%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of March 31,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31,</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,218&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,182&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Work-in-process</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,117&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">153&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">812&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">908&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventory</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,147&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,243&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of Significant Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryMajorClassesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the major categories of inventory such as finished goods, inventoried costs relating to long-term contracts or programs, work in process, raw materials, and supplies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryMajorClassesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6773829408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_DebtObligationsAbstract', window );"><strong>Debt Obligations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt Disclosure</a></td>
<td class="text">Debt Obligations<div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Convertible Debt.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> In November 2014, Lexicon completed an offering of $87.5 million in aggregate principal amount of its 5.25% Convertible Senior Notes due 2021 (the &#8220;Convertible Notes&#8221;).  The conversion feature did not meet the criteria for bifurcation as required by generally accepted accounting principles and the entire principal amount was recorded as long-term debt on the Company&#8217;s condensed consolidated balance sheets.  </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Convertible Notes are governed by an indenture (the &#8220;Indenture&#8221;), dated as of November&#160;26, 2014, between the Company and Wells Fargo Bank, N.A., as trustee.  The Convertible Notes bear interest at a rate of 5.25%&#160;per year, payable semiannually in arrears on June&#160;1 and December&#160;1 of each year, beginning on June&#160;1, 2015. The Convertible Notes mature on December&#160;1, 2021. The Company may not redeem the Convertible Notes prior to the maturity date, and no sinking fund is provided for the Convertible Notes.  </span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Holders of the Convertible Notes may convert their Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, the Company will deliver for each $1,000 principal amount of converted Convertible Notes a number of shares of its common stock equal to the conversion rate, as described in the Indenture. The conversion rate is initially 118.4553 shares of common stock per $1,000 principal amount of Convertible Notes (equivalent to an initial conversion price of $8.442 per share of common stock). The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date, the Company will increase the conversion rate for a holder who elects to convert its Convertible Notes in connection with such a corporate event in certain circumstances.</span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If the Company undergoes a fundamental change, holders may require the Company to repurchase for cash all or any portion of their Convertible Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.</span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the issuance of the Convertible Notes, the Company incurred $3.4 million of debt issuance costs.  The debt issuance costs are amortized as interest expense over the expected life of the Convertible Notes using the effective interest method.  The Company determined the expected life of the debt was equal to the seven-year term of the Convertible Notes.  As of March&#160;31, 2020, the balance of unamortized debt issuance costs was $0.8&#160;million, which offsets long-term debt on the condensed consolidated balance sheets.  As of March&#160;31, 2020, the carrying value of the Convertible Notes was $86.7 million.</span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of the Convertible Notes was $55.2&#160;million as of March&#160;31, 2020 and was determined using Level&#160;2 inputs based on the indicative pricing published by certain investment banks or trading levels of the Convertible Notes, which are not listed on any securities exchange or quoted on an inter-dealer automated quotation system.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Mortgage Loan.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;In August 2018, a wholly owned subsidiary of Lexicon entered into a term loan and security agreement, refinancing the previously existing mortgage on its facilities in The Woodlands, Texas (the &#8220;Property&#8221;).  The loan agreement provides for a $12.9 million mortgage on the Property and has a two-year term with a 10-year amortization.  The mortgage loan bears interest at a rate per annum equal to the greater of (a) the 30-day LIBOR rate plus 5.5% and (b) 7.5% and provides for a balloon payment of $10.3 million due in August 2020.  Lexicon incurred $0.4 million of debt issuance costs in connection with the mortgage loan, which offsets the current portion of long-term debt on the condensed consolidated balance sheets and are amortized as interest expense over the two-year term of the loan agreement.  As of March&#160;31, 2020, the balance of unamortized debt issuance costs was $0.1 million.  The condensed consolidated balance sheet includes mortgage debt, the carrying value of the debt, of $10.7 million as of March&#160;31, 2020 and is included in current portion of long-term debt.  The buildings and land that serve as collateral for the mortgage loan are included in property and equipment at $59.2&#160;million and $2.7&#160;million, respectively, before accumulated depreciation, as of March&#160;31, 2020.  The fair value of the loan agreement approximates its carrying value.&#160;&#160;The fair value of the loan agreement was determined using Level&#160;2 inputs using discounted cash flow analysis, based on the Company&#8217;s estimated current incremental borrowing rate.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2020, Lexicon's wholly owned subsidiary entered into a real estate purchase and sale agreement under which Lexicon agreed to sell its facilities in The Woodlands, Texas.  Such sale is subject to normal and customary closing conditions, including a study period, which extends until June 8, 2020, during which the purchaser may conduct inspections, analyses and other studies of the property and may terminate the agreement in its discretion.  Such sale is also subject to the negotiation and execution by the parties of a leaseback agreement for a period of up to six months with respect to a portion of the property concurrently with closing.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">BioPharma Term Loan.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;In December 2017, Lexicon entered into a loan agreement with BioPharma Credit PLC and BioPharma Credit Investments IV Sub LP under which $150.0 million was funded in December 2017 (the &#8220;BioPharma Term Loan&#8221;). The BioPharma Term Loan matures in December 2022, bears interest at 9% per year, subject to additional interest if an event of default occurs and is continuing, and is payable quarterly. </span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The BioPharma Term Loan is subject to mandatory prepayment provisions that require prepayment upon a change of control or receipt of proceeds from certain non-ordinary course transfers of assets.  The Company may prepay the BioPharma Term Loan in whole at its option at any time.  Any prepayment of the BioPharma Term Loan is subject to customary make-whole premiums and prepayment premiums.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s obligations under the BioPharma Term Loan are secured by a first lien security interest in substantially all of the assets of the Company and certain of its subsidiaries, other than its facilities in The Woodlands, Texas.  The loan agreement contains certain customary representations and warranties, affirmative and negative covenants and events of default applicable to the Company and certain of its subsidiaries, including among other things, covenants restricting dispositions, fundamental changes in the business, mergers or acquisitions, indebtedness, encumbrances, distributions, investments, transactions with affiliates and subordinated debt.  If an event of default occurs and is continuing, all amounts outstanding under the BioPharma Term Loan may be declared immediately due and payable.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the BioPharma Term Loan, the Company incurred $4.1 million of debt issuance costs.  The debt issuance costs are amortized as interest expense over the expected life of the BioPharma Term Loan using the effective interest method.  The Company determined the expected life of the debt was equal to the five-year term of the BioPharma Term Loan. As of March&#160;31, 2020, the balance of unamortized debt issuance costs was $2.2 million, which offsets long-term debt on the </span></div>condensed consolidated balance sheets.  As of March&#160;31, 2020, the carrying value of the BioPharma Term Loan was $147.8 million.The fair value of the BioPharma Term Loan approximates its carrying value.  The fair value of the BioPharma Term Loan was determined using Level&#160;2 inputs using discounted cash flow analysis, based on the Company&#8217;s estimated current incremental borrowing rate.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DebtObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Obligations [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_DebtObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6611506256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Equity Incentive Awards (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract', window );"><strong>Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:50.422%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.069%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.719%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.838%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.016%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected Volatility</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free Interest Rate</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected Term</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dividend<br/>Rate</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employees</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">89&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Officers and non-employee directors</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">77&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2019:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employees</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Officers and non-employee directors</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-based Payment Arrangement, Option, Activity [Table Text Block]</a></td>
<td class="text"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:66.035%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.929%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.570%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,695&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.95&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,301&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.31&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expired</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(202)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.30&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(73)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at March 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,721&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.11&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable at March 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,731&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.83&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</a></td>
<td class="text"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:65.008%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.929%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.597%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,830&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.35&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,060&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.31&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,032)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.02&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(34)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.28&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at March 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,824&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.29&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6611485088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure</a></td>
<td class="text">Commitments and Contingencies<div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Legal Proceedings.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;On January 28, 2019, a purported securities class action complaint captioned Daniel Manopla v. Lexicon Pharmaceuticals, Inc., Lonnel Coats, Jeffrey L. Wade and Pablo Lapuerta, M.D. was filed against the Company and certain of its officers in the U.S. District Court for the Southern District of Texas, Houston Division.  A first amended complaint was filed on July 30, 2019 and Lexicon filed a motion to dismiss such first amended complaint on September 30, 2019.  The plaintiff filed an opposition to Lexicon's motion to dismiss on November 14, 2019 and Lexicon filed a reply in support of its motion to dismiss on December 13, 2019.  The lawsuit purports to be a class action brought on behalf of purchasers of the Company&#8217;s securities during the period from March&#160;11, 2016 through July 29, 2019.  The complaint alleges that the defendants violated federal securities laws by making materially false and misleading statements and/or omissions concerning data from its Phase 3 clinical trials of sotagliflozin in type 1 diabetes patients and the prospects of FDA approval of sotagliflozin for the treatment of type 1 diabetes.  The complaint purports to assert claims for violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.  The complaint seeks, on behalf of the purported class, an unspecified amount of monetary damages, interest, fees and expenses of attorneys and experts, and other relief.</span></div>In addition, Lexicon is from time to time party to claims and legal proceedings that arise in the normal course of its business and that it believes will not have, individually or in the aggregate, a material adverse effect on its results of operations, financial condition or liquidity.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6761713040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents</a></td>
<td class="nump">$ 55,592<span></span>
</td>
<td class="nump">$ 36,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Short-term Investments</a></td>
<td class="nump">193,545<span></span>
</td>
<td class="nump">235,547<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total Cash and Cash Equivalents and Investments</a></td>
<td class="nump">249,137<span></span>
</td>
<td class="nump">271,659<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents</a></td>
<td class="nump">55,592<span></span>
</td>
<td class="nump">36,112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Short-term Investments</a></td>
<td class="nump">193,545<span></span>
</td>
<td class="nump">235,547<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total Cash and Cash Equivalents and Investments</a></td>
<td class="nump">249,137<span></span>
</td>
<td class="nump">271,659<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Short-term Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total Cash and Cash Equivalents and Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Short-term Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total Cash and Cash Equivalents and Investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6783213936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Stock-based Compensation Valuation (Details) - Equity Option [Member]<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, ExpectedVolatilityRate, Employees</a></td>
<td class="nump">89.00%<span></span>
</td>
<td class="nump">63.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors</a></td>
<td class="nump">77.00%<span></span>
</td>
<td class="nump">63.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the employees' option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the officers' and non-employee directors' option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected term assumption that is used in valuing an option on its own shares for employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected term assumption that is used in valuing an option on its own shares for officers and non-employee directors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For officers and non-employee directors, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For employees, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares for employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares for officers and non-employee directors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6784437472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets Parentheticals - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ConsolidatedBalanceSheetsAbstract', window );"><strong>Consolidated Balance Sheets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization, property and equipment</a></td>
<td class="nump">$ 61,302<span></span>
</td>
<td class="nump">$ 61,741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated intangible assets amortization</a></td>
<td class="nump">$ 5,444<span></span>
</td>
<td class="nump">$ 5,003<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value per share</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">225,000<span></span>
</td>
<td class="nump">225,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">107,711<span></span>
</td>
<td class="nump">106,679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares</a></td>
<td class="nump">741<span></span>
</td>
<td class="nump">407<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ConsolidatedBalanceSheetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consolidated Balance Sheets [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ConsolidatedBalanceSheetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6761411152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (66,611)<span></span>
</td>
<td class="num">$ (21,797)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">906<span></span>
</td>
<td class="nump">901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">4,432<span></span>
</td>
<td class="nump">3,411<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">362<span></span>
</td>
<td class="nump">346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">(Increase) decrease in accounts receivable</a></td>
<td class="nump">26,397<span></span>
</td>
<td class="nump">1,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">(Increase) decrease in inventory</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">(Increase) decrease in prepaid expenses and other current assets</a></td>
<td class="num">(2,875)<span></span>
</td>
<td class="num">(2,018)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Decrease in other assets</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Decrease in accounts payable and other liabilities</a></td>
<td class="nump">15,137<span></span>
</td>
<td class="num">(8,171)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Decrease in deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="num">(22,054)<span></span>
</td>
<td class="num">(25,620)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(70)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(33,222)<span></span>
</td>
<td class="num">(87,256)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Maturities of investments</a></td>
<td class="nump">76,000<span></span>
</td>
<td class="nump">79,600<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="nump">42,778<span></span>
</td>
<td class="num">(7,726)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="num">(923)<span></span>
</td>
<td class="num">(941)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of debt borrowings, net of fees</a></td>
<td class="num">(321)<span></span>
</td>
<td class="num">(321)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(1,244)<span></span>
</td>
<td class="num">(1,262)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">19,480<span></span>
</td>
<td class="num">(34,608)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">36,112<span></span>
</td>
<td class="nump">80,386<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">55,592<span></span>
</td>
<td class="nump">45,778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">$ 3,658<span></span>
</td>
<td class="nump">$ 3,698<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>27
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MUQ]^-V'?6K=W_]CX*JAJ^'47Z@M02P,$%     @ CX*;4)E<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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MGW#VB>=:^NXC3,!]PMDGGFOINX\P ?<)9Y]XKC/??80);0UP]HGG.O/=1YB
M^X2S3SS7F>\^PH3<Q]DGGNN,N0\P(?=Q]HGG.F/N TS(?9Q]XKG.F?L<$U3!
MV2>>Z]S?5B!,8%]!./O$<YW[.PN "?WO2YQ]R7.=^^\8P 15</8ESW7N;V$
M)JB"LR]YKG/O35X/F-QAFF%+.9E/YO.I'\[DIA6I5;MW75L7;?2I<2WCS>C8
M&3ZXQC#Y"[^VE5^+=E\V7?2BC6V(7-NRT]HH.Z/TSL[E8#O9\:)2.].?3NUY
M>VWGKA=&'X=6-1G[Y=4?4$L#!!0    ( (^"FU#>QD0""00  -42   8
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M"   &    'AL+W=O<FMS:&5E=',O<VAE970S+GAM;(66;Z^;(!3&OXKQ U3
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M:&5E=',O<VAE970U+GAM;'U4VXZ;,!3\%8L/6(=;=AL!TI*J:J56BK9J^^S
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M?31S.9S!8:%%-UXO>+KCLK]02P,$%     @ CX*;4&_8#K])!   LA8  !@
M  !X;"]W;W)K<VAE971S+W-H965T-BYX;6R-F%USJS80AO^*A_L<D! 2SMB>
MJ1U#.]/.9$ZG[36QY=ASP+A XM-_7_$1)]I=(VYB0Y[=E=X5Z+46U[+Z41^U
M;F8_B_Q<+[UCTUP>?;_>'761U=_*BSZ;_QS*JL@:<UF]^O6ETMF^"RIRGP>!
M](OL=/96B^[><[5:E&]-?CKKYVI6OQ5%5OVWUGEY77K,^[CQ_?1Z;-H;_FIQ
MR5[UG[KYZ_)<F2O_EF5_*O2Y/I7G6:4/2^\7]ICR+J C_C[I:_WE^ZR=RDM9
M_F@O?MLOO: =D<[UKFE39.;C76]TGK>9S#C^'9)ZMYIMX-?O']F3;O)F,B]9
MK3=E_L]IWQR77NS-]OJ0O>7-]_+ZJQXF%'FS8?:_ZW>=&[P=B:FQ*_.Z^SO;
MO=5-60Q9S%"*[&?_>3IWG]<A_T<8'<"' 'X+8.,!X1 0?@:$HP%B"!"W *Y&
M Z(A(/H,&!^2' +D+4"(T0 U!*C/.41= WMUNW8]94VV6E3E=5;U*^Z2M0N;
M/2JS(';MS:[_W?],QVIS]WW%N%SX[VVB@5GW#+<893,;BHEMYHEBYC:S)9@P
ML)F$8IC-I!3#;XQO-+D)PTEA>)= 6 E",.F>B3KFW#.!9/).G9"L$Q)U!&A
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M=',O<VAE970Q,2YX;6QM4]MNG# 0_17+'Q#O DE7*T#*IHI2J956J=H^>V$
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M>);\=WTQU3[>Q-$%KNS.S8OLOL 0T#*.ANB_P0.XA3M/K$8IN?;?J+QK(\7
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M:&5E=#(R+GAM;(V786^;,!"&_PKB!P ^ S95$JG--&W2)E6;MGVFB9.@ L[
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M-&/?04HE=#-)I-V>]"^!^:$6!S7<,GW?C>/P^*#D>1KUX_GWQN8O4$L#!!0
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M)A4[J&Z8Z['HF]Y^HGAK&_IP^%>Q_@]02P,$%     @ CX*;4&I^.[)C P
MJ@X  !D   !X;"]W;W)K<VAE971S+W-H965T,C<N>&ULC5?M<J(P%'T5A@=8
MN'SKJ#/5?MA6.YWN[.YOJE&9 G$A:O?M-X%((=SL\D<@G'//#3?WF$PNM/@H
M#X0PXS-+\W)J'A@[CBVKW!Q(%I??Z)'D_,V.%EG,^&.QM\IC0>)M1<I2R['M
MP,KB)#=GDVKLM9A-Z(FE24Y>"Z,\95E<_)F3E%ZF)IC7@;=D?V!BP)I-CO&>
M?"?LQ_&UX$]6$V6;9"0O$YH;!=E-S1L8OT H"!7B9T(N9>O>$%-YI_1#/#QN
MIZ8M,B(IV3 1(N:7,UF0-!61>!Z_95"ST13$]OTU^GTU>3Z9][@D"YK^2K;L
M,#4CT]B277Q*V1N]+(F<D&\:<O8K<B8IAXM,N,:&IF7U:VQ.):.9C,)3R>+/
M^IKDU?52OPE#2<,)CB0X#<&!?Q)<27"'$CQ)\(82?$GPAQ("20B&$D))"(<2
M(DF(AA)&DC :2@#[6CE[,*4I-@RF7,L-@^L-UX+#X(K#M>2@UMRJEV_5#[<Q
MBV>3@EZ,HF[I8RR< \:<Q8.+T:K#JI>\)TH^>IZYKCNQSB*2Q,QKC-/&V%X7
ML^QCH(M8(U'<KR@63[/)U4%SG3M(!+^KLL P01=SBV'"+N8.PT1=S#V&&74Q
M#PC&LY5OAV!L)>='+([RA9\PC-/%/&,8I=XK#*/4>XUAE%J\8)@ K[B+KTZW
MBN"V5]5($\'#(WA5!*^3@U+K98T)*DQ>81P[LFT;%_)Q(1\14A;,LL;X;:%
MJQ/@.@&BHRRZIZ W(="IA+A*V%?QU64;]F;CA8Y.)\)U(D1'6=;+J*<S"G0R
M(UQFA,@HG?%08\!IZ80.KB+^05 SM1$=I;ON)*BSW#Q?-R'0^38@4DJ3KB2H
M+15X6B7<=6_ 09245I]+4&=2KJVLF 6"<B,5=3L(]8B@H*?XC*!\;2^ QH7
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M>VX"#P2WC4H9C?IQJ&Z'NZ.<X&GIH1&>VBK^!"=O%L2B.$C6JS5?$D%>O%@
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MY=]?WKQ]^>8]R*[CTZ/G:K_2:5[!=!7J/-7R,3UP*S.0-->(IDG&Z(6#POZ
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M%@<<A9;%S/TUD"^*2A>0DPEV2ZQ 9P6:'-SD\[H(D!TG>.PV:+:$QV!5CX8
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MWC(KIA E0DQ:)&^E^WX=P9:]!123B 060[%,Q;F?'\CHH.>#6 (R_)/'>0U
MR"#6*^''?';'CP-(8!C3,W>FW[O3NDG*3X,%CF'SU&_PHNR[%+)Z)6%^C;%A
M2,->U=FY^IT:#P_ASR-*D!A/GL._WR^ I)AH@0Q(G44DUJM1F#H]I4^/X,\S
M[U-_+EJ^G>L$9YD,C[]@+OGTI#'7A^ R$@J<=,DJP97:N DV?#4#PGNK%*PQ
M*3:,_M]T;\_4>[GQ'P0TU(6 QDN#[=?D0VF$IWF5S"1)-0SG5:?1R?FQVE-G
M0_CK.P&GP^AP-%:'P\,Q7CT)*/NPC ,UAM]&2.86FL+#]D\/X<?Q<#QJSM2
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M7]Z\9QJPY* U9%,R"T<!S$U1G2Q_L+7O^(QT"P1-"59.D6_4PX*K(!NTP)V
MG1,-@56!/,9.S=; 3!69&'K'+"=*]?4J%Z%MDO%LV QFAJ ?%H8F"[;U:S9J
M+4G&HG]*;BD@HRFL\U'U6+/='<[UFI0>T6"3E4[9C4=4&X6O>&:C66E!MN5
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M+G)E;'-02P$"% ,4    " "/@IM0)^B'#H(   "Q    $
M@ 'I    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( (^"FU!F</: [P
M "L"   1              "  9D!  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( (^"FU"97)PC$ 8  )PG   3              "  ;<"  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ CX*;4,0T3RXO P  .P\  !@
M             ( !^ @  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4
M Q0    ( (^"FU#>QD0""00  -42   8              "  5T,  !X;"]W
M;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " "/@IM0[;LJX&P"  "W
M"   &               @ &<$   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL
M4$L! A0#%     @ CX*;4!312JMM P  (@X  !@              ( !/A,
M 'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( (^"FU#)D!,2
M\ $  .\$   8              "  >$6  !X;"]W;W)K<VAE971S+W-H965T
M-2YX;6Q02P$"% ,4    " "/@IM0;]@.OTD$  "R%@  &
M@ $'&0  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ CX*;
M4.>I*;'B P  :!$  !@              ( !AAT  'AL+W=O<FMS:&5E=',O
M<VAE970W+GAM;%!+ 0(4 Q0    ( (^"FU!BAIQMM@$  -(#   8
M      "  9XA  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M" "/@IM0JGK %[<!  #2 P  &               @ &*(P  >&PO=V]R:W-H
M965T<R]S:&5E=#DN>&UL4$L! A0#%     @ CX*;4%8]AEVV 0  T@,  !D
M             ( !=R4  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"
M% ,4    " "/@IM0TNGN*K8!  #2 P  &0              @ %D)P  >&PO
M=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( (^"FU#7\+C3MP$
M -(#   9              "  5$I  !X;"]W;W)K<VAE971S+W-H965T,3(N
M>&UL4$L! A0#%     @ CX*;4'TNP?RV 0  T@,  !D              ( !
M/RL  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " "/@IM0
MB$\H\+<!  #2 P  &0              @ $L+0  >&PO=V]R:W-H965T<R]S
M:&5E=#$T+GAM;%!+ 0(4 Q0    ( (^"FU#'0U7>+P(  &P'   9
M      "  1HO  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%
M  @ CX*;4,/;]O"V 0  T@,  !D              ( !@#$  'AL+W=O<FMS
M:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " "/@IM0K1=M0\X!  "<!
M&0              @ %M,P  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+
M 0(4 Q0    ( (^"FU ;!O,PL@$  -(#   9              "  7(U  !X
M;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ CX*;4">%P2&W
M 0  T@,  !D              ( !6S<  'AL+W=O<FMS:&5E=',O<VAE970Q
M.2YX;6Q02P$"% ,4    " "/@IM0YFJKC 0"  #)!0  &0
M@ %).0  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( (^"
MFU#?$WLI4@(  "H(   9              "  80[  !X;"]W;W)K<VAE971S
M+W-H965T,C$N>&UL4$L! A0#%     @ CX*;4,=CMV\: P  >PP  !D
M         ( !#3X  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
M    " "/@IM0Q5],Z!(#  #S#0  &0              @ %>00  >&PO=V]R
M:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( (^"FU!)$]B+V0$  %X$
M   9              "  :=$  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL
M4$L! A0#%     @ CX*;4* /G8&J @  9@L  !D              ( !MT8
M 'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " "/@IM0F9HD
MO1D#  !A#   &0              @ &820  >&PO=V]R:W-H965T<R]S:&5E
M=#(V+GAM;%!+ 0(4 Q0    ( (^"FU!J?CNR8P,  *H.   9
M  "  >A,  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @
MCX*;4)17G%L@1   '@@! !0              ( !@E   'AL+W-H87)E9%-T
M<FEN9W,N>&UL4$L! A0#%     @ CX*;4!IW@IIY @  F@T   T
M     ( !U)0  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " "/@IM0HWLH(>H"
M   $$P  #P              @ %XEP  >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ CX*;4.+-MX%< 0  9A$  !H              ( !CYH  'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ CX*;4,<\J;]_ 0
M.1(  !,              ( !(YP  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2     "0 ) "N"0  TYT

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>73</ContextCount>
  <ElementCount>268</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>15</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="lxrx-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="lxrx-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Consolidated Balance Sheets-Unaudited</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Consolidated Balance Sheets-Unaudited</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="lxrx-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Consolidated Balance Sheets Parentheticals</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals</Role>
      <ShortName>Consolidated Balance Sheets Parentheticals</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="lxrx-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Consolidated Statements of Comprehensive Loss-Unaudited</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss-Unaudited</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="lxrx-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Consolidated Statements of Comprehensive Loss Parentheticals</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss Parentheticals</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="lxrx-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Consolidated Statements of Stockholders' Equity/Deficit-Unaudited</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity/Deficit-Unaudited</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="lxrx-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="lxrx-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Summary of Significant Accounting Policies (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes</Role>
      <ShortName>Summary of Significant Accounting Policies (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="lxrx-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2109102 - Disclosure - Recent Accounting Pronouncements Level 1 (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes</Role>
      <ShortName>Recent Accounting Pronouncements Level 1 (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="lxrx-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2110103 - Disclosure - Cash and Cash Equivalents and Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments</Role>
      <ShortName>Cash and Cash Equivalents and Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="lxrx-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2114104 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="lxrx-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2117105 - Disclosure - Debt Obligations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/DebtObligations</Role>
      <ShortName>Debt Obligations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="lxrx-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2120106 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="lxrx-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2121107 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CollaborationandLicenseAgreements</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="lxrx-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="lxrx-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="lxrx-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2304302 - Disclosure - Summary of Significant Accounting Policies Equity Incentive Awards (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables</Role>
      <ShortName>Summary of Significant Accounting Policies Equity Incentive Awards (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="lxrx-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2311303 - Disclosure - Cash and Cash Equivalents and Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables</Role>
      <ShortName>Cash and Cash Equivalents and Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="lxrx-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2315304 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/FairValueMeasurements</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="lxrx-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2405401 - Disclosure - Summary of Significant Accounting Policies Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="lxrx-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation Valuation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Stock-based Compensation Valuation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="lxrx-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation Summary (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1</Role>
      <ShortName>Summary of Significant Accounting Policies Stock-based Compensation Summary (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="lxrx-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Cash and Cash Equivalents and Investments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1</Role>
      <ShortName>Cash and Cash Equivalents and Investments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="lxrx-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2413407 - Disclosure - Cash and Cash Equivalents and Investments (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2</Role>
      <ShortName>Cash and Cash Equivalents and Investments (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="lxrx-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2416408 - Disclosure - Fair Value Measurements (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/FairValueMeasurementsDetails1</Role>
      <ShortName>Fair Value Measurements (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="lxrx-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - Debt Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/DebtObligationsDetails</Role>
      <ShortName>Debt Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/DebtObligations</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="lxrx-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2423410 - Disclosure - Collaboration and License Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails</Role>
      <ShortName>Collaboration and License Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/CollaborationandLicenseAgreements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="lxrx-20200331.htm">lxrx-20200331.htm</File>
    <File>exh101realestateagrame.htm</File>
    <File>exh102realestateagrame.htm</File>
    <File>exh311certificationofp.htm</File>
    <File>exh312certificationofp.htm</File>
    <File>exh321certificationofp.htm</File>
    <File>lxrx-20200331.xsd</File>
    <File>lxrx-20200331_cal.xml</File>
    <File>lxrx-20200331_def.xml</File>
    <File>lxrx-20200331_lab.xml</File>
    <File>lxrx-20200331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6773783824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_FairValueMeasurementsAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Fair Value, by Balance Sheet Grouping [Table Text Block]</a></td>
<td class="text"><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:45.723%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.334%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.334%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.334%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.339%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets and Liabilities at Fair Value as of March 31, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55,592&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55,592&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">193,545&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">193,545&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">249,137&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">249,137&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:45.723%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.334%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.334%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.334%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.339%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets and Liabilities at Fair Value as of December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,112&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,112&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">235,547&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">235,547&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">271,659&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">271,659&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_FairValueMeasurementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_FairValueMeasurementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6761664480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation, Policy [Policy Text Block]</a></td>
<td class="text">The accompanying condensed consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries. Intercompany transactions and balances are eliminated in consolidation.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Use of Estimates:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The preparation of financial statements in conformity with U. S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cash, Cash Equivalents and Short-Term Investments:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of March&#160;31, 2020 and December&#160;31, 2019, short-term investments consisted of U.S. treasury bills.  The Company&#8217;s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security.&#160;&#160;Unrealized gains and losses on such securities are reported as a separate component of stockholders&#8217; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable [Policy Text Block]</a></td>
<td class="text"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Accounts Receivable:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;Lexicon records trade accounts receivable in the normal course of business related to the sale of products or services, net of an allowance for expected credit losses.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory, Policy [Policy Text Block]</a></td>
<td class="text"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Inventory: </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Inventory is comprised of the Company&#8217;s approved product it is commercializing in the United States, XERMELO</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174; </sup>(telotristat ethyl).  Inventories are determined at the lower of cost or market value with cost determined under the specific identification method and may consist of raw materials, work in process and finished goods.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue [Policy Text Block]</a></td>
<td class="text"><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue Recognition:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Product Revenues</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Product revenues consist of commercial sales of XERMELO in the United States and sales of bulk tablets of XERMELO to Ipsen Pharma SAS (&#8220;Ipsen&#8221;).  Product revenues are recognized when the customer obtains control of the Company&#8217;s product, which occurs upon delivery to the customer.  The Company recognizes product revenue net of applicable reserves for variable consideration, including allowances for customer credits, estimated rebates, chargebacks, discounts, returns, distribution service fees, and government rebates, such as Medicare Part D coverage gap reimbursements in the U.S.  These estimates are based on the most likely amount method for relevant factors such as current contractual and statutory requirements, industry data and forecasted customer buying and payment patterns.  The Company&#8217;s net product revenues reflect the Company&#8217;s best estimates of the amounts of consideration to which it is entitled based on the terms of the respective underlying contracts.  Product shipping and handling costs are considered a fulfillment activity when control transfers to the Company&#8217;s customers and such costs are included in cost of sales.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#160;&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Collaborative Agreements</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues under collaborative agreements include both license revenue and contract research revenue.  The Company performs the following five steps in determining the amount of revenue to recognize as it fulfills its performance obligations under each of its agreements:  (i) identify the contract(s) with a customer; (ii) identify the performance obligation in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation.  The Company applies this five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.  At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct.  The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.  The Company develops assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At contract inception, the Company evaluates whether development milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.  If it is probable that a significant revenue reversal will not occur, the associated development milestone value is included in the transaction price.  Development milestones that are not within the control of the Company or the licensee, including those requiring regulatory approval, are not considered probable of being achieved until those approvals are received.  The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue when (or as) the performance obligation is satisfied.  At the end of each reporting period, the Company re-evaluates the probability of achievement of the development milestones and any related constraint, and if necessary, adjusts its estimates of the overall transaction price.  Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In agreements in which a license to the Company&#8217;s intellectual property is determined distinct from other performance obligations identified in the agreement, the Company recognizes revenue when the license is transferred to the licensee and the licensee is able to use and benefit from the license.  </span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For agreements that include sales-based royalties, including milestones based on a level of sales, the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div>The Company may receive payments from its licensees based on billing schedules established in each contract.  Up-front payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these agreements.  Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Goods and Service [Policy Text Block]</a></td>
<td class="text">Cost of Sales:  Cost of sales consists of third-party manufacturing costs, freight and indirect overhead costs associated with sales of XERMELO. Product shipping and handling costs are included in cost of sales. Cost of sales also includes the amortization of the in-process research and development intangible asset for XERMELO using the straight-line method over the estimated useful life of 14 years.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Research and Development Expenses:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#8217;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company&#8217;s estimates of the clinical study costs and costs to transition activities from Sanofi for development of sotagliflozin for type 2 diabetes, heart failure and chronic kidney disease, including the costs to close out those studies, were based on actual costs incurred for activities completed subsequent to the transition date and estimates of the services to be received and efforts to be expended pursuant to contracts with multiple vendors and the CRO that has conducted and managed and is now closing out the clinical studies on its behalf.  The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#8217;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Payment Arrangement [Policy Text Block]</a></td>
<td class="text"><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Stock-Based Compensation:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;The Company recognizes compensation expense in its condensed consolidated statements of comprehensive loss for share-based payments, including stock options and restricted stock units issued to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div>The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#8217;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in a change in the assumptions used for expected option lives.&#160;&#160;Historical data is used to estimate the expected option life for each group.  Expected volatility is based on the historical volatility in the Company&#8217;s stock price.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text">Net Loss per Common Share: Net loss per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with convertible debt, stock options and restricted stock units are not included because they are antidilutive.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of Significant Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI http://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=SL6953423-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5033-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5212-111524<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5093-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6611357936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_FairValueMeasurementsAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">Fair Value, Measurement Inputs, Disclosure</a></td>
<td class="text">Fair Value Measurements<div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis.  Assets and liabilities recorded at fair value in the condensed consolidated balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value.  The following levels are directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities:</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 1 - quoted prices in active markets for identical investments, which include U.S. treasury securities </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 2 - other significant observable inputs (including quoted prices for similar investments, market corroborated inputs, etc.), which includes corporate debt securities</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 3 - significant unobservable inputs </span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The inputs or methodology used for valuing securities are not necessarily an indication of the credit risk associated with investing in those securities.  The following table provides the fair value measurements of applicable Company assets that are measured at fair value on a recurring basis according to the fair value levels defined above as of March&#160;31, 2020 and December&#160;31, 2019.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:45.723%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.334%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.334%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.334%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.339%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets and Liabilities at Fair Value as of March 31, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55,592&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55,592&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">193,545&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">193,545&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">249,137&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">249,137&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:45.723%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.334%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.334%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.334%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.339%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets and Liabilities at Fair Value as of December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,112&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,112&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">235,547&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">235,547&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">271,659&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">271,659&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company did not have any Level 3 assets or liabilities as of March&#160;31, 2020 or December&#160;31, 2019. Transfers between levels are recognized at the actual date of circumstance that caused the transfer.  There were no transfers between Level 1 and Level 2 during the periods presented.</span></div><div style="text-indent:36pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company also has assets that under certain conditions are subject to measurement at fair value on a non-recurring basis.  These assets include goodwill associated with the acquisitions of Coelacanth Corporation in 2001 and Symphony Icon in 2010, and intangible assets associated with the acquisition of Symphony Icon in 2010. For these assets, measurement at fair value in periods subsequent to their initial recognition is applicable if one or more is determined to be impaired.</span></div><div style="text-indent:36pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Refer to Note 5, Debt Obligations, for fair value measurements of debt obligations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_FairValueMeasurementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_FairValueMeasurementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementInputsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6783541440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements (Details)<br> $ in Thousands, &#8364; in Millions</strong></div></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2014 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration and License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_Lxrx_Sanofiterminationcashpayment', window );">Sanofi termination cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 208,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_Lxrx_sanofifuturecashpayment', window );">Sanofi future cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SanofiRevenueRecognized', window );">Sanofi Revenue Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenTotalPayments', window );">Ipsen Total Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones', window );">Ipsen Maximum Regulatory And Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenMaximumSalesMilestones', window );">Ipsen Maximum Sales Milestones | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenTotalUpfrontPayments', window );">Ipsen Total Upfront Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenMilestonePayment', window );">Ipsen Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenMilestonePaymentReceived', window );">Ipsen Milestone Payment Received</a></td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable', window );">Ipsen Revenue Allocated to License Deliverable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="nump">$ 21,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable', window );">Ipsen Revenue Allocated to Development Deliverable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable', window );">Ipsen Revenue Allocated to Committee Deliverable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenRevenueRecognized', window );">Ipsen Revenue Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_Lxrx_sanofiInitialCashPayment', window );">lxrx_sanofi initial cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration and License Agreements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the maximum regulatory and commercial launch milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_IpsenMaximumRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenMaximumSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the maximum sales milestones payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_IpsenMaximumSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl. This represents the milestone payments received under the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_IpsenMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenMilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the amount of milestone payments earned during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_IpsenMilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This is the amount of the upfront payment allocated to the committee participation deliverable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the amount of the upfront payment allocated to the development services deliverable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the amount of the upfront payment allocated to the license deliverable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_IpsenRevenueAllocatedtoLicenseDeliverable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the revenue recognized in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_IpsenRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenTotalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl. This represents the total payments received to date under the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_IpsenTotalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenTotalUpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the total of the upfront payments under the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_IpsenTotalUpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_Lxrx_Sanofiterminationcashpayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>lxrx_Sanofi termination cash payment - represents the cash payment from Sanofi to terminate the collaboration alliance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_Lxrx_Sanofiterminationcashpayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_Lxrx_sanofiInitialCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>lxrx_sanofi initial cash payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_Lxrx_sanofiInitialCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_Lxrx_sanofifuturecashpayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>lxrx_sanofi future cash payment - represents the future cash payment to be made by Sanofi as part of the termination of the alliance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_Lxrx_sanofifuturecashpayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SanofiRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the revenue recognized in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SanofiRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6783455232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Cash Equivalents and Investments (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CashMember', window );">Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">$ 55,592<span></span>
</td>
<td class="nump">$ 36,112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="nump">55,592<span></span>
</td>
<td class="nump">36,112<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">192,685<span></span>
</td>
<td class="nump">235,463<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">860<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="nump">193,545<span></span>
</td>
<td class="nump">235,547<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Total Short-term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">192,685<span></span>
</td>
<td class="nump">235,463<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">860<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="nump">193,545<span></span>
</td>
<td class="nump">235,547<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_InvestmentsMember', window );">Total Cash and Cash Equivalents and Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">248,277<span></span>
</td>
<td class="nump">271,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">860<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="nump">$ 249,137<span></span>
</td>
<td class="nump">$ 271,659<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_InvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_InvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6783255504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Apr. 23, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">LEXICON PHARMACEUTICALS, INC./DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001062822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">76-0474169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">8800 Technology Forest Place<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">The Woodlands<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">863-3000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LXRX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,969,973<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6769568592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss Parentheticals - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ConsolidatedStatementsOfOperationsAbstract', window );"><strong>Consolidated Statements of Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense', window );">Stock-based compensation expense associated with research and development expense</a></td>
<td class="nump">$ 2,176<span></span>
</td>
<td class="nump">$ 1,768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense', window );">Stock-based compensation expense associated with selling, general and administrative expense</a></td>
<td class="nump">$ 2,256<span></span>
</td>
<td class="nump">$ 1,643<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ConsolidatedStatementsOfOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consolidated Statements of Operations [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ConsolidatedStatementsOfOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation expense included in research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation expense associated with selling, general and administrative expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6615265728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Accounting Pronouncements Level 1 (Notes)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_RecentAccountingPronouncementsAbstract', window );"><strong>Recent Accounting Pronouncements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy</a></td>
<td class="text">Recent Accounting Pronouncements<div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2018, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606.  This targeted amendment to Topic 808 clarifies that certain transactions resulting from a collaborative agreement should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer for a good or service that is a distinct unit-of-account.  This amendment is effective for fiscal years, and interim periods within years presented, beginning after December 15, 2019, and should be applied retrospectively to the date of initial application of Topic 606.  The Company has applied the provisions of Topic 606 to account for its transactions for collaboration arrangements, including recognition, measurement, presentation and disclosure requirement, and adoption of this ASU did not have a material impact on the condensed consolidated financial statements.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and Other, which is intended to simplify the subsequent measurement of goodwill.  The pronouncement allows an entity, during its annual or interim goodwill impairment evaluation, to compare the fair value of a reporting unit with its carrying amount.  An impairment charge is immediately recognized by which the carrying amount exceeds the fair value.  This ASU is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019.  The adoption of this ASU did not have a material impact on the condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_RecentAccountingPronouncementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recent Accounting Pronouncements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_RecentAccountingPronouncementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>38
<FILENAME>0001062822-20-000027-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001062822-20-000027-xbrl.zip
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MM G)OV /R'==WWHN8JKA6JNF<,*561-,?'3?7L+'=C/5'029<9.!B =:8!>
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MWOX"4\"NJ#^:-V464@86VV[U ,T3)O,A@+ZH3 896"$ZB^D<3:]9,C^R89?
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M)\BZ3X[7!:DE5>W[\\R;_([_#U!+ P04    " "/@IM0 X-]W2<(  !&+
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MTK9$/4KN1JO056%T @)?6W: 0!. R UHNKQ+QCP? ?N(>?.Z5"@1=7DCZA_
MH5>-^B(\A4=)C#\/B*?^&277E4 (P"1;=AXH71LHQ8'(S_OA@1+$;'8@L0\#
MOM_;1\#SP_T#?*?GYU6 Q0T% L 7\L?162>.D?#2[JY"Q3X&MA@IT ==&NP
M\^=$6I^540IRWP]MA9;Y?+4F&%#<0[?B#TOXU:MZ08T2<SO:8K62PA]]V#*V
M4DAN)#D@ \OQ52JGGDI+S,.'NO4TQ>=P;0$-<E@S2*E ?BZ34G$J/>B6-V+)
M8% C\*%5&H??8B!!K ZH#^)9/'T_0R/>M] X:1X=;XF,G;/J1H#LGH]WCA.,
MK8D4!']N=<ZI\'"+H4/TG&*"&S'')T:,Y+%4TLV(TFP;EJ+50]FC- 3:FN@*
MO??U[:YRJ"A-@5%B/05+$FV$-\ 3_1'DR*P4!@NV0$%12"*XB0D!@=$J"RPQ
MKS DDGT+B66U@ E7I4^I!!A(4R3:<H)+;;<09J1/.Q2'\+B=/7OPHR(F=ALX
M>JQ+]_#8NY0OOI &VH"DC^]#63S?VOAXKN8 [0GD'@=X7?@5^X;?94H/^-C$
M&9VO5.37M]R#\1-2.%$7G22E(1RM\(2U_C)M';ZAPWGLQ2;8Q>_A ) =; BG
M& 284._)56;BAA7\01"=$>7EPI;#8,F8VP61HE3L@P:$KU'>^ZI^S)B2MZ"J
M4Z%[\O5G3,BS0V0_=\#]U[,#]H?9B\"J+Y,EY>Y5H"_S)@'V"7QJ@^NC51R9
MOM.5$=3J7V!G62:= ]A:C6*-Q(A:A$2;O/H!!@(F?TO%!?^GG<8\8N'W4J+)
M/D;+//&'1(<_-K<OTLH'Z J="Q*9EHA8.J*@PXY$ B*L(AZ+3>84^"TQB4!F
M/9?P--R?J,_/")^$VVH_& Z(MJ19+E#1PB++;L%X1=M1&.&*[+H>B(Q%%F/+
M#(&$$^3=J*K8UG/45TI2]G??25PD-9C/Z@@A\-D70>A_3*G06@_%7>83K29
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MBWX2N0]>4Q?/_,;<W-T?_@502P,$%     @ CX*;4)6G3^="-@$ 7<L/ !$
M  !L>')X+3(P,C P,S,Q+FAT;>R]>5<;2=(O_/_]%/4R\SZW^QP2Y[ZX>[B'
M!NRAKR5L+)N!?SBYH@(MC!:#^/0WLR2!,-@&#*(DEY]G:*E42U9$Y"^6C(SX
M\_]<M%O9%]_KY]W.OU;0&ES)_L_ZG_\? /_Y:^]=MM6UP[;O#++-GM<#[[+S
M?-#,]IWOGV:AUVUG^]W>:?Y% U!<L]D]&_7RX^8@PQ##KW[LO3;<$BV<!893
M!RAS')C@/1#"&X0"A%#;U>/7U!C&(*6 4:< )5  +2@!$'D!B5:8.K;J7E,O
M-7>2>N8Q14Q*HI2&-CC*.;1(IL<V!_'MXAMV^J];%[V+?ZTT!X.SUZ]>G9^?
MK[7\Q5E3]]IZS7;;K]* (2%H97)Z?O/D"]-KK75[Q_$\1%[EG5;>\8E"UZ</
M[C[_^M17@Y[N]$,W/G$0B9WNQ #$ /.KF_2[%"/QK0?#^.#Q&=,+XJU/OW-V
M^MGHOI^>?G'K_'-2G(V44J^*7Z>G#OO@6.NSJY.#[IOBU,D/:?0J<@1<4ZS?
M&]P^/1Z\?>JWAY#X-4-2T/?VQLGQ^]IQ]\L/J2IGQG71S^]Z8*00>O6?VKN/
MMNG;&N2=_D!W[!6MG+^^JJ#J]-'QASM>/IWBOKIB\A3^:OSC[*GY]W@\'4D4
M7Z_=^I]M/]!9.AWX_P[S+_]:V>QV!G%2@L;H+([7CK_]:V7@+P:O"@J^6O]?
M_^M__3G(!RV_GN0>3*7[SU?C@W^^&M_:=-UH_4^7?\GZ@U'+_VO%Y?VSEAZ]
M[G0[:0#YQ>MTHN^-/^;.^4[Q,?Y>C\C0R^WX^1>#/1_^M9);0QG%WCN.,*70
M22N$5(9@1(VTCAQM%4-!D7C7,ZZCV^G1/G\]Q9LW>=_JUOMX_ZY[$X_U5[+<
MQ=L[\GEDMKI?WN&]+P>D-G0GVU\.WZJ3W9.]UN[;;7RX=0P/&Y];M9,/%_7&
M,:U=GK*#QE\GA^T/L'YR<'YPN4W?D7KKX+(;SVLVZ^T/M/[V$SIL[,!:XQ/=
MW:JQW?WM\P-\>%K?.L"UM[6+W3<2OL.'HX-]R^M;AR?U$PL/3ER^NW5\4=]R
MI_6WVZ/ZI1W5WKYIUD\^-^M;VQ>')QM?W-LWN7G[B==/#EN')]N7]<N_FX=O
M/\7GU5MQ;*1^$I^__SD>.XB_[5S&,4^N^1R?Q3J'C2ZNMS^W:XT:J;7?G!XV
MCN$!_H1VMRR.[XH.]^.QD_C;26U4?R/1NT9M4/L(+]XU/ISO?C@BTO. & 92
M.@(HX@)(CAGP#C%.J..6DI7U#U$D;K#SZ;D[GIOQZHO!:]/MMKSN!-U*J'3-
M]XW(=%<POJ6/*U[_B-=LAM>PMG&DC!.&0 8<%P;0$-FL(F, \S(08[&T"*ZL
MO]EX]W'[V=G]K<E\X'6OFLKW8N]%;1->OFML)Q;#^E;D+XQ*7V #M/4<4.E5
M_(0$X"+.9&2<@DBNK"<>S)&]F\->[P9WMSMN*QJ)%7]_S-^/U_RM7=HCHQ&7
MW@40\=J#:-X2H"P- $(9(,=$(*17U@% &)#G!^QK%F]WHKDPVO/'>3^968-Z
M_*5B[X_9.[HY?0.&3%*L@!4P3E\<_QC,HHU*M(NN"D9&1%7\;OL_.YN[]>S]
MOS?V:AN;VY\:.YL1L5>SG?KFVJNM>2+WF.^;<7;W=&NGX_S%__6CBO$_9'S]
M*]RVR$<CS$&@I=#1X=42*!F=$R1""-1%( ]X91TF1G L,;[%XE<WK>Z>#SYB
MKO7]]3^3M_:Z7S@OD>=9X;V]'D2/X%\K_;Q]UDJ>3'&LV4LB<<,-6+OHNVC=
MO[IYC_'C9I]1?.UWA[WB6^&XO)[(V5@8'B-GTQOY0LBFWW*7OH?<][)B0/Y.
MOV]SY__>I-?7%Z]/#]V\^UGA24R_1?^J-TBJJE"9R9&#:'K=]6]7PW0SIY("
M@&_^,OT^?<BK&X2:WF?8R<=$ZS=U).H5&=I>]X<]OSYY?/'C]!;3WZ;?TSWN
MY(/#%-+@? A<4!BT=EIJ%*S%3B,3R-%.07Z*20G(/W9P!Q.*4H#)U8TFOSR0
MHL-"FF^2;!(I>?WIX]:#J0D-L=(8A 4RU'JLF& A($<#MX($/J%F.83Y)C5G
MY?-AU+Q! <)),!&BC V:*D6B,&$GL23*&ZYA(4]((5PR"B U-9%^F@+<(P&9
MC4ZRT#2:8$HR*;B!FDL&K:-C"I1.!E)<ZO$R,#NCWOO>QP1&5Z_G\B]Q6+.G
M%FI*#[J]1TZ^6]>G@UN^TVWGG;MN>U^(O'&+5S='_Z.YKR 4AC.$E.+4(:D8
M=@D,@O64>\V21HM\'VNTT@C K$8;AR;OI=&^EI:':;0;=--"8QV,HIXX*J24
MF@86#+-&.R2P+.:+G =B3-[:'Z?8P_BKBP^[.&OE-A_4?-O$1[@\_CI>\YA$
MM%]_',173]=L_W>8K-]N^ZS;B5_[&Q=Y5-?3T^+Q=K?S<="UI^-[_?GJSD=<
M4>UJ) ^;R/+)H"R*<7#:*ZX5I 9CHQP1!CHO!),RF*5AS89S>5H$T*WW.G<[
MG4U]E@]T:T'8Q(U3EIE L<4T&L_*!,P,=UY'KCFDEX9->WZ@\XYWV[K7R3O'
M_07ACS"6H6 2BRP5+.H"*)UVA$4500G'2\.?#6N'[6$KK??N#IJ^E\[K^6:Z
MVQ>_T['=ME\0EC$C(,94<,0$530:<1)QHQ05R$.NQ-*PK-$KS*#1(JFE8""R
M2B"BG*=61(]5&$\IM4Q&HXJB^3'GI2A@K,%(:Q-UL*!84T,%CJ9GQ!1$'(?P
M!6S-13:>7MX(]LHHP8*5"$7G0=CH0C.-!2=6,1^B$;QT#)V;R?7RS T:(F:I
MPE@P:IA32%!"!#+!2\T$7S[F/K^A]O)<-90Q$WEF*97442N="EQI(0G&W#NW
M?%Q]$?/NY1FMM#+<!H40,]01+#D17D@AE=:$!K1\C'YFH_#E61HH"<$C@1T*
MU')IF*04$^8]Q5(%,;\8[2*;34\5/+[!&AFXIM0;"Z.W93S3POK &8YV/I9,
M^*5AS4O$G)Z.35PA:!0)A$3/2Z)@XKSQFB-L)0U$+P^;YAIS>CK^,$6LM%!'
MF".4T^@:FB!4/ H5U1::I>'/2\><GHYE'C,F*#56!4*%,!HQY*C7T0]$,FJK
MI6'9_&).3\><$.]&0[PCQH9"&;02DLH0G#=2JDG,:2[KVDMC,3Q9,$R+:'US
M(A5#U#)OO, ADC (;0/%<&E8\S(6PU.Q22,ME>3>IOFB*5?!.,H#<0$[BR%>
M&C;-V6)X*OY@JSA&09/XAWJ%%'.<0P(Y"M&TPV%I^//R%L-3L4Q2;I6CC'D7
M:$#6$"<XY8YP;(A&RZ.4YFDQ/!5S$$(XZB5'O/=44)/RP)@7T$2S+L3/+Y#A
MNLBFPXNDWMY,;70R< J]4DY1Z9ER:9^<0@:SZ%3AETA97A:#X^69*P.B3 6'
M*;$4"Z&01C@:_5)!Y2.7EX^Y\UVC>1FN>HR9T11"G[;1."P51PP'1KGV3ANV
M?%Q]\36:EV&TUE9ZJ9 TQ%#IO(18>,>,$L(+I<SR,7J.:S0OP])DT#KH';6"
M4<R9H<Q*9I&Q7!'%P_SV4BRRV?0LFSRBLT&]H4&@Z&Y(C204VJ)H$!%&B<=V
M:5CS A&7I]R+X[2UWF+) J%26NDH#<Q9(3F+'_W2L&F>$9<GY(]*@:_HKC-+
M/36(:,:#0T@+0EG\O^7ASPM'7)Z29=;%>609YLE-0&:\$& 4"\(Z@>C2L&QN
M$9>?8\[5OK/.,(WE&WMCS^+'Z0WNO9>3!"0UP=0C:FA:-Y4TNOLR!!ZDA<8N
MD$FY<:Y[+M5\NLGC@K>[9TG!+:,!*5!T]E(V=-H'PX(T,"W@06IM9*N7=H'R
MMEZ:@2^3I06#-\I1'\W^E%1B-(118VIB(N)JI&GYP]O?X-MV^ZS5'7G_K/Q[
MEJ"V,CX8#JF@/E!'B#38>.HEU8)A2^CB@^)<>//RX @A=YQP(:2SE!"F%(32
M&Z=AT)Y34GY#IAQSZPEM2QP9@+@/3*5]F\1*)+$@V#'BD,?>+"S<[?G^H)?;
M:/T73/D4+:[^WL=/"P)YUG"O39P@A!&*2=!!4<B$(QJFE5:T^) W-_Z\/.QQ
M)Q7S7F@?$$T+>=(Z+K#2@7D'!5Q8V'N!.?:$T,>DH(()@N(LHLY+"34S*.)@
M9)/ 7I6?+3N=+Y$#Z:+;O-G4_>:",,(*Z! G3"J%*8G&MN<8I37OY ACSQ:;
M$9\^7H4UO!WV\D'N%R96&#R*G@_&C'D*E96>26.LY%"[^!RWV(SYV.SV!@W?
M:U^?M"B,P=X2J!RST@E*!-7.<6]D$$[C:"8L@$;Y'F,6CQ]6"&JIX))Z2 G3
M6EBB@P@N_L^3X,IO1;^D*GE"N]G#(*#E"LM@J.)4*R&4AU*+M(&2J,5FQ+Q5
MR1,R1DA"M$[=+Y2DCCBC&4,\U7_47/-%GR'S5B5/R!C&%=1"Q5FC$,46&6DI
MQT;" #TV>@$RY$N@2IZRDJ..FD2+Z.^K9/TJK;2/IG @(41=CQ<@ ^6-SGN?
M=6OH_QI=??QWO*/NV>;HG?_B6S=Y='723N=L..@79Z %4?P>0X6XCQ-'$>HU
M4TQ2*Z) 1#8JSA? =7D*;N$%X18T" :$,/->48>Q9)1(9(/ET&IM%\#C?PIN
MD07AEI%8:$V(##@BHM528Q<1D5"C H1"EE\SE1X)GS)B;9&R0C("':/>1IL"
M&N6P<0YJY8SX-;CUK$CXE-PBCEJ$B(TF.46<:X&M,%ISQKE9B'V1I4?"I]QL
M[*@DV*5MDIH2S0UTQ MMA6 6<SFNO$?1)*DD?B"P!$4(;^1R4(#NF\M1G$K@
M$RR\B"C6W$(/D144!1BM:(>1D\PZ3B0<;]*.Y,)E(->,Y!04P/ )),=)*"$+
MH=B18M/&36>@P='@(5%VY*1*+Y2E$)@;52M34\2GH "/4T0("R&.6(=T4!C1
M8!!W'F-CS=B*$ BGEE1EHH!(Z('D4X1>,/'(1>F/*$]](%IXARSU/D7&H"VV
MJ2 &R1@]6!EKQ+-D5-X//=C3U>O" 5**O?0D.N,.1Q/4,*1DE"2GM- %W3@4
M8[IQJ$HQB6[0C0,H[DFW>*IZ&M2-*(NBMM*0,4Z9L$I(2P1&4$&G*![W)!!3
MNHDRTDW<GV[BZ>A&%:,,48:CCZ-P='VTI"+^EP7!'!^GC@H$)W1#L'SS-((6
MO#?=XJE/,D^M$<P@$U%>1BW/J418>6=U=$=2WP TH1N:TJV$UI&XOW4DGLPZ
MHLBG(O'<R4 I5]&>] $1$:+C%B'.ATFJ,IVF*O/RT4VEADSWSA#F3S1/%85>
M$JV4\=1"9ZB(]D1\J2!MB!IV0C<\I1O&93 MOJ8;OC_=,,#R<72[VBGAA[>W
M24S;[FQ_VIM>?N]]$E%6<20[92;RP#%H/#(24FZ$346SU,0C@E./J(182>^/
ME?3)L!)[[YF7EIHDM@AJB3R7A%DAB8F:>&(+HJDM6,(YS^Z_*X ]V9RWT6#F
MU*:=W=&F49%NT1R4#B'FHE&#[<061%-;L(1TX_>G&W\<W5[=;,#X:J8=^RN7
M?QEW;A^K'B]UU#MI.1A3Q*0D2FEH@Z.<0XOD49JMU]=,NKTW?7[<'+PF_&SP
MQWGN!LW7<8+__W^L%">M_]D_TYWU/TWO5;QT_'E\AUOW2:,%NI4?=U[;2#[?
M2[=(5TQ/,-J>'O>ZPXX#MMOJ]E[WCLUOF+'5Z?\RN 9__V/\VS]@\>^/$,D
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M#Y2 &G +K4L=T6R0*^L;7T^^;Y9(+J]<WFLR%A;\LLS#ZZ+E];O4Y[+P['$
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M[DU<T/2(.*"L"&%D4Y(N'&L?5NY_2?C[G2'.C[LO9*^\W!:I137Z-H>](@M
M%RCX^E'3Y!DHM ";:DK$Q,=;[A7O2LB[EZL4<"<1Y0)0L>B;EA*T;/J0$CV^
MZ-:-!<B2Z/V7V\12+H;]\VO&/"UA"MK_@#)C_HR#ZR6BS)_Y12IG^::GBZ3(
M;-C)!WMI>\NP[U:*)-SXFL6!'!IBI3$("V2H]5@QP4) C@9N!0G\:"=Y_I 0
MM)(Y;_.V;O7_M0*BZ(\S->(M+@:O.\.VZPXFOZ\46S_2P\"QUF>OT\3:Z+CT
MG^WK6;4QV-2]WBA2\7-:Z(M3*5+9%Y.J6 YWY//(;'6_O,-[7PY(;>A.MK\<
MOE4GNR=[K=VWV_APZQ@>-CZW:B<?+NJ-8UJ[/&4'C;].#ML?8/WDX/S@<IN^
M(_76P64WGM=LUML?:/WM)W38V(&UQB>ZNU5CN_O;YP?X\+2^=8!K;VL7NV_D
MQ>Y'U;;M-YW==NVR=FE'!Y<6'32:)P<G>R?U_6UZ>%*+YV[#W?UX#?X4GVW)
M.[+7/&A?M';;A\V#_8/1P<G!Z+"]<U&[_( /&MNL_G;[O+;_B1TV[*C6CN-O
M;%Q,KXG/&A[B3_RP_:9Y>/)W7C_YNWUPLGU9WSILUAJG\"">>]AHM>J7.Z/#
MMY]8;>M-J&_"T;O&]J#V$9X?<:D\IYX!;@0$5,<_&A(-H+*2,6MM2!N6HG0P
MA?]\=5,ROJ'V7VHBE0]C?L(LJC1 I0$600,03H()@1H;-%6*2(VPDU@2Y0V/
M2)(T %((5QJ@7!H 7FD )1TV20- 02R@B@4@O2, .<:HM"P0#E?6"5]%J-(
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M*&<(:R-T4B&KC%7Q[VJIKX*]%Z_64<'>HV%OQG)6R%KCH 0:)<LY\@;HH G
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M=E0[!0B6--7^L4 CSH CB 3AG2 TVM4$L56A8.F"3LNVI%T!Y2\&E//- *J
M\H% .6.&6T0<$P2"8*@&%*>\?"PX\(8&)1ET5N,(E!"N<E2^[4C+!I15:/NA
M1-SLMMOYH.U3)=)46S[!4!RO[]C%"&X_[_/+IT/NAHIE=\BGK_T\KL9%/W_=
MR5O_6AGTAOYK/3DS038Z;G-V>E1Z\T%Z\T9Q4>^X\#RXU(L% >HU YH1#&00
M4"!.,>4D\?TKA5E!4>GF9 5%3VC,5U T)RB:,>&1Y@8K#P&BT@"*7 0E&2B
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M([8A1[30!"@H!:#$&* U-P ;)*B1EDLO7B2J6HG6HHN6M4(&+Q3P6$A (1)
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M;%X!X^8L,'Z\@L.$H3=V^V1IH\_R$."WG4[4$=UAO(F+4N$OK(]&PIGOC5.
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M[3TL;01_K@N9O^K&_WDF>USM>]VN+*#'6$"U68^06XBQ"A PPS2@6$*@O!>
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MI5!^1J',AGDHCP: 1\#35".,> F,Y!1(Q1G45,;#J: E6A6J5$O#E4+YM2)
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M=CYT4VOQV:Q.6=!9"C4U&.,:Y*\F10C=1 B][I9A%(Q;!CE (B! A=5 &FZ
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M"DQ0!&C*A24F> )YP<&"@P4''SK'J>#@[>-@-\7)>2&5"A(8CSF@CF$@I;8
M!N6],TH';PH2%B1\;$AXHX[J/Y[C5$#O[D%OF<R$J9".4@ND<U'](U "C:-5
MC&!J>6PYY)QM[2I,[K;/8<&Z@G5](-U-L.[6DY@*UMT!UG5RF*+\821'/;CQ
M\0='0$/.@$1,6$\BY9@M6%?J*-WW&A[ZZ6 XGI322.LH,>XL0633\QP+@Z\'
M@_<O023BY?[(CH_]OR)H%H7H!@K1BV[_,J08H9AQP#AD@.IH]:G@XV\R4 \M
M$UZ5T\T%\ K@/7@F2 &\'P"\9<I'I(URP0I@!+> $N2!@@X"I>(7'%G#%2Z
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M(HJ'=_O7L3VO3$%^FAN5Y<ISK_,4FF::12^Z@5YTD/2AI?U(H>!,.@E2?W1
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MN!K4;J=$XSJ1,L_?I3*;3;NYIE)9&A;?Y&5;!*^E]C=ZM&["XEW-/?/U6+1
MZ%1I6Y8(S#5&<T&3MB#@A>4"<]VVQ4@S&WX<9&5MNG+E=#S8/YGX>3^\P>N]
MUXM6</F+93.XP;G9-16H\P9-1:,_'_EF'C:BSO@XE; STUQ(.H%=/1Y>5A2Q
MK86X'>]0V:/!V-I9/1G,3J)H='X8%:?Z=%Y>=7[KU3+DRUDL;C:?Y:+DZLE)
MY-=<FJQN<QMRY=5/NJ[RI_,*[FVSGJ:H=97:H,TKM;9-Z>8OUY1JG6PO&DRD
MUGNFJ=1HXVJ^]XF]XA^I<T:N*YM: $UG]:CY;%I79I;E?UL?=A!\NC;1[?TX
MOO0H-_98W#/7_]:3P8%/W<[BTK],+=B?Q8G'L5'=&;S7)W%T=6Q2C=I%KY',
M&*F.>UJPR4J#D'B/E:+;QZFHX+#ZZ%,+DMR08UXU,+UXU&+]I]1Q,$23:QP)
M-)_0O!IZIK)NFG)DYHM\.,LE =N&)7E.:6E=7,,Z5T37;<^C2$"=:P8NEM?,
M<K^KW.M0G^:E.-'3J,J-+JM!/\JEX,_P:.W#<-[QY.P%)A4J7ZY'RYV=5B0K
M/)%8L&'0IF9GJJXX34V35M8P561<W"IR6JKKFQK3-; W;^&5UVG2V5.3H^KD
M9/Z^1_''L!DYF1?17[;?TX,P&X9J.,QKDLS?3[F13-I]\XV6.W6%U(Z@W3=G
M7WV^S"U,)$HN']8MZ+XHV)Z0Y.8]%_N*M(.5-LKK\U:W*'R?ICJ+)G\5^7/O
M?>VOTRA]\X7P7!EI:ZK:E672BV5:=->+IOE11$V;^A0MI$[:5?-]G@5.KB[7
M?GM&>)WX.KD:)ZO%4@<A/2]BXDF&\7FMUZIM@M3B\[)?4MKI"S&88#FB5 L4
M3:N+]C&YYOC81/.@[5S1O*;72?*&IBG&XB6?# 8_53_/2\F>-B*X?:V?)C\W
MM6CU DU^C://#K_XL7/)-+]9OC)>NBAIVX#ILN%@T^0C#?OT<Q;)-C6ZN'#0
M'/.N]^1&X/X4[[I<O?F29DS]*34YC>_:@=&(AM-J$JJF2=\E#SI#Y:R Y NJ
M2:8M2+2-,C>J.&G&"ZG0/+61,5&<F:R=Y.9=W1E\CG3-O#D7;JNRZHR(RET$
M!W[>]W?>&C"G"W<KU*?KSLF.CLZUMY3RB?_]2:,L=2>6J^9.VI4Y_X#X1L>Y
M0'9BG30GG45/>\_<7&3. I.V@5?3N*R^;)U;E6GQW+A\N?=BOO/B<6DFG8FD
MU7&Y]ZV=GB'4-"U_1Z'4D^466]EXES!?FFTU6?#HHC- 1QFXA#//L=ME'#Q9
M,* [,WD79SH<GTS.=WYK=;#!AYE[/^\8M[K;HKX6,5@/QZ/4H&:8-9#FG7*+
M@KR<ETRH+37=J S=W77W79I[+DVNL6-\JNN=-= YZ[94S&2*DXHJZGCDSRF"
M"W!(]IVO<F?E2"3?%/E>ZK4=KFVZ277UNXN9.#6W>'^U39 JF8<+84H/)E7<
M.ZGR^&AIAZ5_ZZA%-LB56CAG.Z]9BLBMXVC:IMURX;NWI<^KR;?G'N?U[.+E
M6^!(>G@+/PM>/6>=SIN^MY+==TW"!I>:'=6L>VZYGDR=IL"_'FXOGG0EQ2*]
M*O\I%W"?5L/VQO-[+"QL'T%COM//$^LLV%RU4U/7W\$\'G'%CH\V316!-6W\
MQN;IKDP''"^5E->#KKU&=OE1+A:?)]ZTM,HSR7T>M\\\&BRW2WY.7M+4?_(T
MF_G->A[[)41?MIF2S,AW;/JW)#+%M:U&K490A66C\^VV%WJC2)VS&+,!/AQ>
MR(M[25O(AG*G\_K<<5*[QG!,&M3QK"5*I*,] K.3.0V:]?^<NUNV[3L[.FEN
M8M,JK"T_MSW4TVHLGGD>AS<2;?='JQIZNWAZH9]?8@ZGMF59E4J^B\A2<0FG
MN:%'I\7"7%UH>HN.,U!?IE.?%XB+:9WEYXNW4@=YTC3F.EF]5"?FN+3HI;KX
M(.%!!N-Q[E>7&W7[D0_5=-X6=3$X,NCC8(S4E+O#&8V2UAIPV;4!&B]./3[5
MP]26K@OW'=18^'HB2R5<6;A&ML^2S*5GN5;B-DCEW3AU2!^EKB_^>.E/RMKA
M_,$M('V33>:]0E+%HS2+9*<M6&<.:JW_MQ&T<0FR>;88=0E&+^8UB5I_NBIA
MV]RCE:=Y.CC2R7WF1QW)L_AH ?!9()SHB.:YJ_'B\Y]WSD?1N]D#F\J$%P=^
MOQG[V^TJ^*EW2ZL1S/VBDV9;)]$TQX .HZ:NG8F))TDSG"5VB+P<\:$Y,'K6
M HN \.<)B/?+[M;33EMZ[\_(+9UXO,6D.5-FGWV>WDEN7)-9S:76G?.^,W,S
MI+E4#[L>C'H9[$M,F!R=TUF]$&AS%>D"STEZ]_,^C6EV>"^W?1+'K7/W[)M<
MU/IML4_.2HN<I=/:[%V;.STW?N3R&^CA16UR-@5M;QK/O>OFTM%*>1%>)[0K
M20B';YZ_\Q%'8, 4:)8.:2D*@19* R>009HA)IP_UU@N>,P)U=H:1QWTFF/'
M84!::R$8.]?IYVD;&LC+GKJUG4T"ZW^X_I+.7M]:B-W!TVY89!ZF;0V"JG8@
M2;T$UJ-9BI8UO>MS@"7:5'6>0F-D1+"HDT:?3(@CK]T\"K.TA[.+]6S$=^?:
M@:/+8SEGWB&:F^/YZ(7/((KNKZWAV,C_9=VUI5>[<=HMC:RH3.O1^RI!:'+*
M3;,5.0\X+ST+V=J*"P$27>:!QK0.C4FX"*I&'3;,AE&TA6PW(SHXC<^]L E9
M2<Z[K8TA2W)>%Q&^F6QW!DHA1A%R@]6:2QJ\-I (&W0TWXTD3*IO9'#=0^Y>
MLW?W1J[C+'O^Y21ICX^WY=V;]^^HD))):@$2D*3L/1X%)V% 2<LDEA 3M.X=
M5E]U@;OK*VWI/UF/3+M7E\D?W[[&:O;4I G9SK*]DA-Y&JT>3*+-,AG7C1WP
MV4=;-^6TK$1]+Q5U;?9%E<1IDUZS>%!V+;32/5TVOP>8V^8+D;^8;W9)1IG=
M?I G-)_R3C=AX8VW1Z.XT.]/%QZ';)_EN-[\NZKK\IY%TRDG:56C*]XFJQ"?
MDMLZJ@,IU:9Y_=8,R\ZD[O2:0.5\@H/!ZYE)'N5D[@^R$S>98I?F?'D;J9H.
M4C3!\OD?TUR_N1OO2RDVIRMZ54N:W$-U.ZH.+E_9B*.4?74N\#ZNW^M1J\HT
MZ]SX[Z+=Z<9U,@R3@Z@[I\ETYJJY6V<1V[2V3H[6!<4:*SM;O4N%)4X[326E
M9,67S^U4$Z\-_;0-S70#9%WG4NV/=8[PM_,Y/YDEJ]2^G8WK3B*W*I_E'F>I
M!WE\WVS ^U&=(L7+I[M9O:+6I0><7I)6=<[=O3*MT[FN.9KKKLD_F=R5C1V_
MW"&-E^*U'HU#E3FURWI)#1W')8M:WG#\-3)I9N73$S_ <1-IXW,*7-PN=<H_
MJX:)'_,CC^IQG,S@8^5&_C3Y:'U<C=58C5].S Y3?&4\F[:1EL7"?O;=9+@V
MB>T"T.B\SI*FD\CW_C^S-JBZB$HU"^!2GL)J0&Z^Z/.8>.,CG,=YFL$A/FTZ
M_RJ3/2GQ)[-Z,M.CZ9F$@60B',^&TRI.:,[3"UH_??6BP8&CC&NC9#;X>2/@
M4>32YO=J$K?]Y[Q":=F:-?+G>'"0DPN2I^](#\.9Z/-QI$5.#6PYKV6\I=L[
MV@[OZV0\)$@^>^<&)1MP[*QSNZ11_<DY@./)I&I"C5$8O3_*KOL(5,/D1:K\
MYWSKG%C8!)*6#O/Y)$V3E])=IN54JDBL3U7\Y[(DPR45G3_)<:LV#AF%6Y)2
M;<-DG5RNVIXN@E!I1BFJ5[DYG"VG4/OWNG9+NTA/9Y-%/"POF3YNR)GK6LP_
MF:3G-VAQ)IVH&F=$''9CRUVC:K(:_*_"N>C4(O25_;\I'GE2)WMTN4>J47,^
MLLTV:;FWDR+X2(^$W:WB_OHH4N<?B0:)W%$69 *\R%D%49G?'R7)$^GP<AC?
MZ[$J\G$N>^^T5LQ)B0&A! %*$072.P(4CBJ^84)YS\Z:;900QC$1SF%+A392
M$N*]%P)'\@3F;W0,Y\%Y]Z9VP>OIV'X$F;D&7>Y:"W-@13V^.')F.^\TUZ22
M/IS$69*+C5*;C(9T>+>)GZ6C% TJ-D<PHHH8E=Y)THJCH&PT[DG:DVW\<!XS
MZ6H@D[2N@_')4OF,(C"JN;9Y0OHRG5^/FL9D,FM3.*)J,3[-QP&ZV>55G92?
MNLF&F<Q%3]8P6CD3!4.2M5DC:#2?"]ZY<V9CX6]K8RS+D/EH,8FD&K1AFSRY
M5HPM4^DNR"QL7DM_CG)MQ7)I>*QYIPOGEI6L=%FCUB0UI!NF7(17)LVLEB^2
M0K*K+L6</Y',DAL^\YH//+-RB]"ZFR>F7GB;,TD%C7[7S0O*P=JZ408:#6>N
M7C1.V>4YEI5['OOISO?EM&^&V+T@AMQ?9/Z>H,0W95,.$R_A(9M4*\A333I&
M:IL^,,>.C!L=Y_P_AG%1P&M[-$ZQ@3;C[RS&K@YJ'@-2XE-.FLB)S2UN3-K@
MP<FL,?5FYD.;"MO)4UVY_S^\U;.)O]!WL "FU??+KHMT\BH:#W'IXZO:23<5
M<9CLPQ!\/JS4;M=L#H9DK^54K)-.0K%I9] @VR*[JC/WYGVZF;;Q,8M.GBEA
MLDG7FJX29DZ$)"-:$RS)C,7KC4^B-3)/$O5?<MI1NYX1.\8YJ7"NGT?V6^!Q
M3NQK#K,E.@Y34$5/DJ7<"H=5YLBI;!>NY HALF-D5D>[J[%<SQY$N(+C5ITG
M$_\^&3I3WX;KYUPY2O;9Y_'@:'P\?N]'?AR-G[0=3[K"SW])9Q_;;*8XERGX
MY)MU:5ZAR6C.$VOV3+)//U7C.A^ZFR3;.(ZM<JI=(ZGF>5D=ZLTFK96?!$.6
MSLTD!\-LV717Y7\C5<9UMAFS:5>U5R?9W9*W)=_9.X5..G5^S2BAGL]'?1JG
M8%1.9JPFJP?+CI9/[(ZZ.$.A(4.3@W@^#G:9KK1P$IY'@,:,3&_0[.O\"LV+
M7LP(2R6@??,5R9OAQKN.HK(\]]* HW= M^<:NR1*SYUS3GN312;P4>U3OO)H
M>I0\7FD_'R3G7_.>!&T/DE&5&2A5_'ERJ80\UO7[:C2OUG(O\9C7;7+.B[ T
M\%XVJN1>4DRR"M-8>9-_STFQMUR7-VG7/^:<AX.OS]^E_G0L6 V@Y1)03RC0
M.L0?EEL>"2.@Q><LN&F#ERN4S\7$]&PZ_K7]H"G+DS]I2_GD^,#)Q#^9_W*N
MVEE7ZTB"?]XKNQIED9^?VP8UE=IA'&71WY9Z;>?3QCQW&K7@3%&CYDL&=RC&
MEW]_Y<5P!UWU)2/T.Z^]\JDH?LO56DU9[@BT7C,6.Y+(M9JQVH&(7_/:.RB+
M?+'2?S[;X?9;AJA^%/2Z9M');Z[3[5?4WQ3"BGL@[$*5_/="22Q4WC@JOZHF
M'T%(^NY^>JM4Q^)5-#D*I3>.THO]_"8:MX6^&T??9U7RW8Q<SD0\MX<?0L_9
MI,9HV0$PF-O^3\K^^9%BW&M'_:+D%J(7HA>B%Z(_%J+WK'6L7(-5?#Y/-2D-
M%3>JH6*3!GZV&49 4A-,/:*&*@*5I#Q^% (/TD)C+PQ5+;MBX'G<:OBE_G))
M+N)>7:?X:@I=_>/TXFC6;[JJ4Q3+=R)8<SMW&=NLHS&T8,Y%4PV US.ZU735
M^'!T]/>S.-MGEAW^_L^CU"'C[9NW]."O/[X<_/[/XX,/%A_^]5N<XP$[VU7C
MQ>^_?3S\8#\??OT(WQ[_=G3X^[^/#C^\__+WLSC'X[>GAU_?HK=_'1Z__3H,
M!]W.3Q0BAQ7A@'OA &40 JU) %82K347Q!BTM2M5:==XPZWW?PIB%L3\!F*2
MNT/,Y /^K?9^[@%^U<'+ I<WA,ME$R))N&3$:*"598!ZJX$2# (:2)""!BPP
MWMI%._?1@JC@Y?W@Y:U;"#^ E_VCVU6Y3]\%CYW&:G%F]HF;U:FDP]TKERF&
MTE$I"S!^&QCQ A@Q1D(X3H$U@41@5 0883&0B$::2TD,L5N[]+(R,+W;]$5)
MZHN2A%=[+7[U]=CIR='=X\$\^/:JF)H_ !%T 1$&<\-DT""" 6Q-3:$8(,@I
MQ()B#JGDMY,8X5^+_O1#^E.O0\/KX/A\$4)EYQU0(A^"Q6&(IFK'N/XNE^@#
M!!1^3))]<\)%KO777;K,\DLR;,[2>R-W.![-)=JS.3L7R78CR7;:<:(J3:FB
MW@.K-054>0LDQQ9PPHB"U#@EH_(KQ-T+M5O9KGW%Y.]R$13$+8C[,.[6@K>W
MB[>=5O <>2:9!<P2"Z@/#B@-,<#&$.FXT![+Y(6E!7 ?!>#>L6%3_+6]]==^
M$V,+L'X;6)=>7(6LC !J )/ID"QE FAL.8AL@;735L"DR,K;\.(6O:SH97WR
M\!9M[79!9>GW]5(SPZ0#)C 'J*0>&.X4",1(2 0.CM^GW_<1:6P]2WA= ^VH
M>R2H6P6D;^')\OSR_/+\^WU^B:D]Y&&"8B]LCKT@$$?,<0B]AI0%:2 -T3J@
MUD8KPLML+R#5V@OQEW+08"VM@,/7G1@9$Q(*9A! *ED!D<S :.V T ;'[Y"+
M9N'6+K^'Q-E'9  4;"W8>C-L+4<2U@-8E\&P2&#./?> T6  18P!99$%GC+O
MK%32$K:UBW=80=9'@:PE&'8[P;#O M)R>&%]('09]I+4:8@1C6JIQ8!:$R&4
M$PD@#EQB'QE X5LZO%!4K:)J]2GL54S;[X6/98 K6 6Y,@I8ZQF@&@I@J$+
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MO"SL;]G0$#(DCST^<NYHIZ'ELS,->MS$3WS[^BK28^1L?TK@[>,SI+>T9FS
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M _IU; =.DM2 [C2$DU&?$LZVT]KN6'>G5/!>8#3^5C\\; ^Q1@E:0+S<<,Y
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M[DZ\=.+ED8N7+J[UH-)E'M<2,L]RJ4,B0J8)MU%.1$8C$G,5:1&FPJAX,ZN
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M\2)93+AVB901;"Y/>48CF?(4]G54K@B:E0^"QGH-!FY= ^/!KFTQ@9,?E'D
M_\+_8VN#(5#"4158X%XFZ,FQ/O*,-:); >ZV2SC \[P%HU8G%I[PS0[.MH,
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M92>U.JFU28?F,4NMGQN)Z 3670JL>30B$3;2*4^)33&[WRA*0/N(21KG*DF
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MTOIF>XNSKXO=7'G=DH-CUO /ABV5&Q4L(RQ7Q<G.'!<X2O-N'H,>IC@J"Y"
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M+QF-.-#0##$M50.9@39!T$'0;6,IO!IP#'Y,"9Y(-6,?5*'[ D^1$O43A2_
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MGTKM2Q1&V@M@$)SE& 265UXEKWPFOWF7W!5>\9-<%0,=ZY156>=%?141YH_
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MUD![K$<VVP9:R]';)_\7X>A'M$4SWG151G_D99[1CW*D6RO[+\CZ8W@+X/U
MWL)Z<8&6"U\G%]K&YJ7<USO3W->SC<V6C1NP^/4:FYOQABNR\:8;FR48HM\=
M%29TVWF=W/+*>&/W&YF)ZI].\IWVZ7-(OK';M&)[9B-B>K6$7-/G?(G5[6
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MX&626PXV4R96Y=KEM6NL?I0,+8!CHCA1!=ZF;BK;11JYQ=+N_M'N+[5>(?;
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M]G4;)Q3#'\Y%^]]MHP@-NV* <3"%@_/$A*ZJ#'0J)U9]561*92ER*:5Y7*8
MQM#7:1W2//JJ)+?'N,S9Q#[2;8$<!\=[C*/ VTC@T%)A(ZB0!;TYY8X2@D4W
MA4D%.9"X+F=7_2 %.9<,$(9QQC'-6%"<-_Q%8/O@'YX?2XIS:P]!%8TFBB7H
MWN4&Q%&0L7=RA_1IY&'<" ?J8J $K)C4$NQ>$NSGN>$@*O0*YX((),',N:.)
MSX'M2-[#PU^$_S-'H^?% 5J6^(F:BJU]*16O@#_C5*4#N#(A37F>1[O>?;94
MLZM4\XG1"O*2? T\HTVDE@[<@Y^,$PM\JJ\4:JH17X9BAB)C+845A?T$R?RH
M(BMS]H]Z+J(0LWH&^L5)NWOR9X<_3WU,+M[(T <:^CE"6]W+I-,]ZG94F!YK
M\#FP>A\J(RBWW=4-Y8//PY!,.\OL %,?@5B+P%;SJ#;*C[*$P.II&5([#6%$
MU;X$(#-C(_X>:UXTQ1*=D^:LX 0[7N-;-S*<[%4C@Y56VY96ER/3).*R(AJ:
M#?:/"&;H^2LHCFDV#/P$)VDF4L0X13C./_-#@;I.<%EE%H[$'3A6*.GR7XLA
M-C>5ZR?F!_=1* /CV2#"P"S/*(Y,%EC=%#^K+G>= %5-G QO,<= ?9@,'.C^
MD?DLT4O-*$,Y9Z-7I!NH@$Z-'"@*A$&NJ0$MQ9S)H0SER-]T/ILN:V#X>#EA
M?<)!(T60!^L'LT3;-6@6\%#VTN@Z[BY"6]AH/R@8/I'2(7H]>G^9RLG_^E/G
M].A]Y[SM8& :B^;TY+ENYWUIP"F/J0NQ]C:6B,J!/4VPP(G3.3KX%T_EA17-
M,$^--9&>\T&Z%$7B9_0Z+1X$+Q)G!,Z^IP.8:(OEX@]?Y>.#.Q8AD"*&Q7UZ
MWPHG;SD)^-[?WOC'LB].O?ZQ/)'=X\Y)O]\;#,21._*.3T^/W$[_/YVCT^Z;
M52BG*71R5DTG>)).M\T;_6L8(_HSVJN><Z,]J(_ R^EL?JM_Y>#Q-8XXE-XB
M\,_3^*PINU7#55@--HJ"(+JG@"<IR3R&6:H=SQ7F- ,%*A+>RF0LXFJW%!P)
M0AQ%HD['.%H/ODK'B6*(GU -F]S0/7KWM"U?%(EEV:9.@=^MG#RC2T261OH2
M"AWS)\,H!J?E@$!0IHE\I__CO6'9XO7OS2/'7<>L="!F[_R0]IN>J\S20:_=
MZ?;),DUC^)^GUZ.LUC9;K8>IM_AE;]#N]L_JOU]Z\5&[L^S*D^[IDZ]=\M1!
M>]!;\O72:Q_Y\K2SD1OWVZ=G)SNUX@WN<7>PA"J>M^)5;WQ(;,*L @R($N!O
M;WIOYED_C:;ONM.'W*93G(\?K2AP%]U5BHZX(E"?\BWGK$;#0&?)T5F4^(5,
M[E<HL)5%>UDCK/A6;_Y^3;BIN>Q4&UZQE>OO$PF_Y^S2DM78@WWL8'^)L(;N
MYPR-2E2_-ZR(KY5RMD>^?T=^KH8S7E-TXEKXG@/LS2=OCWOOCOLQ#D?G$4%*
MR6G!R)<;S)SS,(S0_072"$1((;1K-7/ DLB+++B)\?HJ\BPY>QP._TD\^)-L
MLDA3%"+Y2<R<_RL)6Z^@L5]ST.(%>LK#$$DV_=8O?-+NKO+*<^<,A 2[\'WO
M+:P\F^9I@ T9FG]R72E'HQ6)3[F;^  @- 1-!/&N=^@YHFM0$0C8M.CZ4829
MB&=.YT#[]D\1/NMMX%;$3<42Z7&OX9"IDJ[[OFDGVU".K3VZRDC=IL_NN_E3
M:Q@/\,ER(*!!VZ9(GL.6.[&%S2.]ZLW;MM2P^F!?]8$]V8V<["8,YA']\Z)4
MT)Q-_"2'L3**NX-G&,4;V*279I7%)2YCE5T[R%ZOUSH^7N7PFL($G$G=AI?>
M/WDL#5WOIG<JW/3GF5DO&AQJ%$V^I#W_Z"ZMPLR/&_#;V*9N^^SLQ8WW%]RO
MQM'5RL:Z%77/$77=:E%G]?&F_0YK3#7P\+8>B]^U3:1:.AMLW_%3;&C\9'M<
MUZRXY19#YC8J_L*FM U\6]F\#[+9'MZS;,Q#JLU_3HO' ?4;E#;DK%O7@;"-
MRJ"J_:YH _F^\]9A^?2%&JUIS*OJ[6#87^Q.0_1V;']*1.HG.*W)Z+Y*Q0,U
M,6&O-^R%$PT#!6=!W2&Q=/VI3[>EOWA NO14KPA.-4Z<VUB$#)_FY-'R[E'G
MM%7Z\ZS\9Y\1SHU/!@;T#_Y>]_M<AEBEA8UZ6,O$+5>PDJG"XL"WN)/<R8Z=
M+8B>4+W0^O:\O:2-[ML%TBB&]=1WX_.<+^EXU(<[6G%O6P[(&S=C2#A$FW;=
M*/8(2R_OD9MBBU:B1FC*5,83/Q2:&$>(0*W6=B>"3*Y$#:_L2'N:W2_YC+C+
MM:7[4XD1S6Y+R7MF]&:OQ&)X0-SX2@V:6@;\)5DJ+JH8DU<$MYNG(F-)>I@%
M22>?!18N$ 08P^,P(C#V:ZH_YN[0=IQ/68R8$RU:>CZX9_'U^:WFT'STVG+X
M?1QS#(L/\WK+NANI?5<(ZS4B=M7]4_M0S.-0C(CX>WZ8P<;P, T]6U9QH[IY
M@9,\E3'U_\&9'@RI&K1X,81L)<Z$AP<S(AQ7A&KPD9=#\N$.ZE[<F2-]NB^I
M"RIN%A-@B;1Z8U0/K9@"MS_X".SJ>-B"%RNNKB  -9V$-D!W*1H]W-B.:X>6
M/AGKXW2+6!^KMC#WJCJ8-X400J)_41G #KL'".@&W/LNR2:@'&:-.=QE3=.G
MJFF:___CP]@?@D)>Y=1_ST#PC6;+CGTIN32W87?0!DI[6L/NH-WK]C;10-EK
M]_O=C72_'K7/!JNVOVZC-7-#,?M*+MFT5ZKXR_DY:F\HO]J8[6Q4=&VG=_);
M$.8'F;BQ3SB"FT[+/6E?,6?^M%8M)?,9ZV<AV-44%5U9-_#F[W_M'+4[<^9)
M(]HK5S^/1HF+50.ZS:3KY]+J:+0Y6J7W]*0;\7"<=QPKP)_AXL7.+;IDT$M6
MV^_?..-8CO[V!O[N''40S N<?W!2!?9&RO8XG;SY^R<_3E+G'/QLCWSM-'*^
MP ^=C_3+O,N2 I@(3N2<:U#R_WTH<ONYR4*I1=$](_S:Z7$)0LL9RO1>RM"Y
MD@\'_X!__Q9%7@!OJE'6*6K[Z4)'CO[)@0SU;86<L^IGZ^JG:]6/53]6_31.
M_72KU<^-Q'CMJ] _J@)NL$_*IS(%OY/2#E1';UNBSBH-JS2LTB@KC7&:3M\=
M'M[?W[?A9^W;Z.[P'.2G?R>30^G=BO@0I*HX1$38?K=["&^A_K-+%-L].62O
M!S._G+CS*>_+:J<^']Q"R"(Q80#075$QWS- +ZQ<1VPQ$*/STA?1!-8^^TOB
M7-#8V10T; D0N'_P+Z6CSJ>Q'SA=Y2"1"H)MTT.?*%L-IR-Y=NT8_NV';YNB
MBZPC5#A"O8Z-PUF=9G5:LW0:_-WK=+#6A.;IX;71:,H:Z<+\E#&^0?+Z4W2%
M'J2;D8+Z/()?R!B]HB03["V!!T67](ZZN@CG1L1#$<KDX/-#(&?.N4OE*Z 8
MNZ9"L^*Z2>+:QJVLN+;BNGGBNKNVN/[DAP+^$_[+BNL]%===:UU;<6W%=?/$
M=?<YUC5&.Y:(\:12C@^.3JT<WTTYWCGJM"]_OFFB)-_="L<=%N8-VL?_^>'+
ME7,9)BDUE7V(W(PSGK;4L4G"X^;BGU9X6.'1M'TDX?&+> #[9S(#^R;%T9]@
MJMRX8SD15IHT5)I<G%]9:;+7TF17M[).H%RH+GC\[RL__(H-N%:\-%2\?/CX
MR8H7*UX:N)5UXL7Y($=^Z%OQL@OBY>K\!RM>K'AIX%;6B9<K,92!%2Q-%RS7
M7SY:P6(%2P.WLDZP7#,"V<I^T0+$W^/H)<UC6,9H^4_5/[4@*TV&5.F?]&HA
M58[:G64 )(-E,^D?N7895LM)NW]TW&#DDV]4E/ M\"7^VB3YN)-!Z$_4D8 M
M @BRUE['JM(B!2V65TV%C5J+/L!'^>)YQ[<W#-"HM50<WB-,J+5C&'&QT)(#
MK_SI$\"+5P)FVS8"8J.1\^I@$<]V !;Q]%O (C82S+(&[_ &EBH0%/0I\(9;
M?ZD:4IR#0'LRJ#F!'._>ZYL5A R7^T?FQP1GD.1EA 58[,<'=RS"6ZEK"3N#
MWG%+77CK)RD!#H]%XGA9,'-<D2$ ;CKV$1"=.CSA,8@V##L$7X WB@CF0SD6
MP0A;.?%&5%RI?H#(MS(+X2*Z'[A7XRB&U_,6 6E7.K F^W=/ALP\;@\Z3W7A
MEM\8D2U7]>_6^O*DW3U:%3)SO27#MX-5+W[$X-A"+,DZ=T\.(BX%LCS=@VW\
M%C[5E7SP70P8CD4\$:[,Z(V2%D(2K *X6F]X6S9[!6QFM]%NXW:WL2GIT5W-
M('T0J7S7),+<U8U4N#5G*\\6M:R^;#M_F&V-*O>HL_4P.72NHC"4@7,1"6-*
MA373]HI;K'VQ!]M8+W=4  J?!IOF)%'@>XY^NYW;92N0+"?9;=R!;?S6AA#]
M])V?PG/<C6\MELCY-/</01<NQKX<+<*<O=0PW+U,0YRTCT[Z&TI#G!P]]>(M
M+;G3[O6;7!FW3ZYVXV(6.ZE;;,!BOP,6N\K=&+/X48Y&L9PY5VWG-^%)ZR7L
M)\]8+V$/MG&I]-FOR(452Y:?[#;NQC9NP2CZIO&+(E;Q;]^53A[.:#D7>E@&
M13;.O8D?4J$F_?A\-!)^G!A!CP64R9<*>FR[3K[AA;C=_A9+XK]A<?O:8^Z;
M<FXU1?&7H2<?L*Q9#;IY!;7Q]6>UEX'-0;O7[6TB2MAK]_O=3=RXCX7;J]97
M[W/X\5O4S.H!5S]'JU3([O1V[K^9N$^$^4$F;NQ/T7)J9(WD*X60P9G0=EC#
M'J/'V&$-35VT.?ZY4SW^^1-XP^FKF/[\20[C3,0SI]/;IP'05M.4-(V=XF8U
MC=4T6]4TW6I-<P-78D#V%:B:GP2\BM,9[).>80VP#X(-M$2O66F9G=Q&JQ^L
M?EA7/XS3=/KN\/#^_KZ=2+=]&]T=GH.H].]D<BB]6Q$?@@ 5AYVCTVZ_VSV$
M!:O_[!)Q=D\.V9?I'G7.) E+/T268@V#GVH9>DF?8\KO&B1MRQ&)(U#S2&]7
ME(GS_8@0_$2B4RT.1E(T<,U%-('%S_Z2.!=9'*,^_<*(,U'H?(KBB=,_^)=2
M1ZK44;D]I&U@VW2:U$,@&C@="3=Q)0$&^N';IJ@=Z]X4[DVO8P-I5GU9];5-
M]Z;7><Z 4SN/>F\ELPT\6<EL)?-6)7-W;<F\4/QG)?.^2>:NM9FM9+:2>:N2
MN?L<FQG#%4LD=E(IL@='IU9D[Z;(QI%3ES_?-%%H[VZ-X0[+[0;M(\V;N@R3
M5&"DU,ZK:Z;PN+GXIQ4>5G@T;1_KAM7=N&,Y$5::-%2:7)Q?66FRU])D5[>R
M3J!<B,#-@I6'7UKQLDWQ\N'C)RM>K'AIX%;6B1?G@QSYH6_%RRZ(EZOS'ZQX
ML>*E@5M9)UZNQ% &5K T7;!<?_EH!8L5+ W<RCK!@A!!0#,K^T4+J#^[BVOR
MGZI_=A*MN7_2JP4U.6HOG0HY&)S6?_W(M<O04D[:_:,F0Q_OT3CVOS9)/NYD
M$/H3M11@C?^]GX[;ZUA5SYLJOT=4V*BU5,R5W\3Q[0T#-&HM%8?W!,!!BT;X
M FB$@Y='(SP<1MX,_C5.)\'?_S]02P,$%     @ CX*;4/-&&XW("@  F7$
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MVRS_%@[D4EU4V%Y?DJBME2OO_18Y=X'0F_FQO@$0_RM@%^_^#U!+ P04
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MS/A$K),HF'0N09,4YC%0NQ3+*E"@FOZK,>)_^CY][L;C40XT"0$<2V^#^50
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MG37!2C5;XZ3.KE'JMP"PKB"%I$4E)T.?3N-L6#0W*JOF0T)Q4L):2TK #!M
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M7'N5:;QZMG"F@1?HG,N!]Q0#KE48,B&VNA.6%Y^01$4=I M=JOC=#>O1*\&
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M59<U2[_#$^3%]NU[HL7?9]/3C[P$_SB>\&MC//GB=.)9-=2?+Z-5V(A!+T.
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M&=7EHO .3$>TWX=G\S:]V9.*#B<$ZZ"IBQZ(*)5(Q8 V,;8[=PT1V2%%ZW5
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MT+P!R;(,$C[?#]J7A'/ZSW_[?U!+ P04    " "/@IM0K-K35LV'  #_B04
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M-Y2_^J89$K<Y-Y[J;56)NE*[2I#ZC >01-*#&#$/)IYD4"0"4QP&(O#0XN@
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M8^N#;HG=5_R>@(,NYV;D:=?JGC1'"W'_MWU+M'R\%\NE7L0D?UI$H=KS(QQ
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M>6IU'FU!:VZ*HF'UH# @V;#K?F/S',:6D;%AD!L['M: ME\,\/8R:+WN;%Z
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MT_5Z!H97^SST\Z!VJ]_!H!I9@?9"R2D#_2(*5^2?GQ][LNSSB^+MYIY??GB
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M-V"-A%K=6RQT%+Q!XP:T>( U(*!%!!A(ADC;'_&+LU/"<_Z.1E;O<_Z$!KJ
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M2"+$E7D7<9A*(76+.Q*E'I.^6\T.6\)ST\V[?.MB"IM&D*;%M^D%Z6@#VLZ
MI54X JYCVXD'D&[Z<1I(#>>FL<J&]P'M1T>T!K4H;6E/:V,Z(G)D=;J^WT]O
M;7KN_4R6^C/Y>"]$_4M9K!X5L355LC072[7.?$&:"A5;(P6G",<^)3"BJ?)9
M49Q":BZ'8B:\&(<H=DLHNI:AN>FY;<M)-W5V]<38J;DIX1Y9_6V1O@%K:8 1
M![3RF&KEC41@(Q)H91K)=!P*X2%5YM4\3:I*AT+P4,4.-F[/$$!VEV<R8T29
MHDV(09%]7RPSEHGJD_A6_ZQ ^,<B$K[T(Q$K!>MCB!GW8<(# FF:"LJY8"%R
MR]BT(CLW-;K#-=BR#5J^P6?-.3"LNSKJ=M-@Z8P/#N[8#O<0N+J[TTXP#>HR
MVU&>UBUV0N/(]75[N_=91;D2RELF-%N:.SEMC)VFOHBH5.HI4$XM1@C#1(94
MJ2<L<9"@%'&W5LKG*,U-(ZT9!<LMI\Z'%F<PM3ZWN!ZI\8\N#$@[3(YS>M&-
MQ, '&&>(37V&T2WSB6.,"R_TK3OR\8$LES_K+!2AKXMQ[)/42Z$D5!<*PAP2
MR1,8<"].(@][$6=NY4;VQI^;&EB7S3 \@I9)U]HB^PAV+_\!<!EYT;M!TJ-^
MR$G!KRX;LC_JQ-5"3HIT7"3D]&/]KWUDS362VYR_*(SA(')M-NCHTK*H5J78
M9H\'44HB$D 4^@3B. @@X6IMQU$L$H)B2D/LLL\[49_;HM]A?MWP>H=]L.7?
M)JMZ@+FQLQ=&0WQD=3(DV+WNJ3B#-O0=%GL&)K_?XHS-J;LO[H.X:;RJK!>;
M,,Y')G)29H7) T0H3@5-&&2^IXR5U.>0,HDA08QR3P14>-)&JYVE,#?-M6'R
M!K1L.N54GH>R6PD- M#8L1!+0*R5R$6A.Q2%>G='2:B_'2J(\X-/H@0NRM8N
M],L/]O4[3*=N4UA'O"0U:;WGU)/*Q9 2\I1*B'WJPX2(&&*&11)3'&+BNSD@
MIPG-;6FOS>X=9H'F]J*[[8:NK7-R/6;3>"G.</7P5[JQN-IQ.3/\Q!Y,MY#'
MKLR%Y_OY-.O4GNI3<<O^<Y658N>N_"*)A"\PHU"P5)^D, ^FA(8PU!=B_<#'
M"2:+7-PI7<7MG)@N<E:?>MI\ZKM$Q_OBWZN![DFEC.9"KDN3]:A^T0FQG2=R
M-6S3:(B635WO9LVH5=$09R?#!H\A?8I.>I.Z$#:2'WH,5N]<70G#I M6.GM*
M\$7 , UC1& 24*K<A !#I4PH3*,@%B26DGC"-?AQ@L[<+(IU#8A*\WD#*L.I
MR=$3O'>!C#U<0Q%@C (*4:(+2?)8UY#T?85K*#!EPB,A6SR:+CC*A"SKR= ]
MI#D>QNO<@Q;>87#UPCB2(O)@0)1'JRQ>IG - TB$%_$P2KPX:G%]E5ON=8.A
MVE+\DV%J'V2[$J4)PFEM89>;)I&^N@%ONE?U-?5=3N$P4I67/5+/5>OEE+P=
M%5]./MZ[!<#AN.]6=563G&?YW0+A@!(F!611K+0M$@2FG(20IC&5G)$P"CS'
M1@ =Y.:VF:W]O5.?/]AAV[DM0!?BML[R4#A.XS+WAK!/JP +9*YO&-!%9.JV
M 18"GV@>8//6U3;Q>U*^*TTLCYN\R?>B--06))1)S$D ?9)R75M&MQ*,(F5Y
M,(Q"/Y0^<2HM94%S;NIEWU9^)"7XHMD%RN9IS)#>5LA9U)TMDB&PG-0Z40SK
M/F(-RTUNMV["VNB<48R52Q"-9+B<)?M<1LPE'#H,FHNO]JAO]>:Q$KFIX/K[
MH^([K]L@P"*B:4ICHHP:1'07TRB%-)($1D0&2B.A -NE1W>3F9NV,8R"IJ3M
MFM7V'JRENW,!UF[=,AQ8(ZN3T7%R*%$U"%X35:9ZDX-WK"ZHTK5*>>$;\%9\
MRY06 4)'[4W;A;H !+S-F,@KL<[+6"I9BW)]8?NN%,W]FJ]9?0^:B7BO], #
M 1]O/P*I]'I]+P 77\2R>#1/ZE&84B2BU!<O=FXRKJG_I0*\7-T!I@T;KIM,
MUNK=NLR4J5,#46>/I?['[]_^W?=0\ ,HE!&4<6'H_)YG>@\Q>JG)(_D/\DCR
M'\&G^ZP"I7A4\#7!WGM=X%Q_,(JP_LMJ_=T\MN'@5:ZTEOD5:87\<:#Z6A>_
MD<ZR6N??GJZ:UD4)]HIH77ZZKR?\.EN*\H6:[+NB?%I$0102'_N0"X$A3D/E
M]2*)(?/"($PQ4[]U[(&W-_[<MH>UHV9X!"V3KI[M/H*VKFQO7*;Q72TAZ>&I
MGA3\:M=T?]2)?=&3(AT[GZ<?&Z+HW>:&WH(H#Q+1*(9") '$7L)@FH8<LC0*
M_"1)*4%75+[;T)G;0C[JOKZ]Y+J3^7A-.;PMQ';NY # C;S2K\3LRD)Y1XB,
M5RUO2^H92^8=R=M=-^_X\8GK9[WZSY5)/FD9JMXI0Z[\=$_R=\WUWM\*<YPL
M^!\BN[M7?]Y^$26Y$[^HH>N72LMM5XR/PP#'"$%)?*64DC30Q\(8)@3Y/(K#
M&#.G8^$Y"#4W#7AU1:@;T*"SHQ(J8/!1)CQ1?DZ#T W88'0#6I3 &B9@<-+Y
M80+T+>@PA\D=NZ38,WV'(V\H?\9/<+H*9R/,^2QJI TIUY^CRMH(,SE8G;8Q
M>.MG>>ALLURMI:??1*W<$N81]3]($ZF;:!,&$^YY4/I$>HR%6$BK(_53@\]M
M)][PYK;O[>%EM__T16'L8'++EE+48L#KZZ?$'5(%[HT_J2HZ)=FA2CCY3/\K
M(:PH']<Q:!/K?:$K8I1/+PHN%B'S/,$\!!$)*,0>3R'E1$(F91RA&),HHJXW
M0SKHS6T!;VX\[/!\TT3$]2GKFG.@67>_+-*%NVWL<# TIXDE7@5DKVLD%O ,
M<)NDB\KDETHL1#YUM\3FM7[[_TX!C=N<FQ/O^V*IWJ\:&V41>#R1B$O(/9Q
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MF!')84)8"G&@V4ND'T*,68@025*4&)&MV8N>FT&HE >-]F"KOHZN['4 [/7
M(B9G-R@& =C1H![9K,P(98O@Y6AH3Q1__)"#SVR]2M4^7AE,? ,^BN^9LF1
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MW$QMPG T1C<#M6JC5-$\UV^WT_Q(QL0SN[N'IY/YS',#0H6_KHKU/;T7=>D
M'0DHUSK_8J$S-RI)A5A\_/WK[PN9I!B'S(>4IE1Y"91 BBB#,2=!+ 7W.#(Z
M(+ 3.[>YWBK>%KBH50>=NEN$K<R'P2 P. JX(YN.5\?5(A0X"KX3A0%M< 90
M!P7K!ZHP7%:';0L!EBN: [H-"&8E"#S(Z0OX^.&GSU_!TW)3@O"'\+\#6@*=
M!5N]_\-.'GN@Q7W%I%>%VU1#ZO>%#L]53Z\*$*NW'079K,>K-\!FWMITP37K
M'AX$UNS?'EK\\UFU7)6F40W\K"3<ZV(2U1??;(NHAR62NGY>$J80$R%@@JF
M6"9!R*7 S*Y6PV61<UM@=AH/),LP0-G,T72+W=B'2EMERQ&8+,RA<%N\\Z+4
MB0MWFJ)P6K33^,V!7+893;-E5<AXX4D1^RA*88QC'V+$0YB0F,.8")G(A*9,
M!(OU:DV79C9DKVTK8[&5,-Y7?Z=E@.5.04LNVCW4S&S"0"Q&GOP?#0"P)YD]
M[:I3<MF]YJ<EE3WMUPF9;,<C ]D7MI0OW[-RX4=^RA/!($\#I&9FPF :B0@R
MQ&6,O)@&D5&F26?K<UO(]ZF5M'Z6R_@A<F:S<S >(\]/<RCLV0:ZNNR4.>!
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MT/"!YM$";2)DN+CRW>8%56"3#LY7$U8B_:\(B-GX;>CC0V"0G+3)E^!,Q!Z
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M15(HJP5M,K3M"&%U(1P^)L)NKSK4GIROX$,(GR:;"]Y-052(,R1(D_NDO:6
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M'IR,,__KFUUH0V'HFVQ2</%O+^KQ;^5V#]^CX/;KQV]1\*! 1NA0D%+*R8L
M&#SATG(.SA4$65QTP44E94<WXHEV*$#K?<I%0#&!EJC99&2A Y26&_J1*3U,
M[<D?KT/!/E@;KD/!/@IO(+_E1O6TB@FC*0H8R^3 "8;DRF&!6)RWQ5L,;I :
MOF^Q0\%>.'BH0\$^2FD(4!?I7DH[%+K>VQNL\RB$ Y\CA0A1&106HRR#9/NW
M5#5WN#H?[E"PCVP;0,;-PFD9K$R;5&6LP:+,%GQ@!53M<6LYR]8,DK#[378H
M.,;8'*Z6EC!UF5T:B]<Y()0@*);3GH&+M,ZX]$PYXLW)8?M>M&!OCM#H8QT*
M]A!O*^BX*E>.F&U1)H-1I7:B=1ZBB1&22,BE$Y'K0?HO?9,="HZV. >II0%,
M#5*;' WG62E/ZRKGNI-+"!BK9^!U24&)&/_5H>" #@5[8>L4'0KV470#8+\\
M<KQ;_TY+7SE6.$1?=Q5K$WC!%1 #+AFCT(5!.H_=2U'C:=F#@^7V6/9>--<
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M9E^S:L.V*O[GJU0?YVVPW#E(&,GX,OH2N?&0>1(H54FT@(; V;&$MU)IU&O
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MQ]\_X7R%$V5<4ED6T!'KZLD,8NU\:*24(64OO!RDO.=ALCJARSTE=/6HA@9
M=5-"5_G,DX*(4EL+AF&=/B8L>$1%P8R2)3%,PIT@*^J*GDXP\D\)1GT(?NP
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M=&EO;F]F<"YH=&U02P$"% ,4    " "/@IM0@[-","8(  "9*@  &@
M        @ &I'   97AH,S$R8V5R=&EF:6-A=&EO;F]F<"YH=&U02P$"% ,4
M    " "/@IM0'S&Q/HD%   6(   &@              @ $')0  97AH,S(Q
M8V5R=&EF:6-A=&EO;F]F<"YH=&U02P$"% ,4    " "/@IM0E:=/YT(V 0!=
MRP\ $0              @ '(*@  ;'AR>"TR,#(P,#,S,2YH=&U02P$"% ,4
M    " "/@IM0\T8;C<@*  "9<0  $0              @ $Y80$ ;'AR>"TR
M,#(P,#,S,2YX<V102P$"% ,4    " "/@IM0](_G,8@1  !CIP  %0
M        @ $P; $ ;'AR>"TR,#(P,#,S,5]C86PN>&UL4$L! A0#%     @
MCX*;4&;N'P_?.P  +(P" !4              ( !ZWT! &QX<G@M,C R,# S
M,S%?9&5F+GAM;%!+ 0(4 Q0    ( (^"FU"LVM-6S8<  /^)!0 5
M      "  ?VY 0!L>')X+3(P,C P,S,Q7VQA8BYX;6Q02P$"% ,4    " "/
M@IM0>91D=8-)   650, %0              @ ']00( ;'AR>"TR,#(P,#,S
?,5]P<F4N>&UL4$L%!@     +  L \@(  +.+ @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6781012736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 18, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 20, 2014 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt Issuance Costs, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from Convertible Debt</a></td>
<td class="nump">$ 87.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ConvDebtInstrumentInterestRateStatedPercentage', window );">Conv Debt Instrument Interest Rate Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt Instrument, Convertible, Conversion Ratio</a></td>
<td class="nump">118.4553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.442<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Debt Issuance Cost</a></td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Unamortized Debt Issuance Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt Instrument, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_MortgageDebtInstrument_Revere_LXRX', window );">Mortgage Debt Instrument_Revere_LXRX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.7<span></span>
</td>
<td class="nump">$ 12.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX', window );">Mortgage Debt Interest Rate_Base_Revere_LXRX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX', window );">Mortgage Debt Interest Rate BasePlus_Revere_LXRX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_MortgageDebtBalloonPayment_LXRX', window );">Mortgage Debt Balloon Payment_LXRX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_MortgageDebtIssueCosts_Revere_LXRX', window );">Mortgage Debt Issue Costs_Revere_LXRX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_BuildingsCollateral', window );">Buildings Collateral</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_LandCollateral', window );">Land Collateral</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_BuildingsCollateral">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The buildings that serve as collateral for Lexicon's mortgage loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_BuildingsCollateral</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ConvDebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conv Debt Instrument Interest Rate Stated Percentage - contractual interest rate for convertible debt bonds under the debt agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ConvDebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_LandCollateral">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The land that serves as collateral for Lexicon's mortgage loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_LandCollateral</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_MortgageDebtBalloonPayment_LXRX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Mortgage Debt Balloon Payment_LXRX - Balloon payment due at the end of the 2-year maturity date of mortgage loan with Revere.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_MortgageDebtBalloonPayment_LXRX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_MortgageDebtInstrument_Revere_LXRX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Mortgage Debt Instrument_Revere_LXRX - Principal loan amount borrowed, using Woodlands Campus as collateral</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_MortgageDebtInstrument_Revere_LXRX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Mortgage Debt Interest Rate BasePlus_Revere_LXRX - represents a base for the range of the interest rate that will be charged on the Revere loan. Interest charged will be greater of 30-day LIBOR plus 5.5% or 7.5%</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Mortgage Debt Interest Rate_Base_Revere_LXRX - interest rate in Revere loan agreement is 30-day LIBOR plus 5.5% as base rate. Interest charged is the greater of base or 7.5%</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_MortgageDebtInterestRate_Base_Revere_LXRX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_MortgageDebtIssueCosts_Revere_LXRX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Mortgage Debt Issue Costs_Revere_LXRX - represents the total debt issue costs incurred in connection with the Revere debt agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_MortgageDebtIssueCosts_Revere_LXRX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentOfFinancingAndStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6784502880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Stock-based Compensation Summary (Details 1) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="nump">10,721<span></span>
</td>
<td class="nump">7,695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 7.11<span></span>
</td>
<td class="nump">$ 8.95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</a></td>
<td class="nump">3,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 3.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</a></td>
<td class="nump">202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 13.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</a></td>
<td class="nump">73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 11.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</a></td>
<td class="nump">4,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 9.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</a></td>
<td class="nump">4,824<span></span>
</td>
<td class="nump">2,830<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 4.29<span></span>
</td>
<td class="nump">$ 6.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</a></td>
<td class="nump">3,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 3.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</a></td>
<td class="nump">1,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 7.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</a></td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 5.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>42
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "lxrx-20200331.htm": {
   "axisCustom": 0,
   "axisStandard": 4,
   "contextCount": 73,
   "dts": {
    "calculationLink": {
     "local": [
      "lxrx-20200331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "lxrx-20200331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "lxrx-20200331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lxrx-20200331_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lxrx-20200331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "lxrx-20200331.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd"
     ]
    }
   },
   "elementCount": 284,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 6,
    "total": 6
   },
   "keyCustom": 34,
   "keyStandard": 234,
   "memberCustom": 0,
   "memberStandard": 15,
   "nsprefix": "lxrx",
   "nsuri": "http://www.lexpharma.com/20200331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Document and Entity Information",
     "role": "http://www.lexpharma.com/role/DocumentandEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110103 - Disclosure - Cash and Cash Equivalents and Investments",
     "role": "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments",
     "shortName": "Cash and Cash Equivalents and Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114104 - Disclosure - Fair Value Measurements",
     "role": "http://www.lexpharma.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117105 - Disclosure - Debt Obligations",
     "role": "http://www.lexpharma.com/role/DebtObligations",
     "shortName": "Debt Obligations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120106 - Disclosure - Commitments and Contingencies",
     "role": "http://www.lexpharma.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121107 - Disclosure - Collaboration and License Agreements",
     "role": "http://www.lexpharma.com/role/CollaborationandLicenseAgreements",
     "shortName": "Collaboration and License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryMajorClassesPolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryMajorClassesPolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2304302 - Disclosure - Summary of Significant Accounting Policies Equity Incentive Awards (Tables)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables",
     "shortName": "Summary of Significant Accounting Policies Equity Incentive Awards (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311303 - Disclosure - Cash and Cash Equivalents and Investments (Tables)",
     "role": "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables",
     "shortName": "Cash and Cash Equivalents and Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315304 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.lexpharma.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Consolidated Balance Sheets-Unaudited",
     "role": "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
     "shortName": "Consolidated Balance Sheets-Unaudited",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:InventoryMajorClassesPolicy",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405401 - Disclosure - Summary of Significant Accounting Policies Inventory (Details)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails",
     "shortName": "Summary of Significant Accounting Policies Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:InventoryMajorClassesPolicy",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "i3f18a324e14b49309846f18ff6f8c0bc_D20200101-20200331",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation Valuation (Details)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails",
     "shortName": "Summary of Significant Accounting Policies Stock-based Compensation Valuation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "i3f18a324e14b49309846f18ff6f8c0bc_D20200101-20200331",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "i006d636778dc433599008ebda0fae643_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation Summary (Details 1)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
     "shortName": "Summary of Significant Accounting Policies Stock-based Compensation Summary (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "i006d636778dc433599008ebda0fae643_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "i5874757311014de880a5b19a0ef172e9_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - Cash and Cash Equivalents and Investments (Details 1)",
     "role": "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1",
     "shortName": "Cash and Cash Equivalents and Investments (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "i5874757311014de880a5b19a0ef172e9_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RealizedInvestmentGainsLosses",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RealizedInvestmentGainsLosses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413407 - Disclosure - Cash and Cash Equivalents and Investments (Details 2)",
     "role": "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2",
     "shortName": "Cash and Cash Equivalents and Investments (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RealizedInvestmentGainsLosses",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RealizedInvestmentGainsLosses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416408 - Disclosure - Fair Value Measurements (Details 1)",
     "role": "http://www.lexpharma.com/role/FairValueMeasurementsDetails1",
     "shortName": "Fair Value Measurements (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "i65c277c002ca41af9214fb16de22bcb8_I20171218",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredFinanceCostsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419409 - Disclosure - Debt Obligations (Details)",
     "role": "http://www.lexpharma.com/role/DebtObligationsDetails",
     "shortName": "Debt Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "i65c277c002ca41af9214fb16de22bcb8_I20171218",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredFinanceCostsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "lxrx:Lxrx_Sanofiterminationcashpayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423410 - Disclosure - Collaboration and License Agreements (Details)",
     "role": "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails",
     "shortName": "Collaboration and License Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "lxrx:Lxrx_Sanofiterminationcashpayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Consolidated Balance Sheets Parentheticals",
     "role": "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals",
     "shortName": "Consolidated Balance Sheets Parentheticals",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "i0b3c8bb1271b4ce29575ff1d4f6c73f6_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "lxrx:Netproductrevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Consolidated Statements of Comprehensive Loss-Unaudited",
     "role": "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
     "shortName": "Consolidated Statements of Comprehensive Loss-Unaudited",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "lxrx:Netproductrevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Consolidated Statements of Comprehensive Loss Parentheticals",
     "role": "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals",
     "shortName": "Consolidated Statements of Comprehensive Loss Parentheticals",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "ia7a2afb94e3d47888a4f5fb5cbad1728_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Consolidated Statements of Stockholders' Equity/Deficit-Unaudited",
     "role": "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited",
     "shortName": "Consolidated Statements of Stockholders' Equity/Deficit-Unaudited",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "ia7a2afb94e3d47888a4f5fb5cbad1728_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
     "shortName": "Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Summary of Significant Accounting Policies (Notes)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes",
     "shortName": "Summary of Significant Accounting Policies (Notes)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109102 - Disclosure - Recent Accounting Pronouncements Level 1 (Notes)",
     "role": "http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes",
     "shortName": "Recent Accounting Pronouncements Level 1 (Notes)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200331.htm",
      "contextRef": "icb4542eed612440d8c7789b3214b8cd3_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 15,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "lxrx_BuildingsCollateral": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The buildings that serve as collateral for Lexicon's mortgage loan.",
        "label": "Buildings Collateral",
        "terseLabel": "Buildings Collateral"
       }
      }
     },
     "localname": "BuildingsCollateral",
     "nsuri": "http://www.lexpharma.com/20200331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_CashAndCashEquivalentsAndInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash and Cash Equivalents and Investments [Abstract]",
        "label": "Cash and Cash Equivalents and Investments [Abstract]",
        "terseLabel": "Cash and Cash Equivalents and Investments [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAndInvestmentsAbstract",
     "nsuri": "http://www.lexpharma.com/20200331",
     "xbrltype": "stringItemType"
    },
    "lxrx_CollaborationAndLicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration and License Agreements [Abstract]",
        "label": "Collaboration and License Agreements [Abstract]",
        "terseLabel": "Collaboration and License Agreements [Abstract]"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementsAbstract",
     "nsuri": "http://www.lexpharma.com/20200331",
     "xbrltype": "stringItemType"
    },
    "lxrx_ConsolidatedBalanceSheetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Consolidated Balance Sheets [Abstract]",
        "label": "Consolidated Balance Sheets [Abstract]",
        "terseLabel": "Consolidated Balance Sheets [Abstract]"
       }
      }
     },
     "localname": "ConsolidatedBalanceSheetsAbstract",
     "nsuri": "http://www.lexpharma.com/20200331",
     "xbrltype": "stringItemType"
    },
    "lxrx_ConsolidatedStatementsOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Consolidated Statements of Cash Flows [Abstract]",
        "label": "Consolidated Statements of Cash Flows [Abstract]",
        "terseLabel": "Consolidated Statements of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "ConsolidatedStatementsOfCashFlowsAbstract",
     "nsuri": "http://www.lexpharma.com/20200331",
     "xbrltype": "stringItemType"
    },
    "lxrx_ConsolidatedStatementsOfOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Consolidated Statements of Operations [Abstract]",
        "label": "Consolidated Statements of Operations [Abstract]",
        "terseLabel": "Consolidated Statements of Operations [Abstract]"
       }
      }
     },
     "localname": "ConsolidatedStatementsOfOperationsAbstract",
     "nsuri": "http://www.lexpharma.com/20200331",
     "xbrltype": "stringItemType"
    },
    "lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Consolidated Statements of Stockholders\u2019 Equity [Abstract]",
        "label": "Consolidated Statements of Stockholders\u2019 Equity [Abstract]",
        "terseLabel": "Consolidated Statements of Stockholders\u2019 Equity [Abstract]"
       }
      }
     },
     "localname": "ConsolidatedStatementsOfStockholdersEquityAbstract",
     "nsuri": "http://www.lexpharma.com/20200331",
     "xbrltype": "stringItemType"
    },
    "lxrx_ConvDebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Conv Debt Instrument Interest Rate Stated Percentage - contractual interest rate for convertible debt bonds under the debt agreement",
        "label": "Conv Debt Instrument Interest Rate Stated Percentage",
        "terseLabel": "Conv Debt Instrument Interest Rate Stated Percentage"
       }
      }
     },
     "localname": "ConvDebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://www.lexpharma.com/20200331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_DebtObligationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Obligations [Abstract]",
        "label": "Debt Obligations [Abstract]",
        "terseLabel": "Debt Obligations [Abstract]"
       }
      }
     },
     "localname": "DebtObligationsAbstract",
     "nsuri": "http://www.lexpharma.com/20200331",
     "xbrltype": "stringItemType"
    },
    "lxrx_FairValueMeasurementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair Value Measurements [Abstract]",
        "label": "Fair Value Measurements [Abstract]",
        "terseLabel": "Fair Value Measurements [Abstract]"
       }
      }
     },
     "localname": "FairValueMeasurementsAbstract",
     "nsuri": "http://www.lexpharma.com/20200331",
     "xbrltype": "stringItemType"
    },
    "lxrx_InventoryAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inventory [Abstract]",
        "label": "Inventory [Abstract]",
        "terseLabel": "Inventory [Abstract]"
       }
      }
     },
     "localname": "InventoryAbstract",
     "nsuri": "http://www.lexpharma.com/20200331",
     "xbrltype": "stringItemType"
    },
    "lxrx_IpsenMaximumRegulatoryAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the maximum regulatory and commercial launch milestone payments.",
        "label": "Ipsen Maximum Regulatory And Commercial Milestones",
        "terseLabel": "Ipsen Maximum Regulatory And Commercial Milestones"
       }
      }
     },
     "localname": "IpsenMaximumRegulatoryAndCommercialMilestones",
     "nsuri": "http://www.lexpharma.com/20200331",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenMaximumSalesMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the maximum sales milestones payments.",
        "label": "Ipsen Maximum Sales Milestones",
        "terseLabel": "Ipsen Maximum Sales Milestones"
       }
      }
     },
     "localname": "IpsenMaximumSalesMilestones",
     "nsuri": "http://www.lexpharma.com/20200331",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl. This represents the milestone payments received under the agreement.",
        "label": "Ipsen Milestone Payment",
        "terseLabel": "Ipsen Milestone Payment"
       }
      }
     },
     "localname": "IpsenMilestonePayment",
     "nsuri": "http://www.lexpharma.com/20200331",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenMilestonePaymentReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the amount of milestone payments earned during the period.",
        "label": "Ipsen Milestone Payment Received",
        "terseLabel": "Ipsen Milestone Payment Received"
       }
      }
     },
     "localname": "IpsenMilestonePaymentReceived",
     "nsuri": "http://www.lexpharma.com/20200331",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This is the amount of the upfront payment allocated to the committee participation deliverable.",
        "label": "Ipsen Revenue Allocated to Committee Deliverable",
        "terseLabel": "Ipsen Revenue Allocated to Committee Deliverable"
       }
      }
     },
     "localname": "IpsenRevenueAllocatedtoCommitteeDeliverable",
     "nsuri": "http://www.lexpharma.com/20200331",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the amount of the upfront payment allocated to the development services deliverable.",
        "label": "Ipsen Revenue Allocated to Development Deliverable",
        "terseLabel": "Ipsen Revenue Allocated to Development Deliverable"
       }
      }
     },
     "localname": "IpsenRevenueAllocatedtoDevelopmentDeliverable",
     "nsuri": "http://www.lexpharma.com/20200331",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenRevenueAllocatedtoLicenseDeliverable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the amount of the upfront payment allocated to the license deliverable.",
        "label": "Ipsen Revenue Allocated to License Deliverable",
        "terseLabel": "Ipsen Revenue Allocated to License Deliverable"
       }
      }
     },
     "localname": "IpsenRevenueAllocatedtoLicenseDeliverable",
     "nsuri": "http://www.lexpharma.com/20200331",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the revenue recognized in the period.",
        "label": "Ipsen Revenue Recognized",
        "terseLabel": "Ipsen Revenue Recognized"
       }
      }
     },
     "localname": "IpsenRevenueRecognized",
     "nsuri": "http://www.lexpharma.com/20200331",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenTotalPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl. This represents the total payments received to date under the agreement.",
        "label": "Ipsen Total Payments",
        "terseLabel": "Ipsen Total Payments"
       }
      }
     },
     "localname": "IpsenTotalPayments",
     "nsuri": "http://www.lexpharma.com/20200331",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenTotalUpfrontPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the total of the upfront payments under the agreement.",
        "label": "Ipsen Total Upfront Payments",
        "terseLabel": "Ipsen Total Upfront Payments"
       }
      }
     },
     "localname": "IpsenTotalUpfrontPayments",
     "nsuri": "http://www.lexpharma.com/20200331",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_LandCollateral": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The land that serves as collateral for Lexicon's mortgage loan.",
        "label": "Land Collateral",
        "terseLabel": "Land Collateral"
       }
      }
     },
     "localname": "LandCollateral",
     "nsuri": "http://www.lexpharma.com/20200331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_Lxrx_Sanofiterminationcashpayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "lxrx_Sanofi termination cash payment - represents the cash payment from Sanofi to terminate the collaboration alliance",
        "label": "lxrx_Sanofi termination cash payment",
        "terseLabel": "Sanofi termination cash payment"
       }
      }
     },
     "localname": "Lxrx_Sanofiterminationcashpayment",
     "nsuri": "http://www.lexpharma.com/20200331",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_Lxrx_sanofiInitialCashPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "lxrx_sanofi initial cash payment",
        "label": "lxrx_sanofi initial cash payment",
        "terseLabel": "lxrx_sanofi initial cash payment"
       }
      }
     },
     "localname": "Lxrx_sanofiInitialCashPayment",
     "nsuri": "http://www.lexpharma.com/20200331",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_Lxrx_sanofifuturecashpayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "lxrx_sanofi future cash payment - represents the future cash payment to be made by Sanofi as part of the termination of the alliance",
        "label": "lxrx_sanofi future cash payment",
        "terseLabel": "Sanofi future cash payment"
       }
      }
     },
     "localname": "Lxrx_sanofifuturecashpayment",
     "nsuri": "http://www.lexpharma.com/20200331",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_MortgageDebtBalloonPayment_LXRX": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Mortgage Debt Balloon Payment_LXRX - Balloon payment due at the end of the 2-year maturity date of mortgage loan with Revere.",
        "label": "Mortgage Debt Balloon Payment_LXRX",
        "terseLabel": "Mortgage Debt Balloon Payment_LXRX"
       }
      }
     },
     "localname": "MortgageDebtBalloonPayment_LXRX",
     "nsuri": "http://www.lexpharma.com/20200331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_MortgageDebtInstrument_Revere_LXRX": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Mortgage Debt Instrument_Revere_LXRX - Principal loan amount borrowed, using Woodlands Campus as collateral",
        "label": "Mortgage Debt Instrument_Revere_LXRX",
        "terseLabel": "Mortgage Debt Instrument_Revere_LXRX"
       }
      }
     },
     "localname": "MortgageDebtInstrument_Revere_LXRX",
     "nsuri": "http://www.lexpharma.com/20200331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Mortgage Debt Interest Rate BasePlus_Revere_LXRX - represents a base for the range of the interest rate that will be charged on the Revere loan. Interest charged will be greater of 30-day LIBOR plus 5.5% or 7.5%",
        "label": "Mortgage Debt Interest Rate BasePlus_Revere_LXRX",
        "terseLabel": "Mortgage Debt Interest Rate BasePlus_Revere_LXRX"
       }
      }
     },
     "localname": "MortgageDebtInterestRateBasePlus_Revere_LXRX",
     "nsuri": "http://www.lexpharma.com/20200331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_MortgageDebtInterestRate_Base_Revere_LXRX": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Mortgage Debt Interest Rate_Base_Revere_LXRX - interest rate in Revere loan agreement is 30-day LIBOR plus 5.5% as base rate. Interest charged is the greater of base or 7.5%",
        "label": "Mortgage Debt Interest Rate_Base_Revere_LXRX",
        "terseLabel": "Mortgage Debt Interest Rate_Base_Revere_LXRX"
       }
      }
     },
     "localname": "MortgageDebtInterestRate_Base_Revere_LXRX",
     "nsuri": "http://www.lexpharma.com/20200331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_MortgageDebtIssueCosts_Revere_LXRX": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Mortgage Debt Issue Costs_Revere_LXRX - represents the total debt issue costs incurred in connection with the Revere debt agreement",
        "label": "Mortgage Debt Issue Costs_Revere_LXRX",
        "terseLabel": "Mortgage Debt Issue Costs_Revere_LXRX"
       }
      }
     },
     "localname": "MortgageDebtIssueCosts_Revere_LXRX",
     "nsuri": "http://www.lexpharma.com/20200331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_Netproductrevenue": {
     "auth_ref": [],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net product revenue - amount of revenue recognized from product sales, net of discounts. Sales process constitutes an earnings process.",
        "label": "Net product revenue",
        "terseLabel": "Net product revenue"
       }
      }
     },
     "localname": "Netproductrevenue",
     "nsuri": "http://www.lexpharma.com/20200331",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_RecentAccountingPronouncementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Recent Accounting Pronouncements [Abstract]",
        "label": "Recent Accounting Pronouncements [Abstract]",
        "terseLabel": "Recent Accounting Pronouncements [Abstract]"
       }
      }
     },
     "localname": "RecentAccountingPronouncementsAbstract",
     "nsuri": "http://www.lexpharma.com/20200331",
     "xbrltype": "stringItemType"
    },
    "lxrx_SanofiRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the revenue recognized in the period.",
        "label": "Sanofi Revenue Recognized",
        "terseLabel": "Sanofi Revenue Recognized"
       }
      }
     },
     "localname": "SanofiRevenueRecognized",
     "nsuri": "http://www.lexpharma.com/20200331",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]",
        "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]"
       }
      }
     },
     "localname": "ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract",
     "nsuri": "http://www.lexpharma.com/20200331",
     "xbrltype": "stringItemType"
    },
    "lxrx_Sellinggeneralandadministrativeexpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Selling, general and administrative expenses - the expenses related to selling Lexicon's product as well as general and administrative costs.",
        "label": "Selling, general and administrative expenses",
        "terseLabel": "Selling, general and administrative expenses, included stock-based compensation of $2,256 and $1,643, respectively"
       }
      }
     },
     "localname": "Sellinggeneralandadministrativeexpenses",
     "nsuri": "http://www.lexpharma.com/20200331",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the employees' option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees",
     "nsuri": "http://www.lexpharma.com/20200331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the officers' and non-employee directors' option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors",
     "nsuri": "http://www.lexpharma.com/20200331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The expected term assumption that is used in valuing an option on its own shares for employees.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees",
     "nsuri": "http://www.lexpharma.com/20200331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The expected term assumption that is used in valuing an option on its own shares for officers and non-employee directors.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors",
     "nsuri": "http://www.lexpharma.com/20200331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For officers and non-employee directors, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors",
     "nsuri": "http://www.lexpharma.com/20200331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For employees, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, ExpectedVolatilityRate, Employees",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, ExpectedVolatilityRate, Employees"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees",
     "nsuri": "http://www.lexpharma.com/20200331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares for employees.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee",
     "nsuri": "http://www.lexpharma.com/20200331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares for officers and non-employee directors.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors",
     "nsuri": "http://www.lexpharma.com/20200331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock-based compensation expense included in research and development expense.",
        "label": "Stock-based compensation expense associated with research and development expense",
        "terseLabel": "Stock-based compensation expense associated with research and development expense"
       }
      }
     },
     "localname": "StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense",
     "nsuri": "http://www.lexpharma.com/20200331",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock-based compensation expense associated with selling, general and administrative expense",
        "label": "Stock-based compensation expense associated with selling, general and administrative expense",
        "terseLabel": "Stock-based compensation expense associated with selling, general and administrative expense"
       }
      }
     },
     "localname": "Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense",
     "nsuri": "http://www.lexpharma.com/20200331",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SummaryOfSignificantAccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summary of Significant Accounting Policies [Abstract]",
        "label": "Summary of Significant Accounting Policies [Abstract]",
        "terseLabel": "Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesAbstract",
     "nsuri": "http://www.lexpharma.com/20200331",
     "xbrltype": "stringItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r134",
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Statement, Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r2",
      "r16",
      "r111",
      "r112",
      "r151"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r26",
      "r130"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Accumulated depreciation and amortization, property and equipment"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r49",
      "r50",
      "r51"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r48",
      "r51",
      "r52",
      "r188"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Gain (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r156",
      "r158",
      "r179",
      "r180"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r77",
      "r202"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r109",
      "r210",
      "r225"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r46"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.",
        "label": "Available-for-sale Securities",
        "terseLabel": "Short-term Investments"
       }
      }
     },
     "localname": "AvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r120"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.",
        "label": "Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.",
        "label": "Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAmortizedCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.",
        "label": "Available-for-sale Securities, Amortized Cost Basis",
        "terseLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.",
        "label": "Available-for-sale Securities, Current",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardDateAxis": {
     "auth_ref": [
      "r159",
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Axis]",
        "terseLabel": "Award Date [Axis]"
       }
      }
     },
     "localname": "AwardDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Domain]",
        "terseLabel": "Award Date [Domain]"
       }
      }
     },
     "localname": "AwardDateDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r159",
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r0",
      "r25",
      "r79"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for cash and cash equivalent footnotes,  which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.",
        "label": "Cash and Cash Equivalents Disclosure [Text Block]",
        "terseLabel": "Cash and Cash Equivalents Disclosure"
       }
      }
     },
     "localname": "CashAndCashEquivalentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": {
     "auth_ref": [],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.",
        "label": "Cash and Cash Equivalents, Period Increase (Decrease)",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r6",
      "r80",
      "r82"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r182",
      "r183",
      "r184"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborative Arrangement Disclosure"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r37",
      "r133",
      "r218",
      "r229"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r132",
      "r135"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies Disclosure"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "verboseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value per share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $.001 par value; 225,000 shares authorized; 107,711 and 106,679 shares issued, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r54",
      "r56",
      "r57"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r82",
      "r187",
      "r190",
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Consolidation, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales (including finite-lived intangible asset amortization)"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of Goods and Service [Policy Text Block]"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt Disclosure"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r9",
      "r11",
      "r12",
      "r211",
      "r212",
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Debt Instrument, Convertible, Conversion Price"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r34",
      "r141",
      "r142",
      "r144"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Debt Instrument, Convertible, Conversion Ratio"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r201",
      "r203"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt Instrument, Face Amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r196"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Debt Instrument, Fair Value Disclosure"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r35",
      "r85",
      "r141",
      "r143",
      "r144",
      "r145",
      "r200",
      "r201",
      "r203",
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r137",
      "r202"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "terseLabel": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r202"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Debt Issuance Costs, Gross"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r77",
      "r108"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r61",
      "r87",
      "r89",
      "r90",
      "r91",
      "r92",
      "r96",
      "r220",
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per common share, Basic and Diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r82",
      "r93",
      "r94",
      "r95"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings Per Share, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Share-based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity:"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1",
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r193",
      "r197",
      "r198"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r193",
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table Text Block]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r194",
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r194",
      "r207"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r194",
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value, Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r194",
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.",
        "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]",
        "terseLabel": "Fair Value, Measurement Inputs, Disclosure"
       }
      }
     },
     "localname": "FairValueMeasurementInputsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r129"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated intangible assets amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r125",
      "r126"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Decrease in accounts payable and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "(Increase) decrease in accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Decrease in deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "(Increase) decrease in inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedTerseLabel": "Decrease in other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "(Increase) decrease in prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r127",
      "r128"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net of accumulated amortization of $5,444 and $5,003, respectively"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r58",
      "r107",
      "r199",
      "r202",
      "r221"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r72",
      "r74",
      "r81"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Current [Table]",
        "terseLabel": "Inventory, Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r40"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Inventory, Finished Goods, Gross"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r22",
      "r124"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Inventory, Finished Goods, Net of Reserves"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r43"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "terseLabel": "Inventory, Gross"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryMajorClassesPolicy": {
     "auth_ref": [
      "r24",
      "r82"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the major categories of inventory such as finished goods, inventoried costs relating to long-term contracts or programs, work in process, raw materials, and supplies.",
        "label": "Inventory, Major Classes, Policy [Policy Text Block]",
        "terseLabel": "Inventory, Major Classes, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "InventoryMajorClassesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r1",
      "r43",
      "r121"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r5",
      "r44",
      "r82",
      "r97",
      "r122",
      "r123"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r42"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Inventory, Raw Materials, Gross"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r41"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Inventory, Work in Process, Gross"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r233",
      "r235",
      "r236",
      "r237"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r233",
      "r235",
      "r236",
      "r237"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investment [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r193"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Total Cash and Cash Equivalents and Investments"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Assets held for their financial return, rather than for the entity's operations.",
        "label": "Investments [Member]",
        "terseLabel": "Total Cash and Cash Equivalents and Investments"
       }
      }
     },
     "localname": "InvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r21",
      "r213",
      "r227"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "terseLabel": "Current portion of long-term debt, net of deferred issuance costs"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, net of deferred issuance costs"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r35",
      "r136"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r73",
      "r75",
      "r78"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r53",
      "r55",
      "r60",
      "r78",
      "r94",
      "r219",
      "r230"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New Accounting Pronouncements, Policy"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r47",
      "r49"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax",
        "terseLabel": "Unrealized gain on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Interest and other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": {
     "auth_ref": [
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.",
        "label": "Payment of Financing and Stock Issuance Costs",
        "terseLabel": "Debt Issuance Cost"
       }
      }
     },
     "localname": "PaymentOfFinancingAndStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r159",
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value per share"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $.01 par value; 5,000 shares authorized; no shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r68"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from Convertible Debt"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "terseLabel": "Maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r7",
      "r8",
      "r131",
      "r228"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net of accumulated depreciation and amortization of $61,302 and $61,741, respectively"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PublicUtilitiesInventoryAxis": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of inventory held.",
        "label": "Inventory [Axis]",
        "terseLabel": "Inventory [Axis]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PublicUtilitiesInventoryTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.",
        "label": "Inventory [Domain]",
        "terseLabel": "Inventory [Domain]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RealizedInvestmentGainsLosses": {
     "auth_ref": [
      "r232"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net realized gains or losses on investments during the period, not including gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity.",
        "label": "Realized Investment Gains (Losses)",
        "terseLabel": "Realized Investment Gains (Losses)"
       }
      }
     },
     "localname": "RealizedInvestmentGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Repayment of debt borrowings, net of fees"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r181",
      "r238"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development, including stock-based compensation of $2,176 and $1,768, respectively"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r82",
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expense, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r18",
      "r146",
      "r226"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r149",
      "r150"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Collaborative agreements"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r83",
      "r84"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue [Policy Text Block]"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r59",
      "r105",
      "r106",
      "r110"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "totalLabel": "Total revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RoyaltyIncomeNonoperating": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.",
        "label": "Royalty Income, Nonoperating",
        "terseLabel": "Royalties and other revenue"
       }
      }
     },
     "localname": "RoyaltyIncomeNonoperating",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Schedule of Cash, Cash Equivalents and Short-term Investments [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Investments [Line Items]",
        "terseLabel": "Schedule of Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInvestmentsTable": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A container table for all schedule of investment items. It ties in the \"Legal Entity [Axis]\" to all of its contained line items.",
        "label": "Schedule of Investments [Table]",
        "terseLabel": "Schedule of cash and cash equivalents and investments",
        "verboseLabel": "Schedule of Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1",
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r159",
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r162",
      "r174",
      "r175"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Share-based Payment Arrangement, Option, Activity [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r164",
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r157",
      "r160"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r82",
      "r159",
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-based Payment Arrangement [Policy Text Block]"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r10",
      "r214",
      "r215",
      "r217",
      "r224"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-term Investments [Member]",
        "terseLabel": "Total Short-term Investments"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Significant Accounting Policies [Text Block]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r140"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r39",
      "r140"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r14",
      "r15",
      "r140",
      "r146"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock under Equity Incentive Plans, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r14",
      "r15",
      "r140",
      "r146"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock under Equity Incentive Plans, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Equity Option [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r15",
      "r19",
      "r20",
      "r118"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total stockholder's equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r185",
      "r186",
      "r189"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance, value",
        "periodStartLabel": "Balance, value"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r116",
      "r117",
      "r119"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable [Policy Text Block]"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TradingActivityByTypeAxis": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of trading activity.",
        "label": "Trading Activity [Axis]",
        "terseLabel": "Trading Activity, by Type [Axis]"
       }
      }
     },
     "localname": "TradingActivityByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradingActivityByTypeDomain": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gains and losses on trading activities (including both derivative and nonderivative instruments) recognized in the statement of financial performance, separately by major types of items (such as fixed income/interest rates, foreign exchange, equity, commodity, and credit).",
        "label": "Trading Activity, by Type [Domain]",
        "terseLabel": "Trading Activity, by Type [Domain]"
       }
      }
     },
     "localname": "TradingActivityByTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r38",
      "r147"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r38",
      "r147"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury stock, shares"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r38",
      "r147",
      "r148"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock, at cost, 741 and 407 shares, respectively"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r140",
      "r146",
      "r147"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r153",
      "r155",
      "r216"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury Securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnamortizedDebtIssuanceExpense": {
     "auth_ref": [
      "r27"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.",
        "label": "Unamortized Debt Issuance Expense",
        "terseLabel": "Unamortized Debt Issuance Expense"
       }
      }
     },
     "localname": "UnamortizedDebtIssuanceExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r88",
      "r92"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Shares used in computing net loss per common share, Basic and Diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e4975-111524"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=SL6953423-111524"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5212-111524"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5033-111524"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5093-111524"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14615-108349"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "http://asc.fasb.org/topic&trid=2122478"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-02)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-03)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624186-113959"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "820",
   "URI": "http://asc.fasb.org/topic&trid=2155941"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13467-108611"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13476-108611"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6)(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.3(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(2)(i))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12C(1)(a))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r239": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r241": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r242": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r243": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r244": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6773817744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Notes)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Basis of Presentation:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The accompanying unaudited condensed consolidated financial statements of Lexicon Pharmaceuticals, Inc. (&#8220;Lexicon&#8221; or the &#8220;Company&#8221;) have been prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three-month period ended March&#160;31, 2020 are not necessarily indicative of the results that may be expected for the year ended December&#160;31, 2020.</span></div><div style="text-indent:36pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying condensed consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries. Intercompany transactions and balances are eliminated in consolidation.</span></div><div style="text-indent:36pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For further information, refer to the financial statements and footnotes thereto included in Lexicon&#8217;s annual report on Form 10-K for the year ended December&#160;31, 2019, as filed with the SEC.&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Use of Estimates:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The preparation of financial statements in conformity with U. S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cash, Cash Equivalents and Short-Term Investments:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of March&#160;31, 2020 and December&#160;31, 2019, short-term investments consisted of U.S. treasury bills.  The Company&#8217;s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security.&#160;&#160;Unrealized gains and losses on such securities are reported as a separate component of stockholders&#8217; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Accounts Receivable:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;Lexicon records trade accounts receivable in the normal course of business related to the sale of products or services, net of an allowance for expected credit losses.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Inventory: </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Inventory is comprised of the Company&#8217;s approved product it is commercializing in the United States, XERMELO</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174; </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(telotristat ethyl).  Inventories are determined at the lower of cost or market value with cost determined under the specific identification method and may consist of raw materials, work in process and finished goods. Inventory consisted of the following:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:82.163%;"><tr><td style="width:1.0%;"/><td style="width:51.380%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.689%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:19.886%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.757%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:19.888%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of March 31,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31,</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,218&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,182&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Work-in-process</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,117&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">153&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">812&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">908&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventory</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,147&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,243&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue Recognition:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Product Revenues</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Product revenues consist of commercial sales of XERMELO in the United States and sales of bulk tablets of XERMELO to Ipsen Pharma SAS (&#8220;Ipsen&#8221;).  Product revenues are recognized when the customer obtains control of the Company&#8217;s product, which occurs upon delivery to the customer.  The Company recognizes product revenue net of applicable reserves for variable consideration, including allowances for customer credits, estimated rebates, chargebacks, discounts, returns, distribution service fees, and government rebates, such as Medicare Part D coverage gap reimbursements in the U.S.  These estimates are based on the most likely amount method for relevant factors such as current contractual and statutory requirements, industry data and forecasted customer buying and payment patterns.  The Company&#8217;s net product revenues reflect the Company&#8217;s best estimates of the amounts of consideration to which it is entitled based on the terms of the respective underlying contracts.  Product shipping and handling costs are considered a fulfillment activity when control transfers to the Company&#8217;s customers and such costs are included in cost of sales.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#160;&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Collaborative Agreements</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues under collaborative agreements include both license revenue and contract research revenue.  The Company performs the following five steps in determining the amount of revenue to recognize as it fulfills its performance obligations under each of its agreements:  (i) identify the contract(s) with a customer; (ii) identify the performance obligation in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation.  The Company applies this five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.  At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct.  The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.  The Company develops assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At contract inception, the Company evaluates whether development milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.  If it is probable that a significant revenue reversal will not occur, the associated development milestone value is included in the transaction price.  Development milestones that are not within the control of the Company or the licensee, including those requiring regulatory approval, are not considered probable of being achieved until those approvals are received.  The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue when (or as) the performance obligation is satisfied.  At the end of each reporting period, the Company re-evaluates the probability of achievement of the development milestones and any related constraint, and if necessary, adjusts its estimates of the overall transaction price.  Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In agreements in which a license to the Company&#8217;s intellectual property is determined distinct from other performance obligations identified in the agreement, the Company recognizes revenue when the license is transferred to the licensee and the licensee is able to use and benefit from the license.  </span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For agreements that include sales-based royalties, including milestones based on a level of sales, the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company may receive payments from its licensees based on billing schedules established in each contract.  Up-front payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these agreements.  Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional. </span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cost of Sales: </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Cost of sales consists of third-party manufacturing costs, freight and indirect overhead costs associated with sales of XERMELO. Product shipping and handling costs are included in cost of sales. Cost of sales also includes the amortization of the in-process research and development intangible asset for XERMELO using the straight-line method over the estimated useful life of 14 years. </span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Research and Development Expenses:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#8217;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company&#8217;s estimates of the clinical study costs and costs to transition activities from Sanofi for development of sotagliflozin for type 2 diabetes, heart failure and chronic kidney disease, including the costs to close out those studies, were based on actual costs incurred for activities completed subsequent to the transition date and estimates of the services to be received and efforts to be expended pursuant to contracts with multiple vendors and the CRO that has conducted and managed and is now closing out the clinical studies on its behalf.  The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#8217;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Stock-Based Compensation:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;The Company recognizes compensation expense in its condensed consolidated statements of comprehensive loss for share-based payments, including stock options and restricted stock units issued to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#8217;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in a change in the assumptions used for expected option lives.&#160;&#160;Historical data is used to estimate the expected option life for each group.  Expected volatility is based on the historical volatility in the Company&#8217;s stock price.&#160;&#160;The Company utilized the Black-Scholes valuation model for estimating the fair value of the stock option compensation granted, with the following weighted-average assumptions for options granted in the three months ended March&#160;31, 2020 and 2019:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:50.422%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.069%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.719%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.838%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.016%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected Volatility</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free Interest Rate</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected Term</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dividend<br/>Rate</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employees</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">89&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Officers and non-employee directors</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">77&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2019:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employees</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Officers and non-employee directors</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following is a summary of stock option activity under Lexicon&#8217;s stock-based compensation plans for the three months ended March&#160;31, 2020:</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:66.035%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.929%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.570%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,695&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.95&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,301&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.31&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expired</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(202)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.30&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(73)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at March 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,721&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.11&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable at March 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,731&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.83&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended March&#160;31, 2020, Lexicon granted its employees annual restricted stock units. Outstanding employee restricted stock units vest in three to four annual installments.  The following is a summary of restricted stock units activity under Lexicon&#8217;s stock-based compensation plans for the three months ended March&#160;31, 2020:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:65.008%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.929%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.597%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,830&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.35&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,060&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.31&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,032)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.02&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(34)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.28&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at March 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,824&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.29&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div>Net Loss per Common Share: Net loss per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with convertible debt, stock options and restricted stock units are not included because they are antidilutive.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of Significant Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6761372672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss-Unaudited - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_Netproductrevenue', window );">Net product revenue</a></td>
<td class="nump">$ 7,877<span></span>
</td>
<td class="nump">$ 6,740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaborative agreements</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">2,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyIncomeNonoperating', window );">Royalties and other revenue</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">7,999<span></span>
</td>
<td class="nump">9,216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales (including finite-lived intangible asset amortization)</a></td>
<td class="nump">568<span></span>
</td>
<td class="nump">553<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development, including stock-based compensation of $2,176 and $1,768, respectively</a></td>
<td class="nump">55,181<span></span>
</td>
<td class="nump">12,022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_Sellinggeneralandadministrativeexpenses', window );">Selling, general and administrative expenses, included stock-based compensation of $2,256 and $1,643, respectively</a></td>
<td class="nump">14,688<span></span>
</td>
<td class="nump">14,110<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">70,437<span></span>
</td>
<td class="nump">26,685<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(62,438)<span></span>
</td>
<td class="num">(17,469)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(5,131)<span></span>
</td>
<td class="num">(5,117)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest and other income, net</a></td>
<td class="nump">958<span></span>
</td>
<td class="nump">789<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (66,611)<span></span>
</td>
<td class="num">$ (21,797)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share, Basic and Diluted</a></td>
<td class="num">$ (0.63)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in computing net loss per common share, Basic and Diluted</a></td>
<td class="nump">106,536<span></span>
</td>
<td class="nump">106,054<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on investments</a></td>
<td class="nump">$ 776<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">(65,835)<span></span>
</td>
<td class="num">(21,752)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense', window );">Stock-based compensation expense associated with research and development expense</a></td>
<td class="nump">2,176<span></span>
</td>
<td class="nump">1,768<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense', window );">Stock-based compensation expense associated with selling, general and administrative expense</a></td>
<td class="nump">$ 2,256<span></span>
</td>
<td class="nump">$ 1,643<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_Netproductrevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net product revenue - amount of revenue recognized from product sales, net of discounts. Sales process constitutes an earnings process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_Netproductrevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_Sellinggeneralandadministrativeexpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Selling, general and administrative expenses - the expenses related to selling Lexicon's product as well as general and administrative costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_Sellinggeneralandadministrativeexpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation expense included in research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation expense associated with selling, general and administrative expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6773842896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration and License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Arrangement Disclosure</a></td>
<td class="text">Collaboration and License Agreements<div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Lexicon has derived substantially all of its revenues from drug discovery and development alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, product sales, government grants and contracts, technology licenses, subscriptions to its databases and compound library sales. </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Ipsen.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  In October 2014, Lexicon entered into a License and Collaboration Agreement, which was subsequently amended in March 2015 (collectively, the &#8220;Ipsen Agreement&#8221;), with Ipsen for the development and commercialization of XERMELO outside of the United States and Japan (the &#8220;Licensed Territory&#8221;).  </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Ipsen Agreement, Lexicon granted Ipsen an exclusive, royalty-bearing right and license under its patent rights and know-how to commercialize XERMELO in the Licensed Territory.  Ipsen is responsible for using diligent efforts to commercialize XERMELO in the Licensed Territory pursuant to a mutually approved commercialization plan.  Subject to certain exceptions, Lexicon was responsible for conducting clinical trials required to obtain regulatory approval for XERMELO for carcinoid syndrome in the European Union, including those contemplated by a mutually approved initial development plan, and has the first right to conduct most other clinical trials of XERMELO.  Lexicon was responsible for the costs of all clinical trials contemplated by the initial development plan. The costs of additional clinical trials will be allocated between the parties based on the nature of such clinical trials.  Under the Ipsen Agreement, Ipsen has paid Lexicon an aggregate of $47.2 million through March&#160;31, 2020, consisting of $24.5 million in upfront payments and a $6.4 million milestone payment upon the acceptance of the filing submitted by Ipsen to the European Medicines Agency for XERMELO as an adjunct to somatostatin analog therapy for the long-term treatment of carcinoid syndrome, a $5.1 million milestone upon Ipsen&#8217;s receipt of approval from the European Commission for the marketing of XERMELO in all member states of the European Union, Norway and Iceland, a $3.8 million milestone upon Ipsen&#8217;s first commercial sale in Germany, a $3.8 million milestone upon Ipsen&#8217;s first commercial sale in the United Kingdom, a $1.3 million milestone upon Ipsen&#8217;s receipt of approval from Health Canada and a $2.3 million milestone upon Ipsen&#8217;s first commercial sale in Canada.  In addition, Lexicon is eligible to receive from Ipsen (a) up to an aggregate of approximately $9.6&#160;million upon the achievement of specified regulatory and commercial launch milestones and (b) up to an aggregate of &#8364;72&#160;million upon the achievement of specified sales milestones. Milestone payments that are contingent upon the achievement of a substantive milestone are deemed constrained.  Lexicon is also entitled to tiered, escalating royalties ranging from low twenties to mid-thirties percentages of net sales of XERMELO in the Licensed Territory, subject to a credit for amounts previously paid to Lexicon by Ipsen for the manufacture and supply of such units of XERMELO.  </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Lexicon and Ipsen have entered into a commercial supply agreement pursuant to which Lexicon will supply Ipsen&#8217;s commercial requirements of XERMELO, and Ipsen pays an agreed upon transfer price for such commercial supply.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company considered the following as its performance obligations with respect to the revenue recognition of the $24.5&#160;million upfront payments: </span></div><div style="text-indent:-36pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">The exclusive license granted to Ipsen to develop and commercialize XERMELO in the Licensed Territory;</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">The development services Lexicon is performing for XERMELO;</span></div><div style="text-indent:-36pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">The obligation to participate in committees which govern the development of XERMELO until commercialization; and</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">The obligation to supply commercial supply of XERMELO, under a commercial supply agreement.</span></div><div><span><br/></span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company determined that the license had stand-alone value because it is an exclusive license that gives Ipsen the right to develop and commercialize XERMELO or to sublicense its rights.  In addition, at the time of the agreement, it would have been possible for Ipsen or another third party to conduct clinical trials without assistance from Lexicon.  As a result, the Company considers the license and the development services under the Ipsen Agreement to be separate performance obligations.  The Company recognized the portion of the transaction price allocated to the license immediately because Lexicon delivered the license and earned the revenue at the inception of the arrangement.  The Company recognized as revenue the amount allocated to the development services and the obligation to participate in committees over the period of time Lexicon performed the services, which was completed in 2018.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company determined that the commercial supply agreement is a contingent deliverable at the onset of the Agreement.  There was inherent uncertainty in obtaining regulatory approval at the time of the agreement, thus, making the applicability of the commercial supply agreement outside the control of Lexicon and Ipsen.  As a result, the Company has determined the commercial supply agreement does not meet the definition of a performance obligation that needs to be accounted for at the inception of the arrangement.  The Company has also determined that there is no significant and incremental discount related to the commercial supply agreement that should be accounted for at the inception of the arrangement.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company determined that the initial transaction price was the $24.5&#160;million upfront payments because they were the only payments that were fixed and determinable at the inception of the arrangement.  There was considerable uncertainty at the date of the agreement as to whether Lexicon would earn milestone payments, royalty payments or payments for finished drug product.  As such, the Company did not include those payments in the transaction price.  The Company allocated the transaction price based on the relative best estimate of selling price of each performance obligation.  The Company estimated the selling price of the license deliverable by applying a probability-based income approach utilizing an appropriate discount rate.  The significant inputs the Company used to determine the projected income of the license included: estimated future product sales, estimated cost of goods sold, estimated operating expenses, income taxes, and an appropriate discount rate.  The Company estimated the selling price of the development services by using internal estimates of the cost to hire third parties to perform the services over the expected period to perform the development.  The Company estimated the selling price of the obligation to participate in committees by using internal estimates of the number of internal hours and salary and benefits costs to perform these services. </span></div>As a result of the allocation, the Company recognized $21.2&#160;million of the $24.5&#160;million upfront payments for the license in 2014, and an additional $1.4&#160;million in 2015 upon entering into the amendment.  The Company recognized the $1.7&#160;million allocated to the development services performance obligation over the period of performance as development occurred, and recognized the $0.1&#160;million allocated to the committee participation performance obligation ratably over the period of performance.  Milestone payments that are contingent upon the achievement of a substantive milestone are deemed constrained.  If or when the constraint is determined to be resolved, the Company will re-evaluate the overall transaction price and recognize an adjustment on a cumulative catch-up basis in the period that the adjustment was evaluated.  Revenue recognized under the Agreement was $0.1&#160;million and $2.4 million for the three months ended March&#160;31, 2020 and 2019, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration and License Agreements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6773834336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents and Investments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract', window );"><strong>Cash and Cash Equivalents and Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">Cash and Cash Equivalents Disclosure</a></td>
<td class="text">Cash and Cash Equivalents and Investments<div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of cash and cash equivalents and investments held at March&#160;31, 2020 and December&#160;31, 2019 are as follows:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:51.147%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.980%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.980%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.980%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.985%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of March 31, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55,592&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55,592&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">192,685&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">860&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">193,545&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total short-term investments</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">192,685&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">860&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">193,545&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">248,277&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">860&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">249,137&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,112&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,112&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">235,463&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">94&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">235,547&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total short-term investments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">235,463&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">94&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">235,547&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-18pt;padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total cash and cash equivalents and investments</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">271,575&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">94&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">271,659&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There were no realized losses during either of the three months ended March&#160;31, 2020 and 2019, respectively.  The cost of securities sold is based on the specific identification method.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and Cash Equivalents and Investments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CashAndCashEquivalentsAndInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes,  which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6765882784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents and Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract', window );"><strong>Cash and Cash Equivalents and Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of Cash, Cash Equivalents and Short-term Investments [Table Text Block]</a></td>
<td class="text"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:51.147%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.980%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.980%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.980%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.985%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of March 31, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55,592&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55,592&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">192,685&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">860&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">193,545&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total short-term investments</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">192,685&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">860&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">193,545&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">248,277&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">860&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">249,137&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,112&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,112&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">235,463&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">94&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">235,547&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total short-term investments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">235,463&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">94&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">235,547&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-18pt;padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total cash and cash equivalents and investments</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">271,575&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">94&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">271,659&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and Cash Equivalents and Investments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CashAndCashEquivalentsAndInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
